,,,COVID-19 Interventions,,SOP for Data Entry (Version 4),Bold Products Also Listed Here ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,Product,,,Product Information,,,,,,,,,,Milestones,,Pre-Clinical Development Milestones,,,Manufacturing Milestones,Regulatory Milestones,Clinical Development Milestones,,,Regulatory Milestones,ON THE MARKET,,Highest Status Ongoing Clinical Study (see clinical study tab for more studies),,,,,,,,,,,,,,,,,,,,,,,,
ID,Source?,Product Name - Preferred,Product Name - Chemical,Product Name - Brand,Sponsor,Intervention Type,Indication,Molecule Type,Therapeutic Approach,New/Repurposed,Funding/Manufacturing/Research/Other Partners,Country,Status,Notes,,Current Stage,,Discovery Started,Pre-Clinical Studies Started,Lead Selection Finalized,Clinical Batch Finalized,IND or Equivalent Approval Finalized,Phase 1 Started,Phase 2 Started,Phase 3 Started,NDA or equivalent Approval Finalized,,,Phase,Condition or Disease,Number of Participants,Accepts Healthy Subjects,# of Sites,Sites Locations,Study Start Date,Primary Completion DAte,Study Completion Date,Registry Link,Contact Name,Contact Phone Number,Contact Email,Contact Website,Contact Notes,How to participate,,Data Entry 1 Owner,Date Entry 1 Performed,Data Entry 2 Owner,Date Entry 2 Performed,Data Entry Update Owner,Date Update Performed,,Last Updated
1,No,mRNA-1273,,mRNA-1273,Moderna; National Institute of Allergy and Infectious Diseases,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,CEPI; Lonza; BARDA,United States,Ongoing,mRNA-based vaccine,,Phase 3,,1/11/2020,SKIPPED,1/13/2020,2/7/2020,3/4/2020,3/16/2020,5/29/2020,7/27/2020,,,,2/3,COVID-19,3000,Yes,7,Advanced Clinical Research - Meridian - Idaho; Clinical Research Institute - Minneapolis - Minnesota; Child Healthcare Associates - Liverpool - New York; Lynn Health Sciences Institute - Oklahoma City - Oklahoma; Kool Kids Pediatrics - Houston - Texas; Tekton Research - San Antonio - Texas; Advanced Clinical Research - West Jordan - Utah,,,,https://clinicaltrials.gov/ct2/show/NCT04649151?,,8556636762,clinicaltrials@modernatx.com,,ADOLESCENTS ONLY (Ages 12 to <18),,,Mats,3/27/2020,Matthew,5/31/2020,Priya Kaur,6/18/2020,,6/18/2020
1,Yes,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,,,,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427&draw=2&rank=1,,,,,,,,,,
2,No,NVX-CoV2373,,NVX-CoV2373,Novavax Inc.; Emergent BioSolutions Inc. ,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Other,New,CEPI,United States,Ongoing,not totally clear that it is prophylactic vaccine. P1 expected late spring; Trial is technically Phase I/II but they have only started phase 1 work,,Phase 3,,,3/10/2020,,,,5/25/2020,8/17/2020,9/28/2020,,,,3,COVID-19,30000,Yes,114,Accel Research Sites - Birmingham - Alabama; Centers for American Indian Health - Chinle - Arizona; Synexus Clinical Research US - Glendale - Arizona; HOPE Research Institute - Phoenix - Arizona; AMR Tempe Clinical Research Consortium - Tempe - Arizona; Lynn Institute of the Ozarks - Little Rock - Arkansas; Preferred Research Partners - Little Rock - Arkansas; Anaheim Clinical Trials - Anaheim - California; Advanced Clinical Research - Rancho Paseo - Banning - California; eStudy Site - Chula Vista - California; eStudySite - Corporate Offices - La Mesa - California; Wr-Pri - Los Alamitos - California; National Research Institute - Los Angeles - California; Empire Clinical Research - Pomona - California; University of California Davis Medical Center - Sacramento - California; Benchmark Research - Sacramento - California; Synexus Clinical Research US - Vista - California; Woodland Clinic Medical Group - Woodland - California; University of Colorado Hospital CRS - Aurora - Colorado; Lynn Institute of the Rockies - Colorado Springs - Colorado; Howard University Hospital Howard/ University College of Medicine - Washington - District of Columbia; University Clinical Research-Deland - DeLand - Florida; SIMED Health - Gainesville - Florida; M D Clinical - Hallandale Beach - Florida; Research Centers of America - Hollywood - Florida; Jacksonville Center for Clinical Research - Jacksonville - Florida; Meridien Research/Accel Research - Lakeland - Florida; Miami Veterans Affairs Medical Center - Miami - Florida; Suncoast Research Associates - Miami - Florida; Clinical Neuroscience Solutions Inc - Orlando - Florida; Synexus Clinical Research US - Pinellas Park - Florida; University of South Florida - Tampa - Florida; Jedidiah Clinical Research - Tampa - Florida; Synexus Clinical Research US - The Villages - Florida; Comprehensive Clinical Trials - West Palm Beach - Florida; Ponce de Leon Center - Atlanta - Georgia; Morehouse School Of Medicine - Atlanta - Georgia; Synexus Clinical Research US - Atlanta - Georgia; Atlanta Center for Medical Research - Atlanta - Georgia; Clinical Research Atlanta - Stockbridge - Georgia; Advanced Clinical Research - Meridian - Idaho; Synexus - Chicago - Illinois; Cedar Crosse Research Center - Chicago - Illinois; Providea Health Partners LLC - Mokena - Illinois; Synexus USA - Evansville - Indiana; Buynak Clinical Research - Valparaiso - Indiana; University of Iowa Medical Center - Iowa City - Iowa; Meridian Clinical Research - Sioux City - Iowa; Johnson County Clin-Trials - Lenexa - Kansas; Meridian Clinical Research - Baton Rouge - Louisiana; Med Pharmics - Metairie - Louisiana; Willis-Knighton Physician Network - Shreveport - Louisiana; University Of Maryland School Of Medicine - Baltimore - Maryland; Beth Israel Deaconess Medical Center - Boston - Massachusetts; VA Medical Center - Ann Arbor - Michigan; Wayne State University/ Children's Hospital of Michigan - Detroit - Michigan; University of Minnesota - Minneapolis - Minnesota; Synexus Clinical Research US - Richfield - Minnesota; MedPharmics - Gulfport - Mississippi; The Curators of University of Missouri - Columbia - Missouri; Sundance Clinical Research - Saint Louis - Missouri; Meridian Clinical Research - Norfolk - Nebraska; Meridian Clinical Research Associates - Omaha - Nebraska; University Of Nebraska Medical Center - Omaha - Nebraska; Synexus Clinical Research US - Henderson - Nevada; Stony Brook Responder Vaccine Program - Commack - New York; Weill Cornell Chelsea CRS - New York - New York; University of North Carolina - Chapel Hill - North Carolina; The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health - Charlotte - North Carolina; Carolina Institute for Clinical Research - Fayetteville - North Carolina; Womack Army Medical Center - Fort Bragg - North Carolina; M3 Wake Research - Raleigh - North Carolina; PMG Research of Rocky Mount - Rocky Mount - North Carolina; Synexus Clinical Research - Akron - Ohio; Sterling Research Group - Cincinnati - Ohio; Synexus Clinical Research US - Cincinnati - Ohio; Sterling Research Group - Cincinnati - Ohio; Rapid Medical Research - Cleveland - Ohio; Synexus Clinical Research US - Oklahoma City - Oklahoma; Lynn Health Science Institute - Oklahoma City - Oklahoma; CRISOR - Medford - Oregon; Velocity Clinical Research - Warwick - Rhode Island; Synexus Clinical Research US - Anderson - South Carolina; Medical University of South Carolina - Charleston - South Carolina; American Indian Clinical Trials Research Network - Eagle Butte - South Dakota; PMG Research of Bristol - Bristol - Tennessee; WR Clinsearch - Chattanooga - Tennessee; PMG Research - Knoxville - Tennessee; Clinical Neurosciecne Solutions - Memphis - Tennessee; Meharry Medical College - Nashville - Tennessee; Benchmark Research - Austin - Texas; Benchmark Research - Fort Worth - Texas; Baylor College of Medicine - Houston - Texas; Texas Center for Drug Development - Houston - Texas; Centex Studies - McAllen - Texas; Research Your Health - Plano - Texas; Synexus - San Antonio - Texas; University of Texas Health Science Center San Antonio - San Antonio - Texas; Advanced Clinical Research - West Jordan - Utah; MultiCare Institute for Research & Innovation - Cheney - Washington; University of Washington VTEU - Seattle and King County Public Health STD clinic - Seattle - Washington; PanAmerican Clinical Research Mexico S.A de C.V - Guadalajara - Jalisco - Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Tlalpan - Mexico; PanAmerican Clinical Research Mexico - Juriquilla - Queretaro - Mexico; Unidad de Atencion Medica e Investigacion en Salud (UNAMIS) - Merida - Yucatan - Mexico; Instituto Nacional de Salud Publica (INSP) - Cuernavaca - Centro de Investigacion en Salud Poblacional (CISP) - Cuernavaca - Mexico; CAIMED Investigacion en Salud S.A de C.V - Mexico; ,11/30/2020,3/31/2021,12/30/2022,https://clinicaltrials.gov/ct2/show/NCT04611802,Kristin Ciccarelli,215-616-6815,Kristin.Ciccarelli@iconplc.com        ,https://www.novavax.com/PREVENT-19,,,,James,4/2/2020,Matthew,5/31/2020,,,,5/31/2020
2,Yes,http://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine,http://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine,http://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,,,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,,,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&recrs=ab&draw=2&rank=1,,,,,,,,,
3,No,BNT-162; BNT162b2,,BNT-162; BNT162b2,Pfizer; BioNTech;,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,Polymun,Germany,Ongoing,Expect clinical testing in late april. Note this drug is also being developed in china with fosun pharma. Assumed this is in discovery as no explicit statements aboit preclinical found,,Phase 3,,,3/16/2020,,,,4/23/2020,4/23/2020,7/27/2020,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,Matthew,5/31/2020,,,,5/31/2020
3,Yes,,,,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://biontech.de/,https://biontech.de/,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.fiercebiotech.com/biotech/weeks-to-go-to-covid-19-vaccine-trial-biontech-lands-135m-deal-and-advances-pfizer-talks,,https://clinicaltrials.gov/ct2/show/NCT04380701,,,https://biontech.de/node/159,,,,https://clinicaltrials.gov/ct2/show/NCT04380701,https://clinicaltrials.gov/ct2/show/NCT04380701,https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against,,,,https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against,https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against,https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against,https://clinicaltrials.gov/ct2/show/NCT04380701,https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against,https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against,https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against,,,https://clinicaltrials.gov/ct2/show/NCT04380701,,,,,,,,,,,,,,,
4,No,LNP-nCoVsaRNA,,LNP-nCoVsaRNA,Imperial College London,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,Maravai Lifesciences Inc.; Trilink Biotechnologies Inc.,United Kingdon,Ongoing,Expect clinical testing in summer,,Phase 1,,Assumed Complete,2/10/2020,Assumed Complete,Assumed Complete,Assumed Complete,6/23/2020,,,,,,1,COVID-19,300,Yes,1,NIHR Imperial Clinical Research Facility - London - United Kingdom; Surrey Clinical Research Facility - Surrey - United Kingdom; University Hospital Southampton - Hampshire - United Kingdom; St George's Hospital - London - United Kingdom; ,7/23/2020,7/31/2021,7/31/2021,http://www.isrctn.com/ISRCTN17072692,James Fletcher,,covactrials@imperial.ac.uk,https://www.imperial.ac.uk/covid-19-vaccine-trial/participants-info/,,,,James,4/2/2020,Matthew,5/31/2020,,,,5/31/2020
4,Yes,,,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,Other,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,,,https://www.imperial.ac.uk/news/198533/first-volunteers-receive-imperial-covid-19-vaccine/,https://www.imperial.ac.uk/news/198533/first-volunteers-receive-imperial-covid-19-vaccine/,,,,,https://www.imperial.ac.uk/covid-19-vaccine-trial/,https://www.imperial.ac.uk/covid-19-vaccine-trial/,https://www.imperial.ac.uk/covid-19-vaccine-trial/,https://www.imperial.ac.uk/covid-19-vaccine-trial/,https://www.imperial.ac.uk/covid-19-vaccine-trial/,https://www.imperial.ac.uk/covid-19-vaccine-trial/,https://www.imperial.ac.uk/covid-19-vaccine-trial/,,,,,,https://www.imperial.ac.uk/covid-19-vaccine-trial/,,,,,,,,,,,,
5,No,INO-4800; CELLECTRA® 20000,,INO-4800; CELLECTRA® 20000,Inovio Pharmaceuticals Inc.; Beijing Advaccine Biotechnology.; US Department of Defense.; Ology Bioservices Inc.,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,US DoD; Bill and Melinda Gates Foundation; Coalition for Epidemic Prepardness Innovations Funding,United States,Ongoing,,,Phase 2,,1/23/2020,,,3/24/2020,,4/3/2020,6/22/2020,,,,,2/3,COVID-19,6578,Yes,30,Synexus Clinical Research US - Chandler - Arizona; Central Phoenix Synexus Clinical Research - Phoenix - Arizona; AMR Tempe - Tempe - Arizona; Optimal Research - San Diego - Arizona; AMR South Florida - Coral Gables - Florida; Clinical Research Trials of Florida - Tampa - Florida; AMR Lexington - Lexington - Kentucky; Walter Reed Army Institute of Research - Silver Spring - Maryland; Ascension St John Hospital - Detroit - Michigan; AMR Kansas City - Kansas City - Missouri; AMR Clinical Research Consortium - Las Vegas - Nevada; University of Pennsylvania - Philadelphia - Pennsylvania; Thomas Jefferson University - Philadelphia - Pennsylvania; Tekton Research - San Antonio - Texas; DM Clinical Research - Tomball - Texas; Advanced Clinical Research - West Jordan - Utah;,11/30/2020,9/1/2022,9/1/2022,https://clinicaltrials.gov/ct2/show/NCT04642638  https://clinicaltrials.gov/ct2/show/NCT04447781 https://clinicaltrials.gov/ct2/show/NCT04336410,,267-440-4237,clinical.trials@inovio.com,,,,,Joseph Malinao,4/2/2020,Matthew,5/31/2020,Priya Kaur,6/18/2020,,6/18/2020
5,Yes,INO-4800,INO-4800,,https://www.precisionvaccinations.com/vaccines/ino-4800-dna-coronavirus-vaccine,,COVID-19,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04336410,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04336410,,,,,,https://clinicaltrials.gov/ct2/show/NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,,,,,,,,,,,,,,,
6,No,Ad26.COV2-S; Ad26 SARS-CoV-2,,Ad26.COV2-S; Ad26 SARS-CoV-2,Johnson & Johnson; Janssen Pharmaceutical,Vaccine - Prophylactic,COVID-19,Gene therapies,Vaccine,New,BARDA,United States,Ongoing,Expect clinical testing no later than fall 2020,,Phase 3,,,3/31/2020,,,,7/15/2020,7/15/2020,9/23/2020,,,,3,COVID-19,71045,Yes,110,Achieve Clinical Research - Vestavia Hills - Alabama; Hope Research Institute - Phoenix - Arizona; Woodland International Research Group - Little Rock -  Arkansas; Synexus Clinical Research US - Cerritos -  California; eStudySite - Chula Vista -  California; Benchmark Research - Sacramento -  California; Artemis Institute for Clinical Research - San Diego -  California; Paradigm Clinical Research Centers - Wheat Ridge -  Colorado; JEM Research - Atlantis -  Florida; Prestige Clinical Research Center - Coral Gables -  Florida; Avail Clinical Research - DeLand -  Florida; Health Awareness inc. - Jupiter -  Florida; Altus Research - Lake Worth -  Florida; Compass Research - Melbourne -  Florida; Behavioral Clinical Research  - North Miami -  Florida; Clinical NeuroScience Solutions - Orlando -  Florida; Progressive Medical Research - Port Orange -  Florida; Meridien Research - Saint Petersburg -  Florida; Palm Beach Research Center - West Palm Beach -  Florida; Atlanta Center for Medical Research - Atlanta -  Georgia; Accel Research Sites - Eatonton -  Georgia; Great Lakes Clinical Trials - Chicago -  Illinois; The South Bend Clinic Center for Research - South Bend -  Indiana; Heartland Research Associates - Newton -  Kansas; Centex Studies - Lake Charles -  Louisiana; Centennial Medical Group - Elkridge -  Maryland; Optimal Research - Rockville -  Maryland; Hassman Research Institute - Berlin -  New Jersey; Jersey Shore University Medical Center - Neptune -  New Jersey; Medpharmics - Albuquerque -  New Mexico; Regional Clinical Research - Endwell -  New York; Allergy Asthma Immunology of Rochester - Rochester -  New York; Richmond Behavioral Associates - Staten Island -  New York; American Health Network - Charlotte -  North Carolina; Wilmington Health Associates - Wilmington -  North Carolina; Lynn Health Science Institute - Oklahoma City -  Oklahoma; Medical University of South Carolina - Charleston -  South Carolina; Clinical NeuroScience Solutions - Memphis -  Tennessee; Centennial Medical Center - Nashville -  Tennessee; Tekton Research Inc. - Austin -  Texas; Centex Studies - Houston -  Texas; Centex Studies - Houston -  Texas; Texas Center for Drug Development - Houston -  Texas; Centex Studies - McAllen -  Texas; Endeavor Clinical Trials - San Antonio -  Texas; JBR Clinical Research - Salt Lake City -  Utah; Alliance for Multispeciality Research - Norfolk -  Virginia; Anima - Alken -  Belgium; Institute of Tropical Medicine Antwerp - Antwerpen -  Belgium; Hopital Erasme - Brussel -  Belgium; Center for Vaccinology (CEVAC) - Gent -  Belgium; UZ Leuven - Leuven -  Belgium; Az Sint-Maarten - Mechelen -  Belgium; Private Practice RESPISOM Namur - Namur -  Belgium; IPS Centro Cientifico Asisitencial Jose Luis Accini S.A.S. - Barranquilla -  Colombia; Caja de Compensacion Familiar Cafam - Bogota -  Colombia; CHU de Montpellier - Montpellier -  France; Hopital Saint-Antoine - Paris Cedex 12 -  France; Hopital Cochin - Paris -  France; Groupe Hospitalier Sud Hôpital Haut-Leveque Service d'hematologie - Pessac -  France; CHU Saint-Etienne - Hôpital Nord - Saint-Etienne Cedex 2 -  France; Hopital Purpan - Toulouse Cedex 09 -  France; Hôpital de Brabois Adultes - Vandoeuvre les Nancy -  France; Uniklinik Köln - Köln -  Germany; Klinikum rechts der Isar der TU Munchen - München -  Germany; Riverside Medical Center - Bacolod -  Philippines; West Visayas State University Medical Center - Iloilo City -  Philippines; Tropical Disease Foundation - Makati -  Philippines; Makati Medical Center - Manila -  Philippines; Medical Center Manila - Manila -  Philippines; TREAD Research Tygerberg Hospital - Cape Town -  South Africa; Centre of Tuberculosis Research Innovation - Cape Town -  South Africa; Worthwhile Clinical trials - Johannesburg -  South Africa; Peermed Clinical Trial Centre - Kempton Park -  South Africa; Dr AA Mahomed Medical Centre - Moloto -  South Africa; VX Pharma - Pretoria -  South Africa; Dr J.M. Engelbrecht Trial Site - Somerset West -  South Africa; Be Part Yoluntu Centre - Western Cape -  South Africa; Hosp. Univ. Germans Trias I Pujol - Badalona -  Spain; Hospital Quiron Barcelona - Barcelona -  Spain; Hosp. Clinic I Provincial de Barcelona - Barcelona -  Spain; Hosp. Univ. Vall D'Hebron - Barcelona -  Spain; Hosp. Univ. de La Princesa - Madrid -  Spain; Hosp. Univ. de La Paz - Madrid -  Spain; Hosp. Quiron Madrid Pozuelo - Madrid -  Spain; Clinica Univ. de Navarra - Pamplona -  Spain; Belfast City Hospital - Belfast - United Kingdom; Queen Elizabeth Hospital - Birmingham - United Kingdom; Powys Teaching Local Health Board - Bronllys Hospital - Brecon - United Kingdom; Brighton & Sussex University Hospitals NHS Trust - Brighton - United Kingdom; University Hospitals Bristol NHS Trust - Bristol - United Kingdom; Cambridge University Hospitals NHS Foundation Trust - Cambridge - United Kingdom; Ninewells Hospital - Dundee - United Kingdom; Royal Free Hospital - Hampstead - United Kingdom; Leicester Royal Infirmary - Leicester - United Kingdom; Guy's and St Thomas' Hospital - London - - United Kingdom; Imperial College London and Imperial College Healthcare NHS Trust - London - United Kingdom; Central Manchester University Hospitals NHS Foundation Trust - Manchester - United Kingdom; Newcastle upon Tyne Hospitals NHS Foundation Trust - Newcastle upon Tyne - United Kingdom; University of Oxford - Oxford - United Kingdom; Derriford Hospital - Plymouth - United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust - Sheffield - United Kingdom; Southampton General Hospital - Southampton - United Kingdom; ,11/15/20,5/10/2022,5/11/2023,https://www.clinicaltrials.gov/ct2/show/NCT04614948 https://clinicaltrials.gov/ct2/show/NCT04505722  https://www.clinicaltrials.gov/ct2/show/NCT04436276 https://clinicaltrials.gov/ct2/show/NCT04509947,,844-434-4210,JNJ.CT@sylogent.com,https://www.ensemblestudy.com/ ,,,,James,4/2/2020,Matthew,5/31/2020,,,,5/31/2020
6,Yes,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,COVID-19,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609467/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609467/,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,,https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push,,,https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7,No,Sanofi recombinant vaccine,,Sanofi recombinant vaccine,Sanofi; GSK,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Other,Repurposed-Not Approved,BARDA,France,Ongoing,they are repurposing vaccines that have been preclinically tested for SARS - hence I have put the current status as preclinical; No plans for a phase I trial until July at the earliest,,Pre-Clinical Testing,,,2/18/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,Matthew,5/31/2020,,,,5/31/2020
7,Yes,,,,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,,COVID-19,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,https://www.google.com/search?q=sanofi+pasteur+headquarters&rlz=1C5CHFA_enGB854GB854&oq=sanofi+pastuer+head&aqs=chrome.1.69i57j0l7.7080j1j9&sourceid=chrome&ie=UTF-8,https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00,https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00,,,,,https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8,No,REGN-COV2; REGN10933+REGN10987,,REGN-COV2; REGN10933+REGN10987,Regeneron; HHS,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,,,Phase 3,,2/4/2020,,,,,6/16/2020,6/16/2020,6/16/2020,,,,3,COVID-19,12364,Yes,141,"Birmingham - Alabama; Chandler - Arizona; Mesa - Arizona; Tempe - Arizona; Tucson - Arizona; Rogers - Arkansas; Canoga Park - California; La Mesa - California; La Palma - California; Long Beach - California; Los Angeles - California; Mission Hills - California; Montclair - California; Northridge - California; Oxnard - California; Sacramento - California; San Francisco - California; Santa Monica - California; Stanford - California; Torrance - California; Aurora - Colorado; Colorado Springs - Colorado; Washington - District of Columbia; Boca Raton - Florida; Clearwater - Florida; DeLand - Florida; Fort Pierce - Florida; Gainesville - Florida; Hialeah - Florida; Jacksonville - Florida; Lakeland - Florida; Loxahatchee Groves - Florida; Maitland - Florida; Miami - Florida; Orlando - Florida; Pensacola - Florida; Saint Petersburg - Florida; Sarasota - Florida; Tampa - Florida; West Palm Beach - Florida; Winter Haven - Florida; Winter Park - Florida; Atlanta - Georgia; Augusta - Georgia; Columbus - Georgia; Decatur - Georgia; Eatonton - Georgia; Marietta - Georgia; Sandy Springs - Georgia; Chicago - Illinois; Downers Grove - Illinois; Urbana - Illinois; Indianapolis - Indiana; Ames - Iowa; Iowa City - Iowa; Louisville - Kentucky; Lake Charles - Louisiana; Marrero - Louisiana; Metairie - Louisiana; New Orleans - Louisiana; Shreveport - Louisiana; Baltimore - Maryland; Boston - Massachusetts; Detroit - Michigan; Grand Rapids - Michigan; Royal Oak - Michigan; Minneapolis - Minnesota; Rochester - Minnesota; Gulfport - Mississippi; Jackson - Mississippi; Chesterfield - Missouri; Hazelwood - Missouri; Saint Louis - Missouri; Lincoln - Nebraska; Omaha - Nebraska; Las Vegas - Nevada; Englewood - New Jersey; Hackensack - New Jersey; Morristown - New Jersey; Neptune - New Jersey; Newark - New Jersey; Pennington - New Jersey; Ridgewood - New Jersey; Summit - New Jersey; Teaneck - New Jersy; Albuquerque - New Mexico; Bronx - New York; Brooklyn - New York; Buffalo - New York; Jamaica - New York; New York - New York; Rochester - New York; Syracuse - New York; West Islip - New York; White Plains - New York; Chapel Hill - North Carolina; Charlotte - North Carolina; Concord - North Carolina; Durham - North Carolina; Fayetteville - North Carolina; Greensboro - North Carolina; Raleigh - North Carolina;  Wilmington - North Carolina; Winston-Salem - North Carolina; Cincinnati - Ohio; Columbus - Ohio; Dayton - Ohio; Portland - Oregon; Danville - Pennsylvania; Philadelphia - Pennsylvania; Wilkes-Barre - Pennsylvania; Providence - Rhode Island; Charleston - South Carolina; Clinton - South Carolina; Gaffney - South Carolina; Sioux Falls - South Dakota; Chattanooga - Tennessee; Knoxville - Tennessee; Memphis - Tennessee; Nashville - Tennessee;  Amarillo - Texas; Austin - Texas; Bellaire - Texas; Corpus Christi - Texas; Dallas - Texas; Houston - Texas; Pearland - Texas; Red Oak - Texas; San Antonio - Texas; Sugar Land - Texas; Tyler - Texas; Murray - Utah; Salt Lake City - Utah; Charlottesville - Virginia; Falls Church - Virginia; Richmond - Virginia; Everett - Washington; Seattle - Washington; Yakima - Washington; Madison - Wisconsin; Chisinau - Republic of Moldova; Bucuresti, Romania",6/16/2020,11/25/2020,11/25/2020,https://clinicaltrials.gov/ct2/show/NCT04425629  https://clinicaltrials.gov/ct2/show/NCT04452318   https://clinicaltrials.gov/ct2/show/NCT04519437?term=REGN10933&draw=2&rank=1   https://clinicaltrials.gov/ct2/show/NCT04426695?term=REGN10933%2BREGN10987+placebo&recrs=a&draw=2,,844-734-6643,COVID19SiteInterest@regeneron.com,,,,,Matthew,4/1/2020,,,,,,4/1/2020
8,Yes,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody,https://www.regeneron.com/covid19,,https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody,,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9,No,Vaxart Vaccine,,Vaxart Vaccine,Vaxart,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,,New,Emergent,United States,Ongoing,Oral tablet. Recombinant vaccine. Plan to initiate Phase I trial in second half of 2020.,,Discovery,,3/18/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,3/30/2020,,,,,,3/30/2020
9,Yes,,,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10,No,University of Queensland Vaccine,,University of Queensland Vaccine,University of Queensland,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,,New,CEPI; The Queensland Government; Paul Ramsay Foundation; a2 Milk Company,Australia,Ongoing,Plans for clinical trials in July in Queensland.,,Phase 1,,1/24/2020,,,,,7/14/2020,,,,,,1,COVID-19,120,Yes,1,Herston - Australia,7/13/2020,,,https://clinicaltrials.gov/ct2/show/NCT04495933?term=University+of+Queensland&recrs=a&cond=covid&draw=2&rank=3,Dr Paul Griffin,61 402077302,p.griffin@nucleusnetwork.com.au,,,,,Matthew,3/30/2020,,,,,,3/30/2020
10,Yes,University of Queensland Vaccine,University of Queensland Vaccine,,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,,,,,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,,,,,,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,,,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true,,,,,,,,,,,,
11,No,VIDO-InterVac Vaccine Candidate,,VIDO-InterVac Vaccine Candidate,International Vaccine Centre; University of Saskatchewan; VIDO-InterVac,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,Canadian Federal Government,Canada,Ongoing,,,Pre-Clinical Testing,,2/1/2020,ONGOING,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,3/29/2020,A. Burnett,4/9/2020,Matthew,5/31/2020,,5/31/2020
11,Yes,https://www.technologynetworks.com/tn/news/12m-awarded-for-new-covid-19-vaccine-manufacturing-efforts-332506,https://www.technologynetworks.com/tn/news/12m-awarded-for-new-covid-19-vaccine-manufacturing-efforts-332506,,,https://www.cbc.ca/news/health/coronavirus-covid-19-vido-intervac-saskatchewan-vaccine-1.5508114?__vfz=medium%3Dsharebar,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
12,No,ChAdOx1 nCoV-19; AZD1222 ,,ChAdOx1 nCoV-19; AZD1222 ,AstraZeneca; Jenner Institute; Oxford Vaccine Group; ,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,University of Oxford,United Kingdom,Ongoing,,,Phase 3,,,,,,,3/20/2020,4/23/2020,5/28/2020,,,,3,COVID-19,68296,Yes,90,"Instituto D'or de Pesquisa e Ensino - Salvador - Brazil - Instituto D'Or de Pesquisa e Ensino - Rio de Janeiro - Brazil; Centro de Referência para Imunobiológicos Especiais da Universidade Federal de São Paulo - Sao Paulo - Brazil; PHRU Kliptown - Johannesburg - South Africa; Soweto Clinical Trials Centre - Johannesburg - South Africa; Wits RHI Shuandukani Research Centre - Johannesburg - South Africa; Setshaba Research Centre - Soshanguve - South Africa; Chris Hani Baragwanath Academic Hospital - Soweto - South Africa; FAMCRU - Cape Town - South Africa; Groote Schuur Hospital - Cape Town - South Africa; Fukuoka-shi - Japan; Hachioji-shi - Japan; Minato-ku - Japan; Sumida-ku, Japan; Toshima-ku, Japan; Birmingham - Alabama; Phoenix - Arizona; Little Rock - Arkansas - Los Angeles - California; San Diego - California; San Francisco - California; Torrance - California; Atlantis - Florida; Coral Gables - Florida; Miami Lakes - Florida; Orlando - Florida; Savannah Georgia - Stockbridge - Georgia; Honolulu - Hawaii; Chicago - Illinois; Indianapolis - Indiana; Ankeny - Iowa; Kansas City - Kansas; Wichita - Kansas; Lake Charles - Louisiana; Monroe - Louisiana; Baltimore - Marlyand; Bethesda - Marlyand; Boston - Massachusetts; Ann Arbor - Michigan; Bloomington - Minnesota; Butte - Montana; Omaha - Nebraska; Henderson - Nevada; Portsmouth - New Hampshire; Berlin - New Jersey; New York - New York; Rochester - New York; Valhalla - New York; Durham - North Carolina; Fargo - North Dakota; Cincinnati - Ohio; Columbus - Ohio; Oklahoma City - Oklahoma; Portland - Oregon; Pittsburgh - Pennsylvania; Warwick - Rhode Island; Charleston - South Carolina; Spartanburg - South Carolina; Dakota Dunes - South Dakota; Austin - Texas; Dallas - Texas; Houston - Texas; San Antonio - Texas; The Woodlands - Texas; West Jordan - Utah; Burlington - Vermont; Seattle - Washington; Madison - Wisconsin;",5/28/2020,8/1/2021,8/1/2021,https://clinicaltrials.gov/ct2/show/NCT04324606  https://clinicaltrials.gov/ct2/show/NCT04444674    https://clinicaltrials.gov/ct2/show/NCT04400838 https://www.clinicaltrials.gov/ct2/show/NCT04536051   https://www.clinicaltrials.gov/ct2/show/NCT04444674  https://www.clinicaltrials.gov/ct2/show/NCT04568031   https://www.clinicaltrials.gov/ct2/show/NCT04516746  ,,,vaccinetrials@ndm.ox.ac.uk,https://www.coronaviruspreventionnetwork.org/,For United States: https://www.coronaviruspreventionnetwork.org/;  For Brazil: 01865 611424 vaccinetrials@ndm.ox.ac.uk     ,,,Arshy,3/29/2020,A. Burnett,4/9/2020,Priya Kaur,6/18/2020,,6/18/2020
12,Yes,ChAdOx1,ChAdOx1,https://economictimes.indiatimes.com/news/international/world-news/oxford-university-begins-enrolling-over-500-volunteers-for-coronavirus-vaccine-trial/articleshow/74864754.cms,https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development,https://www.clinicaltrials.gov/ct2/show/NCT04324606,COVID-19,,,,,,,,,,,,,,,,,,,,,,https://www.jackfm.co.uk/news/oxfordshire-news/oxford-uni-clinical-trials-for-covid-19-vaccine-could-begin-next-month/,,,,,https://www.gov.br/pt-br/noticias/saude-e-vigilancia-sanitaria/2020/08/brasil-possui-quatro-estudos-clinicos-de-vacinas-contra-o-coronavirus,,,,,,,,,,,,,,,,,,,
13,No,NIV Pune Vaccine Candidate,,NIV Pune Vaccine Candidate,National Institute of Virology-Pune,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,,India,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,3/29/2020,A. Burnett,4/9/2020,Matthew,5/31/2020,,5/31/2020
13,Yes,https://www.livemint.com/news/india/covid-19-india-becomes-5th-country-globally-to-isolate-virus-strain-11584102221498.html,https://www.livemint.com/news/india/covid-19-india-becomes-5th-country-globally-to-isolate-virus-strain-11584102221498.html,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14,No,Chinese CDC Vaccine,,Chinese CDC Vaccine,Chinese Center for Disease Control and Prevention; Tongji University School of Medicine; Stermirna Therapeutics Co. Ltd,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Unknown,New,Stermirna Therapeutics Co. Ltd,China,Ongoing,Animal Testing,,Pre-Clinical Testing,,1/24/2020,2/10/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/1/2020,A. Burnett,4/9/2020,,,,4/9/2020
14,Yes,,,,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15,No,DelNS1-SARS-CoV2-RBD LAIV,,DelNS1-SARS-CoV2-RBD LAIV,University of Hong Kong,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,,New,CEPI; Xiamen University; Changchun-Baike; Hualan-Bio; Beijing Wantai; Sinovac; CNBG,China,Ongoing,Live-attenuated vaccine. Plans for clinical trials in July. Proof of concept testing done using MeRS-CoV and various animal models.,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,3/30/2020,,,,,,3/30/2020
15,Yes,DelNS1-SARS-CoV2-RBD LAIV,DelNS1-SARS-CoV2-RBD LAIV,,https://fightcovid19.hku.hk/hku-state-key-laboratory-for-emerging-infectious-diseases-joins-global-effort-to-develop-covid-19-vaccine/,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,,https://www.hku.hk/press/news_detail_20788.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16,No,CureVac Vaccine; CVnCoV,,CureVac Vaccine; CVnCoV,CureVac AG,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Unknown,New,CEPI,Germany,Ongoing,Not named yet; 2 products currently undergoing animal studies; plan to start a clinical trial in early summer,,Phase 3,,,,,,,6/15/2020,8/17/2020,12/14/2020,,,,3,COVID-19,37444,Yes,5,University Hospital Tübingen Institut für Tropenmedizin - Tübingen- Germany; Panama city - Panama; München - Bavaria - Germany; Hannover - Germany; Ghent - Belgium,12/14/20,3/5/2021,3/4/2023,https://clinicaltrials.gov/ct2/show/NCT04652102 https://www.clinicaltrials.gov/ct2/show/NCT04449276  https://www.clinicaltrials.gov/ct2/show/NCT04515147,,(+49) 69 76805870,clinicaltrials@curevac.com,,,,,Okezi,4/1/2020,A. Burnett,4/9/2020,,,,4/9/2020
16,Yes,,,,https://www.curevac.com/news/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide,,COVID-19,,,,https://www.curevac.com/our-pipeline,,,https://www.youtube.com/watch?v=1ZMWJJyoK7A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17,No,Ad5-nCoV,,Ad5-nCoV,CanSino Biologics Inc.,Vaccine - Prophylactic,COVID-19,Gene therapies,Other,New,Institute of Biotechnology-Academy of Military Medical Sciences-PLA of China; Jiangsu Province Centers for Disease Control and Prevention; Hubei Provincial Center for Disease Control and Prevention; Tongji Hospital,China,Ongoing,Vaccine candidate is genetically engineered with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein; Immunogenic action; Current study is assessing evaluate the safety reactogenicity and immunogenicity; Active but not recruiting,,Phase 3,,1/1/2020,Completed,,,3/16/2020,3/16/2020,4/12/2020,Target: 9/15/2020,,,,3,COVID-19,47293,Yes,44,"Fundación Socolinsky Centro de Vacunación Proteger - Buenos Aires - Argentina; Hospital Pirovano - Buenos Aires - Argentina; Htal de Alta Complejidad Cuenca Alta Néstor Kirchner - Buenos Aires - Argentina; Hospital Interzonal de Agudos ""San Juan de Dios"" de La Plata - Buenos Aires - Argentina; Hospital Rossi - Buenos Aires - Argentina; Inst. Médico Platense - Buenos Aires - Argentina; Instituto de Investigaciones Clínicas - Buenos Aires - Argentina; Htal Mariano y Luciano de la Vega - Buenos Aires - Argentina; Hospital Houssay - Buenos Aires - Argentina; Hospital Zonal General de Agudos ""Cetrangolo"" - Buenos Aires - Argentina; Instituto Cer - Quilmes - Argentina; Previvax Centro de Vacunación - Córdoba - Argentina; Hospital Dr. Hernan Henriquez Aravena Temuco - Temuco - Chile; CIMER Centro de Investigaciones Medicas Respiratorias Santiago - Providencia - Chile; Hospital San Borja Arriarán Santiago - Santiago - Chile; Clínica Andes Salud Concepción - Concepción - Chile; Hospital de Puerto Montt Dr. Eduardo Schütz Schoroeder Puerto Montt - Puerto Montt - X Región De Los Lagos - Chile; Hospital Base de Osorno - Osorno - Chile; Clinica Alemana de Valdivia Valdivia -  Chile; Centro de investigación Médica Aguascalientes (CIMA) - Aguascalientes - Mexico; Hospital Juárez de México (HJM) - Ciudad de México - Mexico; Instuto de Ciencias Médicas y de la Nutrición Salvador Subirán (INCMNSZ) - Tlalpan - Mexico; Centro de Investigacion Integral MEDIVEST SC - Chhihuahia - Mexico; Hidalgo - Mexico; Instituto Jaliscience de Metabolismo - Guadalajara - Jalisco - Mexico; Asociación de investigación pediátrica y adultos (AINPAD) - Morelia - Mochoacán De Ocampo - Mexico; JM Research - Cuernavaca - Morelos - Mexico; Hospital Metropolitano ""Dr. Bernardo Sepúlveda"" - - Nuevo León - Mexico; Oaxaca site management organization (OSMO) - Oaxaca - Mexico; Centro de Investigación y Avances Médicos Especializados (CIAME) - Cancún -  Mexico; FAICIC - Veracruz - Mexico; Kohler & Milstein Research - Mérida - Mexico; MIRO (Medical Invetigation Research Organisation SC) - Chihuahua - Mexico; Instituto Nacional de Pediatría (INP) - Ciudad de México - Mexico; Instituto de Investigaciones aplicada a las Neurociencias (IIAN) - Durango - Mexico; Administración de Especialistas de Puebla S.C. (UDEP) - Puebla - Mexico; Shifa International Hospital - Pakistan; Shaukat Khanum Memorial Cancer Hospital and Research Centre - Lahore - Pakistan; University of Health Scinces - Lahore - Pakistan; Aga Khan University Hospital - Karachi - Pakistan; The Indus Hospital - Karachi - Pakistan; Ryazan State Medical University - Ryazan'  - Russian Federation; OOO ""Kurator"" - St. Petersburg -  Russian Federation; Research Center Eco-safety - Saint Petersburg - Russian Federation; OOO ""Baltijskaya Meditsina"" - Saint Petersburg - Russian Federation; Research Center Eco-safety - Saint Petersburg - Russian Federation; Federal State Budgetary Institution ""Scientific Research Institute of Influenza named after A. A. Smorodintsev"" of the Ministry of Healthcare of the Russian Federation named after A. A. Smorodintsev"" of the Ministry of Healthcare of the Russian Federation - Saint Petersburg - Russian Federation; Saint Petersburg State Budgetary Healthcare Institution ""City Polyclinic #106"" - Saint Petersburg - Russian Federation; State Budgetary Healthcare Institution of Sverdlovsk Region ""Aramil City Hospital"" - Aramil - Russian Federation; Non-state Institution of Healthcare ""Road Clinical Hospital at Chelyabinsk station of open corporate society ""Russian Railways"" - Chelyabinsk - Russian Federation; Municipal Budgetary Institution ""Central City Clinical Hospital # 6"" - Ekaterinburg - Russian Federation; Moscow State Budgetary Healthcare Institution ""City Polyclinic #2 of the Moscow City Healthcare Department"" - Moscow - Russian Federation; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of Ministry of Healthcare of the Russian Federation (Sechenovsky University) - Moscow - Russian Federation; Private Healthcare Institution ""Clinical Hospital ""RZHD-Meditsina"" of Nizhniy Novgorod"" - Nizhniy Novgorod - Russian Federation; ""Life Benefits Service - Novosibirsk - Russian Federation; OOO ""Clinical and Diagnostic Center ""Ul'tramed"" - Omsk - Russian Federation; Budgetary Institution of Heathcare of Omsk region ""City Clinical Hospital #1 n.a. Kabanova A.N."" - Omsk - Russian Federation; OOO Zvyezdnaya Klinika - Saint Petersburg - Russian Federation; Federal State Budgetary Institution ""Children Scientific and Clinical Centre of Infectional Diseases of Federal Medical and Biological Agency "" - Saint Petersburg - Russian Federation; Federal State Budgetary Educational Institution of Higher Education ""Saratov State Medical University named after V.I. Razumovsky"" the Ministry of Health of the Russian Federation - Clinical hospital n.a. S.R.Mirotvortseva - Saratov - Russian Federation; OOO ""Uromed"" - Smolensk - Russian Federation; OOO ""Medical Scientific and Practical Center"" - Tomsk - Russian Federation; Federal State Budgetary Educational Institution of Higher Education ""Siberia State Medical University"" of the Ministry of Healthcare of the Russian Federation - Tomsk - Russian Federation; State Autonomous Healthcare Institution of Yaroslavl region ""Clinical Emergency Hospital named after N.V. Solovyev"" - Yaroslavl - Russian Federation; Federal State Budgetary Institution ""Scientific Research Institute of Influenza named after A. A. Smorodintsev"" of the Ministry of Healthcare of the Russian Federation - Yaroslavl - Russian Federation; State Budgetary Healthcare Institution of Yaroslavl Region "" Clinical Hospital #2"" - Yaroslavl - Russian Federation; 
",9/15/20,12/30/2021,1/30/2022,https://clinicaltrials.gov/ct2/show/NCT04526990 https://www.clinicaltrials.gov/ct2/show/NCT04540419 https://www.clinicaltrialsarena.com/news/cansino-vaccine-saudi-trial/ https://www.clinicaltrials.gov/ct2/show/NCT04566770  https://www.clinicaltrials.gov/ct2/show/NCT04341389 https://clinicaltrials.gov/ct2/show/NCT04398147 https://www.clinicaltrials.gov/ct2/show/NCT04313127,"Jinbo Gou, MD",86-022-58213600-6051,jinbo.gou@cansinotech.com	,https://clinicaltrials.gov/ct2/show/NCT04526990,"We suggest going to the contact website, scroll down to site location and call/email the site location closest to you directly",,,Okezi,4/1/2020,Andy Zhou,4/7/2020,,,,4/7/2020
17,Yes,Ad5-nCoV,Ad5-nCoV,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,COVID-19,,,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,,https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials  https://www.youtube.com/watch?v=1ZMWJJyoK7A,,,,http://www.cansinotech.com/homes/article/show/56/153.html,http://www.cansinotech.com/homes/article/show/56/153.html,,,http://www.cansinotech.com/homes/article/show/56/153.html,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,,,,,clinicaltrialsarena.com/news/cansino-vaccine-saudi-trial/,clinicaltrialsarena.com/news/cansino-vaccine-saudi-trial/,clinicaltrialsarena.com/news/cansino-vaccine-saudi-trial/,clinicaltrialsarena.com/news/cansino-vaccine-saudi-trial/,,,clinicaltrialsarena.com/news/cansino-vaccine-saudi-trial/,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,,,,,,,,
18,No,GeoVax Vaccine,,GeoVax Vaccine,GeoVax Labs Inc.,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,BravoVax,United States,Ongoing,Using existing vaccine platform called GV-MVA-VLP; 3 candidates have been identified; animal trials soon to begin,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/1/2020,Andy Zhou,4/7/2020,,,,4/7/2020
18,Yes,https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program,,https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program,https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program,,COVID-19,,,,,,,https://www.geovax.com/technology-pipeline/pipeline-summary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19,No,CoVLP,,CoVLP,Medicago,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,,Canada,Ongoing,Company developed a virus-derived plant-like particle of SARS-COV-2 that mimics the structure but lacks genetic material,,Phase 3,,2/21/2020,3/12/2020,,,,7/10/2020,,,,,,3,COVID-19,30612,Yes,,Manna Research (Mirabel) - Mirabel - Quebec - Canada; Diex Research Quebec Inc. - Québec - Quebec - Canada; Diex Recherche Joliette - Saint-Charles-Borromée - Quebec - Canada; Q&T Research Sherbrooke Inc. - Sherbrooke - Quebec - Canada; ,7/10/2020,9/12/2020,4/30/2021,https://www.clinicaltrials.gov/ct2/show/NCT04636697 https://www.clinicaltrials.gov/ct2/show/NCT04662697 https://www.clinicaltrials.gov/ct2/show/NCT04450004,Mary Hardison,1(919)666 0737,mary.hardison@syneoshealth.com        ,,"Active, not recruiting",,,James,4/10/2020,Ivanna Leon,5/31/2020,,,,5/31/2020
19,Yes,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,,https://www.biospace.com/employer/541504/medicago-inc-/,Ongoing,https://www.medicago.com/en/pipeline/,,https://clinicaltrials.gov/ct2/show/NCT04450004,,Date calculated from: https://www.businesswire.com/news/home/20200312005345/en/.,https://www.businesswire.com/news/home/20200312005345/en/,,,,https://clinicaltrials.gov/ct2/show/NCT04450004,,,,,,https://clinicaltrials.gov/ct2/show/NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,,https://clinicaltrials.gov/ct2/show/NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,,,,,,,,,,,,
20,No,AdCOVID (based on NasoVax),,AdCOVID (based on NasoVax),Altimmune,Vaccine - Prophylactic,COVID-19,Gene therapies,Vaccine,Repurposed-Not Approved,University of Alabama at Birmingham (UAB),United States,Ongoing,This is a repurposing of the NasoVax technology (recombinant intranasal) for a COVID-19 vaccine; It should be noted that the provided source on Atimmune's Nasovax-based COVID-19 vaccine was published on February 28. Since then there has been no news on the vaccine until March 30 which is when a new article was published stating that Altimmune will collaborate with UAB to develop AdCOVID. Because AdCOVID possesses the same characteristics as the NasoVax analog (recombinant vaccine - single-dose - and intranasal) I believe that this entry should be reclassified as AdCOVID. NasoVax is still currently in a Phase 2a trial so I have opted to classify AdCOVID as a repurposed-not approved product. Currently working on preclinical animal studies and characterization of vaccine immunogenicity; aims to receive IND approval and enable phase 1 by Q3 2020,,Pre-Clinical Testing,,Completed,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Joseph Malinao,4/2/2020,Andy Zhou,4/7/2020,Ivanna Leon,5/31/2020,,5/31/2020
20,Yes,https://www.precisionvaccinations.com/vaccines/nasovax-influenza-vaccine,https://www.precisionvaccinations.com/vaccines/nasovax-influenza-vaccine,https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate,https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single,Vaccine - Prophylactic,COVID-19,Gene therapies,Vaccine,Repurposed-Not Approved,https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate,https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single,Ongoing,https://altimmune.com/nasovax/ https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate,,Pre-Clinical Testing,,https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate,https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
21,No,IBV; Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine,,IBV; Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine,MIGAL Research Institute,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,Repurposed-Not Approved,Israel Innovation Authority;  Health Ministry and the Headquarters of the National Digital Israel Initiative,Israel,Ongoing,Adaption of Avian CoronaVirus Infectious Bronchitis Virus Vaccine for Human Use. This is an adaptation of the IBV vaccine (against poultry coronavirus) for use in humans against COVID-19; IBV vaccine was based on a protein expression vector and the COVID vaccine will likely work in a similar manner; the Israeli ministries plan to accelerate the approval process to bring the vaccine to the market ASAP; MIGAL believes the vaccine could enter Phase 1 by June 1; it is still in the final stages of development due to delays in receiving the genetic construct; MIGAL has begun trials in mice,,Pre-Clinical Testing,,2/27/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joseph Malinao,4/2/2020,Andy Zhou,4/7/2020,Ivanna Leon,5/31/2020,,5/31/2020
21,Yes,,,,https://www.trialsitenews.com/israel-government-announces-13m-covid-19-research-funds-while-migals-claims-a-covid-19-breakthrough/,,COVID-19,https://migal.org.il/en/node/7010,https://migal.org.il/en/node/7010,,https://www.trialsitenews.com/israel-government-announces-13m-covid-19-research-funds-while-migals-claims-a-covid-19-breakthrough/,,,,,https://www.jpost.com/health-science/israeli-scientists-active-component-of-coronavirus-vaccine-days-away-623228,,https://www.jpost.com/health-science/israeli-scientists-active-component-of-coronavirus-vaccine-days-away-623228,https://www.jpost.com/health-science/israeli-scientists-active-component-of-coronavirus-vaccine-days-away-623228,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
22,No,TNX-1800,,TNX-1800,Tonix Pharmaceuticals,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,,United States,Ongoing,Modified horsepox virus designed to express the SARS-CoV-2 spike protein; currently in the pre-clinical stage of development and Tonix expects preliminary data from animal experiments in Q3 2020,,Pre-Clinical Testing,,2/26/2020,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/1/2020,Andy Zhou,4/7/2020,Ivanna Leon,5/31/2020,,5/31/2020
22,Yes,https://www.tonixpharma.com/,https://www.tonixpharma.com/,,,,COVID-19,https://www.tonixpharma.com/news-events/press-releases/detail/1199/tonix-pharmaceuticals-reports-first-quarter-2020-financial,https://www.tonixpharma.com/news-events/press-releases/detail/1199/tonix-pharmaceuticals-reports-first-quarter-2020-financial,https://www.tonixpharma.com/news-events/press-releases/detail/1199/tonix-pharmaceuticals-reports-first-quarter-2020-financial,,https://www.tonixpharma.com/contact,https://www.tonixpharma.com/news-events/press-releases/detail/1195/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year,https://www.tonixpharma.com/news-events/press-releases/detail/1195/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year,,https://www.tonixpharma.com/news-events/press-releases/detail/1195/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year,,https://www.tonixpharma.com/news-events/press-releases/detail/1191/tonix-pharmaceuticals-announces-research-collaboration-with,https://www.tonixpharma.com/news-events/press-releases/detail/1195/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
23,No,Clover Recombinant subunit vaccine,,Clover Recombinant subunit vaccine,Clover Biopharmaceuticals,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Glaxosmithkline; Dynavax,China,Ongoing,,,Phase 1,,Completed,Ongoing,,,,6/19/2020,,,,,,1,COVID-19,150,Yes,1,Linear Clinical Research - Nedlands - Australia,6/19/2020,10/20/2020,3/30/2021,https://clinicaltrials.gov/ct2/show/NCT04405908,Min Dong,86 010 82022300,min.dong@cloverbiopharma.com,,,,,Anusha Joshi,4/1/2020,Tatum Braun,4/11/2020,Ivanna Leon,5/31/2020,,5/31/2020
23,Yes,https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus,https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus,https://www.clinicaltrialsarena.com/comment/clover-biopharmaceuticals-covid-19-vaccine/,,,COVID-19,https://www.clinicaltrialsarena.com/comment/clover-biopharmaceuticals-covid-19-vaccine/,https://www.clinicaltrialsarena.com/comment/clover-biopharmaceuticals-covid-19-vaccine/,https://www.clinicaltrialsarena.com/comment/clover-biopharmaceuticals-covid-19-vaccine/,http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=42,http://www.cloverbiopharma.com/index.php?m=content&c=index&a=lists&catid=51,https://www.clinicaltrialsarena.com/comment/clover-biopharmaceuticals-covid-19-vaccine/,,,https://clinicaltrials.gov/ct2/show/NCT04405908,,https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,https://clinicaltrials.gov/ct2/show/NCT04405908,,,,,,https://clinicaltrials.gov/ct2/show/NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,,https://clinicaltrials.gov/ct2/show/NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,,,,,,,,,,,,
24,No,Linear DNA Vaccine,,Linear DNA Vaccine,Applied DNA Sciences; Takis Biotech; Linearx Inc.,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Applied DNA Sciences; Takis Biotech,United States; Rome - Italy,Ongoing,PCR produced linear DNA vaccine,,Pre-Clinical Testing,,Completed,3/18/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Azmi,4/1/2020,Tatum Braun,4/11/2020,Ivanna Leon,5/31/2020,,5/31/2020
24,Yes,,,,https://adnas.com/coronavirus-preclinical-trials-italy-ministry-health/,,COVID-19,https://adnas.com/coronavirus-preclinical-trials-italy-ministry-health/,https://adnas.com/coronavirus-preclinical-trials-italy-ministry-health/,https://adnas.com/coronoavirus-applied-dna-linearx-takis-biotech-vaccine/,https://adnas.com/coronoavirus-applied-dna-linearx-takis-biotech-vaccine/,https://adnas.com/coronoavirus-applied-dna-linearx-takis-biotech-vaccine/,,https://adnas.com/coronavirus-preclinical-trials-italy-ministry-health/,,,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
25,No,Predictive Oncology Vaccine AI Platform,,Predictive Oncology Vaccine AI Platform,Predictive Oncology,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,Soluble Therapeutics,United States,Ongoing,Vaccine will be based on a new self-assembling nanoparticle technology called Non Specific Protein (NSP)-10,,Discovery,,3/12/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,James,4/10/2020,Ivanna Leon,5/31/2020,,,,5/31/2020
25,Yes,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,https://www.pharmaceutical-technology.com/news/predictive-oncology-covid-19-vaccine/,https://www.globenewswire.com/news-release/2020/05/06/2028420/0/en/Predictive-Oncology-and-Dr-Daniel-Carter-Collaborating-to-Develop-a-Potential-COVID-19-Vaccine-Utilizing-Novel-Nanoparticle-Vaccine-Platform-Based-on-NSP-10.html,https://www.globenewswire.com/news-release/2020/05/06/2028420/0/en/Predictive-Oncology-and-Dr-Daniel-Carter-Collaborating-to-Develop-a-Potential-COVID-19-Vaccine-Utilizing-Novel-Nanoparticle-Vaccine-Platform-Based-on-NSP-10.html,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,https://www.globenewswire.com/news-release/2020/05/06/2028420/0/en/Predictive-Oncology-and-Dr-Daniel-Carter-Collaborating-to-Develop-a-Potential-COVID-19-Vaccine-Utilizing-Novel-Nanoparticle-Vaccine-Platform-Based-on-NSP-10.html,,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,James,4/11/2020,,,,,,4/11/2020
26,No,AJ Vaccines; S protein Vaccine,,AJ Vaccines; S protein Vaccine,AJ Vaccines,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,,Denmark,Ongoing,the vaccine being developed is an S protein vaccine,,Pre-Clinical Testing,,Completed,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/1/2020,Tatum Braun,4/11/2020,Ivanna Leon,5/31/2020,,5/31/2020
26,Yes,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,https://ajvaccines.com/news/,https://ajvaccines.com/news/,https://ajvaccines.com/news/,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://ajvaccines.com/news/,https://ajvaccines.com/news/,,https://ajvaccines.com/news/,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum Braun,4/11/2020,,,,4/11/2020
27,No,remdesivir,remdesivir,GS-5734,Gilead Sciences Inc,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Not Approved,Gilead Sciences,United States,On Market,Other trials undertaken by NIAD-USA; INSERM-France; China Japanese friendship hospital; No of study is increasing rapidly,,On Market,,,,,,,,,3/15/2020,,5/1/2020,,,,,,,,,,,,,,,,,,,Okezi,4/1/2020,Tatum Braun,4/11/2020,Ivanna Leon,5/31/2020,,5/31/2020
27,Yes,remdesivir,remdesivir,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w,https://www.gilead.com/purpose/advancing-global-health/covid-19,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w,https://www.drugbank.ca/drugs/DB14761,,https://www.gilead.com/utility/contact,https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials#,https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials,,https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials#,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04292730,,,,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/record/NCT04292730,,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,,,https://clinicaltrials.gov/ct2/show/record/NCT04292730,,,,,,https://clinicaltrials.gov/ct2/show/NCT04292730,,,,,,,,,
28,No,lopinavir; ritonavir,lopinavir; ritonavir,Kaletra; Aluvia,AbbVie,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,AbbVie,Multiple,Ongoing,Unclear what to do with this one - abbvie is not the sponsor but is the manufacturer of the drug. Some studies are published: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true; https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.full.pdf. Note that for the highest study there were multiple phase 4 so I picked the largest one that had already started recruiting,,Phase 4,,,,,,,,,,,,,4,COVID-19,400,No,1,Wuhan - China,02/01/2020,06/01/2020,07/01/2020,https://clinicaltrials.gov/ct2/show/NCT04255017,Qing Ning,,qning@vip.sina.com,,,,,James,4/2/2020,Ivanna Leon,5/31/2020,,,,5/31/2020
28,Yes,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/factsheet-coronavirus-030420.pdf,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true,COVID-19,https://www.drugbank.ca/drugs/DB01601; https://www.drugbank.ca/drugs/DB01601,https://www.kaletra.com/,https://www.drugbank.ca/drugs/DB01601; https://www.drugbank.ca/drugs/DB01601,https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/factsheet-coronavirus-030420.pdf,,,,,,,,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04255017?term=lopinavir+ritonavir&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04255017?term=lopinavir+ritonavir&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,,,,,,,,,,,,,,,
29,No,Sarilumab,Sarilumab,Kevzara,Regeneron; Sanofi,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Unites States,Ongoing,,,Phase 3,,,,,,,,3/16/2020,,,,,,,,,,,,,,,,,,,COMPLETED,,,James,4/2/2020,Ivanna Leon,5/31/2020,,,,5/31/2020
29,Yes,https://www.drugbank.ca/drugs/DB11767,https://www.drugbank.ca/drugs/DB11767,https://www.drugbank.ca/drugs/DB11767,http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19,http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19,COVID-19,https://www.drugbank.ca/drugs/DB11767,https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical,https://www.drugbank.ca/drugs/DB11767,,https://www.google.com/search?rlz=1C5CHFA_enGB854GB854&sxsrf=ALeKk022og2HFqxgB2OGNk6Vdmns2VRRhQ%3A1585861871624&ei=71SGXuTZJYKvggfAjrv4BA&q=regeneron+&oq=regeneron+&gs_lcp=CgZwc3ktYWIQAzIICAAQgwEQkQIyBAgAEEMyBQgAEIMBMgUIABCDATIFCAAQgwEyBQgAEIMBMgIIADICCAAyBQgAEIMBMgUIABCDAToECAAQRzoECCMQJzoFCAAQkQI6BwgAEBQQhwJQ2U1Y2ltgp1xoAHABeACAAYYBiAGSB5IBAzYuM5gBAKABAaoBB2d3cy13aXo&sclient=psy-ab&ved=0ahUKEwikjZXs08roAhWCl-AKHUDHDk8Q4dUDCAs&uact=5,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2,,,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,James,4/3/2020,,,,,,4/3/2020
30,No,hydroxychloroquine,hydroxychloroquine,Plaquenil; Hydroquin; Axemal; Dolquine; Quensyl; Quinoric,Sanofi SA; Amneal Pharmaceuticals INc.; Rising Pharma Holdings Inc.; University of Minnesota; University of Oxford; IHU-Méditerranée Infection; Sandoz Inc.; Bayer AG; University of Washington; Patient-Centerede Outcomes Research Institute; World Health Organization; New York State Department of Health,Vaccine - Prophylactic,COVID-19,Small molecule,Antimalarial drugs,Repurposed-Approved,Instituto de Investigación Marqués de Valdecilla,France,Ongoing,,,Phase 4,,,,,,,,,,,,,4,COVID 19,800,No,,,04/06/2020,11/06/2020,11/06/2020,,Javier Crespo,,javiercrespo1991@gmail.com,,,,,James,4/4/2020,Param Patel,6/2/2020,,,,6/2/2020
30,Yes,hydroxychloroquine,hydroxychloroquine,,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html; https://www.npr.org/sections/coronavirus-live-updates/2020/03/31/824572119/clinical-trials-set-to-determine-if-anti-malaria-drug-effective-against-covid-19,COVID-19,https://www.drugbank.ca/drugs/DB01611,https://www.drugbank.ca/drugs/DB01612,https://www.drugbank.ca/drugs/DB01613,,,,,,,,,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=4,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=5,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=6,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=7,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=8,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=9,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=10,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=11,,,,,,,,,
31,No,TJ003234,TJ003234,TJM2,I-Mab Biopharma,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,,China,Ongoing,AntiBody against GM-CSF. Previously passed a phase 1 trial. INDs submitted for phase II clinical trials in China USA and South Korea.,,Phase 2,,,,,,,Completed,4/11/2020,,,,,2,COVID-19,384,No,8,GW Medical Faculty Associates - Washington - DC; OSF Healthcare Saint Francis Medical Center - Peoria - Illinois; Indiana University Health - Indianapolis - Indiana; Medpharmics - Metairie - Louisiana; Ochsner Medical Center - New Orleans - Louisinia; University of Mississippi Medical Center - Jackson - Mississippi; Oregon Health and Science University - Portland - Oregon; Temple University Hospital - Philadelphia - Pennsylvania,4/11/2020,9/1/2020,9/1/2020,https://clinicaltrials.gov/ct2/show/NCT04341116,,240-767-6981,US.Info@I-MabBiopharma.com,,,,,Matthew,4/1/2020,Param Patel,6/2/2020,,,,6/2/2020
31,Yes,TJ003234,TJ003234,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,https://clinicaltrials.gov/ct2/show/NCT03794180,,http://www.i-mabbiopharma.com/en/article-491.aspx,https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70,https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70,,https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70,,,,,,,https://clinicaltrials.gov/ct2/show/NCT03794180,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
32,No,AT-100,,AT-100,Airway Therapeutics,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,,United States,Ongoing,Recombinant surfactant protein developed to treat bronchopulmonary dysplatia. No timeline for clinical trials.,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/1/2020,Param Patel,6/2/2020,,,,6/2/2020
32,Yes,AT-100,,AT-100,https://www.airwaytherapeutics.com/at-100/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/at-100/,https://www.airwaytherapeutics.com/at-100/,,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
33,No,TZLS-501,,TZLS-501,Tiziana Life Sciences,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,Tiziana Life Sciences; Novimmune,United Kingdom,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,3/29/2020,Anna,,Param Patel,6/2/2020,,6/2/2020
33,Yes,TZLS-501,,TZLS-501,https://www.marketwatch.com/story/uk-biotech-tiziana-life-sciences-says-its-tzls-501-may-be-of-use-in-treating-coronavirus-2020-03-11,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
34,No,OYA1,,OYA1,OyaGen,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,OyaGen,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,3/29/2020,Anna,,Param Patel,6/2/2020,,6/2/2020
34,Yes,OYA1,,OYA1,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
35,No,BPI-002,,BPI-002,BeyondSpring Inc,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,BeyondSpring Inc,United States,Ongoing,Also being considered as a vaccine adjuvant to stimulate long term immunity; Very little information is available on development stages - A patent has been filed for it by the company but it is not clear what that translates to; Information in column T was seen on just one website,,Pre-Clinical Testing,,,3/13/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/2/2020,Anna,,Param Patel,6/2/2020,,6/2/2020
35,Yes,BPI-002,BPI-002,,https://www.biospace.com/article/releases/beyondspring-files-for-patent-protection-on-bpi-002-for-the-treatment-of-viral-infections-including-covid-19/,,COVID-19,,,,https://www.beyondspringpharma.com/otherpipeline/index.aspx,,,https://www.biospace.com/article/releases/beyondspring-files-for-patent-protection-on-bpi-002-for-the-treatment-of-viral-infections-including-covid-19/,,,,,https://adisinsight.springer.com/drugs/800049541,,,,,,,https://www.beyondspringpharma.com/pipelineoverview/index.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,
36,No,Ifenprodil,Ifenprodil,NP-120,Algernon Pharmaceuticals,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,Cascade chemistry,Canada,Ongoing,Therapeutic approach - receptor antagonist; Drug originally evaluated for treatment of Idiopathic Pulmonary Fibrosis,,Phase 2,,,Completed,,,,,6/1/2020,,,,,2,COVID-19,20,No,5,Vale Medical Practice - Brookvale - Australia; Concord Repatriation General Hospital - Concord - Australia; Cairns Hospital - Cairns - Australia; University of Otago - Christchurch - New Zealand; Waikato Hospital - Hamilton - New Zealand,06/2020,03/2021,06/2021,https://clinicaltrials.gov/ct2/show/NCT04318704,Nancy Stewart,,nstewart@gvicds.com,,,,,Okezi,4/2/2020,Anna,,Param Patel,6/2/2020,,6/2/2020
36,Yes,NP-120 (Ifenprodil),NP-120 (Ifenprodil),,https://algernonpharmaceuticals.com/ipf-np-120/,,ARDS,,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,,,,,,,,,
37,No,APN01,,APN01,University of British Columbia; APEIRON Biologics,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,Austrian government,Austria,Ongoing,,,Phase 2,,,,,,,,4/6/2020,,,,,2,COVID-19,200,No,9,Insbruck - Austria; Wien - Austria; Wien - Austria; Copenhagen - Denmark; Herlev - Denmark; Hillerød - Denmark; Hvidovre - Denmark; Hamburg - Germany; München - Germany,04/2020,12/2020,12/2020,https://clinicaltrials.gov/ct2/show/NCT04335136,Sonja Höller,,sonja.hoeller@apeiron-biologics.com,,,,,James,4/10/2020,Param Patel,6/2/2020,,,,6/2/2020
37,Yes,APN01,APN01,,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://clinicaltrials.gov/ct2/show/NCT00886353,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://www.google.com/search?q=apeiron+biologics&rlz=1C5CHFA_enGB854GB854&oq=apeir&aqs=chrome.0.69i59j69i57j0l2j46j69i60l3.1226j0j7&sourceid=chrome&ie=UTF-8,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,,,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,,,,,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,,,,,,,,,,,,,,,
38,No,Brilacidin Tetrahydrochloride,Brilacidin Tetrahydrochloride,Brilacidin,Innovation Pharmaceuticals,Therapeutic,COVID-19,Small molecule,Antibiotics and antiparasitics,Repurposed-Not Approved,Innovation Pharamaceuticals,United States,Ongoing,,,Pre-Clinical Testing,,3/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joseph Malinao,4/2/2020,Param Patel,6/2/2020,,,,6/2/2020
38,Yes,Brilacidin,Brilacidin,https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e5c0bbea72c2f71ab0978ee/1583090668780/IPIX+Brilacidin+Defensin+Mimetics+-+COVID-19+Overview+March+1+2020+update.pdf,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
39,No,leronlimab,leronlimab,PRO-140,CytoDyn,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,RedChip companies,United States,Ongoing,Patient treatment underway via Emergency IND; Phase 2 trial protocol filed,,Phase 2,,,,,,,,,,,,,2,COVID-19,390,No,11,UCLA - Los Angeles - California; Esienhower Health - Rancho Mirage - California; Yale - New Haven - Connecticut; Beth Israel Harvard - Boston - Massachusetts; St Barnabas - Livinston - New Jersey; Altantic Health System Hospital - Morristown - New Jersey; Montefiore Medical Center - Bronx - New York; Novant Health - Winston Salem - North Carolina; Ohio Health - Columbus - Ohio; Oregon Health and Sciences University - Portland - Oregon; University of Texas - Houston - Texas,04/15/2020,12/31/2020,04/01/2021,https://clinicaltrials.gov/ct2/show/NCT04347239,Kush Dhody,301-956-2536,kushd@amarexcro.com,,,,,Anusha Joshi,4/1/2020,Param Patel,6/2/2020,,,,6/2/2020
39,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
40,No,Novel Viral Inhibitor,Novel Viral Inhibitor,BTX-025,BIOXYTRAN,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,New,Bioxytran,United States,Ongoing,Novel galectin inhibitor for use in COVID-19. Currently pre-clinical.,,Discovery,,,3/24/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Azmi,4/1/2020,Param Patel,6/2/2020,Hanna ,5/29/2020,,6/2/2020
40,Yes,Novel Viral Inhibitor,Novel Viral Inhibitor,,https://www.globenewswire.com/news-release/2020/03/24/2005534/0/en/Bioxytran-Licenses-Novel-Viral-Inhibitor-for-COVID-19-Patients.html,https://www.globenewswire.com/news-release/2020/03/24/2005534/0/en/Bioxytran-Licenses-Novel-Viral-Inhibitor-for-COVID-19-Patients.html,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Azmi,3/31/2020,,,,,,3/31/2020
41,No,tocilizumab,tocilizumab,Actemra,Roche,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,Roche,United States,Ongoing,first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA).,,Phase 3,,,,,,,,,3/19/2020,,,,3,COVID-19,450,No,67,,04/03/2020,6/24/20,7/28/20,https://clinicaltrials.gov/ct2/show/NCT04320615,,,,,COMPLETED,,,Azmi,4/1/2020,Hanna ,5/29/2020,,,,5/29/2020
41,Yes,Actemra,Actemra,,,https://www.roche.com/media/releases/med-cor-2020-03-19.htm,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
42,No,BCX4430,BCX4430,Galidesivir,Biocryst Pharmaceuticals,Therapeutic,Other,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,NIAID;BARDA-NIH,United States,Ongoing,Neucleoside analogue for Yellow Fever broad spectrum.,,Phase 1,,,,,,,4/9/2020,,,,,,1,COVID-19,66,No,1,Sao Paulo - Brazil,04/09/2020,5/31/21,05/31/2020,https://clinicaltrials.gov/ct2/show/NCT03891420,,919-859-1302,clinicaltrials@biocryst.com,,,,,Azmi,4/3/2020,Hanna ,5/29/2020,,,,5/29/2020
42,Yes,Galidesivir,Galidesivir,,,http://ir.biocryst.com/news-releases/news-release-details/biocryst-completes-phase-1-clinical-trial-galidesivir,COVID-19,,,https://www.drugbank.ca/drugs/DB11676,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT03891420?term=Galidesivir&cond=COVID&draw=2&rank=1,,,,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT03891420?term=Galidesivir&cond=COVID&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03891420?term=Galidesivir&cond=COVID&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03891420?term=Galidesivir&cond=COVID&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03891420?term=Galidesivir&cond=COVID&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03891420?term=Galidesivir&cond=COVID&draw=2&rank=1,,,,https://www.clinicaltrials.gov/ct2/show/NCT03891420?term=Galidesivir&cond=COVID&draw=2&rank=1,,,,,,,,,,,,,,,
43,No,REGN10933+REGN10987; REGN-COV2,,REGN10933+REGN10987; REGN-COV2,Regeneron,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,There is conflicting information. I found a trial that used these drugs for MERS suggesting it is reporpused-not approved but here it says they are starting a first in human trial: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/ -- The combination of neutralising monoclonal antibodies REGN3048 and REGN3051 is being studied against coronavirus infection in a first-in-human clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).,,Phase 3,,,,,,,,,,,,,3,COVID-19,2000,Yes,107,,6/30/2020,4/11/2021,4/11/2021,https://clinicaltrials.gov/ct2/show/NCT04452318,844-734-6643,,COVID19SiteInterest@regeneron.com,,,,,James,4/10/2020,Hanna ,5/29/2020,,,,5/29/2020
43,Yes,REGN3048-3051,REGN3048-3051,,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://clinicaltrials.gov/ct2/show/NCT03301090?term=REGN3048&draw=2&rank=1,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://www.google.com/search?q=regeneron&rlz=1C5CHFA_enGB854GB854&oq=regeneron&aqs=chrome..69i57j0l3j69i60l4.1356j0j7&sourceid=chrome&ie=UTF-8,,https://clinicaltrials.gov/ct2/show/NCT03301090?term=REGN3048&draw=2&rank=1; https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,,Implied P1 from first in human here: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
44,No,Interferon beta,Interferon beta,SNG001,Synairgen Research,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,Public funding through shares,United Kingdom,Ongoing,inhaled forumation of beta-1a interferon,,Phase 2,,,,,,,,3/16/2020,,MHRA and HRA approval,,,,,,,,,,,,,,,,,,,,Zain,4/2/2020,Hanna ,5/29/2020,,,,5/29/2020
44,Yes,https://www.synairgen.com/covid-19/,,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.morningstar.co.uk/uk/news/AN_1585205934091906300/synairgen-raises-cash-to-go-towards-covid-19-drug-trial.aspx,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,,https://www.synairgen.com/covid-19/,,,,,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,,https://www.clinicaltrialsarena.com/news/cansino-synairgen-covid-19-trials/,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,,,,,,,,,,,,,,,,,,
45,No,AmnioBoost,,AmnioBoost,Lattice Biologics,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,Lattice Biologics,United States,Ongoing,,,Phase 1,,,,,,,3/17/2020,,,,,,1,COVID-19,10,No,1,Seattle - USA,03/17/2020,,,,,,,,,,,Zain,4/2/2020,Hanna ,5/29/2020,,,,5/29/2020
45,Yes,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,,,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,,,,,,,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,,,,,,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,,,,,,,,,,,,,,,,,,
46,No,Enanta Therapeutic,,Enanta Therapeutic,Enanta Pharmaceuticals,Therapeutic,COVID-19,Unknown,Antiviral drugs-not specified,New,Enanta Pharmaceuticals,United States,Ongoing,direct acting antiviral; Starting phase II study for RSV patients,,Discovery,,3/13/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/2/2020,Hanna ,5/29/2020,,,,5/29/2020
46,Yes,,,,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx; https://www.pharmaceutical-technology.com/news/enanta-pharmaceuticals-covid-19-drugs/,,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
47,No,COVID-HIG,,COVID-HIG,Emergent BioSolutions,Therapeutic,COVID-19,Unknown,Other,New,US Government; BARDA; ASPR,,Ongoing,Manufactured using plasma donations from people who have recovered from COVID19 with antibodies; human hyperimmune product; NIAID has agreed to include COVID-HIG product candidate in one of its clinical studies of treatment of COVID-19 upon availability of clinicla material.,,Discovery,,4/2/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hanna ,5/29/2020,,,,,,5/29/2020
47,Yes,,,,,,COVID-19,,https://www.biospace.com/article/releases/emergent-biosolutions-partners-with-u-s-government-for-comprehensive-response-to-expedite-development-of-plasma-derived-therapy-for-covid-19/,https://www.biospace.com/article/releases/emergent-biosolutions-partners-with-u-s-government-for-comprehensive-response-to-expedite-development-of-plasma-derived-therapy-for-covid-19/,https://www.biospace.com/article/releases/emergent-biosolutions-partners-with-u-s-government-for-comprehensive-response-to-expedite-development-of-plasma-derived-therapy-for-covid-19/,,,https://www.biospace.com/article/releases/emergent-biosolutions-partners-with-u-s-government-for-comprehensive-response-to-expedite-development-of-plasma-derived-therapy-for-covid-19/; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,No,LEAPS COVID-19,,LEAPS COVID-19,CEL-SCI,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,CEL-SCI; University of Georgia’s (UGA’s) Center for Vaccines,USA,Ongoing,immunotherapy,,Phase 1,,1/3/2020,3/23/2020,,,,,,,,,,1,COVID-19,,,,,,,,,,,,,,,,Ekaterina Zvorykina,4/2/2020,Hanna ,5/29/2020,,,,5/29/2020
48,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
49,No,Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG),Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG),TAK-888,Takeda Pharmaceutical Company,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,Takeda Pharmaceutical Company,Japan,On Hold,a plasma-derived therapy,,Phase 1,,3/6/2020,,,,,,,,,,,1,COVID-19,,,,,,,,,,,,,,,,Ekaterina Zvorykina,4/2/2020,Hanna ,5/29/2020,,,,5/29/2020
49,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
50,No,Azithromycin; Hydroxychloroquine,Azithromycin; Hydroxychloroquine,,Pfizer; Intermountain Healthcare; University of Utah Health; Fondation Mediterranee Infection,Therapeutic,COVID-19,Other,Antibiotics and antiparasitics,Repurposed-Not Approved,Pfizer,USA,Ongoing,,,Discovery,,,,,,,,,,,,,,COVID-19,20,No,,,,,,,,,,,,,,Ekaterina Zvorykina,4/2/2020,Andrew Chen,5/31/2020,,,,5/31/2020
50,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,https://pfe-pfizercom-prod.s3.amazonaws.com/news/ZithroComboStatement.pdf,https://pfe-pfizercom-prod.s3.amazonaws.com/news/ZithroComboStatement.pdf,https://pfe-pfizercom-prod.s3.amazonaws.com/news/ZithroComboStatement.pdf,,,https://pfe-pfizercom-prod.s3.amazonaws.com/news/ZithroComboStatement.pdf,,,,,,,,,,,,,,,,,,,
51,No,OT-101,,OT-101,Mateon Therapeutics,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Other,Repurposed-Not Approved,,United States,Ongoing,Appears to still be in vitro testing,,Pre-Clinical Testing,,,3/18/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Daisy,,James,4/10/2020,Andrew Chen,5/31/2020,,5/31/2020
51,Yes,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate,http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate,http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate,,http://investor.mateon.com/,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,,,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,,,http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
52,No,Southwest Research Institute Screening Platform,,Southwest Research Institute Screening Platform,Southwest Research Institute,Therapeutic,COVID-19,Unknown,Other,New,Texas Biomedical Research Institute,United States,Ongoing,Developed Rhodium a novel-structure based virtual screening tool that can help screen millions of drug compounds and speed up preliminary efficacy and safety evaluations,,Discovery,,2/19/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,James,4/10/2020,Andrew Chen,5/31/2020,,,,5/31/2020
52,Yes,,,,https://www.swri.org/swri-covid-19-response-resources,https://www.swri.org/swri-covid-19-response-resources,https://www.swri.org/swri-covid-19-response-resources,https://www.swri.org/swri-covid-19-response-resources,https://www.swri.org/swri-covid-19-response-resources,Assumed given large number of compounds investigated: https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research,https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research,https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research,https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research,https://www.swri.org/sites/default/files/rhodium-covid19-infographic.pdf,,,,https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
53,No,NanoViricides Therapeutic,,NanoViricides Therapeutic,NanoViricides,Therapeutic,COVID-19,Other,Antiviral drugs-not specified,New,,United States,Ongoing,,,Pre-Clinical Testing,,3/16/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,James,4/10/2020,Andrew Chen,5/31/2020,,,,5/31/2020
53,Yes,http://www.nanoviricides.com/,http://www.nanoviricides.com/,,http://www.nanoviricides.com/,http://www.nanoviricides.com/,http://www.nanoviricides.com/,http://www.nanoviricides.com/,http://www.nanoviricides.com/,http://www.nanoviricides.com/,,http://www.nanoviricides.com/,http://www.nanoviricides.com/,,,http://www.nanoviricides.com/,,http://www.nanoviricides.com/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
54,No,VIR-7831,,VIR-7831,Vir Biotechnology Inc.; GSK; Biogen Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Wuxi Biologics; Biogen,United States,Ongoing,2 different modifications of one single clone of antibody originally developed against SARS-CoV-1; shown to act as both vaccine and therapeutic,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/1/2020,Andrew Chen,5/31/2020,,,,5/31/2020
54,Yes,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer; https://www.biospace.com/article/vir-biotechnology-ids-2-monoclonal-antibodies-against-the-covid-19-coronavirus/,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.vir.bio/contact/,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
55,No,VIR-2703; ALN-COV,,VIR-2703; ALN-COV,Alnylam; Vir Biotechnology,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Antiviral drugs-antiretrovirals,New,,United States,Ongoing,350 candidates undergoing in vitro test,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/1/2020,Andrew Chen,5/31/2020,,,,5/31/2020
55,Yes,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,,https://www.vir.bio/contact/,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,,,,,https://investors.alnylam.com/press-release?id=24656,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
56,No,siRNA against  SARS-CoV-2,,siRNA against  SARS-CoV-2,Sirnaomics,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Antiviral drugs-antiretrovirals,New,,United States,Ongoing,150 candidates under in vitro test,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/1/2020,Andrew Chen,5/31/2020,,,,5/31/2020
56,Yes,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,,https://sirnaomics.com/contact-us/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib,,https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib,,,https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
57,No,UPDATE1,UPDATE1,LY3819253; LY-CoV555,AbCellera Biologics; Eli Lilly and Company,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Vaccine Research Centre - NIAID,Canada,Ongoing,Monoclonal antibodies; 500 antibody sequences isolated 03/12/2020,,Discovery,,3/5/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/1/2020,Andrew Chen,5/31/2020,,,,5/31/2020
57,Yes,https://www.genengnews.com/news/to-develop-coronavirus-treatment-lilly-taps-abcellera-antibody-platform/,,https://www.genengnews.com/news/to-develop-coronavirus-treatment-lilly-taps-abcellera-antibody-platform/,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
58,No,BDB-001,,BDB-001,Beijing Defengrei Biotechnology - Staidson,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Staidson (Beijing) Biopharmaceuticals Co. Ltd; InflaRx,China,Ongoing,Anti-C5a Antibody; Phase 2 trial number 2020L0003,,Phase 2,,Repurposed,SKIPPED,SKIPPED,SKIPPED,2/7/2020,SKIPPED,,,,,,2,COVID-19,,No,,,,,,,,,,,,,,Gabbie,4/1/2020,Andrew Chen,5/31/2020,,,,5/31/2020
58,Yes,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,,,,COVID-19,,,https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1.full.pdf,,,,,,https://www.bioworld.com/articles/433447-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads,,,,,,https://www.staidson.com/article/147.html,,https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1,,,,,https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1.full.pdf,,,,,,,,,,,,,,,,,,,,,,,,
59,No,siltuximab,siltuximab,Sylvant,EUSA Pharma,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,Ergomed; Papa Giovanni XXIII Hospital,England,Ongoing,Clinical trial NCT04322188 started but phase UNKNOWN,,,,Repurposed,SKIPPED,SKIPPED,SKIPPED,,,,,,,,,COVID-19,50,No,1,Papa Giovanni XXIII Hospital - Italy,03/19/2020,05/19/2020,,,,,,,,,,Gabbie,4/2/2020,Andrew Chen,5/31/2020,,,,5/31/2020
59,Yes,https://www.clinicaltrialsarena.com/news/eusa-pharma-siltuximab-study-covid-19/,https://www.clinicaltrialsarena.com/news/eusa-pharma-siltuximab-study-covid-19/,,,,COVID-19,,,,,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04322188,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
60,No,47D11,,47D11,Harbour Biomed,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Mount Sinai; Utrecht University; Eurasmus MC,China,Ongoing,Monoclonal antibodies created in lab that target COVID-19 infected cells as well as similar proteins of molecules that cause SARS,,Pre-Clinical Testing,,3/12/2020,3/12/2020,3/12/2020,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/2/2020,Joshuah Yon,5/29/2020,,,,5/29/2020
60,Yes,https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf+html,,https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf+html,,,COVID-19,https://www.nature.com/articles/s41467-020-16256-y#change-history,https://www.bloomberg.com/news/articles/2020-05-04/scientists-create-antibody-that-defeats-coronavirus-in-lab,,,,,https://www.bloomberg.com/news/articles/2020-05-04/scientists-create-antibody-that-defeats-coronavirus-in-lab,,https://www.bloomberg.com/news/articles/2020-05-04/scientists-create-antibody-that-defeats-coronavirus-in-lab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
61,No,PolyTope mAb Therapy,,PolyTope mAb Therapy,ImmunoPrecise Antibodies Ltd; EVQLV,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Canada,Ongoing,Monoclonal antibodies candidates created using AI - computations - and statistics that will target multiple epitopes. 1200 ideal candidates will be chosen and validated in vitro.,,Pre-Clinical Testing,,3/12/2020,3/30/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Rebecca Taylor,4/1/2020,Joshuah Yon,5/29/2020,,,,5/29/2020
61,Yes,,,,https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html,https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html,COVID-19,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,,https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html ; https://www.genengnews.com/covid-19-candidates/immunoprecise-antibodies-ipa-and-evqlv/,,https://www.immunoprecise.com/immunoprecises-artificial-intelligence-partner-evqlv-submits-first-panel-of-optimized-antibody-sequences-to-coronavirus-for-polytope-mab-therapy-program/,,https://www.immunoprecise.com/immunoprecise-announces-the-launch-of-polytope-mab-therapy-tm-to-tackle-coronavirus-pandemic/,https://www.immunoprecise.com/immunoprecises-artificial-intelligence-partner-evqlv-submits-first-panel-of-optimized-antibody-sequences-to-coronavirus-for-polytope-mab-therapy-program/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
62,No,IFX-1,,IFX-1,InflaRx,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,,Germany,Ongoing,Monoclonal antibodies,,Phase 2,,2/1/2020,3/1/2020,,,2/1/2020,3/1/2020,3/31/2020,3/31/2020,,,,2,COVID-19,130,No,3,University Amsterdam - Amsterdam - Netherlands ; University Maastricht - Masstrict - Netherlands,03/31/20,5/31/2021,8/31/2021,https://clinicaltrials.gov/ct2/show/NCT04333420,Korinna Pilz,,korinna.pilz@inflarx.de	,,,,,Rebecca Taylor,4/2/2020,Joshuah Yon,5/29/2020,,,,5/29/2020
62,Yes,,,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,COVID-19,https://www.nature.com/articles/d41587-020-00005-z,https://www.nature.com/articles/d41587-020-00005-z,https://www.inflarx.de/Home/Research---Development/Pipeline.html,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,https://www.nature.com/articles/d41587-020-00005-z,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,,https://www.inflarx.de/Home/Investors/Press-Releases/02-2020-InflaRx-Announces-Positive-Initial-Data-from-Ongoing-Phase-IIa-Open-Label-Study-with-IFX-1-in-Patients-Suffering-from-Pyoderma-Gangraenosum-.html,https://www.inflarx.de/Home/Investors/Press-Releases/02-2020-InflaRx-Announces-Positive-Initial-Data-from-Ongoing-Phase-IIa-Open-Label-Study-with-IFX-1-in-Patients-Suffering-from-Pyoderma-Gangraenosum-.html,,,https://www.genengnews.com/virology/coronavirus/catching-up-to-coronavirus-top-60-treatments-in-development/,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,https://www.nature.com/articles/d41587-020-00005-z,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,,,,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04333420?term=InflaRx&draw=2&rank=5,,,,,,,,,4/3/2020,,,,,,4/3/2020
63,No,Plitidepsin,Plitidepsin,Aplidin,Pharmamar; Centro Nacional Biotecnologia,Therapeutic,COVID-19,Small molecule,Antiviral drugs-immunosupressive,Repurposed-Approved,CSIC,Spain,Ongoing,Anti-melanoma agent ; Currenlt approved in Australia for the treatment of multiple myeloma and demonstrated antiviral activity in vitro; Protcol for Phase 2 clinical trial for COVID-19 treatment was submitted on 04/02/2020 and is being evaluated.,,Phase 2,,2/1/2020,3/13/2020,,,,3/1/2020,4/1/2020,,,,,2,COVID-19,,No,,Spanish Hospitals,04/00/2020,,,,,,,,,,,Rebecca Taylor,4/2/2020,Joshuah Yon,5/29/2020,,,,5/29/2020
63,Yes,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,,COVID-19,https://www.drugbank.ca/drugs/DB04977,https://www.researchgate.net/publication/26280244_The_mechanism_of_action_of_plitidepsin,https://www.pharmamar.com/wp-content/uploads/2018/12/PR_Approval-APLIDIN-Australia.pdf,https://www.oncozine.com/plitidepsin-a-novel-anti-cancer-agent-possibly-active-against-covid18/,http://pharmamar.com/?lang=en,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505631/ ; http://pharmamar.com/wp-content/uploads/2020/04/PR_clinical_trial_plitidepsin_covid19_DEF.pdf,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,https://www.thepharmaletter.com/article/pharmamar-says-its-drug-aplidin-could-treat-covid-19,https://www.contractpharma.com/contents/view_breaking-news/2020-03-13/pharmamar-reports-positive-results-for-aplidin-against-coronavirus/,,,,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,,,,,,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,,,,,,,,,,,,,,,,,
64,No,Danoprevir ; Ritonavir,Danoprevir ; Ritonavir,Ganovo,Ascletis Pharma,Therapeutic,COVID-19,Small molecule,Protease Inhibitor,Repurposed-Approved,Shaoxing Government,China,Ongoing,Danoprevir has been approved in China for treatment of Hepititis C ; Ritonavir is found in a combination FDA-approved product for treamtent of Hepititis C virus ; A Phase 4 clinical trial was completed by no results have been posted ; 2nd Phase 4 clinical trial is currently underway.,,Phase 4,,,,,,1/25/2020,2/27/2020,3/10/2020,,,,,,,,,,,,,,,,,,,,,,Rebecca Taylor,4/2/2020,Joshuah Yon,5/29/2020,,,,5/29/2020
64,Yes,,,,https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/,https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/,https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/,https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/,https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/,https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/,https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/,https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/,https://www.clinicaltrialsarena.com/news/ascletis-pharma-coronavirus-pneumonia-study/,https://pubmed.ncbi.nlm.nih.gov/30117020/ ; https://clinicaltrials.gov/ct2/show/NCT04291729?term=Ganovo&draw=1&rank=1 ; https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345276?term=Ganovo&draw=1&rank=2,,,,,,,,,,,,,,,
65,No,LUNAR-COV19,,LUNAR-COV19,Arcturus,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Duke-National University of Singapore,United States,Ongoing,mRNA vaccine. They color code where in the pipeline their drugs are. Someone who can tell shades of blue apart better than me should double check their current status. On 05/08/2020 preclinical data was reported to have strong support for human vaccine clinical trials to begin this summer.,,Phase 2,,3/27/2020,5/8/2020,,,,8/11/2020,8/11/2020,,,,,1/2,COVID-19,92,Yes,1,SingHealth Investigational Medicine Unit Singapore General Hospital - Singapore - Singapore;,8/4/2020,12/2020,1/2021,https://clinicaltrials.gov/ct2/show/NCT04480957,"Steve Hughes, MD",858-900-2660,steveh@arcturusrx.com,,,,,Matthew,4/8/2020,Joshuah Yon,5/29/2020,,,,5/29/2020
65,Yes,https://arcturusrx.com/pipeline/#lunarcovid19,,https://arcturusrx.com/pipeline/#lunarcovid19,,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,https://www.globenewswire.com/news-release/2020/03/27/2007544/0/en/Arcturus-COVID-19-Vaccine-to-Benefit-from-Duke-NUS-Genetic-Correlation-System.html,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19 ;  https://www.genengnews.com/covid-19-candidates/arcturus-therapeutics-and-duke-nus/,,https://arcturusrx.com/pipeline/#lunarcovid19 ; https://www.genengnews.com/covid-19-candidates/arcturus-therapeutics-and-duke-nus/ ; https://www.globenewswire.com/news-release/2020/05/08/2030402/0/en/Arcturus-Reports-Additional-Supportive-Preclinical-Data-for-its-COVID-19-Vaccine-Candidate-LUNAR-COV19.html,,https://www.globenewswire.com/news-release/2020/03/27/2007544/0/en/Arcturus-COVID-19-Vaccine-to-Benefit-from-Duke-NUS-Genetic-Correlation-System.html,https://www.globenewswire.com/news-release/2020/05/08/2030402/0/en/Arcturus-Reports-Additional-Supportive-Preclinical-Data-for-its-COVID-19-Vaccine-Candidate-LUNAR-COV19.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
66,No,Favipiravir,Favipiravir,Avigan; favilavir; T-705,Fujifilm; Peking University First Hospital;,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,,Japan,Ongoing,Japan has stockpile of 2 million ; Interim clinical test reports no clear efficiency so Japan has given up fasttracking approval. Clinical studies will still continue to show efficacy.,,Phase 4,,,,,,,,,3/31/2020,,,,,COVID-19,150,No,11,Anhui Medical University Affiliated First Hospital - Hefei - China; Guiqiang Wang - Beijing - China; Peking University First Hospital - Beijing - China; Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology - Wuhan - China; Ezhou Central Hospital - Wuhan - China; Huoshenshan Hospital of Wuhan - Wuhan - China; Jinyintan Hospital of Wuhan - Wuhan - China; Tongji Hospital of Huazhong University of Science and Technology - Wuhan - China; West Hospital Union Hospital Huazhong University of Science and Technology - Wuhan - China; Wuhan Pulmonary Hospital - Wuhan - China; Zhongnan Hospital of Wuhan University - Wuhan - China,3/8/2020,5/31/2020,5/31/2020,,,,,,,,,Matthew,4/1/2020,Joshuah Yon,5/29/2020,,,,5/29/2020
66,Yes,,,,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211 ; https://english.kyodonews.net/news/2020/05/10107f9396b1-breaking-news-japan-gives-up-on-approving-avigan-in-may-minister.html,,https://clinicaltrials.gov/ct2/show/NCT04359615?term=Avigan&phase=3&draw=2&rank=1,,,,,,,,,https://www.fujifilm.com/jp/en/news/hq/3211,,,,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,,https://clinicaltrials.gov/ct2/show/NCT04310228,,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,,,,,,,,,,,,,,,,
67,No,Zydus Cadila DNA plasmid Vaccine,,Zydus Cadila DNA plasmid Vaccine,Zydus Cadila,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,India,Ongoing,Uses a measles vector. They also are working on a DNA vaccine.,,Phase 2,,2/15/2020,4/5/2020,,,7/3/2020,7/15/2020,8/6/2020,,,,,2,COVID-19,1000,Yes,9,,7/13/2020,,,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306,Ravindra Mittal,For India: 07948040000,r.mittal@zyduscadila.com;         makova@hacettepe.edu.tr        ,,,,,Matthew,4/8/2020,Joshuah Yon,5/29/2020,,,,5/29/2020
67,Yes,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://www.indiatoday.in/mail-today/story/zydus-cadila-serum-institute-too-in-the-hunt-for-coronavirus-vaccine-1663434-2020-04-05,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,,https://www.indiatoday.in/mail-today/story/zydus-cadila-serum-institute-too-in-the-hunt-for-coronavirus-vaccine-1663434-2020-04-05,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://www.indiatoday.in/mail-today/story/zydus-cadila-serum-institute-too-in-the-hunt-for-coronavirus-vaccine-1663434-2020-04-05,,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_vaccine_for_COVID-19_ZyCoV-D)_successfully_completes_preclinical_development_and_receives_permission_to_initiate_human_clinical_trials.pdf,https://www.hindustantimes.com/india-news/zydus-cadilla-begins-human-dosing-in-trials/story-WI0sdKieiVMbnWdoAhJ8ZK.html,https://www.hindustantimes.com/india-news/zydus-cadilla-begins-human-dosing-in-trials/story-WI0sdKieiVMbnWdoAhJ8ZK.html,,,,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_vaccine_for_COVID-19_ZyCoV-D)_successfully_completes_preclinical_development_and_receives_permission_to_initiate_human_clinical_trials.pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_vaccine_for_COVID-19_ZyCoV-D)_successfully_completes_preclinical_development_and_receives_permission_to_initiate_human_clinical_trials.pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_vaccine_for_COVID-19_ZyCoV-D)_successfully_completes_preclinical_development_and_receives_permission_to_initiate_human_clinical_trials.pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_vaccine_for_COVID-19_ZyCoV-D)_successfully_completes_preclinical_development_and_receives_permission_to_initiate_human_clinical_trials.pdf,,,,,,,,,,,,,,,,,,,,,
68,No,CoronaVac,,CoronaVac,Sinovac Biotech Ltd.,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,China,Ongoing,"Dynaxax is contributing an adjuvant to boost immune responses in vaccinated patients and Sinovac is contributing an inactivated coronavirus vaccine candidate. Based on a SARS platform. Very little direct information. ""many months"" before its current stage of research is complete. Promise of efficacy has been shown in primates.",,Phase 3,,,,,,,4/16/2020,5/20/2020,7/21/2020,,,,3,COVID-19,29398,Yes,12,"Universidade de Brasilia - Brasilia - Brazil; Universidade Federal de Minas Gerais - Belo Horizonte - Brazil; Hospital das Clinicas da Universidade Federal do Parana - Curitiba - Brazil; Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul - Porto Alegre - Brazil; Hospital da Clinicas da UNICAMP - Campinas - Brazil; Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo - Ribeirao Preto - Brazil; Instituto de Infectologia Emilio Ribas - Sao Paulo - Brazil; Centro de Pesquisa Clinicas do Instituto Central do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - Sao Paulo - Brazil; Instituto Israelita de Ensino e Pesquisa Albert Einstein - Sao Paulo - Brazil; Universidade Municipal de Sao Caetano do Sul - Sao Caetano do Sul - Brazil; Faculdade de Medicina de Sao Jose do Rio Preto - Sao Jose do Rio Preto - Brazil; Instituto de Infectologia Evandro Chagas - Rio de Janeiro - Brazil; Hasan Dikidin Hospital - Bundang - Indonesia; TR Ministry of Health Ankara City Hospital - Ankara - Turkey; TR Ministry of Health Provincia Heath Directorate Ankara Training and Research Hospital - Ankara - Turkey; Ankara University Faculty od Medicine - Ankara - Turkey; Cukurova University Faculty of Medicine - Adana - Turkey; Hacettepe Univercity Faculty of Medicine Department of Infectious Diseases and Clinical Microbiology - Ankara - Turkey; TC Ministry of Health Ankara Provicnial Health Directorate Health SCiences University Ankara Ataturk Chest Disease and Thoracic Surgery Training and Research Hospital - Ankara - Turkey; Bursa Uludag University Faculty of Medicine - Bursa - Turkey; Dicle University Faculty of Medicine - Dyarbakir - Turkey; Gaziantep University Faculty of Medicine - Gaziantep - Turkey; Acibadem Atakent Hospital - Istanbul - Turkey; Altinbas University Medical Park Bahcelievler Infectious Disease and Microbiology - Istanbul - Turkey; Cerrahpasa Faculty of Medicine - Istanbul - Turkey; Istanbul Medipol University Faculty of Medicine - Istanbul - Turkey; Istanbul University Istanbul Faculty of Medicine - Istanbul - Turkey; TR Ministry of HEalth Instanbul Provincial Health Directorate Marmara University Istanbul Pendik Education and Research Hospital - Istanbul - Turkey; TR Ministry of Health Istanbul Provincial Helath Directorate Prof Dr Cemil Tascioglu City Hospital - Istanbul - Turkey; TR Ministry of Health Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital - Istanbul - Turkey; Ege University Faculty of Medicine Hospital - Izmir - Turkey; Republic of Turkey Ministry of Health Izmir Provincial Health Directorate Health Sciences University Dr Suat Seren Chest Diseases and Chest Srugery Training and Research Hospital - Izmir - Turkey; TR Ministry of health Izmir Provincial Helath Directorate Izmir Health Sciences University Tepecik Training and Research Hospital - Ismir - Turkey; TR Minsitry of Health Kayseri City Training and Research Hospital - Kayseri - Turkey; Kocaeli University Faculty of Medicine - Kocaeli - Turkey; Malatya Inonu University of Medicine - Malatya - Turkey; Karadeniz Technical University Medical Faculty Hospital - Trabzon - Turkey; Centro de Especialidades Medicas, Santiago, Chile;",7/1/2020,9/1/2021,10/1/2021,https://clinicaltrials.gov/ct2/show/NCT04352608  https://clinicaltrials.gov/ct2/show/NCT04383574  https://www.clinicaltrials.gov/ct2/show/NCT04551547  https://clinicaltrials.gov/ct2/show/NCT04456595  https://www.clinicaltrials.gov/ct2/show/NCT04508075  https://www.clinicaltrials.gov/ct2/show/NCT04582344  https://clinicaltrials.gov/ct2/show/NCT04617483,For Brazil: Ricardo Palacios,For Brazil: 551137232121; For Turkey: +90 (312) 305 12 96,ricardo.palacios@butantan.gov.br; makova@hacettepe.edu.tr; katia@med.puc.cl,,For Indonesian Sites: +6222-2033755 ext 14101 novilia@biofarma.co.id For Turkey Sites: +90 (312) 305 12 96 makova@hacettepe.edu.tr For Brazil: 55 11 37232121 Ricardo.palacios@butantan.gov.br For Chile: Katia Abarca +56996797787 katia@med.puc.cl or Alvaro Rojas +56934056808 arojasgo@uc.cl,,,Matthew,4/8/2020,Joshuah Yon,5/30/2020,,,,5/30/2020
68,Yes,http://www.sinovac.com/?optionid=748,,http://www.sinovac.com/?optionid=748,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,http://www.sinovac.com/?optionid=748,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1 ; https://www.fool.com/investing/2020/05/29/dynavax-stock-soars-264-today-on-covid-19-vaccine.aspx,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4/9/2020,,,,,,4/9/2020
69,No,Wuhan Institute Inactivated Vaccine,,Wuhan Institute Inactivated Vaccine,Sinopharm; Wuhan Institute of Biological Products; ,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,China,Ongoing,Currently entered in Phase 2 Clinical Trial and will take about a year to complete a Phase 3 trial.,,Phase 3,,,,,,,4/12/2020,4/25/2020,7/15/2020,,,,3,COVID-19,16120,,,,7/15/2020,,9/13/2020,https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving,,,,,,,,Mathew,4/8/2020,Joshuah Yon,5/30/2020,,,,5/30/2020
69,Yes,,,,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,,,,,,,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-abu-dhabi-idUSKCN24H14T,,,,https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-abu-dhabi-idUSKCN24H14T,https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-abu-dhabi-idUSKCN24H14T,https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-abu-dhabi-idUSKCN24H14T,https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-abu-dhabi-idUSKCN24H14T,,https://www.firstpost.com/health/first-phase-3-human-trials-of-sinopharms-covid-19-vaccine-with-inactivated-virus-begins-in-abu-dhabi-8618421.html; https://www.thenational.ae/world/mena/coronavirus-saudi-arabia-and-bahrain-to-start-vaccine-trials-1.1061883; https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm/peru-to-test-china-sinopharms-covid-19-vaccine-in-phase-3-trial-idUSKCN25G0G9,,,,,,,,,,,,,,,,,,,
70,No,Codagenix Live-Attenuated Vaccine,,Codagenix Live-Attenuated Vaccine,Codagenix; Serum Institute of India,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,United States,Ongoing,Live-Attenuated vaccine. Country might need to be switched to India later. Targeting September for human trials and 2022 for release.,,Pre-Clinical Testing,,2/13/2020,5/28/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/8/2020,Joshuah Yon,5/30/2020,,,,5/30/2020
70,Yes,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.fortuneindia.com/technology/covid-19-vaccine-possible-by-q2-of-2022-adar-poonawalla/104401,https://www.fortuneindia.com/technology/covid-19-vaccine-possible-by-q2-of-2022-adar-poonawalla/104401,,https://www.fortuneindia.com/technology/covid-19-vaccine-possible-by-q2-of-2022-adar-poonawalla/104401,,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.hindustantimes.com/cities/serum-institute-confident-of-manufacturing-covid-vaccine-s-100-million-doses-if-trials-establish-efficacy/story-MrVAw982iSC2IdxAqWt9II.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
71,No,MVA-S encoded,,MVA-S encoded,DZIF - German Center for Infection Research,Vaccine - Prophylactic,COVID-19,Unknown,Vaccine,Repurposed-Not Approved,,Germany,Ongoing,The MVA vaccine for MERS acts as a basis for developing a vaccine for COVID-19. The first-human trial for MVA was completed 04/22/2020 and demonstrated safety and triggered the development of antibodies and T cell immunity.,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/8/2020,Joshuah Yon,5/30/2020,,,,5/30/2020
71,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.sciencedaily.com/releases/2020/04/200422132600.htm,https://www.sciencedaily.com/releases/2020/04/200422132600.htm,https://www.sciencedaily.com/releases/2020/04/200422132600.htm,https://www.sciencedaily.com/releases/2020/04/200422132600.htm,https://www.sciencedaily.com/releases/2020/04/200422132600.htm,,https://www.sciencedaily.com/releases/2020/04/200422132600.htm,https://www.sciencedaily.com/releases/2020/04/200422132600.htm,https://www.sciencedaily.com/releases/2020/04/200422132600.htm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
72,No,Greffex Vaccine,,Greffex Vaccine,Greffex,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,United States,On Hold,They lack funding to start animal trials.,,Discovery,,3/11/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/9/2020,Kristine Su,5/30/2020,,,,5/30/2020
72,Yes,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,,https://markets.businessinsider.com/news/stocks/greffex-inc-completes-covid-19-vaccine-and-prepares-for-testing-1028986183,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
73,No,AdaptVac Vaccine,,AdaptVac Vaccine,AdaptVac; PREVENT-nCoV consortium,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,PREVENT-nCOV Consortium; Bavarian Nordic; AGC Biologics,Denmark,Ongoing,Consortium of Danish companies and universities. One of the universities will likely be the sponsor when they go to clinical trials.,,Discovery,,3/9/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/9/2020,Kristine Su,5/30/2020,,,,5/30/2020
73,Yes,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_8a2ffeae006e4e64981c2275ce894c89.pdf; https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_643c666ae7d84b0fb2189e635332a363.pdf,https://www.adaptvac.com/,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_8a2ffeae006e4e64981c2275ce894c89.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_8a2ffeae006e4e64981c2275ce894c89.pdf,,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
74,No,Vaccine,,Vaccine,ExpreS2ion Biotechnologies ApS,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Combination,New,,Denmark,Ongoing,Being utilized in various COVID-19 therapeutic developments,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/8/2020,Kristine Su,5/30/2020,,,,5/30/2020
74,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,"https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project,c3102671","https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project,c3102671","https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project,c3102671","https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project,c3102671","https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project,c3102671",,https://news.cision.com/expres2ion-biotechnologies,"https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project,c3102671","https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project,c3102671",,"https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project,c3102671",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
75,No,USAMRIID Vaccine,,USAMRIID Vaccine,WRAIR; USAMRIID,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/9/2020,Kristine Su,5/30/2020,,,,5/30/2020
75,Yes,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,,,https://www.wired.com/story/the-us-armys-virus-research-lab-gears-up-to-fight-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
76,No,VaxHit,,VaxHit,Vaxil Bio Therapeutics,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,,Israel,Ongoing,Utilized single peptide technology,,Pre-Clinical Testing,,2/13/2020,Started 03/2020,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,Kristine Su,5/30/2020,,,,5/30/2020
76,Yes,https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf,,https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf,https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf,https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf,https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf,https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf,https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf,https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf,,https://vaxil-bio.com/,https://vaxil-bio.com/vaxil-provides-update-on-preclinical-experiment/,https://www.bioworld.com/COVID19products,,https://vaxil-bio.com/vaxil-provides-update-on-preclinical-experiment/,,https://vaxil-bio.com/vaxil-announces-the-identification-of-a-potential-corona-virus-vaccine-and-provides-an-update-in-the-previously-announced-debt-financing/,https://www.globenewswire.com/news-release/2020/03/27/2007667/0/en/VAXIL-COMMENCES-PRECLINICAL-COVID-19-VACCINE-TRIAL-AND-FILES-AN-ADDITIONAL-COVID-19-PATENT.html,https://www.globenewswire.com/news-release/2020/03/27/2007667/0/en/VAXIL-COMMENCES-PRECLINICAL-COVID-19-VACCINE-TRIAL-AND-FILES-AN-ADDITIONAL-COVID-19-PATENT.html,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,,,,,,4/8/2020
77,No,FlowVax COVID 19,,FlowVax COVID 19,Flow Pharma,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,University of Texas Medical Branch at Galveston,United States,Ongoing,Approach - Biodegradable microsphere peptide vaccine targeting SARS-CoV-2 nucleocapsid; T-cell vaccine; Expected to be used for pre- and post-exposure prophylaxis;  Currently being tested on nonhuman primates,,Pre-Clinical Testing,,,Started 04/2020,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,Kristine Su,5/30/2020,,,,5/30/2020
77,Yes,https://www.flowpharma.com/,,https://www.flowpharma.com/,https://www.flowpharma.com/,https://www.flowpharma.com/,https://www.flowpharma.com/,https://www.flowpharma.com/,https://www.flowpharma.com/,https://www.flowpharma.com/,https://www.accesswire.com/584325/Flow-Pharma-Announces-Start-of-Pre-Clinical-Efficacy-Study-for-FlowVax-COVID-19-Vaccine,https://www.flowpharma.com/,https://www.flowpharma.com/,https://www.flowpharma.com/,,https://www.accesswire.com/584325/Flow-Pharma-Announces-Start-of-Pre-Clinical-Efficacy-Study-for-FlowVax-COVID-19-Vaccine,,,https://www.accesswire.com/584325/Flow-Pharma-Announces-Start-of-Pre-Clinical-Efficacy-Study-for-FlowVax-COVID-19-Vaccine,https://www.accesswire.com/584325/Flow-Pharma-Announces-Start-of-Pre-Clinical-Efficacy-Study-for-FlowVax-COVID-19-Vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,,,,,,4/8/2020
78,No,EPV-CoV19,,EPV-CoV19,EpiVax Inc.,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,Generex Biotechnology; GAIA Vaccine Foundation; Entos Pharmaceuticals,United States,Ongoing,Peptide-based epitope driven vaccine candidate; Expected to stimulate protective T-cell response; Expected to protect against severe disease rather than protect against infection; Specifically targeted at healthcare workers; Availability of no-cost licenses for the vaccine recipe for developing world countries who have GMP facilities for production of the vaccine; Phase 1 trial expected to begin in 3 months,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,Kristine Su,5/30/2020,,,,5/30/2020
78,Yes,https://epivax.com/home/vaccine-services/covid-19,,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,https://www.generex.com/covid-19; https://epivax.com/home/vaccine-services/covid-19,,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/pipeline/epv-cov19,,https://epivax.com/home/vaccine-services/covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,,,,,,4/8/2020
79,No,EpiVax Vaccine,,EpiVax Vaccine,EpiVax; University of Georgia,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,,United States,Ongoing,This seems to be separate from the partnership between Epivax and Generex; Also seems to be in pre-discovery phase as no specific mechanism has been identified,,Discovery,,Started 03/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,Kristine Su,5/30/2020,,,,5/30/2020
79,Yes,,,,https://epivax.com/news/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,https://news.uga.edu/uga-researchers-developing-coronavirus-vaccine/,,https://epivax.com/home/vaccine-services/covid-19,,https://news.uga.edu/uga-researchers-developing-coronavirus-vaccine/,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
80,No,gp96-mediated vaccine,gp96-mediated vaccine,COVID 19 Vaccine,Heat Biologics Inc; University of Miami; Zolovax Inc.,Vaccine - Prophylactic,COVID-19,Cell therapies,Vaccine,New,University of Miami,United States,Ongoing,Mechanism of action - gp96 + Viral Antigens,,Pre-Clinical Testing,,Started 03/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,Kristine Su,5/30/2020,,,,5/30/2020
80,Yes,https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b,https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,,https://www.heatbio.com/product-pipeline/covid-19-vaccine,,https://physician-news.umiamihealth.org/miller-school-and-heat-biologics-to-collaborate-on-covid-19-vaccine/,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
81,No,T-cell therapies,,T-cell therapies,Baylor College of Medicine; AlloVir,Therapeutic,COVID-19,Cell therapies,Other antiviral drugs,New,,United States,Ongoing,T-cell therapy; Baylor college of medicine is also pushing for testing of a vaccine developed against SARS-Cov-1 in 2016 - not much information about this,,Discovery,,Started 03/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,Kristine Su,5/31/2020,,,,5/31/2020
81,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
82,No,IBIO-200,,IBIO-200,iBio Inc,Vaccine - Prophylactic,COVID-19,Small molecule,Vaccine,New,Texas A&M University System Laboratories,United States,Ongoing,Virus-like particle; Developed using FastPharming technology; Patent filed in March 2020,,Pre-Clinical Testing,,,Started 03/2020,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,Kristine Su,5/31/2020,,,,5/31/2020
82,Yes,https://www.ibioinc.com/pipeline,,https://www.ibioinc.com/pipeline,https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates,https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates,https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates,https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates,https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates,https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates,https://www.ibioinc.com/news/ibio-announces-advancement-of-covid-19-vaccine-program,https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates,https://www.ibioinc.com/therapeutics-and-vaccines,https://www.ibioinc.com/pipeline,,https://www.ibioinc.com/therapeutics-and-vaccines,,,https://www.ibioinc.com/news/ibio-announces-advancement-of-covid-19-vaccine-program,https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
83,No,OncoGen Vaccine,,OncoGen Vaccine,OncoGen,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,,Romania,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,Kristine Su,5/31/2020,,,,5/31/2020
83,Yes,,,,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://oncogen.ro/recognition-by-who/,https://oncogen.ro/recognition-by-who/,https://oncogen.ro/recognition-by-who/,https://oncogen.ro/recognition-by-who/,https://oncogen.ro/recognition-by-who/,,https://oncogen.ro/recognition-by-who/,https://oncogen.ro/recognition-by-who/,,,https://oncogen.ro/recognition-by-who/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
84,No,Measles Vector Vaccine,,Measles Vector Vaccine,Merck; Themis; Institute Pasteur,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,Themis Bioscience GmbH; University of Pittsburg - Center for Vaccine Research; CEPI - MSD,France,Ongoing,Molecule type - DNA based vaccine; Based on the use of measles vaccine as a vector,,Discovery,,Started 03/2020,,No,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,Meg ,5/29/2020,,,,5/29/2020
84,Yes,https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut,,https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut,https://www.pasteur.fr/en/press-area/coronavirus-mobilisation/coronavirus-covid-19-research-projects,,,,,,https://www.pasteur.fr/en/press-area/press-documents/cepi-collaborates-institut-pasteur-consortium-develop-covid-19-vaccine,,,http://pasteur.fr/en/press-area/coronavirus-mobilisation/coronavirus-covid-19-research-projects#p1 https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut,,,,https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut,,https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,Meg ,5/30/2020,,,,5/30/2020
85,No,RNACure 2019-nCoV Vaccine Candidate VLP,,RNACure 2019-nCoV Vaccine Candidate VLP,Fudan University; Shanghai JiatTong University; RNACure Biopharma,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,RNACure Biopharma,China,Ongoing,,,Pre-Clinical Testing,,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,Meg ,5/29/2020,,,,5/29/2020
85,Yes,,,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.fudan.edu.cn/en/2020/0307/c344a104281/page.htm,,http://rnacure.com/pipeline,,,http://rnacure.com/pipeline,,,http://rnacure.com/pipeline,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg ,5/29/2020,,,,5/29/2020
86,No,Stermina 2019-nCoV Vaccine Candidate,,Stermina 2019-nCoV Vaccine Candidate,China CDC; Tongji University; Stermina,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Stermina Therapeutics,China,Ongoing,,,Pre-Clinical Testing,,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,Meg ,5/29/2020,,,,5/29/2020
86,Yes,,,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.wired.com/story/everything-you-need-to-know-about-coronavirus-vaccines/,https://www.wired.com/story/everything-you-need-to-know-about-coronavirus-vaccines/,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.wired.com/story/everything-you-need-to-know-about-coronavirus-vaccines/,https://www.wired.com/story/everything-you-need-to-know-about-coronavirus-vaccines/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg ,5/29/2020,,,,5/29/2020
87,No,OpenCorona 2019-nCoV Vaccine Candidate,,OpenCorona 2019-nCoV Vaccine Candidate,Karolinska Institute; CobraBiologics,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Horizon 2020,Sweden,Ongoing,,,Pre-Clinical Testing,,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,Meg ,5/29/2020,,,,5/29/2020
87,Yes,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg ,5/29/2020,,,,5/29/2020
88,No,ReiThera 2019-nCoV Vaccine Candidate,,ReiThera 2019-nCoV Vaccine Candidate,ReiThera; Leukocare; and Univercell,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,,Italy,Ongoing,expected to enter clinical trials summer 2020,,Phase 1,,,Ongoing,,,,7/29/2020,,,,,,1,COVID-19,90,Yes,,,7/29/2020,,,https://www.aifa.gov.it/sperimentazioni-cliniche-covid-19,,,dirsan@inmi.it,https://www.inmi.it/vaccino-covid,,,,Arshy,4/7/2020,Meg ,5/29/2020,,,,5/29/2020
88,Yes,https://born2invest.com/articles/italian-biotech-companies-entered-the-race-to-find-a-vaccine-against-covid-19/,https://born2invest.com/articles/italian-biotech-companies-entered-the-race-to-find-a-vaccine-against-covid-19/,,https://www.genengnews.com/topics/bioprocessing/single-dose-adenovirus-based-covid-19-vaccine-planned/,,,https://www.genengnews.com/topics/bioprocessing/single-dose-adenovirus-based-covid-19-vaccine-planned/,https://www.genengnews.com/topics/bioprocessing/single-dose-adenovirus-based-covid-19-vaccine-planned/,,,https://born2invest.com/articles/italian-biotech-companies-entered-the-race-to-find-a-vaccine-against-covid-19/,https://www.genengnews.com/topics/bioprocessing/single-dose-adenovirus-based-covid-19-vaccine-planned/,https://www.genengnews.com/topics/bioprocessing/single-dose-adenovirus-based-covid-19-vaccine-planned/,,https://www.genengnews.com/topics/bioprocessing/single-dose-adenovirus-based-covid-19-vaccine-planned/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg ,5/29/2020,,,,5/29/2020
89,No,COVIGEN; BioNet 2019-nCoV Vaccine Candidate,,COVIGEN; BioNet 2019-nCoV Vaccine Candidate,BioNet Asia,Vaccine - Prophylactic,COVID-19,Gene therapies,Vaccine,New,,Thaialnd,Ongoing,phase 1/2 trial is planned for Q3 2020,,Pre-Clinical Testing,,completed,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,Meg ,5/29/2020,,,,5/29/2020
89,Yes,http://www.bionet-asia.com/media/news-events/,http://www.bionet-asia.com/media/news-events/,,https://www.nationthailand.com/news/30383030,,,http://www.bionet-asia.com/media/news-events/,http://www.bionet-asia.com/media/news-events/,,,,,http://www.bionet-asia.com/media/news-events/,,,,,http://www.bionet-asia.com/media/news-events/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg ,5/29/2020,,,,5/29/2020
90,No,Ivermectin,Ivermectin,Ivomec,Doherty Institute; Monash University,Therapeutic,COVID-19,Small molecule,Antibiotics and antiparasitics,Repurposed-Approved,,Australia,Ongoing,,,Phase 2,,,,,,,,6/1/2020,,,,,2,COVID-19,60,No,1,Johns Hopkins Hospital- Baltimore- Maryland,06/01/2020,11/2021,11/2021, https://clinicaltrials.gov/ct2/show/NCT04374279  ,Catherine H Marshall,410-955-0231,chm@jhmi.edu,,,NOT YET RECRUITING,,Arshy,4/7/2020,Meg ,5/29/2020,,,,5/29/2020
90,Yes,https://www.thejakartapost.com/news/2020/04/06/covid-19-antiparasitic-drug-can-kill-coronavirus-within-two-days-study-finds.html,https://www.thejakartapost.com/news/2020/04/06/covid-19-antiparasitic-drug-can-kill-coronavirus-within-two-days-study-finds.html,,https://www.thejakartapost.com/news/2020/04/06/covid-19-antiparasitic-drug-can-kill-coronavirus-within-two-days-study-finds.html,https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists,https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists,https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists,https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists,https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=2,,,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=2,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=2,https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=3,https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=4,https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=5,https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=6,https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=7,,,,https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=2,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04374279?term=ivermectin&cond=%22Coronavirus+Infections%22&draw=2,,,,Meg ,5/29/2020,,,,5/29/2020
91,No,Vaccine,,Vaccine,Tulane University,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,NIH,United States,Ongoing,,,Discovery,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,Meg ,5/29/2020,,,,5/29/2020
91,Yes,https://www.newswise.com/articles/tulane-university-awarded-10-3-million-to-test-therapeutics-vaccines-for-novel-coronavirus,https://www.newswise.com/articles/tulane-university-awarded-10-3-million-to-test-therapeutics-vaccines-for-novel-coronavirus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg ,5/29/2020,,,,5/29/2020
92,No,Vaxcelerate vaccine; Hoth Voltron 2019-nCoV Vaccine Candidate; HaloVax,,Vaxcelerate vaccine; Hoth Voltron 2019-nCoV Vaccine Candidate; HaloVax,Hoth Therapeutics;  Voltron Therapeutics; Vaccine and Immunotherapy Center,Vaccine - Prophylactic,COVID-19,Combination,Vaccine,New,Hoth; Voltron; MGH,United States,Ongoing,,,Discovery,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,Meg ,5/29/2020,,,,5/29/2020
92,Yes,https://finance.yahoo.com/news/hoth-surges-collaboration-voltron-covid-134601408.html,https://finance.yahoo.com/news/hoth-surges-collaboration-voltron-covid-134601408.html,,https://www.globenewswire.com/news-release/2020/03/24/2005714/0/en/Emerging-Markets-Report-Hoth-Therapeutics-is-Working-on-a-Potential-Coronavirus-Vaccine-COVID-19.html,,,https://www.sec.gov/Archives/edgar/data/1711786/000121390020007153/ea119888ex99-1_hoththerap.htm,https://www.sec.gov/Archives/edgar/data/1711786/000121390020007153/ea119888ex99-1_hoththerap.htm,,https://www.sec.gov/Archives/edgar/data/1711786/000121390020007153/ea119888ex99-1_hoththerap.htm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
93,No,STI-6991,,STI-6991,Sorrento Therapeutics,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Jack Carew,5/17/2020,,,,,,5/17/2020
93,Yes,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,https://www.sciencedirect.com/science/article/pii/S2590098620300130?via%3Dihub,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,,https://sorrentotherapeutics.com/contact-us/,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,,,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Jack Carew,5/18/2020,,,,,,5/18/2020
94,No,VTP-500,,VTP-500,Vaccitech,Vaccine - Prophylactic,Other,Protein-based (including monoclonal antibodies),Vaccine,New,UNIVERSITY OF OXFORD; JANSSEN; CEPI,United Kingdom,Ongoing,MERS,,Phase 1,,,,,,,3/14/2018,,,,,,,,,,,,,,,,,,,,,,,Jack Carew,5/17/2020,,,,,,5/17/2020
94,Yes,https://www.vaccitech.co.uk/pipeline/,,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,,https://www.vaccitech.co.uk/pipeline/,,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT03399578,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,,,https://clinicaltrials.gov/ct2/show/study/NCT03399578,,,https://clinicaltrials.gov/ct2/show/study/NCT03399578,,,,,,,,,,,,
95,No,mRNA vaccines,,mRNA vaccines,Sanofi; Translate Bio,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Sanofi Pasteur,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Jack Carew,5/17/2020,,,,,,5/17/2020
95,Yes,https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00,https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00,https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00,https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00,https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00,https://translate.bio/pipeline/,https://translate.bio/pipeline/,https://translate.bio/pipeline/,https://translate.bio/pipeline/,https://translate.bio/pipeline/,https://translate.bio/pipeline/,https://translate.bio/pipeline/,,,https://translate.bio/pipeline/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
96,No,nebulized Ampion,nebulized Ampion,,Ampio Pharmaceuticals,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,In Phase 3 Trials for Osteoarthritis of the Knee,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Jack Carew,5/17/2020,,,,,,5/17/2020
96,Yes,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,https://www.drugbank.ca/drugs/DB14940,https://www.drugbank.ca/drugs/DB14940,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,,,,https://ampiopharma.com/pipeline/,,https://ampiopharma.com/wp-content/uploads/2020/04/01-Apr-2020-Ampion-SARS-COV-2-and-ARDS-Flyer_v4.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
97,No,Piclidenoson,Piclidenoson,,Can-Fite BioPharma Ltd.,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Petach Tikva-Israel,Ongoing,In Phase 3 Trials for Rhumetoid Arthritis,,Phase 2,,,,,,4/13/2020,,4/6/2020,,,,,2,COVID-19,40,No,1,Rabin Medical Center,10/6/20,3/6/21,7/6/21,https://clinicaltrials.gov/ct2/show/NCT04333472,Zivit Harpaz,,Zivit@canfite.co.il,,,NOT YET RECRUITING,,Jack Carew,5/17/2020,,,,,,5/17/2020
97,Yes,http://www.canfite.com/?KPageId=19,http://www.canfite.com/?KPageId=19,,http://www.canfite.com/?KPageId=19,http://www.canfite.com/?KPageId=19,https://ir.canfite.com/press-releases/detail/894/can-fite-to-explore-the-anti-coronavirus-effects-of-piclidenoson-in-collaboration-with-lewis-katz-school-of-medicine-at-temple-university,http://www.canfite.com/?KPageId=19,https://ir.canfite.com/press-releases/detail/894/can-fite-to-explore-the-anti-coronavirus-effects-of-piclidenoson-in-collaboration-with-lewis-katz-school-of-medicine-at-temple-university,http://www.canfite.com/?KPageId=18,,https://ir.canfite.com/press-releases/detail/897/can-fite-piclidenoson-is-submitted-for-compassionate-use-treatment-for-coronavirus-patients-in-israel,https://ir.canfite.com/press-releases/detail/897/can-fite-piclidenoson-is-submitted-for-compassionate-use-treatment-for-coronavirus-patients-in-israel,https://ir.canfite.com/press-releases/detail/897/can-fite-piclidenoson-is-submitted-for-compassionate-use-treatment-for-coronavirus-patients-in-israel,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,,,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,,,,,,,,,,,
98,No,BDB-1,BDB-1,IFX-1,InflaRx N.V.,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Netherlands,Ongoing,,,Phase 2,,,,,,,,3/31/2020,3/31/2020,,,,2,COVID-19,130,No,2,University of Amsterdam - Amsterdam - Netherlands; University of Maastricht - Maastricht - Netherlands,3/31/20,5/31/21,8/31/21,https://clinicaltrials.gov/ct2/show/NCT04333420,Korinna Pilz,,korinna.pilz@inflarx.de,,,,,Jack Carew,5/17/2020,,,,,,5/17/2020
98,Yes,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.inflarx.de/Home/Research---Development/Pipeline.html,https://www.inflarx.de/Home/Research---Development/Pipeline.html,https://www.inflarx.de/Home/Research---Development/Pipeline.html,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.inflarx.de/Home/Research---Development/Pipeline.html,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,,,,,,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/study/NCT04333420?term=Inflarx&draw=1&rank=5#contacts,https://www.clinicaltrials.gov/ct2/show/study/NCT04333420?term=Inflarx&draw=1&rank=5#contacts,https://www.clinicaltrials.gov/ct2/show/study/NCT04333420?term=Inflarx&draw=1&rank=5#contacts,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,,,,,,,,,,,,
99,No,remestemcel-L,remestemcel-L,Ryoncil,Mesoblast Limited,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,,,Phase 3,,3/10/2020,,,,4/6/2020,,,4/30/2020,,,,3,COVID-19,300,No,15,University of Southern California - Los Angeles - California; Emory University - Atlanta - Georgia; Lutheran Hospital - Fort Wayne - Indiana; Ochsner Clinic- New Orleans - Louisiana; University of Maryland - Baltimore - Maryland; Brigham and Women's Hospital - Boston - Massachusetts; University of Michigan - Ann Arbor - Michigan; Dartmouth-Hitchcock - Lebanon - New Hampshire; Mount Sinai Health - New York - New York; Mission Hospital - Asheville - North Carolina; Duke University Medical Center - Durham - North Carolina; Cleveland Clinic Foundation - Cleveland - Ohio; University of Pennsylvania Health System - Philadelphia - Pennsylvania; Baylor Smith & White - Plano - Texas; University of Virginia - Charlottesville - Virginia,4/30/20,4/1/21,4/1/22,https://clinicaltrials.gov/ct2/show/NCT04371393,Mary Beth Marks,,mary.marks@mountsinai.org,,,,,Jack Carew,5/17/2020,,,,,,5/17/2020
99,Yes,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,http://investorsmedia.mesoblast.com/static-files/336699fe-c5ab-41f2-801e-404c3739275c,http://investorsmedia.mesoblast.com/static-files/336699fe-c5ab-41f2-801e-404c3739275c,http://investorsmedia.mesoblast.com/static-files/c1428818-0b9f-44f9-bb4f-79ad518002cc,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,http://investorsmedia.mesoblast.com/static-files/c1428818-0b9f-44f9-bb4f-79ad518002cc,,,,http://investorsmedia.mesoblast.com/static-files/f9eb8ecd-9c72-4207-8a51-0187607948b6,,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/study/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14#contacts,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,,,,,,,,,,,
100,No,tocilizumab,tocilizumab,Actemra,Genetech,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,Biomedical Advanced Research and Development Authority;U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response,United States,Ongoing,,,Phase 3,,,,,,,,,4/3/2020,,,,3,COVID-19,450,No,69,"University of California San Diego- La Jolla- California; eStudySite- La Mesa- California; David Geffen School of Medicine UCLA- Los Angeles- California; Stanford University- Stanford- California; Denver Health Medical Center- Denver- Colorado; University of Miami Miller School of Medicine- Miami- Florida; Rush University Medical Center- Chicago- Illinois; Ochsner Clinic Foundation- Baton Rouge- Louisiana; Baystate Health System- Springfield- Massachusetts; Mayo Clinic PPDS- Rochester- Minnesota; Hackensack University Medical Center- Hackensack- New Jersey; Robert Wood Johnson University Hospital/Rutgers- New Brunswick New Jersey; James J Peters Veterans Administration Medical Center – NAVREF- Bronx- New York Duke University Medical Center-Durham- North Carolina; Cleveland Clinic Foundation; Pulmonary Allergy & Critical Care Medicine- Cleveland- Ohio; Thomas Jefferson University- Philadelphia- Pennsylvania; Baylor St. Luke's Medical Center- Houston- Texas; Ben Taub General Hospital – HCHD- Houston- Texas; Intermountain Medical Group- Saint George- Utah; Salt Lake City- Utah; Evergreen Health Infectious Disease- Kirkland- Washington; Swedish Hospital Medical Center- Seattle- Washington; Hamilton General Hospital Pharmacy- Ontario- Canada; St. Joseph's Healthcare Hamilton- Ontario - Canada; University Health Network- Toronto- Canada; Toronto Western Hospital- Toronto- Canada; Clinical Research Institute of Montreal- Montreal- Canada; Rigshospitalet Copenhagen University Hospital- Copenhagen- Denmark; Hvidovre Hospital- Hvidovre- Denmark; Odense Universitets hospital- Odense- Denmark; Sjællands Universitetshospital- Roskilde- Denmark; Centre Hospitalier Departemental de Vendee- La Roche Sur Yon- France; Centre Hospitalier et Universitaire de Limoges- Limoges- France; Hôpital de La Croix Rousse- Lyon- France; Hotel Dieu- Nantes- France; Hopital de la Pitie Salpetriere- Paris- France; HOPITAL COCHIN university hospital- Paris- France; CHRU de Tours Pharmacie- Tours- France; Universitatsklinikum Dusseldorf- Germany; Medizinische Hochschule- Hannover- Germany; Universitatsklinikum Schleswig Holstein- Klinik fur Allgemeine Innere Medizin - Kiel- Germany; Uniklinik Köln- Köln- Germany; LMU Klinikum der Universitat Munchen- Munchen- Germany; Azienda Ospedaliera Dei Colli- Napoli- Italy; Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS- Roma-Italy; ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica- Bergamo- Italy; ASST Fatebenefratelli Sacco- Milano- Italy;
Azienda Ospedaliera San Gerardo di Monza- Monza MI- Italy; Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria- Pavia- Italy; Amphia Ziekenhuis- Breda- Netherlands; St. Antonius Ziekenhuis Nieuwegein- Nieuwegein- Netherlands; Erasmus MC- Rotterdam- Netherlands; Universitair Medisch Centrum Utrecht- Utrecht- Netherlands; Hospital Universitario de Bellvitge- Barcelona- Spain; Hospitalet de Llobregat- Barcelona- Spain; Hospital Universitari Vall d'Hebron- Barcelona- Spain; Hospital Clinic de Barcelona- Barcelona- Spain; Hospital Universitario La Paz- Madrid- Spain; Hospital Universitario Ramon y Cajal- Madrid- Spain; Hospital General Universitario Gregorio Maranon- Madrid- Spain; Hospital Universitario HM Sanchinarro-CIOCC- Madrid- Spain; Greater Glasgow and Clyde Health Board- Glasgow- United Kingdom; Leeds Teaching Hospitals NHS Trust- Leeds- United Kingdom; University College Hospital- London- United Kingdom; Royal Free Hospital- London- United Kingdom; St George's Clinical Research Facility- London- United Kingdom; Imperial College London- London- United Kingdom; North Manchester General Hospital- Manchester- United Kingdom; Salford Royal Hospital- Salford- United Kingdom;
",04/03/2020,06/24/2020,07/28/2020,https://clinicaltrials.gov/ct2/show/NCT04320615,Hoffmann-La Roche,888-662-6728,,,,COMPLETED,,Meg,5/29/2020,,,,,,5/29/2020
100,Yes,,,,https://www.gene.com/media/press-releases/14855/2020-05-27/genentech-initiates-phase-iii-clinical-t,,,https://www.drugbank.ca/drugs/DB06273,https://www.drugbank.ca/drugs/DB06274,https://www.drugbank.ca/drugs/DB06275,https://www.gene.com/media/press-releases/14855/2020-05-27/genentech-initiates-phase-iii-clinical-t,https://www.gene.com/media/press-releases/14855/2020-05-27/genentech-initiates-phase-iii-clinical-t,https://www.gene.com/media/press-releases/14855/2020-05-27/genentech-initiates-phase-iii-clinical-t,,,https://www.gene.com/media/press-releases/14855/2020-05-27/genentech-initiates-phase-iii-clinical-t,,,,,,,,,https://www.gene.com/media/press-releases/14855/2020-05-27/genentech-initiates-phase-iii-clinical-t,,,,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04320615?term=COVACTA&draw=2&rank=1#contacts,,,,,,,,,
101,No,Diammonium glycyrrhizinate,Diammonium glycyrrhizinate,,Sino Biopharmaceuticals,Therapeutic,COVID-19,Other,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,China,Ongoing,Unclear if any clincial trials are occuring,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/29/2020,,,,,,5/29/2020
101,Yes,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diammonium-glycyrrhizinate,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diammonium-glycyrrhizinate,,,,,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diammonium-glycyrrhizinate,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diammonium-glycyrrhizinate,https://pubchem.ncbi.nlm.nih.gov/compound/Diammonium-glycyrrhizinate,,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diammonium-glycyrrhizinate,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diammonium-glycyrrhizinate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
102,No,T89,T89,Dantonic,Tasly Pharmaceuticals; Arbor Pharmaceuticals Inc.,Therapeutic,ARDS,Other,Other,Repurposed-Not Approved,Tasly Pharmaceuticals,China,Ongoing,T89 is an industrialized botanical drug formula developed from traditional Chinese Medicine. It is a mixture of multiple plant extracts and other excipients. It is to be tested for increasing blood O2 saturation in the ongoing clinical trial registered in US. The trial was approved but not yet recruiting.,,,,,,,,,,,2/26/2020,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/9/2020,Meg,5/29/2020,,,,5/29/2020
102,Yes,https://clinicaltrials.gov/ct2/show/NCT04285190,https://clinicaltrials.gov/ct2/show/NCT04285190,https://clinicaltrials.gov/ct2/show/NCT04285190,https://clinicaltrials.gov/ct2/show/NCT04285190,https://clinicaltrials.gov/ct2/show/NCT04285190,https://clinicaltrials.gov/ct2/show/NCT04285190,https://www.taslyus.com/pipeline/t89/,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://www.taslyus.com/pipeline/t89/,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://www.taslyus.com/pipeline/t89/,,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,,,,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,,,,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,,,,,,,,,,,,,,,
103,No,Monoclonal Antibodies,,Monoclonal Antibodies,AstraZeneca PLC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/9/2020,,,,,,4/9/2020
103,Yes,https://www.astrazeneca.com/media-centre/articles/2020/researching-antibodies-to-target-covid-19.html,,https://www.astrazeneca.com/media-centre/articles/2020/researching-antibodies-to-target-covid-19.html,https://www.astrazeneca.com/media-centre/articles/2020/researching-antibodies-to-target-covid-19.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
104,No,Monoclonal Antibodies,,Monoclonal Antibodies,Celltrion,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Celltrion,,Ongoing,they have 300 candidates now will narrow down to fewer candidates,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/9/2020,,,,,,4/9/2020
104,Yes,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.centerforbiosimilars.com/news/celltrion-amgen-join-race-to-develop-antisarscov2-antibodies,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
105,No,Monoclonal Antibodies,,Monoclonal Antibodies,Israel Institute for Biological Research (IIBR); Dyadic International Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,IIBR; Dyadic,,Ongoing,IIBR will use the manufacturing platform of Dyadic to produce their monoclonal antibody candidate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/9/2020,,,,,,4/9/2020
105,Yes,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
106,No,mavrilimumab,mavrilimumab,KPL-301,Kiniksa Pharmaceuticals,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Kiniksa Pharmaceuticals; Virginia Commonwealth University,Italy; US,Ongoing,The drug had up to phase-2 trial for other indications. Successfully used in Covid-19 pts in Italy (did not find the exact trial description).,,Phase 2,,,,,,,,4/20/2020,,,,,2,COVID-19,10,No,1,"Richmond - Virginia
",,,,,,,,,,,,Yiwei Liu,4/9/2020,,,,,,4/9/2020
106,Yes,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://www.kiniksa.com/our-pipeline/mavrilimumab/,https://www.kiniksa.com/our-pipeline/mavrilimumab/,https://www.kiniksa.com/our-pipeline/mavrilimumab/,https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab; https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab; https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab; https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/results?term=Mavrilimumab; https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab,,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,,,,,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,,,,,,,,,,,,,,,,,,,
107,No,Plasma-derived hyperimmune globulin therapy,,Plasma-derived hyperimmune globulin therapy,CoVIg-19 Plasma Alliance; Biotest; BPL; CSL Behring; LFB; Octapharma; Takeda; ADMA Biologics; BioPharma Plasma; GC Pharma; Sanquin,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,Biotest; Bio Products Laboratory; Octa Pharma; LFB; CSL Behrig,Japan,Ongoing,Takeda started development as TAK-888. Several groups working on immunoglobulin strategies are now working together. They need plasma donors.,,Discovery,,3/6/2020,,,,,,,,,,,,,,,,,,,,,,,,https://www.donatingplasma.org/donation/find-a-donor-center,,,,Matthew,4/24/2020,,,Mats Olsen,5/19/2020,,5/19/2020
107,Yes,https://www.takeda.com/newsroom/newsreleases/2020/covig-19-plasma-alliance-builds-strong-momentum-through-expanded-membership-and-clinical-trial-collaboration/,,https://www.takeda.com/newsroom/newsreleases/2020/covig-19-plasma-alliance-builds-strong-momentum-through-expanded-membership-and-clinical-trial-collaboration/,https://www.takeda.com/newsroom/newsreleases/2020/covig-19-plasma-alliance-builds-strong-momentum-through-expanded-membership-and-clinical-trial-collaboration/,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19,https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19,https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19,https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19,,https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19,,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.donatingplasma.org/donation/find-a-donor-center,,,,,,,,,
108,No,Plasma Immunoglobulins,,Plasma Immunoglobulins,CERS (actually spelt Cerus Corporation),Therapeutic,COVID-19,Other,Other,New,Cerus Corporation; California Department of Public Health; University of California; Irvine’s Vaccine Development Research Laboratory; Vitalant Research Institute; California National Primate Research Center; Enable Biosciences,United States,Ongoing,Convalescent Plasma,,Discovery,,3/26/2020,,,,,,,,,,,Discovery,COVID-19,,,,,,,,,,,,,,,,Rahman A,4/22/2020,,,,,,4/22/2020
108,Yes,,,,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,,,,,,,,,,,,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,
109,No,Plasma Immunoglobulins,,Plasma Immunoglobulins,Grifols,Therapeutic,COVID-19,Other,Other,New,Grifols; BARDA; FDA,United States,Ongoing,Convalescent Plasma,,Discovery,,3/25/2020,,,,,,,,,,,Discovery,COVID-19,,,,,,,,,,,,,,,,Rahman A,4/22/2020,,,,,,4/22/2020
109,Yes,,,,,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,,,,,,,,,,,,,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,
110,No,Plasma Immunoglobulins,,Plasma Immunoglobulins,Mount Sinai Health System,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,Mayo Clinic,United States,Ongoing,Convalescent Plasma Program. Ongoing. No dates given.,,Phase 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rahman A,4/22/2020,,,,,,4/22/2020
110,Yes,,,,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,,,,,,,,,,,,,,,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,,,,,,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,,,,,,,,,,,,,,,,,,,,
111,No,Plasma Immunoglobulins,,Plasma Immunoglobulins,China National Biotec,Therapeutic,COVID-19,Other,Other,Repurposed-Not Approved,China National Biotec Group,China,Ongoing,Convalescent Plasma Program. Ongoing. No dates given.,,Phase 2,,,,,,,,2/20/2020,,,,,2,COVID-19,10,No,3,Wuhan Jinyintan Hospital; Jiangxia District Hospital of Integrative Traditional Chinese and Western Medicine - Wuhan; First People’s Hospital of Jiangxia District - Wuhan,,,,,,,,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
111,Yes,,,,http://www.xinhuanet.com/english/2020-02/14/c_138783268.htm,http://www.xinhuanet.com/english/2020-02/14/c_138783268.htm,http://www.xinhuanet.com/english/2020-02/14/c_138783268.htm,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,,,https://www.pnas.org/content/early/2020/04/02/2004168117,,,,,,,,http://www.xinhuanet.com/english/2020-02/14/c_138783268.htm,,,,,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,,,,,,,,,,,,,,,,,,,
112,No,Aviptadil,,Aviptadil,NeuroRx; Relief Therapeutics,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,NeuroRx,United States,Ongoing,Vasoactive Intestinal Polypeptide which inhibits inflammatory cytokines causing ARDS,,Phase 3,,,,,,,,,4/1/2020,4/1/2020,,,3,COVID-19,144,No,4,Miller School of Medicine - University of Miami Medical Center - Florida - United States; Robert I Grossman School of Medicine - NYU Langone Medical Center - New York - United States; Thomas Jefferson University Hospital - Philadelphia - Pennsylvania - United States; Rambam Health Care Campus - Haifa - Israel,05/15/2020,8/1/20,9/1/20,https://clinicaltrials.gov/ct2/show/NCT04311697,Robert E Besthof,,rbesthof@neurorxpharma.com,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
112,Yes,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,,,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,,,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,,,,,,,,,,,,,,,
113,No,STI-4398; COVIDTRAP,,STI-4398; COVIDTRAP,Sorrento Therapeutics inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,New,Sorrento Theraputics,United States,Ongoing,Designed to block the SARS-CoV-2 virus from binding and infecting respiratory epithelial cells - which is expected to effectively interrupt the viral life cycle,,Pre-Clinical Testing,,,3/20/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
113,Yes,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,https://sorrentotherapeutics.com/,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,,,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,,,,,,,,,,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,,,,,,,,,,,,,,,,,,,,,,,,
114,No,INOpulse,,INOpulse,Bellerophon Therapeutics Inc.,Therapeutic,Other,Small molecule,Other,Repurposed-Not Approved,Bellerophon Therapeutics,United States,Ongoing,Inhaled Nitric Oxide at Phase 2 for  for COPD - ILD - Sarcoidosis,,Phase 2,,,,,,,,,,,,,2,COVID-19,500,No,,,,,,,,,,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
114,Yes,,,,,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://www.bellerophon.com/,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,,,http://www.bellerophon.com/pipeline/,,,,,,,,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-receives-approval-commence-phase-2-trial-ph-copd,,,,,http://www.bellerophon.com/ ; http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,,,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,,,,,,,,,,,,,,,,,,
115,No,SNX-5542,,SNX-5542,Esanex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
115,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
116,No,crofelemer,crofelemer,Mytesi,Jaguar Health,Therapeutic,COVID-19,Other,Other,Repurposed-Not Approved,Jaguar Health,USA,Failed,antidiarrheal for those on anti-retroviral therapy - used in HIV patients - permission sought from FDA for use in COVID patients,,Discovery,,,,,,,,,,Denied: Emergency Use Authorisation (EUA),,,,,,,,,,,,,,,,,,,,Zain,4/12/2020,,,,,,4/12/2020
116,Yes,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://www.marketscreener.com/JAGUAR-HEALTH-INC-59550999/news/JAGUAR-HEALTH-INC-Other-Events-form-8-K-30397142/,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,,https://www.reuters.com/article/brief-jaguar-health-says-declined-to-iss/brief-jaguar-health-says-declined-to-issue-an-eua-for-crofelemer-at-this-time-idINFWN2BY04H,,,,,,,,,,https://www.reuters.com/article/brief-jaguar-health-says-declined-to-iss/brief-jaguar-health-says-declined-to-issue-an-eua-for-crofelemer-at-this-time-idINFWN2BY04H,,,,,,,,,,,,,,,,,,,,,,,,,,,
117,No,Leibniz Instutute Therapeutic,,Leibniz Instutute Therapeutic,Leibniz Institute,,,,,,,,,could not find therapeutic use; only antibody test for covid?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/12/2020,,,,,,4/12/2020
117,Yes,,,,,,,,,,,,,https://www.wbur.org/commonhealth/2020/04/10/covid-19-coronavirus-antibody-testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
118,No,Allergan Therapeutic,,Allergan Therapeutic,Allergan,,,,,,,,,could not find any therapeutic drug/vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/12/2020,,,,,,4/12/2020
118,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
119,No,CD24Fc,,CD24Fc,OncoImmune,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Approved,OncoImmune,USA,Ongoing,first-in-class recombinant fusion protein (biologic),,Phase 3,,,,,,,,,4/8/2020,No,,,3,COVID-19,230,No,1,University of Maryland - Baltimore - Maryland,04/08/20,May 2021,May 2022,,,,,,,,,Zain,4/12/2020,,,,,,4/12/2020
119,Yes,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,http://www.oncoimmune.com/product-development/,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,,,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,,,,,,,,,,,,,,,,
120,No,PUL-042 Inhalation Solution,,PUL-042 Inhalation Solution,Pulmotect,Therapeutic,COVID-19,Other,Other,New,Pulmotect,USA,Ongoing,2 Clinical Trials: one for short term immunisation; also one for reducing severity (link below for latter),,Phase 2,,,,,,,,4/1/2020,,No,,,2,COVID-19,200,No,,Houston Methodist Hospital - Houston - Texas,April 2020,September 2020,October 2020,,,,,,,,,Zain,4/13/2020,,,,,,4/13/2020
120,Yes,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://www.clinicaltrials.gov/ct2/show/NCT04312997,,https://clinicaltrials.gov/ct2/show/NCT04313023,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04313023,,https://clinicaltrials.gov/ct2/show/NCT04313023,,,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,,,,,,,,,,,,,,,,
121,No,DDRI Therapeutic,,DDRI Therapeutic,Digestive Disease Research Institute,,,,,,,,,could not find therapeutic drug/vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/13/2020,,,,,,4/13/2020
121,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
122,No,INSERM Therapeutic,,INSERM Therapeutic,INSERM,Therapeutic,COVID-19,Other,Other,Repurposed-Not Approved,National Insitute for Health and Medical Research,France,Ongoing,Clinical Trials - stage unknown - to test 4 therapes: Remdesevir; Hydroxychloroquine; Lopinavir and Rotinavir; plus IFN-beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/13/2020,,,,,,4/13/2020
122,Yes,,,,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments#,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
123,No,Nitric Oxide,Nitric Oxide,,Massachusetts General Hospital; Mallincrodt plc,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,Massachusetts General Hospital,USA,Ongoing,4 Current/upcoming trials - to assess use of Nitric Oxide for treating COVID patients - and also potentially preventing the disease,,Phase 2,,,,,,,,3/23/2020,,,,,2,COVID-19,102,No,2,Massachusetts General Hospital - Massachusetts; Xijing Hospital - China,03/23/20,03/01/21,03/01/22,,,,,,,,,Zain,4/13/2020,,,,,,4/13/2020
123,Yes,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,,https://clinicaltrials.gov/ct2/show/NCT04290871,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04290871,,,,,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,,,,,,,,,,,,,,,,
124,No,Tocilizumab,Tocilizumab,RoActerma,National Cancer Institute,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,Roche and BARDA,United states,Ongoing,Phase 3 approved,,Phase 2,,,,,,FDA,,,,,,,2,COVID-19,400,,,,,,,,,,,,,,,Anusha Joshi,4/10/2020,,,,,,4/10/2020
124,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
125,No,oseltamivir,oseltamivir,Tamiflu,Rajavithi Hospital; Roche AG,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Approved,Rajavithi Hospital,Thailand,Ongoing,,,Phase 3,,,,,,,,,4/15/2020,,,,3,COVID-19,320,No,,,04/15/2020,10/31/2020,11/30/2020,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
125,Yes,https://clinicaltrials.gov/ct2/show/NCT04303299,https://clinicaltrials.gov/ct2/show/NCT04303299,,https://www.drugbank.ca/drugs/DB00198,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
126,No,Hydroxychloroquine; Lopinavir; Ritonavir; Interferon-β 1a ,Hydroxychloroquine; Lopinavir; Ritonavir; Interferon-β 1a ,,Shahid Beheshti Univeristy of Medical Sciences,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
126,Yes,https://www.smartpatients.com/trials/NCT04343768,https://www.smartpatients.com/trials/NCT04343768,,https://www.smartpatients.com/trials/NCT04343768,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,,,,,,,
127,No,sofosbuvir; ledipasvir,sofosbuvir; ledipasvir,,Tehran University of Medical Sciences,Therapeutic,COVID-19,Small molecule,,,,Iran,Ongoing,,,Phase 2,,,,,,FDA,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
127,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
128,No,Beijing Chaoyang Hospital Therapeutic,,Beijing Chaoyang Hospital Therapeutic,Beijing Chaoyang Hospital; Capital Medical University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
128,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
129,No,Beijing You'an Hospital Therapeutic,,Beijing You'an Hospital Therapeutic,Beijing You'an Hospital; Capital Medical University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
129,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,,,,,,,
130,No,Carrimycin,Carrimycin,,Capital Medical University; Shenyang Tonglian Group Co. Ltd.,Therapeutic,COVID-19,,,,Beijing YouAn Hospital,China,Ongoing,,,Phase 4,,,,,,NMPA,,,,,,,4,COVID-19,520,No,11,,02/27/2020,02/28/2021,02/28/2021,,,,,,,,,Anusha Joshi,4/12/2020,,,,,,4/12/2020
130,Yes,https://clinicaltrials.gov/ct2/show/record/NCT04286503,https://clinicaltrials.gov/ct2/show/record/NCT04286503,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
131,No,Interleukin-6 monoclonal antibody,Interleukin-6 monoclonal antibody,CMAB806,JinYu Bio-Technology,Therapeutic,ARDS,,,,,China,Ongoing,Study goes to May 31st,,Phase 2,,Completed,Completed,Completed,Completed,,Skipped,2/20/2020,,,,,2,COVID-19,60,No,1,Wuhan - China,02/20/2020,05/31/2020,05/31/2020,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,,,,,,,Matthew,4/24/2020,,,,,,4/24/2020
131,Yes,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,,,,,,,,,,,,,,
132,No,Mesenchymal Stem Cells,Mesenchymal Stem Cells,CAStem,Beijing 302 Hospital,Therapeutic,COVID-19,Cell therapies,Other,New,,China,Ongoing,,,Phase 2,,Completed,Completed,Completed,Completed,,Skipped,3/5/2020,,,,,2,COVID-19,90,No,2,Maternal and Child Hospital of Hubei Province - Wuhan - China; Wuhan Huoshenshan Hospital - Wuhan - China,03/05/2020,05/12/2020,07/09/2020,https://clinicaltrials.gov/ct2/show/NCT04288102,,,,,,COMPLETED,,Matthew,4/24/2020,,,,,,4/24/2020
132,Yes,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,http://www.xinhuanet.com/english/2020-03/05/c_138846353.htm,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,,,https://clinicaltrials.gov/ct2/show/NCT04288102,,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,,,,,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,,,,,,,,,,,,,,,
133,No,NKG2D-ACE2 CAR-NK Cells,NKG2D-ACE2 CAR-NK Cells,,Chongqing Public Health Medical Center,Therapeutic,COVID-19,Cell therapies,Other,New,Chongqing Sidemu Biotechnology,China,Ongoing,Phase I/II Trial,,Phase 2,,Completed,Completed,Completed,Completed,,3/21/2020,3/21/2020,,,,,2,COVID-19,90,No,1,Chongqing Public Health Medical Center,03/21/2020,05/31/2020,09/30/2020,https://clinicaltrials.gov/ct2/show/NCT04324996,Min Liu,,gwzxliumin@foxmail.com,,,,,Matthew,4/26/2020,,,,,,4/26/2020
133,Yes,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,,https://clinicaltrials.gov/ct2/show/NCT04324996,,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,,,,,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,,,,,,,,,,,,,,,
134,No,Long-acting interferon alpha-2a; ribavirin,Long-acting interferon alpha-2a; ribavirin,,Foshan First People's Hospital,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,New,,China,Ongoing,,,Phase 2,,Completed,Completed,Completed,Completed,,Skipped,2/26/2020,,,,,2,COVID-19,30,No,5,Foshan First People's Hospital - Foshan - China; Zhongshan Second People's Hospital - China; The Ninth People's Hospital of Dongguan - China; Jiangmen Central Hospital - China; Foshan Fourth People's Hospital - China,02/26/2020,08/26/2020,08/26/2020,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,,,,,,,Matthew,4/26/2020,,,,,,4/26/2020
134,Yes,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,,,,,,,,,,,,,,
135,No,Triazavirin,Triazavirin,,Health commission of Heilongjiang province,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,,China,Ongoing,Originally developed in Russia for Influenza.,,Phase 3,,Completed,Completed,Completed,Completed,,Completed,Completed,2/15/2020,,,,3,COVID-19,240,No,4,The First Affiliated Hospital of Harbin Medical University - China; The Second Affiliated Hospital of Harbin Medical University - China; The Fourth Affiliated Hospital of Harbin Medical University - China; Heilongijiang Provincial Hospital - China,02/15/2020,05/28/2020,05/28/2020,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,,,,,,,Matthew,4/26/2020,,,,,,4/26/2020
135,Yes,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,https://www.drugbank.ca/drugs/DB15622,https://www.drugbank.ca/drugs/DB15622,https://www.drugbank.ca/drugs/DB15622,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,https://www.drugbank.ca/drugs/DB15622,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,,,,,,,,,,,,,,
136,No,azvudine,azvudine,,Henan Provincial People's Hospital,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Not Approved,,China,Ongoing,http://www.chictr.org.cn/showprojen.aspx?proj=50507,,Phase 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/20/2020,,,,,,4/20/2020
136,Yes,https://www.digitaltrends.com/health-fitness/coronavirus-covid-19-vaccines-treatments-list/,https://www.digitaltrends.com/health-fitness/coronavirus-covid-19-vaccines-treatments-list/,,https://www.digitaltrends.com/health-fitness/coronavirus-covid-19-vaccines-treatments-list/,https://en.wikipedia.org/wiki/Azvudine,http://www.ecns.cn/news/sci-tech/2020-04-15/detail-ifzviiqq6926898.shtml,https://en.wikipedia.org/wiki/Azvudine,https://en.wikipedia.org/wiki/Azvudine,https://en.wikipedia.org/wiki/Azvudine,,http://www.ecns.cn/news/sci-tech/2020-04-15/detail-ifzviiqq6926898.shtml,http://www.ecns.cn/news/sci-tech/2020-04-15/detail-ifzviiqq6926898.shtml,http://www.chictr.org.cn/showprojen.aspx?proj=49532,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
137,No,Pirfenidone,Pirfenidone,Esbriet,Huilan Zhang,Therapeutic,Pneumonia,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,China,Ongoing,,,Phase 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/20/2020,,,,,,4/20/2020
137,Yes,https://en.wikipedia.org/wiki/Pirfenidone,,https://en.wikipedia.org/wiki/Pirfenidone,,,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,https://en.wikipedia.org/wiki/Pirfenidone,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,,,,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,,,,,,,,,,,,,Phase 3,,294,,,,2/4/2020,4/30/2020,6/1/2020,,,,,,,,,Arshy,,,,,,,
138,No,Chloroquine,Chloroquine,,Hwa Mei Hospital; University of Chinese Academy of Sciences,Therapeutic,COVID-19,Small molecule,Antimalarial drugs,Repurposed-Approved,,China,Ongoing,,,Phase 3,,,,,,,,,,,,,3,COVID-19,294,No,1,Tongji hospital affiliated to huazhong university of science and technology - Wuhan - Hubei - China,2/4/20,4/30/20,6/1/20,,,,,,,,,Arshy,4/20/2020,,,,,,4/20/2020
138,Yes,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935,,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935,,,https://en.wikipedia.org/wiki/Chloroquine#Medical_uses,https://en.wikipedia.org/wiki/Chloroquine#Medical_uses,https://en.wikipedia.org/wiki/Chloroquine#Medical_uses,,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
139,No,XueBiJing,XueBiJing,XueBiJing,Jingzhou First People's Hospital,Therapeutic,Pneumonia,Other,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,N/A,China,Ongoing,Traditional Chinese Medicine; 5-herb combination,,Phase 1,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,Completed,2/18/2020,,,,,,1,COVID-19,60,No,1,Jingzhou First People's Hospital - Hubei - China,02/18/2020,,,http://www.chictr.org.cn/showprojen.aspx?proj=50306,,,,,,,,Gabbie,4/6/2020,,,,,,4/6/2020
139,Yes,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,https://reader.elsevier.com/reader/sd/pii/S0254627211600113?token=59E71863CD81881AD517D44BB2CFB5E0524ACEE75F7729C3AEEE19F30F987FC7F744F2B5CEC187F763578C32AA680098,https://clinicaltrials.gov/ct2/show/study/NCT03475732,,http://www.chictr.org.cn/showprojen.aspx?proj=50306,https://clinicaltrials.gov/ct2/show/study/NCT03475732,https://clinicaltrials.gov/ct2/show/study/NCT03475732,,https://clinicaltrials.gov/ct2/show/study/NCT03475732,,https://clinicaltrials.gov/ct2/show/NCT03475732,,,,https://clinicaltrials.gov/ct2/show/study/NCT03475732,http://www.chictr.org.cn/showprojen.aspx?proj=50306,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,,,http://www.chictr.org.cn/showprojen.aspx?proj=50306,,,,,,,,,,,,,,,
140,No,Methylprednisolone,Methylprednisolone,,Peking Union Medical College Hospital,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,Zhongda Hospital; Renmin Hospital of Wuhan University,China,Ongoing,,,Phase 2,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,Completed,,1/26/2020,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/6/2020,,,,,,4/6/2020
140,Yes,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://www.drugbank.ca/drugs/DB00959,https://www.drugbank.ca/drugs/DB00959,https://www.drugbank.ca/drugs/DB00959,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,,https://www.drugbank.ca/drugs/DB00959,,,,https://www.drugbank.ca/drugs/DB00959,,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,,,,,,,,,,,,,,,
141,No,Favipiravir; Tocilizumab,Favipiravir; Tocilizumab,,Peking University First Hospital,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,N/A,China,Ongoing,Favipiravir - Small molecule; Tocilizumab - protein based; Anti-viral and monoclonal antibody combination,,,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,,3/8/2020,,,,,,0,COVID-19,150,No,9,Anhui Medical University Affiliated First Hospital - Hefei - Anhui - China; Peking University First Hospital - Beijing - China; Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology - Hubei - China; Ezhou Central Hospital - Hubei - China; Huoshenshan Hospital of Wuhan - Hubei - China; Jinyintan Hospital of Wuhan - Hubei - China; Tongji Hospital of Huazhong University of Science and Technology - Hubei - China; West Hospital Union Hospital Huazhong University of Science and Technology - Hubei - China; Wuhan Pulmonary Hospital - Hubei - China; Zhongnan Hospital of Wuhan University - Hubei - China,03/08/2020,05/01/2020,05/01/2020,https://clinicaltrials.gov/ct2/show/NCT04310228,Guiqiang Wang,,john131212@sina.com,,,,,Gabbie,4/6/2020,,,,,,4/6/2020
141,Yes,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://www.drugbank.ca/drugs/DB12466; https://www.drugbank.ca/drugs/DB06273,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://www.drugbank.ca/drugs/DB06273 ; https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=favipravir&searcher=drugs,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,,https://www.drugbank.ca/drugs/DB06273 ; https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=favipravir&searcher=drugs,,,,https://www.drugbank.ca/drugs/DB06273 ; https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=favipravir&searcher=drugs,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,,,,,,,,,,,,,,,
142,No,RO-0622,RO-0622,Azvudine,People's Hospital of Guangshan County,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Not Approved,N/A,China,Ongoing,,,Phase 0,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,N/A,,,,,,,0,COVID-19,20,No,1,People's Hospital of Guangshan County - Henan - China,02/16/2020,04/16/2020,,http://www.chictr.org.cn/showprojen.aspx?proj=49532,,,,,,,,Gabbie,4/7/2020,,,,,,4/7/2020
142,Yes,https://en.wikipedia.org/wiki/Azvudine,https://en.wikipedia.org/wiki/Azvudine,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,https://pubchem.ncbi.nlm.nih.gov/compound/Azvudine#section=Structures,https://www.ncbi.nlm.nih.gov/pubmed/25144636,https://en.wikipedia.org/wiki/Azvudine,,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,,,http://www.chictr.org.cn/showprojen.aspx?proj=49532,,https://en.wikipedia.org/wiki/Azvudine,,,,,,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,,http://www.chictr.org.cn/showprojen.aspx?proj=49532,,,,,,,,,,,,,,,
143,No,Noscapine,Noscapine,Noscovid,Qazvin University of Medical Sciences,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,N/A,Iran,Ongoing,,,Phase 2,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,,,4/17/2020,,,,,2,COVID-19,125,No,1,Velayat Hospital -  Quazvin - Iran,04/17/2020,,,https://en.irct.ir/trial/46576,,,,,,,,Gabbie,4/7/2020,,,,,,4/7/2020
143,Yes,http://ethics.research.ac.ir/ProposalViewEn.php?id=125991,http://ethics.research.ac.ir/ProposalViewEn.php?id=125991,https://www.irct.ir/trial/46576,http://ethics.research.ac.ir/ProposalViewEn.php?id=125991,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.drugbank.ca/drugs/DB06174,https://pubchem.ncbi.nlm.nih.gov/compound/Noscapine,https://www.drugbank.ca/drugs/DB06174,,http://en.qums.ac.ir/Portal/home/?124884/Velayat-Hospital,https://www.irct.ir/trial/46576,,,https://www.irct.ir/trial/46576,,https://pubchem.ncbi.nlm.nih.gov/compound/Noscapine,,,,,,https://www.irct.ir/trial/46576,,,,,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,,,https://www.irct.ir/trial/46576,,,,,,,,,,,,,,,
144,No,Bevacizumab,Bevacizumab,Avastin,Qilu Hospital of Shandong University; Genentech Inc.; Roche,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,Renmin Hospital of Wuhan University; Ialy Moriggia Pelascini Gravedona Hospital S.p.A; Wuhan University; Jiangbei Union Hospital of Huazhong University of Science and Technology; Shandong Provincial Chest Hospital,China,Ongoing,,,,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,,,,,,,,,COVID-19,140,No,1,Qilu Hospital of Shandong University - Shandong - China,03/17/2020,06/30/2020,07/31/2020,https://clinicaltrials.gov/ct2/show/NCT04305106,Jiaojiao Pang,,jiaojiaopang@126.com,,,,,Gabbie,4/8/2020,,,,,,4/8/2020
144,Yes,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/bevacizumab,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://www.drugbank.ca/drugs/DB00112,https://www.drugbank.ca/drugs/DB00112,https://www.drugbank.ca/drugs/DB00112,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,,,https://clinicaltrials.gov/ct2/show/NCT04305106,,https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/bevacizumab,,,,https://www.drugs.com/history/avastin.html,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,,,,,,,,Gabbie,,,,,,,
145,No,Leflunomide,Leflunomide,,Renmin Hospital of Wuhan University; University of Chicago,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/8/2020,,,,,,4/8/2020
145,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
146,No,Bromhexine Hydrochloride,Bromhexine Hydrochloride,Bisolvon,Second Affiliated Hospital of Wenzhou Medical University,Therapeutic,Pneumonia,Small molecule,Other,Repurposed-Approved,WanBangDe Pharmaceutical Group Co. Ltd.,China,Ongoing,,,,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,SKIPPED,,,,,,,,COVID-19,18,No,1,The Second AffIliated Hospital of Wenzhou Medical University - Zhejiang - China,02/16/2020,05/10/2020,06/01/2020,https://clinicaltrials.gov/ct2/show/NCT04273763,,,,,,NOT RECRUITING,,Gabbie,4/9/2020,,,,,,4/9/2020
146,Yes,https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=,https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=,https://www.drugbank.ca/drugs/DB09019,https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=,https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=,https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=,https://www.drugbank.ca/drugs/DB09019,https://www.drugsbanks.com/bisolvon/,https://www.drugbank.ca/drugs/DB09019,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,,,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,,https://www.drugbank.ca/drugs/DB09019,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,,,,,,,,,
147,No,Interferon beta; Favipiravir,Interferon beta; Favipiravir,Avigan,Shahid Beheshti University of Medical Sciences,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Approved,ChemRar; RDIF,Iran,Ongoing,Used to treat Influenza,,Phase 3,,,,,,,3/17/2020,3/27/2020,4/1/2020,,,,3,COVID-19,80,No,1,Japan,,,,,,,,,,,,Rebecca Taylor,4/8/2020,,,,,,4/8/2020
147,Yes,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.drugbank.ca/drugs/DB12466,https://www.ncbi.nlm.nih.gov/pubmed/25333492,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.thepharmaletter.com/article/russia-s-rdif-backs-chemrar-for-the-production-of-favipiravir-against-covid-19,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,,https://www.clinicaltrialsarena.com/news/fujifilm-avigan-covid-19-trial-japan/,,,,,,,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.clinicaltrialsarena.com/news/fujifilm-avigan-covid-19-trial-japan/,,,,https://www.clinicaltrialsarena.com/news/fujifilm-avigan-covid-19-trial-japan/,https://www.thepharmaletter.com/article/russia-s-rdif-backs-chemrar-for-the-production-of-favipiravir-against-covid-19,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.clinicaltrialsarena.com/news/fujifilm-avigan-covid-19-trial-japan/,,,,,,,,,,,,,,,,,,,
148,No,Darunavir; cibicistat,Darunavir; cibicistat,Prezcobix,Shanghai Public Health Clinical Center; Johnsons & Johnson; Janssen; Gilead,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,Repurposed-Approved,Johnson and Johnson,China; United States,Ongoing,Treat pneumonia,,Phase 3,,,,,,,,,,,,,3,COVID-19,30,No,1,Shanghai: China,01/30/20,08/31/20,12/31/20,,,008602137990333 ext 3222,,,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
148,Yes,https://aidsinfo.nih.gov/drugs/397/darunavir/0/patient,,https://aidsinfo.nih.gov/drugs/397/darunavir/0/patient,,,,https://www.drugbank.ca/drugs/DB01264,https://www.europeanpharmaceuticalreview.com/news/111977/johnson-johnson-launch-response-to-coronavirus/,https://www.drugbank.ca/drugs/DB01264,https://www.europeanpharmaceuticalreview.com/news/111977/johnson-johnson-launch-response-to-coronavirus/,https://www.natureindex.com/institution-outputs/china/shanghai-public-health-clinical-center-fudan-university/52cf526a140ba04763000006,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,,https://clinicaltrials.gov/ct2/show/NCT04252274,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04252274,,,,,,,,,
149,No,PD1; thymosin; Camrelizumab,PD1; thymosin; Camrelizumab,,Southeast University - China,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,Repurposed-Approved,NIHR,China,Ongoing,Cancer therapy,,Phase 2,,,,,,,,,,,,,2,COVID-19,,,,,,04/20/20,,,,,,,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
149,Yes,https://www.cebm.net/covid-19/registered-trials-and-analysis/,,https://www.cebm.net/covid-19/registered-trials-and-analysis/,,,,https://www.frontiersin.org/articles/10.3389/fimmu.2019.02298/full,https://www.frontiersin.org/articles/10.3389/fonc.2019.00873/full,https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0779-5,https://www.cebm.net/covid-19/registered-trials-and-analysis/,https://www.seu.edu.cn/english/,https://www.cebm.net/covid-19/registered-trials-and-analysis/,https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0636-7,,,,,,,,,,,,,,,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20032020v3-posting.pdf,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20032020v3-posting.pdf,,,,,,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20032020v3-posting.pdf,,,,,,,,,,,,,,,,,
150,No,Meplazumab,Meplazumab,,Tang-Du Hospital; Jingsu Pacific Meinuoke Biopharmaceutical Co.; Fourth Military Medical University,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,National Science and Technology Major Project,,Ongoing,Treat pneumonia,,Phase 2,,,,,,,,2/3/2020,,,,,2,COVID-19,17,No,1,Tang Du: China,02/03/20,02/10/20,,,,,,,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
150,Yes,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,,,,,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1,,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1,,,,,,,,,,,,,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,,,,,,,,,,,,,,,,,,,
151,No,Fingolimod,Fingolimod,Gilenya,The First Affiliated Hospital of Fujian Medical University; Novartis AG,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,NIHR,China,Ongoing,Treats MS,,Phase 2,,,,,,,,2/22/2020,,,,,2,COVID-19,30,No,1,Fuzhou: China,02/22/20,07/01/20,07/01/20,,,,wanjinchen75@fjmu.edu.cn,,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
151,Yes,https://www.drugbank.ca/drugs/DB08868,,https://www.drugbank.ca/drugs/DB08868,,,,https://www.drugbank.ca/drugs/DB08868,https://www.ncbi.nlm.nih.gov/pubmed/17785617,https://www.ncbi.nlm.nih.gov/pubmed/17785617,http://www.io.nihr.ac.uk/wp-content/uploads/migrated_new/11115-Fingolimod-oral.pdf,https://en.fjmu.edu.cn/,https://www.drugbank.ca/drugs/DB08868,https://www.drugbank.ca/drugs/DB08868,,https://clinicaltrials.gov/ct2/show/NCT04280588,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
152,No,ASCO9F; ritonavir; favipiravir,ASCO9F; ritonavir; favipiravir,Avigan,Tongji Hospital,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,Repurposed-Approved,Self funding; National Natural Science Foundation of China,China,Ongoing,HIV protease inhibitor,,Phase 2,,,,,,,,,,,,,2,COVID-19,119,No,1,China,04/06/2020,,,,,,,,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
152,Yes,https://www.ncbi.nlm.nih.gov/pubmed/32147628,https://www.ncbi.nlm.nih.gov/pubmed/32147628,https://www.europeanpharmaceuticalreview.com/news/116491/positive-results-from-initial-lopinavir-ritonavir-covid-19-clinical-trial/,,https://www.drugbank.ca/drugs/DB00503,,https://www.drugbank.ca/drugs/DB00503,https://www.drugbank.ca/drugs/DB00503,https://www.drugbank.ca/drugs/DB00503,http://www.chictr.org.cn/sourceofspendsprojen.aspx,https://english.tjh.com.cn/,http://www.chictr.org.cn/sourceofspendsprojen.aspx,https://www.drugbank.ca/drugs/DB00503,,https://www.europeanpharmaceuticalreview.com/news/116491/positive-results-from-initial-lopinavir-ritonavir-covid-19-clinical-trial/,,,,,,,,,,,,,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,,,,,,,,,,,,,,,,,,
153,No,Nitric Oxide (g),Nitric Oxide (g),,Xijing Hospital,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Approved,Private,China,Ongoing,,,Phase 2,,2/1/2020,3/1/2020,,,,,3/1/2020,,,,,2,COVID-19,,No,2,China,03/01/2020,03/01/2021,02/01/2022,,,,,,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
153,Yes,https://clinicaltrials.gov/ct2/show/NCT04290858,https://clinicaltrials.gov/ct2/show/NCT04290858,,,,,https://clinicaltrials.gov/ct2/show/NCT04290858,https://clinicaltrials.gov/ct2/show/NCT04290858,https://clinicaltrials.gov/ct2/show/NCT04290858,https://www.marketwatch.com/press-release/nu-med-plus-closely-monitoring-outcomes-on-two-new-human-clinical-trials-using-inhaled-nitric-oxide-in-treatment-of-covid-19-2020-03-25?mod=mw_quote_news,https://aospine.aofoundation.org/education/fellowship/spine-centers-asia-pacific/xijing-hospital,https://www.marketwatch.com/press-release/nu-med-plus-closely-monitoring-outcomes-on-two-new-human-clinical-trials-using-inhaled-nitric-oxide-in-treatment-of-covid-19-2020-03-25?mod=mw_quote_news,,,https://clinicaltrials.gov/ct2/show/NCT04290858,,https://www.streetwisereports.com/article/2020/03/26/inhaled-nitric-oxide-being-tested-as-covid-19-treatment.html,https://www.streetwisereports.com/article/2020/03/26/inhaled-nitric-oxide-being-tested-as-covid-19-treatment.html,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04290858,,,,https://www.marketwatch.com/press-release/nu-med-plus-closely-monitoring-outcomes-on-two-new-human-clinical-trials-using-inhaled-nitric-oxide-in-treatment-of-covid-19-2020-03-25?mod=mw_quote_news,,https://clinicaltrials.gov/ct2/show/NCT04290858,https://clinicaltrials.gov/ct2/show/NCT04290858,https://clinicaltrials.gov/ct2/show/NCT04290858,,,,,,,,,,,,,,,,
154,No,Vitamin C; Sodium Ascorbate,Vitamin C; Sodium Ascorbate,,ZhiYong Peng,Therapeutic,COVID-19,Small molecule,Antioxidant,Repurposed-Approved,,China,Ongoing,Prevent cytokine induced damage to lungs,,Phase 2,,2/1/2020,,,,,,2/14/2020,,,,,2,COVID-19,140,No,1,Zhongnan Hospital of Wuhan University; China,02/14/20,09/30/20,09/30/20,,,8618672396028,pengzy5@hotmail.com,,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
154,Yes,https://www.drugbank.ca/drugs/DB14482,https://www.drugbank.ca/drugs/DB14482,,,,,https://www.drugbank.ca/drugs/DB14482,https://www.medicinenet.com/script/main/art.asp?articlekey=228745,https://lpi.oregonstate.edu/mic/vitamins/vitamin-C,,https://www.researchgate.net/scientific-contributions/2136361683_Zhiyong_Peng,https://www.medicinenet.com/script/main/art.asp?articlekey=228745,https://www.medicinenet.com/script/main/art.asp?articlekey=228745,,https://www.medicinenet.com/script/main/art.asp?articlekey=228745,,https://clinicaltrials.gov/ct2/show/NCT04264533,,,,,,https://clinicaltrials.gov/ct2/show/NCT04264533,,,,,https://clinicaltrials.gov/ct2/show/NCT04264533,,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,,,,,,,https://www.medicinenet.com/script/main/art.asp?articlekey=228745,,,,,,,,,
155,No,antibody,antibody,CYNK-001,Celularity Incorporated; Sorrento Therapeutics; IDRI; Lung Biotechnology PBC,Therapeutic,COVID-19,Cell therapies,Antiviral drugs-broad spectrum,New,Sorrento Therapeutics Inc.,USA,Ongoing,,,Phase 2,,1/29/2020,3/30/2020,,,4/2/2020,4/2/2020,,,,,,2,COVID-19,86,No,2,Hackensack University Medical Center - Hackensack - New Jersey - United States; Multicare Health System - Tacoma - Washington - United States,5/13/2020,12/30/2020,6/30/2021,https://clinicaltrials.gov/ct2/show/NCT04365101,,,CYNK-001-COVID-19@idri.org,,,,,Ekaterina,4/6/2020,Natalie Tang,6/2/2020,,,,6/2/2020
155,Yes,,,,https://clinicaltrials.gov/ct2/show/NCT04365101,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04365101,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04365101,https://clinicaltrials.gov/ct2/show/NCT04365101,https://clinicaltrials.gov/ct2/show/NCT04365101,https://clinicaltrials.gov/ct2/show/NCT04365101,https://clinicaltrials.gov/ct2/show/NCT04365101,https://clinicaltrials.gov/ct2/show/NCT04365101,https://clinicaltrials.gov/ct2/show/NCT04365101,https://clinicaltrials.gov/ct2/show/NCT04365101,https://clinicaltrials.gov/ct2/show/NCT04365101,https://clinicaltrials.gov/ct2/show/NCT04365101,,,,,,,,,,,,,,,
156,No,ACE-MAB™; STI-4920; CMAB020,,ACE-MAB™; STI-4920; CMAB020,Sorrento Therapeutics Inc.; Mabpharm Limited,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,Repurposed-Not Approved,Sorrento Therapeutics Inc.; Mabpharm Limited,USA,Ongoing,bispecific ACE-MAB fusion protein,,Pre-Clinical Testing,,,3/24/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina,4/6/2020,Natalie Tang,6/2/2020,,,,6/2/2020
156,Yes,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,,https://www.biospace.com/article/releases/sorrento-collaborates-with-mabpharm-on-development-and-commercialization-of-ace-mab-to-potentially-treat-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
157,No,antibody,antibody,Gene MAb™,SmartPharm Therapeutics Inc.; Sorrento Therapeutics Inc.,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Sorrento Therapeutics Inc.,USA,Ongoing,uses Gene MAb™ platform for ab delivery,,Discovery,,3/23/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina,4/6/2020,Natalie Tang,6/2/2020,,,,6/2/2020
157,Yes,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,,https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
158,No,antibody,antibody,Anti-Corona Immunoglobulin (IgG),Kamada Ltd.; Kedrion Biopharma Inc.,Therapeutic,COVID-19,Other,Monoclonal antibodies,Repurposed-Not Approved,Kamada,Israel,Ongoing,plasma of recovered people w ab is used in patients,,Pre-Clinical Testing,,3/11/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina,4/6/2020,Natalie Tang,6/2/2020,,,,6/2/2020
158,Yes,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,,https://www.kamada.com/news/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
159,No,antibody,,antibody,Centivax; Swiftscale Biologics,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Centivax,USA,Ongoing,,,Pre-Clinical Testing,,3/19/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina,4/6/2020,Natalie Tang,6/3/2020,,,,6/3/2020
159,Yes,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,,,https://www.distributedbio.com/covid19,,https://www.distributedbio.com/covid19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
160,No,antibody,antibody,Human mAb 47D11,Erasmus MC; Utrecht University,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Erasmus MC,Netherlands,Ongoing,,,Pre-Clinical Testing,,3/10/2020,3/23/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina,4/6/2020,Natalie Tang,6/3/2020,,,,6/3/2020
160,Yes,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,,,https://www.nature.com/articles/s41467-020-16256-y,,https://www.nature.com/articles/s41467-020-16256-y,https://www.nature.com/articles/s41467-020-16256-y,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina,6/4/2020,,,,,,6/4/2020
161,No,darunavir; cobicistat; CYP3A inhibitor,darunavir; cobicistat; CYP3A inhibitor,,Shanghai Public Health Clinical Center; Zhongnan Hospital of Wuhan University; Johnson & Johnson,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Kinase inhibitors,Repurposed-Not Approved,Janssen Pharmaceutical Companies;Shanghai Public Health Clinical Center,,Ongoing,,,Phase 3,,1/30/2020,,,,,TARGET: 8/31/2020,,,,,,3,COVID-19,30,No,1,Shanghai Public Health Clinical Center - Shanghai - Shanghai - China - 201508,1/2020,8/31/20,12/31/20,https://clinicaltrials.gov/ct2/show/NCT04252274,,,luhongzhou@fudan.edu.cn,,,,,Ekaterina,4/6/2020,Natalie Tang,6/6/2020,,,,6/6/2020
161,Yes,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,,,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,,,,,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,,,,,,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,,,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir%3B+cobicistat%3B+CYP3A+inhibitor&cond=covid&draw=2&rank=2,,,,,,,,,,,,
162,No,Umifenovir,Umifenovir,Arbidol,Pharmstandard,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,China’s Ruijin Hospital,China,Ongoing,Membrane fusion inhibitor,,Phase 4,,2/7/2020,,,,,,,,,,,4,COVID-19,40,No,1,Loghman Hakim Hospital -Shahid Beheshti University of Medical Sciences and Health Services - Tehran - Iran,4/15/2020,4/22/2020,4/24/2020,https://clinicaltrials.gov/ct2/show/NCT04350684,,,,,,,,Ekaterina,4/6/2020,Natalie Tang,6/6/2020,,,,6/6/2020
162,Yes,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,,,,,,,,,,,https://www.thepharmaletter.com/article/worldwide-research-and-collaboration-needed-to-combat-covid-19-says-globaldata,,,https://clinicaltrials.gov/ct2/show/NCT04350684?term=Umifenovir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04350684?term=Umifenovir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04350684?term=Umifenovir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04350684?term=Umifenovir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04350684?term=Umifenovir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04350684?term=Umifenovir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04350684?term=Umifenovir&draw=2&rank=1,,,,,,,,,,,,,,,
163,No,baloxavir marboxil,baloxavir marboxil,Xofluza,Roche; The First Hospital Affiliated to Zhejiang University's Medical School,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,The First Hospital Affiliated to Zhejiang University's Medical School; Roche,,Ongoing,polymerase acidic endonuclease inhibitor,,Phase 1,,,,,,,4/2/2020,,,,,,1,COVID-19,30,No,1,The First Affiliated Hospital Zhejiang University School of Medicine  - Hangzhou - China,4/2/2020,5/31/2020,,http://www.chictr.org.cn/showprojen.aspx?proj=49013,,,qiuyq@zju.edu.cn,,,,,Ekaterina,4/6/2020,Natalie Tang,6/6/2020,,,,6/6/2020
163,Yes,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,,http://www.chictr.org.cn/showprojen.aspx?proj=49013,,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49013,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,http://www.chictr.org.cn/showprojen.aspx?proj=49013,,http://www.chictr.org.cn/showprojen.aspx?proj=49013,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49013,,,,,,,,,
164,No,placenta-based cells,placenta-based cells,PLX cell product,Pluristem Therapeutics; BIH Center for Regenerative Therapy; Berlin Center for Advanced Therapies,Therapeutic,COVID-19,Cell therapies,Antiviral drugs-not specified,New,Pluristem Therapeutics; BIH Center for Regenerative Therapy; Berlin Center for Advanced Therapies,Israel; USA; Germany; Italy,Ongoing,placenta-based cell therapy,,Phase 2,,3/13/2020,,,,5/8/2020,3/30/2020,6/8/2020,,,,,,,,,,,,,,,,,,,,,,Ekaterina,4/6/2020,Natalie Tang,6/6/2020,,,,6/6/2020
164,Yes,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/FDA-Clearance-COVID-19-FINAL.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,,https://www.pluristem.com/wp-content/uploads/2020/05/FDA-Clearance-COVID-19-FINAL.pdf,,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,,,,https://www.pluristem.com/wp-content/uploads/2020/05/FDA-Clearance-COVID-19-FINAL.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,,,,,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,,https://www.pluristem.com/wp-content/uploads/2020/05/PSTI-28-day-follow-up-FOR-RELEASE.pdf,,,,,,,,,,,,,,,,,,,
165,No,Thalidomide,Thalidomide,,Celgene Corp.; The First Affiliated Hospital of Wenzhou Medical University,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,Second Affliated Hospital of Wenzhou Medical University; Wenzou Central Hospital,China,Ongoing,An approved drug with noted immunosuppressive and anti-angiogenic activity; used for a number of immunological and inflammatory disorders; clinical trials aim to see if these properties of thalidomide can be used to prevent or treat COVID-19 induced lung injury instead of functioning as a direct antiviral; note that there is a second study with the same sponsors and utilizing thalidomide as well - but that includes the use of low does hormones as well and only enrolls 40 participants; discovery start - NDA approval - and on the market are completed with respect to thalidomide itself without taking into account its prospective use in treating COVID-19,,Phase 2,,Completed,,,,,,2/20/2020,,,,,2,COVID-19,100,No,,,02/20/2020,05/30/2020,06/30/2020,https://clinicaltrials.gov/ct2/show/NCT04273529 ; https://clinicaltrials.gov/ct2/show/NCT04273581,,,,,,,,Andy Zhou,4/11/2020,Natalie Tang,6/6/2020,,,,6/6/2020
165,Yes,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,Ongoing,https://www.drugbank.ca/drugs/DB01041 https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=2,,Phase 2,,https://www.drugbank.ca/drugs/DB01041,,,,,,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020785s000_ThalidomideTOC.cfm,https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020785s000_ThalidomideTOC.cfm,,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1 https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=2,No,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=2,,,,,,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,,,,,,,,,
166,No,Losartan,Losartan,ARB; Cozaar,University of Minnesota,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,Bill and Melinda Gates Foundation,United States,Ongoing,Approved drug used to treat hypertension by functioning as an angiotensin II receptor blocker; study intends to track COVID-19 patients' risk status in the ICU using the Sequential Organ Failure Assessment (SOFA) respiratory score following treatment with losartan or a placebo,,Phase 2,,Completed,,,,,,4/2/2020,,,,,2,COVID-19,561,No,3,Hennepin County Medical  Center - Minneapolis - Minnesota; M Health Fairview University of Minnesota Medical Center - Minneapolis - Minnesota; University of Minnesota - Minneapolis - Minnesota; Mayo Clinic Health System - Rochester - Minnesota,04/09/2020,04/01/2021,04/01/2021,https://clinicaltrials.gov/ct2/show/NCT04311177 ; https://clinicaltrials.gov/ct2/show/NCT04312009,Christopher Tignanelli,612-624-4373,Covid19trial@umn.edu,,,,,Andy Zhou,4/11/2020,Natalie Tang,6/6/2020,,,,6/6/2020
166,Yes,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1,Ongoing,https://www.drugbank.ca/drugs/DB00678 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,,Phase 2,,https://www.drugbank.ca/drugs/DB00678,,,,,,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1,,https://www.drugbank.ca/drugs/DB00678,https://www.drugbank.ca/drugs/DB00678,,,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04311177?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1,No,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04311177?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,,,,,,,,,
167,No,sildenafil citrate,sildenafil citrate,,Tongji Hospital,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,China,Ongoing,Approved drug used to treat pulmonary arterial hypertension ; angina ; and erectile dysfunction; study evaluates rate of disease remission ; rate of entering the critical stage ; and time of entering the critical stage after treatment with sildenafil citrate,,Phase 3,,Completed,,,,,,,2/9/2020,,,,3,COVID-19,10,No,1,Wuhan - China,02/09/2020,03/01/2020,11/09/2020,https://clinicaltrials.gov/ct2/show/NCT04304313,,,,,,,,Andy Zhou,4/11/2020,,,,,,4/11/2020
167,Yes,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1,Ongoing,https://www.drugbank.ca/drugs/DB00203 https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,,Phase 3,,https://www.drugbank.ca/drugs/DB00203,,,,,,,https://www.drugbank.ca/drugs/DB00203,https://www.drugbank.ca/drugs/DB00203#reference-A175732,https://www.drugbank.ca/drugs/DB00203#reference-A175732,,,,,,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,,Andy Zhou,,,,,,,
168,No,a lipic acid,a lipic acid,,Zhongshan Hospital; Fudan University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/11/2020,,,,,,4/11/2020
168,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,,,,,,,
169,No,Chloroquine phosphate,Chloroquine phosphate,,Jingzhou Central Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/11/2020,,,,,,4/11/2020
169,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,,,,,,,
170,No,Ebastine; Lopinavir; Interferon a,Ebastine; Lopinavir; Interferon a,,Wuhan Red Cross Hospital; Minanyang Central Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/11/2020,,,,,,4/11/2020
170,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
171,No,Danoprevir; Ritonavir; Interferon,Danoprevir; Ritonavir; Interferon,,The Ninth Hospital of Nanchang; Ascletis Pharmaceuticals,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,Ascletis Pharmaceutials Co. Ltd.,China,Ongoing,Danoprevir is an oral hepatitis C virus protease inhibitor approved in China in June 2018; used in a phase 4 trial that began 02/17/2020 to observe its effects on the rate of composite adverse outcomes and time to recovery among other measures,,Phase 4,,Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/11/2020,,,,,,4/11/2020
171,Yes,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,Ongoing,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,No,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,,,,,,,,
172,No,Mesenchymal Stem Cells,Mesenchymal Stem Cells,,Chinese Academy of Medical Sciences,Therapeutic,COVID-19,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,Puren Hospital Affliated to Wuhan University of Science and Technology; Shanghai University; Qingdao Co-orient Watson Biotechnology group co. LTD; Basic Medical Sciences - Chinese Academy of Medical Sciences,China,Ongoing,MSCs have been shown to exert antiinflammatory and immunoregulatory functions - promote regeneration of damaged tissues - and inhibit tissue fibrosis; trial aims to explore MSC's potential to treat COVID-19 patients,,Phase 1,,Completed,,,,,2/1/2020,,,,,,1,COVID-19,30,No,1,Wuhan - China,02/01/2020,06/30/2020,06/30/2020,https://clinicaltrials.gov/ct2/show/NCT04339660,Yan Liu,,447822853@qq.com,,,,,Andy Zhou,4/11/2020,,,,,,4/11/2020
172,Yes,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,Therapeutic,COVID-19,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,Ongoing,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,Phase 1,,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,,,,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,,,,,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,No,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,,,,,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,,,,,,,,
173,No,Recombinant ACE2,Recombinant ACE2,,The First Affiliated Hospital of Guangzhou Medical University,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,,China,On Hold,Study to investigate if there is efficacy signal that warrants a large Phase 2B trial or harm that suggests trial should not be done; study in question has a not applicable phase; status is withdrawn as of 03/17/2020 (which is why many cells were left blank),,Phase 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/11/2020,,,,,,4/11/2020
173,Yes,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,https://clinicaltrials.gov/ct2/show/NCT04287686,https://clinicaltrials.gov/ct2/show/NCT04287686,On Hold,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,,Phase 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
174,No,Washed micrbiota transplantation,Washed micrbiota transplantation,,The Second Hospital of Nanjing Medical University,Therapeutic,Pneumonia,Cell therapies,,Repurposed-Not Approved,The Second Hospital of Nanjing Medical University,China,On Hold,Molecule type - microbiota. The recent study on using washed microbiota transplantation (WMT) as rescue therapy in critically ill patients with AAD demonstrated the important clinical benefits and safety of WMT. Additionally the recent animal study provided direct evidence supporting that antibiotics could decrease gut microbiota and the lung stromal interferon signature and facilitate early influenza virus replication in lung epithelia. Importantly the above antibiotics caused negative effects can be reversed by fecal microbiota transplantation (FMT) which suggested that FMT might be able to induce a significant improvement in the respiratory virus infection.,,Discovery,,2/5/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Natalie Tang,4/9/2020,,,,,,4/9/2020
174,Yes,,,,,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://www.smartpatients.com/trials/NCT04251767,https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/,,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,,,,,,,,,,,https://www.smartpatients.com/trials/NCT04251767,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,,,,,,https://www.smartpatients.com/trials/NCT04251767,,,,,,,,,
175,No,Dipyridamole,Dipyridamole,Persantine,The First Affiliated Hospital of Guangzhou Medical University,Therapeutic,COVID-19,Other,,Repurposed-Approved,Major regional immunity cultivation project - 91742109,China,Ongoing,Type - vasodilator,,Phase 4,,,,,,,,,,,,,4,COVID-19,460,No,6,The First Affiliated Hospital of Guangzhou Medical University - Guangdong province - Guangdong province - China; Wuhan University People's Hospital - Hubei province - China; Union Hospital Affiliated to Tongji  Medical College of Huazhong University of science and technology - Hubei province - China; Wuhan Huangpi District Hospital of traditional Chinese Medicine  - Hubei province - China; Dawu County People's Hospital - Hubei province - China; The First Affiliated Hospital of Wenzhou Medical University - Zhejiang province - China,02/10/2020,04/10/2020,,http://www.chictr.org.cn/showprojen.aspx?proj=49864,Qingling Zhang,,zqling68@hotmail.com,,,,,Natalie Tang,4/9/2020,,,,,,4/9/2020
175,Yes,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/,https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full.pdf,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/,,http://www.chictr.org.cn/showprojen.aspx?proj=49864,,,,,,,,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,,http://www.chictr.org.cn/showprojen.aspx?proj=49864,,,,,,,,,,,,,,,
176,No,Bromhexine hydrochloride; Arbidol umifenovir; Favipiravir; Interferon a2b,Bromhexine hydrochloride; Arbidol umifenovir; Favipiravir; Interferon a2b,,The Second Affiliated Hospital of Wenzhou Medical University; WanBangDe Pharmaceutical Group,Therapeutic,COVID-19,,Antiviral drugs-broad spectrum,Repurposed-Approved,,China,Ongoing,On going recruitment,,,,,,,,,,,,,,,,COVID-19,60,No,1,The Second AffIliated Hospital of Wenzhou Medical University - Wenzhou - Zhejiang - China,02/16/2020,04/15/2020,30/04/2020,https://clinicaltrials.gov/ct2/show/NCT04273763,,,,,,NOT RECRUITING,,Natalie Tang,4/9/2020,,,,,,4/9/2020
176,Yes,,,,,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,,,,,,https://clinicaltrials.gov/ct2/show/NCT04273763,,Natalie Tang,4/9/2020,,,,,,4/9/2020
177,No,Dihydroartemisinin; piperaquine; arbidol umifenovir; interferon a,Dihydroartemisinin; piperaquine; arbidol umifenovir; interferon a,,The First Affiliated Hospital of Nanchang University,Therapeutic,Pneumonia,,Antiviral drugs-not specified; Anti-malarial,,,China,Failed,Cancelled by investigator,,Phase 4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Natalie Tang,4/11/2020,,,,,,4/11/2020
177,Yes,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/,,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,,,,,,,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,,,,,,,,
178,No,Human Immunoglobulin (pH4),Human Immunoglobulin (pH4),Intravenous Immunoglobulin,Peking Union Medical College Hospital,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,Tongji Hospital of Tongji Medical College; Huazhong University of Science and Technology,China,Ongoing,,,Phase 2,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,,,2/10/2020,,,,,2,Pneumonia,80,No,1,Peking Union Medical College Hospital,02/10/2020,04/30/2020,06/30/2020,https://clinicaltrials.gov/ct2/show/NCT04261426,Taisheng Li,,litsh@263.net,,,NOT YET RECRUITING,,Gabbie,4/6/2020,Arshy,4/20/2020,,,,4/20/2020
178,Yes,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://www.drugbank.ca/drugs/DB00028,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://www.drugbank.ca/drugs/DB00028,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,,https://www.drugbank.ca/drugs/DB00028,,,,,,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,,,,,,,,,,,,,,,
179,No,Tocilizumab,Tocilizumab,RoActemra,Peking University First Hospital; Genentech Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,N/A,China,Ongoing,Being used in above trial,,,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,SKIPPED,3/8/2020,,,,,,0,Covid-19,150,No,9,Anhui Medical University Affiliated First Hospital - Hefei - Anhui - China; Peking University First Hospital - Beijing - China; Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology - Hubei - China; Ezhou Central Hospital - Hubei - China; Huoshenshan Hospital of Wuhan - Hubei - China; Jinyintan Hospital of Wuhan - Hubei - China; Tongji Hospital of Huazhong University of Science and Technology - Hubei - China; West Hospital Union Hospital Huazhong University of Science and Technology - Hubei - China; Wuhan Pulmonary Hospital - Hubei - China; Zhongnan Hospital of Wuhan University - Hubei - China,03/08/2020,05/01/2020,05/01/2020,https://clinicaltrials.gov/ct2/show/NCT04310228,Guiqiang Wang,,john131212@sina.com,,,,,Gabbie,4/6/2020,Arshy,4/20/2020,,,,4/20/2020
179,Yes,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://www.drugbank.ca/drugs/DB06273,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,https://www.drugbank.ca/drugs/DB06273,,,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,,,,,,,,,,,,,,
180,No,Anulohuaxian,Anulohuaxian,Anulohuaxian,Peking University First Hospital,Therapeutic,COVID-19,Other,Unknown,Repurposed-Approved,N/A,China,Ongoing,Traditional Chinese Medicine,,,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,UNNOWN,,,,,,,0,Covid-19,750,No,8,The Second People's Hospital of Fuyang - Anhui - China; Ezhou Central Hospital - Hubei - China; Huoshenshan Hospital of Wuhan - Hubei - China; Jinyintan Hospital of Wuhan - Hubei - China; Tongji Hospital of Huazhong University of Science and Technology - Hubei - China; West Hospital Union Hospital Huazhong University of Science and Technology - Hubei - China; Wuhan Pulmonary Hospital - Hubei - China; Zhongnan Hospital of Wuhan University - Hubei - China; Wenzhou Medical University Affiliated First Hospital - Zhejiang - China	,04/01/2020,06/01/2020,12/01/2020,https://clinicaltrials.gov/ct2/show/NCT04334265,Guiqiang Wang,,john131212@sina.com,,,,,Gabbie,4/6/2020,Arshy,4/20/2020,,,,4/20/2020
180,Yes,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://journals.lww.com/md-journal/fulltext/2019/05310/the_efficacy_of_chinese_patent_medicine_combined.18.aspx,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708750/,,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://journals.lww.com/md-journal/fulltext/2019/05310/the_efficacy_of_chinese_patent_medicine_combined.18.aspx,,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708750/,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,,,,,,,,,,,,,,,
181,No,Allogeneic human dental pulp stem cells,Allogeneic human dental pulp stem cells,,Renmin Hospital of Wuhan University,Therapeutic,Pneumonia,Cell therapies,Other,Repurposed-Not Approved,Beijing SH Bio-Tech Corporation - Beijing - China; Utooth Biological Technology Co. Ltd. - Hubei - China,China,Ongoing,,,Phase 1,,REPURPOSED,,,,,4/6/2020,,,,,,1,COVID-19,20,No,1,Renmin Hospital of Wuhan University (East Campus) - Hubei - China,04/06/2020,12/31/2020,03/31/2021,https://clinicaltrials.gov/ct2/show/NCT04336254,Qingsong Ye,,	qingsongye@foxmail.com,,,,,Gabbie,4/8/2020,Arshy,4/20/2020,,,,4/20/2020
181,Yes,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429131/,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,,,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429131/,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,,,,,,,,,,,,,,,
182,No,IBIO-100,,IBIO-100,iBio Inc,Therapeutic,Other,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,,United States,Ongoing,Being repurposed to treat idiopathic pulmonary fibrosis; Previously granted orphan drug designation for treatment of systemic sclerosis investigated to systemic scleroderma,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,Arshy,4/20/2020,,,,4/20/2020
182,Yes,,,,https://www.ibioinc.com/pipeline#IBIO100,,,,,,,https://www.ibioinc.com/pipeline#IBIO100,,https://www.ibioinc.com/pipeline#IBIO100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
183,No,chloroquine; azithromycin,chloroquine; azithromycin,,Population Health Research,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/20/2020,,,,,,4/20/2020
183,Yes,,,,https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
184,No,Favipiravir; Baloxavir marboxil,Favipiravir; Baloxavir marboxil,,First Hospital Affiliated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/26/2020,,,,,,4/26/2020
184,Yes,,,,https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Shanghai - Shanghai - China -,,,,,,,,,,,,,,,,,,,
185,No,Ruxolitinib,Ruxolitinib,Jakafi; Jakavi,Tongji Hospital; Incyte Corporation; Novartis AG,Therapeutic,Other,Small molecule,Kinase inhibitors,Repurposed-Approved,,Switzerland,Ongoing,Being evaluated for treatment of COVID 19 associated cytokine storm,,,,,Assume completed,,,,Assume completed,Assume completed,Assume completed,,,,Expanded Access ,COVID 19,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04355793,,18554633463,medinfo@incyte.com,,,,,Okezi,4/26/2020,,,,,,4/26/2020
185,Yes,https://www.janssen.com/lack-evidence-support-use-darunavir-based-treatments-sars-cov-2-0,https://www.janssen.com/lack-evidence-support-use-darunavir-based-treatments-sars-cov-2-0,https://www.globenewswire.com/news-release/2020/04/02/2011153/0/en/Novartis-announces-plan-to-initiate-clinical-study-of-Jakavi-in-severe-COVID-19-patients-and-establish-international-compassionate-use-program.html,https://www.bioworld.com/COVID19products,,,,,,,https://www.janssen.com/lack-evidence-support-use-darunavir-based-treatments-sars-cov-2-0,,https://www.globenewswire.com/news-release/2020/04/02/2011153/0/en/Novartis-announces-plan-to-initiate-clinical-study-of-Jakavi-in-severe-COVID-19-patients-and-establish-international-compassionate-use-program.html,,,,,,,,,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04355793?term=ruxolitinib&cond=covid+19&draw=1&rank=2,,,,,,,,,,,,,,,
186,No,Peginterferon Lambda-1a,Peginterferon Lambda-1a,Peginterferon Lambda-1a,Stanford University; Eiger Biopharmaceuticals Inc.,Therapeutic,COVID-19,Other,Other,Repurposed-Not Approved,,United States,Ongoing,,,Phase 2,,,Assume completed,,,,Assume completed,Assume completed,Assume completed,,,,2,COVID 19,120,No,1,Stanford University School of Medicine - Stanford - California,04/24/2020,08/14/2020,05/01/2021,https://clinicaltrials.gov/ct2/show/NCT04331899,Upinder Singh,,usingh@stanford.edu,,,,,Okezi,4/26/2020,,,,,,4/26/2020
186,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04331899,https://clinicaltrials.gov/ct2/show/study/NCT04331899,https://clinicaltrials.gov/ct2/show/study/NCT04331899,,,,https://clinicaltrials.gov/ct2/show/NCT04331896,https://clinicaltrials.gov/ct2/show/NCT04331897,https://clinicaltrials.gov/ct2/show/NCT04331898,https://clinicaltrials.gov/ct2/show/NCT04331899,,,,,,,,,,,,,,,
187,No,LV-SMENP-DC; Synthetic Minigene Vaccine,,LV-SMENP-DC; Synthetic Minigene Vaccine,Shenzhen Geno-Immune Medical Institute,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,Shenzhen Third People's Hospital; Shenzhen Second People's Hospital,China,Ongoing,Vaccine to treat and prevent severe Covid-19 pneumonia; Innovative COVID19 minigenes engineered based on multiple viral genes using an efficient lentiviral vector system to express viral proteins and immune modulatory genes to modify dendritic cells and to activate T cells,,Phase 2,,,Assume completed,,,,,,,,,,2,COVID 19,100,No,3,Shenzhen Geno-Immune Medical Institute-Shenzhen-Guangdong-China; Shenzhen Third People's Hospital-Shenzhen-Guangdong-China; Shenzhen Second People's Hospital-Shenzhen-Guangdong-China,03/24/2020,07/31/2023,12/31/2024,https://clinicaltrials.gov/ct2/show/NCT04276896,Lung-Ji Chang,For China: +86(755)8672 5195,c@szgimi.org,,,,,Okezi,4/26/2020,,,,,,4/26/2020
187,Yes,https://www.nature.com/articles/d41573-020-00073-5,,https://www.nature.com/articles/d41573-020-00073-5,https://www.nature.com/articles/d41573-020-00073-5,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04276896,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04276896,https://clinicaltrials.gov/ct2/show/NCT04276896,,,,https://clinicaltrials.gov/ct2/show/NCT04276896,https://clinicaltrials.gov/ct2/show/NCT04276896,https://clinicaltrials.gov/ct2/show/NCT04276896,https://clinicaltrials.gov/ct2/show/NCT04276896,https://clinicaltrials.gov/ct2/show/NCT04276897,,,,,,,,,,,,,,,
188,No,aAPC Vaccine,,aAPC Vaccine,Shenzhen Geno-Immune Medical Institute,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,,Shenzhen Third People's Hospital; Shenzhen Second People's Hospital,China,Ongoing,Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes to the artificial antigen presenting cells,,Phase 1,,,Assume completed,,,,Started,,,,,,1,COVID 19,100,No,3,Shenzhen - Guangdong - China,02/15/2020,07/31/2023,12/31/2024,https://clinicaltrials.gov/ct2/show/NCT04299724,Lung-Ji Chang,For China: +86(755)8672 5195,c@szgimi.org,,,,,Okezi,4/26/2020,,,,,,4/26/2020
188,Yes,https://www.nature.com/articles/d41573-020-00073-5,,https://www.nature.com/articles/d41573-020-00073-5,https://www.nature.com/articles/d41573-020-00073-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04299724,,https://clinicaltrials.gov/ct2/show/NCT04299724,https://clinicaltrials.gov/ct2/show/NCT04299724,https://clinicaltrials.gov/ct2/show/NCT04299724,https://clinicaltrials.gov/ct2/show/NCT04299724,,,,,,,,,,,,,,,
189,No,Peptide-based therapeutic,,Peptide-based therapeutic,48Hour Discovery Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,New,48Hour Discovery Inc.,USA,Ongoing,,,Discovery,,2/14/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/5/2020,A. Burnett,5/29/2020,,,,5/29/2020
189,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,5/29/2020,,,,5/29/2020
190,No,Pharmetrx therapeutics,,Pharmetrx therapeutics,Afecta Pharmaceuticals Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,Afecta Pharmaceuticals Inc.,USA,Ongoing,The compounds were identified using PharmetRx® Afecta's proprietary artificial intelligence platform and demonstrate bioactivity via two key therapeutic mechanisms of action-(1) immunomodulation similar to that of hydroxychloroquine or (2) inhibition of viral replication or attachment to host cells.,,Pre-Clinical Testing,,2/14/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/5/2020,A. Burnett,5/29/2020,,,,5/29/2020
190,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/6/2020,A. Burnett,5/29/2020,,,,5/29/2020
191,No,Active Agent,,Active Agent,Aicuris Anti-infective Cures GmbH,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,Repurposed-Not Approved,Aicuris Anti-infective Cures GmbH,Germany,Ongoing,,,Discovery,,2/4/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/5/2020,A. Burnett,5/29/2020,,,,5/29/2020
191,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/8/2020,A. Burnett,5/29/2020,,,,5/29/2020
192,No,Antiviral component,,Antiviral component,Aikido Pharma Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,Aikido Pharma Inc.; the University of Maryland -Baltimore,USA,Ongoing,"The compounds seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus.",,Pre-Clinical Testing,,2/14/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/5/2020,A. Burnett,5/29/2020,,,,5/29/2020
192,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/10/2020,A. Burnett,5/29/2020,,,,5/29/2020
193,No,reproxalap(reactive aldehyde species (RASP) inhibitor),reproxalap(reactive aldehyde species (RASP) inhibitor),ADX-629; reproxalap,Aldeyra Therapeutics Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,Aldeyra Therapeutics Inc.,USA,Ongoing,,,Phase 2,,,,,,,2/14/2020,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/5/2020,A. Burnett,5/29/2020,,,,5/29/2020
193,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,05.05.2027,A. Burnett,5/29/2020,,,,5/29/2020
194,No,Eculizumab,Eculizumab,Soliris,Alexion Pharmaceuticals Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Alexion Pharmaceuticals Inc.,USA,On Hold,replaced by Ultomiris(ravulizumab-cwvz) for further tests.,,Pre-Clinical Testing,,3/24/2020,3/24/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/7/2020,A. Burnett,5/29/2020,,,,5/29/2020
194,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,05.07.2029,A. Burnett,5/29/2020,,,,5/29/2020
195,No,recombinant sialidase,recombinant sialidase,DAS-181,Ansun Biopharma Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,Repurposed-Not Approved,Ansun Biopharma Inc.;Renmin Hospital of Wuhan University,USA,Ongoing,,,Phase 1,,3/6/2020,4/2/2020,,,,4/30/2020,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/7/2020,A. Burnett,5/29/2020,,,,5/29/2020
195,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,05.07.2031,A. Burnett,5/29/2020,,,,5/29/2020
196,No,Methioninase,Methioninase,SARS-CoV-2 targeting recombinant methioninase,Anticancer Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,Anticancer Inc.; AntiCancer Beijing,USA; China,Ongoing,,,Pre-Clinical Testing,,2/3/2020,2/3/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/7/2020,A. Burnett,5/29/2020,,,,5/29/2020
196,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,05.07.2033,A. Burnett,5/29/2020,,,,5/29/2020
197,No,Solnatide,,Solnatide,Apeptico Forschung und Entwicklung GmbH,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,Apeptico Forschung und Entwicklung GmbH;The Austrian Research Promotion Agency,Austria,Ongoing,Solnatide IMP has been designed for activation of the pulmonary epithelial sodium channel (ENaC) and for the restoration of the injured endothelial-epithelial barrier of pulmonary alveoli.,,Phase 2,,4/1/2020,,,,,4/28/2020,5/4/2020,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/7/2020,A. Burnett,5/29/2020,,,,5/29/2020
197,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,05.07.2035,A. Burnett,5/29/2020,,,,5/29/2020
198,No,Cannabinoid-based therapy,,Cannabinoid-based therapy,Applied Biology Inc.; Applied Bonanics LLC,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,Applied Biology Inc.; Applied Bonanics LLC,USA,Ongoing,cannabinoids may act as anti-androgens,,Discovery,,4/14/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/7/2020,A. Burnett,5/29/2020,,,,5/29/2020
198,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,5/28/2020,,,,5/28/2020
199,No,AT-001,,AT-001,Applied Therapeutics Inc.,Therapeutic,Other,Small molecule,Other,Repurposed-Not Approved,,United States,Ongoing,Aldose Reductase Inhibitor; New York Hospital Investigator Initiated Studies used under an emergency IND,,,,,,,,Emergency-Completed,,,,,,,,,,,,,,,,,,,,,,,,Ivanna,4/24/2020,A. Burnett,5/29/2020,,,,5/29/2020
199,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-ind-and-investigator-initiated,https://www.sec.gov/Archives/edgar/data/1697532/000104746919002659/a2238624zs-1a.htm,https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-ind-and-investigator-initiated,https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-ind-and-investigator-initiated,,https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-ind-and-investigator-initiated,https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-ind-and-investigator-initiated,https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-ind-and-investigator-initiated,,,,,,,,https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-ind-and-investigator-initiated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
200,No,Small molecules,,Small molecules,Aptorum Group Ltd,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,Repurposed-Not Approved,,China,Ongoing,3 molecules targeting two viral replication enzymes- 3CL-Protease and RNA dependent RNA Polymerase; Pre-Clinical studies will be taken over by the University of Hong Kong; Covar Pharmaceuticals is another collaborator,,Discovery,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna,4/26/2020,A. Burnett,5/29/2020,,,,5/29/2020
200,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3,https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3,https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3,https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3,,https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3,https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3,https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3,,https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3,,https://www.businesswire.com/news/home/20200330005263/en/Aptorum-Group-Collaborates-Covar-Pharmaceuticals-Investigate-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
201,No,ALT-100,,ALT-100,Aqualung Therapeutics Corp.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,eNAMPTOR is a platform of three products which includes ALT-100,,Pre-Clinical Testing,,Completed,Assumed Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna,4/25/2020,,,,,,4/25/2020
201,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.aqualungtherapeutics.com/enamptor/,https://www.aqualungtherapeutics.com/enamptor/,https://www.aqualungtherapeutics.com/enamptor/,https://www.aqualungtherapeutics.com/enamptor/,,https://www.aqualungtherapeutics.com/contact,https://www.aqualungtherapeutics.com/pipeline/,https://aqualungtherapeutics.reportablenews.com/pr/aqualung-therapeutics-advances-its-investigational-monoclonal-antibody-into-ind-enabling-studies-of-acute-respiratory-distress-syndrome-ards-and-ventilator-induced-lung-injury-vili,,https://www.aqualungtherapeutics.com/pipeline/,,https://www.aqualungtherapeutics.com/pipeline/,https://www.technologynetworks.com/biopharma/blog/antibody-to-treat-lung-inflammation-may-offer-potential-in-covid-19-332369,https://www.aqualungtherapeutics.com/key-activities-and-press/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
202,No,TMC-310911; ritonavir,TMC-310911; ritonavir,ASC09F,Ascletis Pharma Inc.,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,Repurposed-Approved,,China,Ongoing,HIV-1 Protease Inhibitor; Another clinical trial with oseltamivir retracted due to insufficient patients; ASC09-Ritonavir vs Lopinavir-Ritonavir trial sponsor is First Affiliated Hospital of Zhejiang University and Ascletis is collaborator,,,,Assumed Completed,Assumed Completed,Assumed Completed,Completed,Completed,Completed,Completed,Started,,,,,COVID19,160,No,,,02/07/2020,05/31/2020,06/30/2020,https://clinicaltrials.gov/ct2/show/NCT04261907,Xiaowei Xu,,xxw69@126.com,,,Not Yet Recruiting,,Ivanna,4/26/2020,,,,,,4/26/2020
202,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://ascletis.com.cn/single/145.html,https://www.drugbank.ca/drugs/DB15623; https://www.drugbank.ca/drugs/DB00503,https://www.drugbank.ca/drugs/DB15623; https://www.drugbank.ca/drugs/DB00503,https://www.drugbank.ca/drugs/DB15623; https://www.drugbank.ca/drugs/DB00503,,http://ascletis.com.cn/single2/139.html,http://ascletis.com.cn/single/145.html,https://www.drugbank.ca/drugs/DB15623; https://www.drugbank.ca/drugs/DB00503; https://clinicaltrials.gov/ct2/show/record/NCT04261907,,http://ascletis.com.cn/single/145.html,,http://ascletis.com.cn/single/145.html,http://ascletis.com.cn/single/145.html,http://ascletis.com.cn/single/145.html,http://ascletis.com.cn/single/145.html,http://ascletis.com.cn/single/145.html,http://ascletis.com.cn/single/145.html,http://ascletis.com.cn/single/145.html,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49075,http://www.chictr.org.cn/showprojen.aspx?proj=49352,,https://clinicaltrials.gov/ct2/show/record/NCT04261907,,,https://clinicaltrials.gov/ct2/show/record/NCT04261907,https://clinicaltrials.gov/ct2/show/record/NCT04261907,https://clinicaltrials.gov/ct2/show/record/NCT04261907,https://clinicaltrials.gov/ct2/show/record/NCT04261907,,,,,,https://clinicaltrials.gov/ct2/show/record/NCT04261907,,,,,,,,,
203,No,acalabrutinib,acalabrutinib,Calquence,AstraZeneca plc,Therapeutic,ARDS,Small molecule,Kinase inhibitors,Repurposed-Approved,,United Kingdom,Ongoing,Acerta Pharma B.V. discovered acalabrutinib and is a collaborator on the clinical trial,,Phase 2,,Completed,Completed,Assumed Completed,Assumed Completed,Assumed Completed,Skipped,Target: 04/24/2020,,,,,2,COVID19,428,No,1,Barcelona - Spain,06/12/2020,11/26/2020,11/26/20,https://clinicaltrials.gov/ct2/show/NCT04346199,,1-877-240-9479,information.center@astrazeneca.com,,,Not Yet Recruiting,,Ivanna,4/26/2020,,,,,,4/26/2020
203,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html,https://www.drugbank.ca/drugs/DB11703,https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html,https://www.drugbank.ca/drugs/DB11703,,https://www.astrazeneca.com/our-company/contact-us.html,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,https://www.acerta-pharma.com/about/,,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,,https://www.astrazeneca.com/our-therapy-areas/oncology.html#OurOncologypipeline,https://www.astrazeneca.com/our-therapy-areas/oncology.html#OurOncologypipeline,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,https://www.astrazeneca.com/our-therapy-areas/oncology.html#OurOncologymedicines,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,,,,,https://clinicaltrials.gov/ct2/show/NCT04346199,https://clinicaltrials.gov/ct2/show/NCT04346199,https://clinicaltrials.gov/ct2/show/NCT04346199,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,https://clinicaltrials.gov/ct2/show/study/NCT04346199,https://clinicaltrials.gov/ct2/show/study/NCT04346199,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,,,,,,https://clinicaltrials.gov/ct2/show/record/NCT04346199?view=record,,,,,,,,,
204,No,ribavirin inhalation solution,ribavirin inhalation solution,Virazole,Bausch Health Cos. Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Approved,Hospira Inc.,Canada,Ongoing,Control # 238007 for Canadian Clinical Trial Website - works best with Internet Explorer; first posted on Clinicaltrials.gov 04/22/2020,,Phase 1,,,,,,Assumed Completed,Target: 04/2020,,,,,,1,COVID19,50,No,,,09/2020,04/2021,4/1/21,https://clinicaltrials.gov/ct2/show/NCT04356677,Alexandre Brkovic,514-904-4863,Alexandre.Brkovic@bauschhealth.com,,,Not Yet Recruiting,,Ivanna,4/25/2020,,,,,,4/25/2020
204,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ir.bauschhealth.com/news-releases/2020/04-13-2020-120008693,https://www.drugbank.ca/drugs/DB00811,http://www.virazole.com/,https://www.drugbank.ca/drugs/DB00811,http://www.virazole.com/,https://www.bioworld.com/COVID19products,https://ir.bauschhealth.com/news-releases/2020/04-13-2020-120008693,https://health-products.canada.ca/ctdb-bdec/search-recherche.do;jsessionid=6E35384F37BD4DFE705B0CEA1440F945,,https://clinicaltrials.gov/ct2/show/study/NCT04356677,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04356677,,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04356677,https://clinicaltrials.gov/ct2/show/study/NCT04356677,https://clinicaltrials.gov/ct2/show/study/NCT04356677,https://clinicaltrials.gov/ct2/show/study/NCT04356677,,,https://clinicaltrials.gov/ct2/show/record/NCT04356677,https://clinicaltrials.gov/ct2/show/record/NCT04356677,,https://clinicaltrials.gov/ct2/show/record/NCT04356677,,,,,,https://clinicaltrials.gov/ct2/show/record/NCT04356677,,,,,,,,,
205,No,niclosamide,niclosamide,Niclocide,Bayer AG; Union Therapeutics A/S; Ana Therapeutics,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Approved,,United States,Ongoing,Voluntarily withdrawn from market by Bayer in 1996; Another Brand name is Yomesan,,Pre-Clinical Testing,,Assumed Completed,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna,4/25/2020,,,,,,4/25/2020
205,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00052,https://www.drugbank.ca/drugs/DB06803,https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00052,https://www.drugbank.ca/drugs/DB06803,,https://www.kxan.com/news/coronavirus/can-an-existing-drug-be-re-purposed-to-treat-covid-19-patients-ut-researchers-working-to-find-out/,https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00052,https://www.drugbank.ca/drugs/DB06803; https://www.bayer.co.za/static/documents/MSDS/PIs/YOMESAN_EN_PI.pdf,,https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00052,,https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00052,https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00052,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
206,No,Nanobody,,Nanobody,Beroni Group; Tianjin University,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,,China,Ongoing,Beroni Group submitted Emergency Use Authorization for COVID-19 Rapid Test Detection Kit to FDA in March,,Discovery,,2/20/2020,Target: 04/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna,4/26/2020,,,,,,4/26/2020
206,Yes,https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/,,https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/,https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/,https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/,https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/,,https://www.beronigroup.com/2020/03/06/beroni-group-collaborates-with-tianjin-university-to-develop-novel-solution-for-coronavirus-covid-19/,https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/,https://www.beronigroup.com/2020/04/01/beroni-group-announces-submission-of-emergency-use-authorization-to-us-fda-for-its-covid-19-rapid-test-detection-kit/,,https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/,,https://www.beronigroup.com/2020/03/06/beroni-group-collaborates-with-tianjin-university-to-develop-novel-solution-for-coronavirus-covid-19/,https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
207,No,recombinant human plasma gelsolin,recombinant human plasma gelsolin,rhu-pGSN,Bioaegis Therapeutics Inc.,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,New,,United States,Ongoing,Next step is to move into Phase 2b,,Phase 2,,Assumed Completed,Assumed Competed,Completed,Assumed Completed,Assumed Completed,,,,,,,,,,,,,,,,,,,,,,,,Ivanna,4/26/2020,,,,,,4/26/2020
207,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioaegistherapeutics.com/covid19/plasma-gelsolin-to-protect-tissue-organs-in-severe-coronavirus-infection-without-compromising-pathogen-response/,https://www.bioaegistherapeutics.com/covid19/plasma-gelsolin-to-protect-tissue-organs-in-severe-coronavirus-infection-without-compromising-pathogen-response/,https://www.bioaegistherapeutics.com/covid19/plasma-gelsolin-to-protect-tissue-organs-in-severe-coronavirus-infection-without-compromising-pathogen-response/,https://www.bioaegistherapeutics.com/covid19/plasma-gelsolin-to-protect-tissue-organs-in-severe-coronavirus-infection-without-compromising-pathogen-response/,,https://www.bioaegistherapeutics.com/overview-immunotherapy-treatment/,http://www.globenewswire.com/news-release/2020/04/02/2010466/0/en/Small-NJ-Biotech-Firm-BioAegis-Therapeutics-Accelerating-Multiple-Clinical-Trial-Submissions-for-Severe-COVID-19-Pneumonia-Patients.html,https://www.bioaegistherapeutics.com/covid19/plasma-gelsolin-to-protect-tissue-organs-in-severe-coronavirus-infection-without-compromising-pathogen-response/,,https://www.bioaegistherapeutics.com/covid19/plasma-gelsolin-to-protect-tissue-organs-in-severe-coronavirus-infection-without-compromising-pathogen-response/,,https://www.bioaegistherapeutics.com/news/may-17-2011-bioaegis-therapeutics-signs-exclusive-option-human-protein-clinical-development/,https://www.bioaegistherapeutics.com/news/september-2018-bioaegis-therapeutics-enrolls-first-patients-in-phase-1b-2a-community-acquired-pneumonia-study-and-raises-4-mm-in-equity-round/,https://www.bioaegistherapeutics.com/news/may-17-2011-bioaegis-therapeutics-signs-exclusive-option-human-protein-clinical-development/,https://clinicaltrials.gov/ct2/show/study/NCT03466073,https://clinicaltrials.gov/ct2/show/study/NCT03466073,https://clinicaltrials.gov/ct2/show/record/NCT03466073,https://clinicaltrials.gov/ct2/show/record/NCT03466073,,,,,https://clinicaltrials.gov/ct2/show/study/NCT03466073,https://clinicaltrials.gov/ct2/show/study/NCT03466073,https://clinicaltrials.gov/ct2/show/study/NCT03466073,https://clinicaltrials.gov/ct2/show/record/NCT03466073,https://clinicaltrials.gov/ct2/show/study/NCT03466073,,https://clinicaltrials.gov/ct2/show/record/NCT03466073,https://clinicaltrials.gov/ct2/show/record/NCT03466073,https://clinicaltrials.gov/ct2/show/record/NCT03466073,https://clinicaltrials.gov/ct2/show/record/NCT03466073,,,,,,,,,,,,,,,
208,No,Antibodies,,Antibodies,Bioduro LLC,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,Wuxi-Jiangsu local government,China,Ongoing,Final product aim is a Nanobody-an antibody but contains only a single very small unit needed for recognition and disruption of the COVID-19 targets,,Discovery,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna,4/26/2020,,,,,,4/26/2020
208,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://bioduro.com/article/bioduro-announces-covid19-nanobody/,https://bioduro.com/article/bioduro-announces-covid19-nanobody/,https://bioduro.com/article/bioduro-announces-covid19-nanobody/,https://bioduro.com/article/bioduro-announces-covid19-nanobody/,https://bioduro.com/article/bioduro-announces-covid19-nanobody/,https://bioduro.com/article/bioduro-announces-covid19-nanobody/,https://bioduro.com/article/bioduro-announces-covid19-nanobody/,https://bioduro.com/article/bioduro-announces-covid19-nanobody/,,https://bioduro.com/article/bioduro-announces-covid19-nanobody/,,https://bioduro.com/article/bioduro-announces-covid19-nanobody/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
209,No,Vazegepant; BHV-3500,,Vazegepant; BHV-3500,Biohaven Pharmaceutical Holding Co. Ltd.,Therapeutic,COVID-19,Small molecule,Other,New,,United States,Ongoing,CGRP receptor antagonist that is to be administered intranasally; currently in phase 2/3 trial to evaluate efficacy and potential for quick onset,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,4/8/2020,Assume completed,4/25/2020,4/25/2020,,,,2,COVID-19,120,No,2,Georgetown University Medical Center - Washington D.C; Thomas Jefferson University Hospital - Philadelphia - Pennsylvania,04/25/2020,04/2021,04/2021,https://clinicaltrials.gov/ct2/show/NCT04346615,Elyse Stock,,clinicaltrials@biohavenpharma.com,,,,,Andy Zhou,5/8/2020,,,,,,5/8/2020
209,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Small molecule,Other,New,,https://www.biohavenpharma.com/index.php/contact-us,Ongoing,https://www.biohavenpharma.com/science-pipeline/cgrp/bhv-3500,,Phase 3,,https://www.biohavenpharma.com/investors/news-events/press-releases/04-09-2020,https://www.biohavenpharma.com/investors/news-events/press-releases/04-09-2020,https://www.biohavenpharma.com/investors/news-events/press-releases/04-09-2020,https://www.biohavenpharma.com/investors/news-events/press-releases/04-09-2020,https://www.biohavenpharma.com/investors/news-events/press-releases/04-09-2020,https://www.biohavenpharma.com/investors/news-events/press-releases/04-09-2020,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,,,,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,No,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04346615?intr=vazegepant&draw=2&rank=1,,,,,,,,,
210,No,anti-viroporin therapeutics,,anti-viroporin therapeutics,Biotron Ltd.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,New,,Australia,Ongoing,Biotron is currently testing whether their small molecules that target viroporins (virus-encoded proteins) will be effective against SARS CoV-2; the E protein of SARS CoV-2 was shown to be a viroporin and can potentially be a good target,,Discovery,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,5/8/2020,,,,,,5/8/2020
210,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Small molecule,Antiviral drugs-broad spectrum,New,https://www.ausbiotech.org/news/australian-biotech-at-the-forefront-of-global-health-responses,https://www.ausbiotech.org/news/australian-biotech-at-the-forefront-of-global-health-responses,Ongoing,https://www.ausbiotech.org/news/australian-biotech-at-the-forefront-of-global-health-responses,,Discovery,,https://www.ausbiotech.org/news/australian-biotech-at-the-forefront-of-global-health-responses,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
211,No,BOLD-100,,BOLD-100,Bold Therapeutics Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Not Approved,University of Ottawa,Canada,Ongoing,Small molecule that downregulates GRP78 with the intention to treat cancer; completed phase 1 that involved 41 cancer patients with tolerable safety profile; currently under investigation for potential therapeutic effects among COVID-19 patients: downregulating GRP78 shows promise because SARS CoV-2 can bind to GRP78; note that there are no details on the phase 1 trial aside from the number of subjects,,Phase 1,,Assume Completed,Assume Completed,Assume Completed,Complete,Complete,Complete,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,5/8/2020,,,,,,5/8/2020
211,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Not Approved,https://www.thepharmaletter.com/article/bold-therapeutics-partners-with-academia-to-study-bold-100-as-covid-19-therapy,https://www.thepharmaletter.com/article/bold-therapeutics-partners-with-academia-to-study-bold-100-as-covid-19-therapy,Ongoing,https://www.bold-therapeutics.com/COVID-19,,Phase 1,,https://www.bold-therapeutics.com/COVID-19,https://www.bold-therapeutics.com/COVID-19,https://www.bold-therapeutics.com/COVID-19,https://www.bold-therapeutics.com/COVID-19,https://www.bold-therapeutics.com/COVID-19,https://www.bold-therapeutics.com/COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
212,No,monoclonal antibodies,,monoclonal antibodies,Brii Biosciences; Columbia University; Tsinghua University; 3rd People's Hospital of Shenzhen,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Brii Biosciences,China; United States,Ongoing,Working on discovering monoclonal antibodies against SARS CoV-2; aims to begin clinical trials within 6 months,,Discovery,,Started,,,,,Target: 11/2020,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,5/8/2020,,,,,,5/8/2020
212,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,https://www.briibio.com/news/45.html,https://www.briibio.com/news/45.html,Ongoing,https://www.briibio.com/news/45.html,,Discovery,,https://www.briibio.com/news/45.html,,,,,https://www.briibio.com/news/45.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
213,No,Auxora,Auxora,CM-4620-IE,Calcimedica Inc.,Therapeutic,Pneumonia,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,Originally developed to treat acute pancreatitis; currently undergoing phase 2 to observe efficacy in COVID-19 patients; functions by inhibiting CRAC channels to alleviate inflammation,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,4/9/2020,Assume completed,4/8/2020,,,,,2,COVID-19,120,No,3,Henry Ford Hospital - Detroit - Michigan; Methodist Hospital - Saint Louis Park - Minnesota; Regions Hospitla - Saint Paul - Minnesota,04/08/2020,03/2021,04/2021,https://clinicaltrials.gov/ct2/show/NCT04345614,Sudarshan Hebbar,,sudarshan@calcimedica.com,,,,,Andy Zhou,5/9/2020,Gabbie Wilson,6/7/2020,,,,6/7/2020
213,Yes,https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia,https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia,https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia,https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia,https://www.calcimedica.com/news/calcimedica-announces-positive-topline-data-from-interim-analysis-of-trial-evaluating-auxora-in-patients-with-severe-covid-19-pneumonia,,https://www.biospace.com/article/releases/fda-grants-calcimedica-permission-to-begin-dosing-cm4620-ie-in-patients-with-severe-covid-19-pneumonia-under-a-newly-opened-ind/,Ongoing,https://www.biospace.com/article/releases/fda-grants-calcimedica-permission-to-begin-dosing-cm4620-ie-in-patients-with-severe-covid-19-pneumonia-under-a-newly-opened-ind/,,Phase 2,,https://www.biospace.com/article/releases/fda-grants-calcimedica-permission-to-begin-dosing-cm4620-ie-in-patients-with-severe-covid-19-pneumonia-under-a-newly-opened-ind/,https://www.biospace.com/article/releases/fda-grants-calcimedica-permission-to-begin-dosing-cm4620-ie-in-patients-with-severe-covid-19-pneumonia-under-a-newly-opened-ind/,https://www.biospace.com/article/releases/fda-grants-calcimedica-permission-to-begin-dosing-cm4620-ie-in-patients-with-severe-covid-19-pneumonia-under-a-newly-opened-ind/,https://www.biospace.com/article/releases/fda-grants-calcimedica-permission-to-begin-dosing-cm4620-ie-in-patients-with-severe-covid-19-pneumonia-under-a-newly-opened-ind/,https://www.biospace.com/article/releases/fda-grants-calcimedica-permission-to-begin-dosing-cm4620-ie-in-patients-with-severe-covid-19-pneumonia-under-a-newly-opened-ind/,https://www.biospace.com/article/releases/fda-grants-calcimedica-permission-to-begin-dosing-cm4620-ie-in-patients-with-severe-covid-19-pneumonia-under-a-newly-opened-ind/,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,,,,,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,No,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,,,,,,https://clinicaltrials.gov/ct2/show/NCT04345614?intr=CM-4620-IE&draw=2&rank=2,,,,,,,,,
214,No,CAP-1002,,CAP-1002,Capricor Therapeutics Inc.,Therapeutic,COVID-19,Cell therapies,Other,New,,United States,Ongoing,Currently not approved for clinical investigation but FDA has granted expanded access protocol to treat up to 20 more COVID-19 patients after 6 compassionate care cases were treated successfully; plans to launch a randomized and placebo-controlled trial; drug is a cardiac cell therapy that modifies immune activity to promote cellular regeneration,,Phase 1,,Assume Completed,Assume Completed,,,,,,,,,,1,COVID-19,,No,,,,,,,,,,,,,,Andy Zhou,5/9/2020,Gabbie Wilson,6/7/2020,,,,6/7/2020
214,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,http://capricor.com/product-pipeline/cap-1002/,http://capricor.com/product-pipeline/cap-1002/,http://capricor.com/product-pipeline/cap-1002/,,http://capricor.com/contact/,Ongoing,https://www.bioworld.com/articles/434747-capricors-covid-19-success-gets-fda-and-market-attention https://www.biospace.com/article/releases/new-capricor-data-reports-100-percent-survival-in-critical-covid-19-patients-treated-with-cap-1002u-s-fda-approves-company-s-expanded-access-protocol-to-treat-additional-patients/,,http://capricor.com/product-pipeline/,,https://www.biospace.com/article/releases/new-capricor-data-reports-100-percent-survival-in-critical-covid-19-patients-treated-with-cap-1002u-s-fda-approves-company-s-expanded-access-protocol-to-treat-additional-patients/,https://www.biospace.com/article/releases/new-capricor-data-reports-100-percent-survival-in-critical-covid-19-patients-treated-with-cap-1002u-s-fda-approves-company-s-expanded-access-protocol-to-treat-additional-patients/,,,,,,,,,,http://capricor.com/product-pipeline/,https://clinicaltrials.gov/ct2/show/NCT04338347,https://clinicaltrials.gov/ct2/show/NCT04338347,https://clinicaltrials.gov/ct2/show/NCT04338347,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/record/NCT04338347,,,,,,,,,
215,No,antibodies,,antibodies,Carterra Inc.; La Jolla Institute for Immunology,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Coronavirus Immunotherapy Consortium (CoVIC),United States,Ongoing,Carterra will use proprietary LSA platform to simultaneously screen and characterize antibodies to quickly determine ones that are effective against SARS CoV 2,,Discovery,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,5/9/2020,,,,,,5/9/2020
215,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,https://www.bioworld.com/COVID19products,https://carterra-bio.com/news/carterra-inc-selected-by-the-la-jolla-institute-of-immunology-to-provide-antibody-screening-and-characterization-for-the-coronavirus-immunotherapy-consortium-covic/,Ongoing,https://carterra-bio.com/news/carterra-inc-selected-by-the-la-jolla-institute-of-immunology-to-provide-antibody-screening-and-characterization-for-the-coronavirus-immunotherapy-consortium-covic/,,https://www.bioworld.com/COVID19products,,https://carterra-bio.com/news/carterra-inc-selected-by-the-la-jolla-institute-of-immunology-to-provide-antibody-screening-and-characterization-for-the-coronavirus-immunotherapy-consortium-covic/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie Wilson,6/7/2020,,,,6/7/2020
216,No,CK-0802,,CK-0802,Cellenkos Inc.,Therapeutic,ARDS,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,Intends to collaborate with BARDA; the application for a phase-1 randomised double-blind trial has been approved by FDA; CK-0802 is an allogenic cell therapy that consists of TREG cells derived from umbilical cord blood units; hypothesized to improve ARDS by interrupting cytokine storm and resolving inflammation; pre-clinical studies showed favorable results; has been used in clinical trials for other inflammatory disorders,,Phase 1,,Assume Completed,Complete,,,6/2/2020,Not yet initiated,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,5/9/2020,Gabbie Wilson,6/7/2020,,,,6/7/2020
216,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.co.uk/news-releases/cellenkos-r-inc-announces-fda-clearance-to-initiate-phase-1-double-blinded-randomized-placebo-controlled-trial-of-cryopreserved-cord-blood-derived-t-regulatory-cells-ck0802-for-treatment-of-covid-19-associated-acute-respiratory-distress-syn-891362475.html,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,https://www.biospace.com/article/releases/cellenkos-inc-focuses-on-the-development-of-cell-therapy-for-treatment-of-covid-19-mediated-acute-respiratory-distress-syndrome-cov-ards-/,Ongoing,https://www.biospace.com/article/releases/cellenkos-inc-focuses-on-the-development-of-cell-therapy-for-treatment-of-covid-19-mediated-acute-respiratory-distress-syndrome-cov-ards-/ ; https://www.prnewswire.co.uk/news-releases/cellenkos-r-inc-announces-fda-clearance-to-initiate-phase-1-double-blinded-randomized-placebo-controlled-trial-of-cryopreserved-cord-blood-derived-t-regulatory-cells-ck0802-for-treatment-of-covid-19-associated-acute-respiratory-distress-syn-891362475.html,,https://www.prnewswire.co.uk/news-releases/cellenkos-r-inc-announces-fda-clearance-to-initiate-phase-1-double-blinded-randomized-placebo-controlled-trial-of-cryopreserved-cord-blood-derived-t-regulatory-cells-ck0802-for-treatment-of-covid-19-associated-acute-respiratory-distress-syn-891362475.html,,https://www.biospace.com/article/releases/cellenkos-inc-focuses-on-the-development-of-cell-therapy-for-treatment-of-covid-19-mediated-acute-respiratory-distress-syndrome-cov-ards-/,https://www.biospace.com/article/releases/cellenkos-inc-focuses-on-the-development-of-cell-therapy-for-treatment-of-covid-19-mediated-acute-respiratory-distress-syndrome-cov-ards-/,,,https://www.prnewswire.co.uk/news-releases/cellenkos-r-inc-announces-fda-clearance-to-initiate-phase-1-double-blinded-randomized-placebo-controlled-trial-of-cryopreserved-cord-blood-derived-t-regulatory-cells-ck0802-for-treatment-of-covid-19-associated-acute-respiratory-distress-syn-891362475.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
217,No,Mesenchymal stem cells,,Mesenchymal stem cells,CellTex Therapeutics Corp.,Therapeutic,COVID-19,Cell therapies,Other,Repurposed-Approved,,United States,Ongoing,Celltex submitted an emergency expanded access clinical study to the United States Food and Drug Administration (FDA) that would allow patients with COVID-19 to receive infusions of autologous Adipose-tissue derived Mesenchymal Stem Cells (AdMSCs),,,,Assume Completed,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie Wilson,6/7/2020,,,,6/7/2020
217,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://celltexbank.com/celltex-has-submitted-emergency-expanded-access-clinical-study-for-subjects-with-coronavirus-2019-covid-19-using-multiple-dose-infusions-of-autologous-adipose-tissue-derived-mesenchymal-stem-cells/,https://celltexbank.com/celltex-has-submitted-emergency-expanded-access-clinical-study-for-subjects-with-coronavirus-2019-covid-19-using-multiple-dose-infusions-of-autologous-adipose-tissue-derived-mesenchymal-stem-cells/,,https://celltexbank.com/celltex-has-submitted-emergency-expanded-access-clinical-study-for-subjects-with-coronavirus-2019-covid-19-using-multiple-dose-infusions-of-autologous-adipose-tissue-derived-mesenchymal-stem-cells/,,https://www.linkedin.com/company/celltex-therapeutics-corporation/,,https://celltexbank.com/celltex-has-submitted-emergency-expanded-access-clinical-study-for-subjects-with-coronavirus-2019-covid-19-using-multiple-dose-infusions-of-autologous-adipose-tissue-derived-mesenchymal-stem-cells/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
218,No,anti-LIGHT,,anti-LIGHT,Cerecor Inc.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,,United States,Ongoing,Fully human antibody targetting the cytokine storm in COVID-19 ARDS; antibody to LIGHT which has been shown to play key role in viral pneumonia; FDA has approved a randomised double blind placebo-controlled proof of concept clinical trial; also being developed for Pediatric-onset Crohn’s Disease,,Phase 2,,3/26/2020,5/26/2020,Assume Completed,Assume Completed,5/28/2020,Assume Completed,6/1/2020,,,,,2,COVID-19,,No,11,Hoag Memorial Hospital - Newport Beach - California; Midway Immunology and Research Center - Fort Pierce - Florida; Triple O Research Institute P.A. - West Palm Beach - Florida; Parkview Research Center - Fort Wayne - Indiana; MedPharmics - Metairie - Louisiana; LSUHSC - Shreveport - Louisiana; Cape Fear Valley Medical Center - Fayetteville - North Carolina; Temple University Hospital - Philadelphia - Pennsylvania; AnMed Health Medical Center - Anderson - South Carolina; Lowcountry Infectious Diseases - Charleston - South Carolina; BRCR Global Texas - McAllen - Texas,06/2020,10/2020,11/2020,https://clinicaltrials.gov/ct2/show/NCT04412057,Jeffrey Wilkins,610-457-5095,jwilkins@cerecor.com,,,,,,,,,,,,
218,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/05/28/2040087/0/en/Cerecor-Announces-FDA-Clearance-of-IND-for-CERC-002-in-COVID-19-Induced-ARDS.html,https://www.globenewswire.com/news-release/2020/05/28/2040087/0/en/Cerecor-Announces-FDA-Clearance-of-IND-for-CERC-002-in-COVID-19-Induced-ARDS.html,https://www.globenewswire.com/news-release/2020/05/28/2040087/0/en/Cerecor-Announces-FDA-Clearance-of-IND-for-CERC-002-in-COVID-19-Induced-ARDS.html,https://www.globenewswire.com/news-release/2020/05/28/2040087/0/en/Cerecor-Announces-FDA-Clearance-of-IND-for-CERC-002-in-COVID-19-Induced-ARDS.html,,https://www.cerecor.com/about/contact,,https://www.globenewswire.com/news-release/2020/05/28/2040087/0/en/Cerecor-Announces-FDA-Clearance-of-IND-for-CERC-002-in-COVID-19-Induced-ARDS.html,,https://clinicaltrials.gov/ct2/show/record/NCT04412057,,https://ir.cerecor.com/press-releases/detail/90/cerecor-announces-exploration-of-the-role-of-an,https://ir.cerecor.com/press-releases/detail/90/cerecor-announces-exploration-of-the-role-of-an,,,https://www.globenewswire.com/news-release/2020/05/28/2040087/0/en/Cerecor-Announces-FDA-Clearance-of-IND-for-CERC-002-in-COVID-19-Induced-ARDS.html,,https://clinicaltrials.gov/ct2/show/record/NCT04412057,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04412057,https://clinicaltrials.gov/ct2/show/study/NCT04412057,https://clinicaltrials.gov/ct2/show/study/NCT04412057,https://clinicaltrials.gov/ct2/show/study/NCT04412057,https://clinicaltrials.gov/ct2/show/study/NCT04412057,https://clinicaltrials.gov/ct2/show/study/NCT04412057,https://clinicaltrials.gov/ct2/show/study/NCT04412057,https://clinicaltrials.gov/ct2/show/study/NCT04412057,https://clinicaltrials.gov/ct2/show/study/NCT04412057,https://clinicaltrials.gov/ct2/show/study/NCT04412057,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04412057,,,,Gabbie Wilson,6/7/2020,,,,6/7/2020
219,No,Chromovert,,Chromovert,Chromocell Corp.,Therapeutic,COVID-19,Other,Other,,,United States,Ongoing,NOT a treatment or a vaccine but tecnology. The tecnology is called Chromovert and is used to accelerate drug discovery against hard-to-express biological target.  It has been successfully used to identify a novel non-addictive pain blocker that is in clinical development and it has identified a number of compounds in its pipeline that may help address COVID-19-related disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,4/22/2020,Gabbie Wilson,6/7/2020,,,,6/7/2020
219,Yes,https://www.prnewswire.com/news-releases/chromocell-makes-chromovert-technology-and-novel-compounds-available-to-support-covid-19-research-301036544.html,,https://www.prnewswire.com/news-releases/chromocell-makes-chromovert-technology-and-novel-compounds-available-to-support-covid-19-research-301036544.html,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.com/news-releases/chromocell-makes-chromovert-technology-and-novel-compounds-available-to-support-covid-19-research-301036544.html,https://www.prnewswire.com/news-releases/chromocell-makes-chromovert-technology-and-novel-compounds-available-to-support-covid-19-research-301036544.html,https://www.prnewswire.com/news-releases/chromocell-makes-chromovert-technology-and-novel-compounds-available-to-support-covid-19-research-301036544.html,,,https://www.linkedin.com/company/chromocell-corporation/,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,4/23/2020,Gabbie Wilson,6/7/2020,,,,6/7/2020
220,No,WP1122,WP1122,2-DG,CNS Pharmaceuticals; WPD Pharmaceuticals Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,WPD Pharmaceuticals Inc.,United States,Ongoing,research was done by University of Frankfurt; 2-DG inhibits glycolysis which prevents coronavirus replication in Caco-2 cells,,Pre-Clinical Testing,,Assumed Completed,4/13/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,4/22/2020,Gabbie Wilson,6/7/2020,,,,6/7/2020
220,Yes,https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/,https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products; https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.drugbank.ca/drugs/DB08831,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/,https://cnspharma.com/,https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/,https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/ ; https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/,,https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/,,,https://www.biospace.com/article/releases/cns-pharmaceuticals-announces-independent-university-research-confirms-active-compound-in-wp1122-completely-prevents-coronavirus-replication-in-vitro-wp1122-is-subject-to-development-agreement-with-wpd-pharmaceuticals/,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,4/25/2020,,,,,,4/25/2020
221,No,protase inhibtors,,protase inhibtors,Cocrystal Pharma Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,New,Kansas State University Research Foundation,United States,Ongoing,the compouds are protase inhibitors with a novel mechanism of action,,Pre-Clinical Testing,,Assumed Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,4/22/2020,Gabbie Wilson,6/8/2020,,,,6/8/2020
221,Yes,https://www.cocrystalpharma.com/news/press-releases/detail/91/cocrystal-pharma-expands-exclusive-license-agreement-with,,https://www.cocrystalpharma.com/news/press-releases/detail/91/cocrystal-pharma-expands-exclusive-license-agreement-with,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.cocrystalpharma.com/development-pipeline/coronavirus/coronavirus-protease-inhibitor,https://www.cocrystalpharma.com/about/overview,https://www.cocrystalpharma.com/development-pipeline/coronavirus/coronavirus-protease-inhibitor,https://www.cocrystalpharma.com/development-pipeline/coronavirus/coronavirus-protease-inhibitor,https://www.bioworld.com/COVID19products,https://www.cocrystalpharma.com/contact-us,https://www.cocrystalpharma.com/about/overview,https://www.cocrystalpharma.com/news/press-releases/detail/91/cocrystal-pharma-expands-exclusive-license-agreement-with,,https://www.cocrystalpharma.com/news/press-releases/detail/91/cocrystal-pharma-expands-exclusive-license-agreement-with,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,4/27/2020,,,,,,4/27/2020
222,No,NK immunotherapies,,NK immunotherapies,Cytovia Inc.; Macromoltek Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Macromoltek,United States,Ongoing,Bifunctional antibodies - NK activating antibodies combined with novel antibodies neutralising or blocking SARS CoV2,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,4/22/2020,Gabbie Wilson,6/8/2020,,,,6/8/2020
222,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.genengnews.com/a-lists/vanquishing-the-virus-160-covid-19-drug-and-vaccine-candidates-in-development/5/,https://www.globenewswire.com/news-release/2020/04/07/2012885/0/en/CYTOVIA-Therapeutics-and-MACROMOLTEK-to-Develop-Dual-Acting-Natural-Killer-Immunotherapy-Against-SARS-CoV2-COVID-19.html,https://www.globenewswire.com/news-release/2020/04/07/2012885/0/en/CYTOVIA-Therapeutics-and-MACROMOLTEK-to-Develop-Dual-Acting-Natural-Killer-Immunotherapy-Against-SARS-CoV2-COVID-19.html,https://www.globenewswire.com/news-release/2020/04/07/2012885/0/en/CYTOVIA-Therapeutics-and-MACROMOLTEK-to-Develop-Dual-Acting-Natural-Killer-Immunotherapy-Against-SARS-CoV2-COVID-19.html,https://www.globenewswire.com/news-release/2020/04/07/2012885/0/en/CYTOVIA-Therapeutics-and-MACROMOLTEK-to-Develop-Dual-Acting-Natural-Killer-Immunotherapy-Against-SARS-CoV2-COVID-19.html,https://www.globenewswire.com/news-release/2020/04/07/2012885/0/en/CYTOVIA-Therapeutics-and-MACROMOLTEK-to-Develop-Dual-Acting-Natural-Killer-Immunotherapy-Against-SARS-CoV2-COVID-19.html,https://www.globenewswire.com/news-release/2020/04/07/2012885/0/en/CYTOVIA-Therapeutics-and-MACROMOLTEK-to-Develop-Dual-Acting-Natural-Killer-Immunotherapy-Against-SARS-CoV2-COVID-19.html,https://www.globenewswire.com/news-release/2020/04/07/2012885/0/en/CYTOVIA-Therapeutics-and-MACROMOLTEK-to-Develop-Dual-Acting-Natural-Killer-Immunotherapy-Against-SARS-CoV2-COVID-19.html,,https://www.genengnews.com/a-lists/vanquishing-the-virus-160-covid-19-drug-and-vaccine-candidates-in-development/5/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/1/2020,,,,,,5/1/2020
223,No,Transcrocetinate UPDATE1,Transcrocetinate UPDATE1,Trans Sodium Crocetinate,Diffusion Pharmaceuticals Inc.,Therapeutic,ARDS,Small molecule,Other,Repurposed-Approved,University of Virginia Health; the Integrated Translational Research Institute of Virginia; Romanian National Institute of Infectious Diseases; ARENSIA Exploratory Medicine GmbH,United States,Ongoing,Believed to benefit patients that present with significantly impaired oxygen levels due to COVID-19,,Phase 1,,Assume Completed,5/1/2020,,,5/26/2020,,,,,,,1,ARDS,24,No,,,,,,,,,,,,,,Meg,4/23/2020,Gabbie Wilson,6/8/2020,,,,6/8/2020
223,Yes,https://www.drugbank.ca/drugs/DB05974,https://www.drugbank.ca/drugs/DB05974,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Evaluating-TSC-Against-Acute-Respiratory-Distress-Syndrome-ARDS-in-COVID-19-Patients/default.aspx,https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Evaluating-TSC-Against-Acute-Respiratory-Distress-Syndrome-ARDS-in-COVID-19-Patients/default.aspx,https://www.bioworld.com/COVID19products ; https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html,https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Evaluating-TSC-Against-Acute-Respiratory-Distress-Syndrome-ARDS-in-COVID-19-Patients/default.aspx,https://www.bioworld.com/COVID19products,https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Receives-Accelerated-FDA-Response-to-Proposed-TSC-COVID-19-Clinical-Trial-Program/default.aspx,,https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Evaluating-TSC-Against-Acute-Respiratory-Distress-Syndrome-ARDS-in-COVID-19-Patients/default.aspx,,,https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html,,,https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Receives-Accelerated-FDA-Response-to-Proposed-TSC-COVID-19-Clinical-Trial-Program/default.aspx,,,,,,,https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html,https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html,https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html,https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html,https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html,https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html,https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html,,,,,,,,,https://www.globenewswire.com/news-release/2020/05/20/2036342/0/en/Diffusion-Pharmaceuticals-Expands-Clinical-Trial-Program-of-TSC-for-the-Treatment-of-COVID-19-Patients-to-Include-the-Romanian-National-Institute-of-Infectious-Diseases.html,,Meg,5/3/2020,,,,,,5/3/2020
224,No,UPDATE1,UPDATE1,LY3127804,Eli Lilly and Co.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,,United States,Ongoing,"Selective against angiopoietin 2, which is elevated in ARDS patients",,Phase 2,,Completed,,,,Completed,,4/20/2020,,,,,2,COVID-19,200,No,2,NorthShore University HealthSystem - Evanston - Illinois; Franciscan St. Francis Health - Indianapolis - Indiana,04/20/2020,11/30/2020,11/30/2020,https://clinicaltrials.gov/ct2/show/NCT04342897,,,Clinicaltrials.gov@lilly.com,,,,,Meg,5/23/2020,Andy Zhou,5/25/2020,,,,5/25/2020
224,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.pharmaceutical-business-review.com/news/lilly-baricitinib-covid-19/,https://www.pharmaceutical-business-review.com/news/lilly-baricitinib-covid-19/,https://www.pharmaceutical-business-review.com/news/lilly-baricitinib-covid-19/,https://www.thestreet.com/latest-news/eli-lilly-studying-two-potential-treatments-for-covid-19,,https://www.pharmaceutical-business-review.com/news/lilly-baricitinib-covid-19/,https://www.pharmaceutical-business-review.com/news/lilly-baricitinib-covid-19/,"http://www.pharmatimes.com/news/lilly_to_test_olumiant,_ly3127804_against_covid-19_1338253",,https://www.pharmaceutical-business-review.com/news/lilly-baricitinib-covid-19/,,"http://www.pharmatimes.com/news/lilly_to_test_olumiant,_ly3127804_against_covid-19_1338253",,,,"http://www.pharmatimes.com/news/lilly_to_test_olumiant,_ly3127804_against_covid-19_1338253",,https://clinicaltrials.gov/ct2/show/NCT04342897,,,,,https://clinicaltrials.gov/ct2/show/NCT04342897,https://clinicaltrials.gov/ct2/show/NCT04342897,https://clinicaltrials.gov/ct2/show/NCT04342897,No,https://clinicaltrials.gov/ct2/show/NCT04342897,https://clinicaltrials.gov/ct2/show/NCT04342897,https://clinicaltrials.gov/ct2/show/NCT04342897,https://clinicaltrials.gov/ct2/show/NCT04342897,https://clinicaltrials.gov/ct2/show/NCT04342897,https://clinicaltrials.gov/ct2/show/NCT04342897,,,,,,https://clinicaltrials.gov/ct2/show/NCT04342897,,Meg,5/5/2020,,,,,,5/5/2020
225,No,Baricitinib,Baricitinib,Olumiant,Eli Lilly and Co.; Incyte Corp,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Approved,National Institute of Allergy and Infectious Diseases,United States,Ongoing,Oral JAK1/JAK2 inhibitor previously approved for treatment of arthritis; Bioworld classifies the trial as a phase 2/3 hybrid but there exists no detailed entry for said trial,,Phase 3,,,,,,,,,Started,,,,,,,,,,,,,,,,,,,,,Meg,4/24/2020,Andy Zhou,5/25/2020,,,,5/25/2020
225,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/,https://www.drugbank.ca/drugs/DB11817,https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/,https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/,https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/,https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/,https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/ https://www.bioworld.com/COVID19products,,https://www.biospace.com/article/eli-lilly-to-begin-testing-ra-drug-olumiant-and-an-anti-ang2-drug-in-covid-19-patients/ https://www.bioworld.com/COVID19products,,,,,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,Meg,5/7/2020,,,,,,5/7/2020
226,No,COVID-HIG; COVID-EIG,,COVID-HIG; COVID-EIG,Emergent Biosolutions Inc.,Therapeutic,COVID-19,Cell therapies,Other,New,Biomedical Advanced Research and Development Authority; Emergent and the National Institute of Allergy and Infectious Diseases,United States,Ongoing,No indication that COVID-HIG or EIG (human and horse hyperimmune plasma - respectively) are entering pre-clinical or phase 1 trials any time soon; no projected dates either,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,4/24/2020,Andy Zhou,5/25/2020,,,,5/25/2020
226,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=,https://www.fool.com/investing/2020/03/25/fda-facilitating-use-of-plasma-from-recovered-pati.aspx,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=,,https://www.fool.com/investing/2020/03/25/fda-facilitating-use-of-plasma-from-recovered-pati.aspx https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-partners-us-government-comprehensive?field_nir_news_date_value[min]=,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/9/2020,,,,,,5/9/2020
227,No,Allocetra,,Allocetra,Enlivex Therapeutics Ltd.,Therapeutic,COVID-19,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,Israel Innovation Authority,Israel,Ongoing,Undergoing multi-center investigator-initiated phase 2 trial as of May 7 but no entry on clinicaltrials; drug aims to balance immune response and prevent cytokine storm,,Phase 2,,Completed,,,,,Completed,5/7/2020,,,,,,,,,,,,,,,,,,,,,,Meg,4/24/2020,Andy Zhou,5/26/2020,,,,5/26/2020
227,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.enlivex.com/investor-relations/#b2iLibScrollTo,https://www.enlivex.com/allocetra/,https://www.enlivex.com/allocetra/,https://www.enlivex.com/investor-relations/#b2iLibScrollTo,https://www.enlivex.com/investor-relations/#b2iLibScrollTo,https://www.enlivex.com/investor-relations/#b2iLibScrollTo,https://www.enlivex.com/investor-relations/#b2iLibScrollTo,https://www.enlivex.com/investor-relations/#b2iLibScrollTo https://www.enlivex.com/allocetra/,,https://www.enlivex.com/investor-relations/#b2iLibScrollTo,,https://www.enlivex.com/investor-relations/#b2iLibScrollTo,,,,,https://www.enlivex.com/investor-relations/#b2iLibScrollTo,https://www.enlivex.com/investor-relations/#b2iLibScrollTo,,,,,,,,,,,,,,,,,,,,,,,5/11/2020,,,,,,5/11/2020
228,No,ENU-200,,ENU-200,Ennaid Therapeutics LLC,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-antiretrovirals,Repurposed-Approved,Catalent Inc.,United States,Ongoing,Oral drug intended for asymptomatic and mild to moderate cases; Ennaid in discussions with FDA and other agencies to bring ENU200 to market within 6-9 months through phase 3 in-home self-dosing clinical trial,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kristine Su,5/3/2020,Andy Zhou,5/26/2020,,,,5/26/2020
228,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ennaidthera.com/science/,https://ennaidthera.com/science/,https://ennaidthera.com/science/,https://ennaidthera.com/science/,https://ennaidthera.com/catalent-signs-development-agreement-with-ennaid-therapeutics-on-its-covid-19-lead-program/,https://ennaidthera.com/science/,https://ennaidthera.com/science/,https://ennaidthera.com/science/ https://www.prnewswire.com/news-releases/ennaid-therapeutics-announces-development-of-enu200-a-new-antiviral-therapeutic-for-the-treatment-of-covid-19-301034232.html,,https://www.dallasweekly.com/articles/black-woman-scientist-files-patent-for-coronavirus-treatment/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kristine Su,5/4/2020,,,,,,5/4/2020
229,No,FP-1201-lyo,FP-1201-lyo,Interferon-beta-1a; traumakine,Faron Pharmaceuticals Oy,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,Repurposed-Approved,,Finland,Ongoing,Tested with ritonavir and lopinavir in the WHO Solidarity Trial; the researchers who completed the first study is currently conducting two more,,Phase 2,,,,,,,3/18/2020,,,,,,,,,,,,,,,,,,,,,,,Kristine Su,5/4/2020,Andy Zhou,5/26/2020,,,,5/26/2020
229,Yes,https://www.faron.com/index.php/pipeline/traumakine-fp-1201-lyo,https://www.faron.com/index.php/pipeline/traumakine-fp-1201-lyo,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.faron.com/news-events/news-and-press-releases?rnsid=1387792&cid=2223,https://www.faron.com/news-events/news-and-press-releases?rnsid=1387792&cid=2223,https://www.sciencedirect.com/science/article/pii/S0166354220302059,https://www.faron.com/news-events/news-and-press-releases?rnsid=1387792&cid=2223,,https://www.faron.com/contact,https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-; https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-; https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30894-1/fulltext https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2,,,,,,,https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2&rank=3,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04343768?term=Interferon-beta-1a&sort=nwst&draw=2,,Kristine Su,5/3/2020,Andy Zhou,5/26/2021,,,,5/26/2021
230,No,niclosamide,niclosamide,FW-1022,Firstwave Bio Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Approved,,United States,Ongoing,Oral drug targeting GI symptoms; expected to reach clinical trials in mid-2020 in the European Union and United States,,Phase 3,,,,,,,,,,,,,3,COVID-19,480,No,,,May-1,May-1,May-1,https://clinicaltrials.gov/ct2/show/NCT04372082,Karine Faure,,karine.faure@chru-lille.fr,,,NOT YET RECRUITING,,Kristine Su,5/3/2020,Andy Zhou,5/26/2020,,,,5/26/2020
230,Yes,https://www.firstwavebio.com/pipeline/,https://www.firstwavebio.com/pipeline/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.firstwavebio.com/firstwave-bio-to-initiate-phase-2a-2b-study-of-fw-1022-a-proprietary-form-of-niclosamide-to-treat-covid-19/,https://www.firstwavebio.com/firstwave-bio-to-initiate-phase-2a-2b-study-of-fw-1022-a-proprietary-form-of-niclosamide-to-treat-covid-19/,https://www.firstwavebio.com/firstwave-bio-to-initiate-phase-2a-2b-study-of-fw-1022-a-proprietary-form-of-niclosamide-to-treat-covid-19/,https://www.firstwavebio.com/firstwave-bio-to-initiate-phase-2a-2b-study-of-fw-1022-a-proprietary-form-of-niclosamide-to-treat-covid-19/,,https://www.firstwavebio.com/firstwave-bio-to-initiate-phase-2a-2b-study-of-fw-1022-a-proprietary-form-of-niclosamide-to-treat-covid-19/,https://www.firstwavebio.com/firstwave-bio-to-initiate-phase-2a-2b-study-of-fw-1022-a-proprietary-form-of-niclosamide-to-treat-covid-19/,https://www.firstwavebio.com/firstwave-bio-to-initiate-phase-2a-2b-study-of-fw-1022-a-proprietary-form-of-niclosamide-to-treat-covid-19/,,https://www.firstwavebio.com/pipeline/,,,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10,https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10,https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10,https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10,,,https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10,https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10,https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10,https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04372082?term=niclosamide&draw=2&rank=10,,Kristine Su,5/3/2020,Andy Zhou,5/26/2023,,,,5/26/2023
231,No,FIB Therapeutic,,FIB Therapeutic,Flanders Institute for Biotechnology,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Labs of Jason McLellan (University of Texas at Austin- US); Markus Hoffman and Stefan Pohlmann (German Primate Center - Leibniz Institute for Primate Research - Gottingen - Germany),Germany,Ongoing,Isolated and characterized antibody that can bind conserved epitope on spike protein and neutralize lab virus as of May 7; moving to enter preclinical testing,,Discovery,,3/16/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kristine Su,5/4/2020,Andy Zhou,5/26/2020,,,,5/26/2020
231,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx,http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx,http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx,http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx,http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx,http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx,http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx,https://www.sciencedaily.com/releases/2020/05/200506104425.htm,,http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx,,http://www.vib.be/en/news/Pages/VIB-moves-forward-in-the-development-of-a-COVID-19-prophylactic.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kristine Su,5/3/2020,Andy Zhou,5/26/2021,,,,5/26/2021
232,No,gammaglobulin,gammaglobulin,rCIG,Gigagen Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,,United States,Ongoing,Polyclonal antibodies; will not enter clinical trials until early 2021,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kristine Su,5/3/2020,Andy Zhou,5/27/2020,,,,5/27/2020
232,Yes,https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502,https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502,https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502,https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502,https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502,,https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502,https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502,https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502 https://healthadvancesblog.com/2020/05/13/protective-antibody-therapy-preventing-future-covid-19-outbreaks/,,https://gigagen.com/#pipeline,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kristine Su,,,,,,,
233,No,emtricitabine; tenofovir,emtricitabine; tenofovir,Truvada,Gilead Sciences Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,United States,Ongoing,Previously accepted HIV treatment that combines emtricitabine and tenofovir repurposed to treat COVID 19,,Phase 3,,,,,,,,,4/15/2020,,,,3,COVID-19,4000,Yes,65,Spain,4/15/2020,12/31/2020,12/31/2020,https://clinicaltrials.gov/ct2/show/NCT04334928,Julia del Amo,,jamo@mscbs.es; rpolor@mscbs.es,,,,,Kristine Su,5/3/2020,Andy Zhou,5/27/2020,,,,5/27/2020
233,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.gilead.com/science-and-medicine/medicines,https://www.gilead.com/science-and-medicine/medicines,https://www.gilead.com/science-and-medicine/medicines,https://www.gilead.com/science-and-medicine/medicines,https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071,https://www.gilead.com/,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,https://www.pharmacytimes.com/ajax/prep-medications-may-be-potential-covid-19-treatments,,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2,,,,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2&rank=2,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04334928?term=emtricitabine&sort=nwst&draw=2,,,,Andy Zhou,5/27/2021,,,,5/27/2021
234,No,GTB-3550 (OXS-3550),GTB-3550 (OXS-3550),Trike therapeutic,GT Biopharma Inc.; Cytovance Biologics,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,Repurposed-Not Approved,,United States,Ongoing,Currently in clinical trial for acute myeloid lukemia; however it has not been cleared for clinical trials in COVID-19 patients - note that the clinical trial information in columns AD to AM is not representative of the COVID-19 pipeline,,Phase 2,,,,,,,1/21/2020,3/31/2020,,,,,2,High-risk myelodysplastic syndromes; acute myelogenous leukemia; systemic mastocytosis; mast cell leukemia,60,No,1,University of Minnesota Minneapolis - Minneapolis - Minnesota,1/1/2020,2/1/2024,8/1/2025,https://clinicaltrials.gov/ct2/show/NCT03214666,Jeffrey S Miller,612-625-7409,mille011@umn.edu,,,,,Kristine Su,5/3/2020,Andy Zhou,5/27/2020,,,,5/27/2020
234,Yes,https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration,https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration,https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration,https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration,https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration,,https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration,https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration,https://www.gtbiopharma.com/news-media/press-releases/detail/182/gt-biopharma-and-cytovance-biologics-announce-collaboration,,https://www.gtbiopharma.com/news-media/press-releases/detail/185/gt-biopharma-announces-commencement-of-retreatment-of,,,,,,https://www.gtbiopharma.com/news-media/press-releases/detail/159/gt-biopharma-receives-fda-clearance-to-commence,https://www.gtbiopharma.com/news-media/press-releases/detail/180/gt-biopharma-provides-update-concerning-triketm-drug,https://www.gtbiopharma.com/news-media/press-releases/detail/185/gt-biopharma-announces-commencement-of-retreatment-of,,,,,https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03214666?term=gtb-3550&draw=2&rank=1,,,,,,,,,,,,,,,
235,No,Harrington Therapeutic,,Harrington Therapeutic,Harrington Discovery Institute,Therapeutic,COVID-19,Unknown,Unknown,New,,United States,Ongoing,Aims to accelerate near-term therapies to treat COVID-19; developed a proven model to allow other scientists to accelerate their breakthrough discovers; overall I believe this entry should be deleted - very vague and little promise of anything; if anything this entry is more of a call to action for others to find therapies than a therapy in itself,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kristine Su,5/3/2020,Andy Zhou,5/27/2020,,,,5/27/2020
235,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Unknown,Unknown,New,,https://www.uhhospitals.org/harrington-discovery-institute/multimedia/hdi-press-releases/hdi-at-uh-to-aid-in-global-fight-against-coronavirus-pandemic,Ongoing,https://www.uhhospitals.org/harrington-discovery-institute/multimedia/hdi-press-releases/hdi-at-uh-to-aid-in-global-fight-against-coronavirus-pandemic,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
236,No,HLCM-051,,HLCM-051,Healios K.K.,Therapeutic,ARDS,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,New,Healios K.K.; Athersys Inc.,Japan; USA,Ongoing,stem cell therapy,,Phase 2,,1/1/2019,,,,,,4/14/2020,,,,,2,COVID-19,30,No,2,Hirosaki University Hospital - Hirosaki - Japan; Saiseikai Kumamoto Hospital - Kumamoto - Japan,1/1/2019,12/31/2020,5/31/2021,https://clinicaltrials.gov/ct2/show/NCT03807804,Tetsuya Oe,,t.oe@healios.jp,,,,,Kristine Su,5/3/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
236,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.healios.co.jp/en/development/ssc/,https://www.healios.co.jp/en/development/ssc/,https://www.healios.co.jp/en/development/ssc/,https://www.healios.co.jp/en/development/ssc/,,https://www.healios.co.jp/en/,https://www.healios.co.jp/en/development/ssc/,,,https://www.healios.co.jp/en/development/ssc/,,,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT03807804?term=HLCM-051&sort=nwst&draw=2&rank=1,,,,,,,,,,,,,,,
237,No,HB-adMSCs,,HB-adMSCs,Hope Biosciences LLC,Therapeutic,COVID-19,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,New,Medrio,United States,Ongoing,"Clinical study mentioned is one of three, two more are in earlier stages",,Phase 2,,,,,,,,4/14/2020,4/24/2020,,,,2,COVID-19,56,Yes,1,Hope Biosciences - Sugar Land - Texas,5/7/2020,12/31/2020,12/31/2020,https://clinicaltrials.gov/ct2/show/NCT04349631,,,,,,BY INVITATION,,Kristine Su,5/3/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
237,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.hope.bio/clinical-trials,https://www.hope.bio/clinical-trials,https://www.pharmaceutical-business-review.com/news/hope-biosciences-covid-19-stem-cell/,https://www.medindia.net/health-press-release/Medrio-Assisting-Hope-Biosciences-to-Combat-COVID-19-with-New-Stem-Cell-Clinical-Trial-461667-1.htm#,https://www.medindia.net/health-press-release/Medrio-Assisting-Hope-Biosciences-to-Combat-COVID-19-with-New-Stem-Cell-Clinical-Trial-461667-1.htm#,https://www.hope.bio/clinical-trials,https://www.hope.bio/clinical-trials,https://www.hope.bio/clinical-trials,,https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071,,,,,,,,https://www.pharmaceutical-business-review.com/news/hope-biosciences-covid-19-stem-cell/,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04349631?term=HB-adMSCs&sort=nwst&draw=2&rank=3,,,,,,https://www.hope.bio/clinical-trials,,,,,,,,,
238,No,humanized monoclonal antibody (class IgG1 kappa),humanized monoclonal antibody (class IgG1 kappa),Lenzilumab,Humanigen Inc.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Catalent;Humanigen Inc.,United States,Ongoing,,,Phase 3,,,Assume completed,,,,Assume completed,Assume completed,Assume completed,,,,3,COVID 19,238,No,16,Mayo Clinic - Phoenix - Arizona; University of Southern California - Los Angeles - California; Baptist Medical Center - Jacksonville - Florida; Mayo Clinic - Jacksonville - Florida; AdventHealth Orlando - Orlando - Florida; Emory University - Emory - Georgia; St. Elizabeth Healthcare -Edgewood - Kentucky; Hennepin County Medical Center - Minneapolis - Minnesota - Mayo Clinic - Rochester - Minnesota; Dartmouth-Hitchcock - Lebanon - New Hampshire; Saint Barnabas Medical Center - Livingston - New Jersey; Atrium Health - Charlotte -  North Carolina; St. David's Healthcare - Austin - Texas; St. David's North Austin Medical Center - Austin - Texas; Texas Health - Dallas - Texas,05/2020,09/01/2020,09/01/2020,https://clinicaltrials.gov/ct2/show/NCT04351152,,,,,,,,Okezi,4/26/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
238,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.humanigen.com/press/FDA-Approves-Initiation-of-Humanigen%E2%80%99s-Phase-III-Study-of-Lenzilumab-in-COVID-19-Patients,https://www.bioworld.com/COVID19products,,,,,,https://www.humanigen.com/press/FDA-Approves-Initiation-of-Humanigen%E2%80%99s-Phase-III-Study-of-Lenzilumab-in-COVID-19-Patients,,,,,,,,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04351152?term=lenzilumab&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04351152?term=lenzilumab&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04351152?term=lenzilumab&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04351152?term=lenzilumab&draw=2&rank=3,,,,,,,,,,,,,,,
239,No,endonuclease,endonuclease,,SRI International; Iktos,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,New,Iktos SAS,United States,Ongoing,Considering the use of endonuclease inhibitors that have been proven useful in blocking the SARS virus,,Discovery,,3/1/2020,,,,,No,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/26/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
239,Yes,,,,https://www.sri.com/iktos-and-sri-international-announce-collaboration-to-combine-artificial-intelligence-and-novel-automated-discovery-platform-for-accelerated-development-of-new-anti-viral-therapies/press-release/,https://www.bioworld.com/COVID19products,,,,,,,,https://www.sri.com/iktos-and-sri-international-announce-collaboration-to-combine-artificial-intelligence-and-novel-automated-discovery-platform-for-accelerated-development-of-new-anti-viral-therapies/press-release/,,,,https://www.sri.com/iktos-and-sri-international-announce-collaboration-to-combine-artificial-intelligence-and-novel-automated-discovery-platform-for-accelerated-development-of-new-anti-viral-therapies/press-release/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
240,No,Monoclonal Antibody,Monoclonal Antibody,,ImmuneCyte Life Sciences Inc.; Thermogenesis Holdings Inc.,Therapeutic,COVID-19,Other,Monoclonal antibodies,New,ImmuneCyte Life Sciences Inc.; Thermogenesis Holdings Inc.,United States,Ongoing,,,Discovery,,4/1/2020,,,,,No,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/26/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
240,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,https://thermogenesis.com/thermogenesis-and-immunecyte-joint-venture-developing-several-convalescent-plasma-and-antibody-therapeutic-approaches-against-covid-19-featured-on-fox40-and-other-local-news-outlets/,,,,https://thermogenesis.com/thermogenesis-and-immunecyte-joint-venture-developing-several-convalescent-plasma-and-antibody-therapeutic-approaches-against-covid-19-featured-on-fox40-and-other-local-news-outlets/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
241,No,Low Dose Naltrexone,Low Dose Naltrexone,Lodonal - CYTO 106; IRT-101,Cytocom Inc.,Therapeutic,COVID-19,Unknown,Antiviral drugs-broad spectrum,Repurposed-Not Approved,Immune therapeutics Inc.,United States,Ongoing,Initially developed for use in HIV; Has shown efficacy in decreasing replication of H1N1 influenza,,Phase 2,,,Assume completed,,,,Assume completed,Started,,,,,2,COVID-19,,,,,,,,,,,,,,,,Okezi,4/26/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
241,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
242,No,Avdoralimab,,Avdoralimab,Innate Pharma SA; Marseille Immunopole,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Assistance Publique Hopitaux De Marseille,France,Ongoing,In phase 1 development for treatment of solid tumors including hepatocellular carcinoma and non-small cell lung cancer,,Phase 2,,Completed,Completed,"
",,,,4/27/2020,,,,,2,COVID-19,108,No,1,Marseille - France,04/27/2020,06/27/2020,10/27/2020,https://clinicaltrials.gov/ct2/show/NCT04371367,Nicolas Schleinitz,,nicolas.schleinitz@ap-hm.fr,,,,,Param Patel,5/7/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
242,Yes,Avdoralimab,Avdoralimab,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=1,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/record/NCT04371367,https://www.innate-pharma.com/en/news-events/press-releases/first-patient-dosed-avdoralimab-phase-ii-clinical-trial-covid-19-patients-severe-pneumonia,https://www.innate-pharma.com/en/news-events/press-releases/first-patient-dosed-avdoralimab-phase-ii-clinical-trial-covid-19-patients-severe-pneumonia,https://www.innate-pharma.com/en/news-events/press-releases/first-patient-dosed-avdoralimab-phase-ii-clinical-trial-covid-19-patients-severe-pneumonia,https://clinicaltrials.gov/ct2/show/study/NCT04371367,https://clinicaltrials.gov/ct2/show/study/NCT04371367,https://clinicaltrials.gov/ct2/show/study/NCT04371367,https://www.innate-pharma.com/en/news-events/press-releases/first-patient-dosed-avdoralimab-phase-ii-clinical-trial-covid-19-patients-severe-pneumonia,,https://clinicaltrials.gov/ct2/show/study/NCT04371367,,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=1,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=1,,,,,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=1,,,,,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=1,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=3,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=4,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=5,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=6,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=7,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=8,https://clinicaltrials.gov/ct2/show/NCT04371367?term=avdoralimab&cond=covid&draw=1&rank=9,,,,,,,,,"
",,,,,,,
243,No,Namilumab,Namilumab,IZN-101,Izana Bioscience Ltd,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Humanitas Research Group,Company based in the United Kingdom; Trial occuring in Italy,Ongoing,At the Humanitas Research Hospital,,Phase 2,,Completed,Completed,,,,,,,,,,2,COVID-19,,,,Milan - Italy,,,,,,,,,,,,Param Patel,5/7/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
243,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,https://www.pharmaceutical-technology.com/news/izana-namilumab-covid-19-study/,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,http://www.pharmatimes.com/news/izana_intiates_study_assessing_namilumab_for_covid-19_1337405,,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,,,,,,,,,,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,https://izanabio.com/initiation-of-two-centre-compassionate-use-study-involving-namilumab-in-the-treatment-of-individual-patients-with-rapidly-worsening-covid-19-infection-in-italy/,,,,,,,,,,,,,,,,"
",,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
244,No,camrelizumab plus thymosin,camrelizumab plus thymosin,Airuka,Jingsu HengRui Medicine Co.,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Southeast University,China,Ongoing,Originally intended for the treatment of Hodgkin Lymphoma and hepatocellular carcinoma,,Phase 2,,Completed,Completed,,,,,2/10/2020,,,,,2,COVID-19,120,No,1,Southeast University,02/10/2020,04/30/2020,10/31/2020,https://clinicaltrials.gov/ct2/show/NCT04268537,Jianfeng Xie,,,,,,,Param Patel,5/7/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
244,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,,https://clinicaltrials.gov/ct2/show/NCT04268537,,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,,,,,https://clinicaltrials.gov/ct2/show/NCT04268537,,,,,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,,,,,,,,,,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
245,No,monoclonal antibody,monoclonal antibody,Tocilizumab biosimilar,Jinyu Biotechnology Co. Ltd.,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Central South Hospital of Wuhan University,China,Ongoing,Originally intended for the treatment of Rheumatoid arthritis and systemic juvenile idiopathic arthritis,,Phase 2,,Completed,Completed,,,,,2/25/2020,,,,,2,COVID-19,60,No,1,Central South Hospital; Wuhan University,02/25/2020,,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,Zhiyong Peng ,,Pengzy5@hotmail.com,,,,,Param Patel,5/8/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
245,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030196,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030196,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030197,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030198,,,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030196,,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030196,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030196,,,,,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030196,,,,,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030196,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030197,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030198,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030199,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030200,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030201,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030202,,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030196,http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030197,,,,,,,,,,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
246,No,Antibodies,Antibodies,,Junshi Biosciences Ltd; Institute of Microbiology of the Chinese Academy of Sciences,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,"Junshi Biosciences Ltd; Institute of Microbiology of the Chinese Academy of Sciences -
Eli Lilly",China;USA,Ongoing,Antibody treatment for the neutralization of COVID-19 (The drug candidate is designed to prevent the binding of viruses to host cell surface receptor ACE2),,Pre-Clinical Testing,,,,,,,,,,,,,Pre-Clinical,COVID-19,,,,,,,,,,,,,,,,Param Patel,5/8/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
246,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,"https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure
","https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure
","https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure
","https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure
",,https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure,https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure,https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure,https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure,https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure,,,,,,,,,,,,,https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure,https://asia.nikkei.com/Spotlight/Caixin/Eli-Lilly-partners-with-Shanghai-Junshi-for-COVID-19-cure,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
247,No,selinexor,selinexor,Xpovio,Karyopharma Therapeutics Inc.,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,"Karyopharm Therapeutics Inc 
",Global,Ongoing,,,Phase 2,,Completed,Completed,,,,,4/30/2020,,,,,2,COVID-19,230,No,33,United States; Austria; France; Israel; Spain; The United Kingdom,04/17/2020,08/31/2020,08/31/2020,https://clinicaltrials.gov/ct2/show/NCT04349098,Jatin Shah,(617) 658-0600,jshah@karyopharm.com,,,,,Param Patel,5/8/2020,Ekaterina Zvorykina,5/26/2020,,,,5/26/2020
247,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=6,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=7,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=8,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=10,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=11,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=12,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=13,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=14,,,,https://clinicaltrials.gov/ct2/show/NCT04355676?term=Selinexor&cond=covid&draw=2&rank=1,,,,,https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation,https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation,https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation,https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation,https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation,https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation,https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation,https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation,https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation,https://clinicaltrials.gov/ct2/show/NCT04349098?term=Selinexor&cond=covid&draw=2&rank=2#contactlocation,,,,,,,,,,,,,,,
248,No,ARM/NK Therapy,,ARM/NK Therapy,Kleo Pharmaceuticals Inc.; Green Cross Labcell,Therapeutic,COVID-19,Combination,Other,Repurposed-Not Approved,Kleo Pharmaceuticals Inc.; Green Cross Labcell,,Ongoing,,,Pre-Clinical Testing,,Completed,Ongoing,"
",,,,,,,,,,,,,,,,,,,,,,,,,,Param Patel,5/8/2020,,,,,,5/8/2020
248,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=605,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=606,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=607,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=608,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=609,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=610,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=611,,,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=605,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=606,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=607,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=608,,,,,,,,,,,,,https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=605,,,,,,,,,,,,,,,,,,,,,
249,No,Panaphix,,Panaphix,Komipharm International Co. Ltd.,Therapeutic,COVID-19,Unknown,Unknown,New,Komipharm International,South Korea,Ongoing,,,Pre-Clinical Testing,,"
",,,,,,,,,,,,,,,,,,,,,,,,,,,,Param Patel,5/8/2020,,,,,,5/8/2020
249,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html,https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html,https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html,https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html,https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html,https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html,https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html,https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html,,,,https://www.biospectrumasia.com/news/39/15559/novotech-wins-cro-contract-for-covid-19-clinical-trial-in-south-korea.html,,,,,,,,,,,,,,,,,,,
250,No,Giapreza,,Giapreza,La Jolla Pharmaceutical Co.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Approved,La Jolla Pharmaceutical Co.,Italy; United Kingdom,Ongoing,,,Phase 2,,,,,,,,,,,,,"
","
",,,,,,,,,,,,,,,,Param Patel,5/8/2020,,,,,,5/8/2020
250,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.rxlist.com/giapreza-drug.htm,https://www.rxlist.com/giapreza-drug.htm,https://www.giapreza.com/about-giapreza/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,https://www.bioworld.com/COVID19products,COVID-20,,,,"
",,,,,,,,,,,,,,,,,,,
251,No,Lemellosome,,Lemellosome,Lamellar Biomedical Ltd.,Therapeutic,ARDS,Nucleic acid based therapies/vaccines,Other,Repurposed-Not Approved,Lamellasome Biomedical,United Kingdom,Ongoing,Novel treatment based on using lipid vesicles for nucleic acid delivery,,Discovery,,,,,,,,,,,,,Discovery,COVID-19,,,,,,,,,,,,,,,,Param Patel,5/9/2020,,,,,,5/9/2020
251,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.lamellar.com/news/9/59/Lamellar-Biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-COVID-19-using-its-unique-LAMELLASOME-Technology.html,https://www.lamellar.com/news/9/59/Lamellar-Biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-COVID-19-using-its-unique-LAMELLASOME-Technology.html,https://www.lamellar.com/news/9/59/Lamellar-Biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-COVID-19-using-its-unique-LAMELLASOME-Technology.html,https://www.lamellar.com/news/9/59/Lamellar-Biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-COVID-19-using-its-unique-LAMELLASOME-Technology.html,https://www.lamellar.com/news/9/59/Lamellar-Biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-COVID-19-using-its-unique-LAMELLASOME-Technology.html,https://www.lamellar.com/,https://www.lamellar.com/news/9/59/Lamellar-Biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-COVID-19-using-its-unique-LAMELLASOME-Technology.html,https://www.lamellar.com/,,https://www.lamellar.com/news/9/59/Lamellar-Biomedical-launches-program-designed-to-prevent-the-severe-respiratory-effects-of-COVID-19-using-its-unique-LAMELLASOME-Technology.html,,,,,,,,,,,,,https://www.lamellar.com/lamellasome-and-pulmonary-diseases/,https://www.lamellar.com/lamellasome-and-pulmonary-diseases/,,,,,,,,,,,,,,,,,,,,,,,
252,No,fenretinide,fenretinide,LAU-7b,Laurent Pharmaceuticals Inc.,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Canada,Ongoing,"Novel drug for CF, but Phase 2 will include 200 COVID-19 patients",,Phase 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/8/2020,,,,,,5/8/2020
252,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/laurent-pharmaceuticals-joins-battle-against-covid-19,https://www.drugbank.ca/drugs/DB05076,https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/laurent-pharmaceuticals-joins-battle-against-covid-19,https://www.manchestertimes.com/news/business/laurent-pharmaceuticals-receives-health-canada-s-approval-to-initiate-covid-19-clinical-trial/article_a59fbdf1-509a-569f-a9c4-841fa17608ae.html,,https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/laurent-pharmaceuticals-joins-battle-against-covid-19,https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/laurent-pharmaceuticals-joins-battle-against-covid-19,https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/laurent-pharmaceuticals-joins-battle-against-covid-19,,https://www.manchestertimes.com/news/business/laurent-pharmaceuticals-receives-health-canada-s-approval-to-initiate-covid-19-clinical-trial/article_a59fbdf1-509a-569f-a9c4-841fa17608ae.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/9/2020,,,,,,5/9/2020
253,No,tranexamic acid,tranexamic acid,LB-1148,Leading Biosciences Inc.; University of Alabama,Therapeutic,ARDS,Small molecule,Other,Repurposed-Not Approved,,United States,Ongoing,,,Phase 2,,,,,,Open IND,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/10/2020,,,,,,5/10/2020
253,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://pipelinereview.com/index.php/2020040774270/Small-Molecules/Leading-BioSciences-Announces-Potential-for-Investigational-Drug-LB1148-to-Treat-Multiple-Organ-Dysfunction-Syndrome-in-COVID-19-Patients.html,https://pipelinereview.com/index.php/2020040774270/Small-Molecules/Leading-BioSciences-Announces-Potential-for-Investigational-Drug-LB1148-to-Treat-Multiple-Organ-Dysfunction-Syndrome-in-COVID-19-Patients.html,https://leadingbiosciences.com/lb1148/,https://leadingbiosciences.com/lb1148/,,https://leadingbiosciences.com/,https://leadingbiosciences.com/lb1148/,,,https://leadingbiosciences.com/lb1148/,,,,,,https://leadingbiosciences.com/lb1148/,,,,,,,,,,,,,,,,,,,,,,,,,5/11/2020,,,,,,5/11/2020
254,No,chloroquine or hydroxychloroquine,chloroquine or hydroxychloroquine,Sanofi SA; Amneal Pharmaceuticals INc.; Rising Pharma Holdings Inc.; University of Minnesota; University of Oxford; IHU-Méditerranée Infection; Sandoz Inc.; Bayer AG; University of Washington; Patient-Centerede Outcomes Research Institute; World Health Organization; New York State Department of Health; National Institute or Respiratory Diseases - Mexico;,Lupus Therapeutics,Therapeutic,COVID-19,Small molecule,Antimalarial drugs,Repurposed-Approved,,United States,On Hold,"On March 28th, FDA issued emergency use authorization of chloroquine phosphate and hydroxychloroquine sulfate",,Phase 3,,,,,,,,,,,3/28/2020,,,,,,,,,,,,,,,,,,,Priya Kaur,5/12/2020,,,,,,5/12/2020
254,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/13/2020,,,,,,5/13/2020
255,No,Thiolanox,,Thiolanox,Mallinckrodt plc; Novoteris LLC,Therapeutic,ARDS,Other,Antiviral drugs-not specified,Repurposed-Approved,,Canada,Ongoing,Inhaled gaseous Nitric Oxide,,Phase 2,,,,,,,,,,,,,2,COVID-19,20,No,1,Diamond Centre-Vancouver-Canada,10/24/17,12/31/20,3/31/21,https://clinicaltrials.gov/ct2/show/NCT03331445,Chris C Miller,778-899-0607,chris@nitricsolutions.com,,,"Active, NOT RECRUITING",,Priya Kaur,5/14/2020,,,,,,5/14/2020
255,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://pharmaphorum.com/news/mallinckrodt-novoteris-nitric-oxide-will-start-covid-19-trial/,https://eyewire.news/articles/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/,https://pharmaphorum.com/news/mallinckrodt-novoteris-nitric-oxide-will-start-covid-19-trial/,https://eyewire.news/articles/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/,,https://eyewire.news/articles/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/,https://eyewire.news/articles/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/,https://eyewire.news/articles/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/15/2020,,,,,,5/15/2020
256,No,Prototype powders,,Prototype powders,Mannkind Corp.; Immix Biopharma Inc.,Therapeutic,ARDS,Other,Other,New,,United States,Ongoing,Pulmonary Drug Delievery,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/16/2020,,,,,,5/16/2020
256,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.ondrugdelivery.com/mannkind-refocuses-pipeline-resources-in-response-to-covid-19-pandemic/,https://www.bioworld.com/COVID19products,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/17/2020,,,,,,5/17/2020
257,No,Antibodies,,Antibodies,Medicago Inc.; Laval University,Therapeutic,COVID-19,Cell therapies,Monoclonal antibodies,New,Canadian Institutes for Health Research,Canada,Ongoing,,,Pre-Clinical Testing,,,,,,Pending,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/18/2020,,,,,,5/18/2020
257,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.medicago.com/en/covid-19-programs/,https://www.medicago.com/en/covid-19-programs/,https://www.medicago.com/en/covid-19-programs/,https://www.medicago.com/en/covid-19-programs/,,https://www.medicago.com/en/,https://www.medicago.com/en/covid-19-programs/,,,https://www.medicago.com/en/covid-19-programs/,,,,,,https://www.medicago.com/en/covid-19-programs/,,,,,,,,,,,,,,,,,,,,,,,,,5/19/2020,,,,,,5/19/2020
258,No,ibudilast,ibudilast,MN-166,Medicinova Inc.,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/20/2020,,,,,,5/20/2020
258,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.medicago.com/en/covid-19-programs/,https://www.medicago.com/en/covid-19-programs/,https://www.clinicaltrialsarena.com/news/yale-ibudilast-covid-19-trial/,https://www.clinicaltrialsarena.com/news/yale-ibudilast-covid-19-trial/,,https://www.clinicaltrialsarena.com/news/yale-ibudilast-covid-19-trial/,https://www.clinicaltrialsarena.com/news/yale-ibudilast-covid-19-trial/,,,https://www.medicago.com/en/covid-19-programs/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/21/2020,,,,,,5/21/2020
259,No,Ivermectin,,Ivermectin,Medincell SA; Merck,Therapeutic,COVID-19,Small molecule,Antibiotics and antiparasitics,Repurposed-Approved,,United States,Ongoing,,,Phase 3,,,,,,,,,,,,,,COVID-19,50,Yes,1,- New Delhi- India,4/25/20,7/25/20,7/25/20,https://clinicaltrials.gov/ct2/show/NCT04373824,Sandeep Budhiraj,,sbudhiraja@maxhealthcare.com,,,,,Priya Kaur,5/22/2020,,,,,,5/22/2020
259,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.ncbi.nlm.nih.gov/pubmed/28942281,https://www.ncbi.nlm.nih.gov/pubmed/28942281,https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans,,https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans,https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans,,,https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/23/2020,,,,,,5/23/2020
260,No,WP-1122,,WP-1122,Moleculin Biotech Inc.; University of Texas Medical Branch,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,New,,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/24/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
260,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.com/news-releases/moleculin-announces-active-compound-in-wp1122-reduces-coronavirus-replication-in-vitro-by-100-301037143.html,https://www.prnewswire.com/news-releases/moleculin-announces-active-compound-in-wp1122-reduces-coronavirus-replication-in-vitro-by-100-301037143.html,https://www.prnewswire.com/news-releases/moleculin-announces-active-compound-in-wp1122-reduces-coronavirus-replication-in-vitro-by-100-301037143.html,https://www.prnewswire.com/news-releases/moleculin-announces-active-compound-in-wp1122-reduces-coronavirus-replication-in-vitro-by-100-301037143.html,,https://www.moleculin.com/covid-19/,https://www.moleculin.com/covid-19/,,,https://www.moleculin.com/covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5/25/2020,,6/4/2020,,,,6/4/2020
261,No,Colchicine,,Colchicine,Montreal Heart Institute; NYU Grossman School of Medicine,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Canada,Ongoing,,,Phase 3,,,,,,,,,,,,,3,COVID-19,6000,Yes,4,-San Francisco- California; New York University School of Medcine - New York - New York; Montreal Heart Institute - Montreal - Canada; Hospital Universitario La Paz - Madrid- Spain,3/23/20,12/1,12/1,https://clinicaltrials.gov/ct2/show/NCT04322682,Priscilla Hsue,6282068257,priscilla.hsue@ucsf.edu,,,,,Priya Kaur,5/26/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
261,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.icm-mhi.org/en/new-clinical-trial-treatment-covid-19-positive-patients-start-nyu-grossman-school-medicine,https://www.bioworld.com/COVID19products,https://www.icm-mhi.org/en/new-clinical-trial-treatment-covid-19-positive-patients-start-nyu-grossman-school-medicine,https://www.drugbank.ca/drugs/DB01394,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/3/2020,,,,6/3/2020
262,No,CD-16; N-803; mesenchymal stem cells,,CD-16; N-803; mesenchymal stem cells,Nantkwest Inc.; Immunitybio Inc.,Therapeutic,COVID-19,Cell therapies,Antiviral drugs-not specified,Repurposed-Not Approved,Nantkwest Inc.; Immunitybio Inc.;National Institute of Allergy and Infectious Diseases.,USA,Ongoing,CD-16 off-the-shelf natural killer cells to enhance antibody killing of infected cells given alone or combined with Convalescent Plasma (CP) in combination with ImmunityBio’s IL-15 superagonist N-803 and Avelumab,,Pre-Clinical Testing,,4/15/2020,4/15/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,4/23/2020,Anusha Joshi ,6/3/2020,,,,6/3/2020
262,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/3/2020,,,,6/3/2020
263,No,Pritumumab,,Pritumumab,Nascent Biotech Inc.,Therapeutic,COVID-19,Cell therapies,Monoclonal antibodies,Repurposed-Not Approved,Nascent Biotech Inc.,USA,Ongoing,a natural human IgG1 kappa antibody that has been derived from a B cell isolated from regional draining lymph node of a cervical carcinoma patient,,Pre-Clinical Testing,,3/3/2020,3/19/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,4/23/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
263,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/3/2020,,,,6/3/2020
264,No,nitric oxide,nitric oxide,Nitricil therapeutic,Novan Inc.,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,Wainwright & Co. LLC,USA,Ongoing,,,Pre-Clinical Testing,,3/20/2020,4/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,4/25/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
264,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/3/2020,,,,6/3/2020
265,No,ST-266,,ST-266,Noveome Biotherapeutics Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,Noveome Biotherapeutics Inc.; US government,USA,Ongoing,,,Pre-Clinical Testing,,3/30/2020,,,,,TARGET: 9/1/2020,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,4/25/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
265,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/3/2020,,,,6/3/2020
266,No,small interfering RNAs,small interfering RNAs,RNAi therapeutic,Olix Pharmaceuticals,Therapeutic,COVID-19,,Antiviral drugs-antiretrovirals,New,OliX Pharmaceuticals Inc,South Korea,Ongoing,The siRNAs would operate within the RNAi pathway where it interferes with the expression of the genes with complementary nucleotide sequences by degrading mRNA after transcription resulting in no translation.,,Pre-Clinical Testing,,3/23/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,4/25/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
266,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/3/2020,,,,6/3/2020
267,No,KTH-222,,KTH-222,Oncology Pharma Inc.; Kalos Therapeutics Inc.,Vaccine - Prophylactic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,Kalos Therapeutics;Oncology Pharma Inc.,USA,Ongoing,anticancer drug,,Pre-Clinical Testing,,4/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,4/25/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
267,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,25.04.2020,,6/3/2020,,,,6/3/2020
268,No,VNAR antibodies,,VNAR antibodies,Ossianix Inc.,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,Lundbeck; Ossianix Inc.,USA; UK,Ongoing,,,Pre-Clinical Testing,,4/8/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,4/25/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
268,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/3/2020,,,,6/3/2020
269,No,ostrich IgY antibodies,ostrich IgY antibodies,Ostrich antibodies,Ostrich Pharma USA (Ostrigen),Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,Ostrich Pharma USA,USA; Japan,Ongoing,,,Phase 1,,3/30/2020,4/1/2020,,,,4/1/2020,,,,,,1,,,,,Rinku Medical Clinic,01/04/2020,,,,,,,,,,,Ekaterina Zvorykina,4/25/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
269,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6/3/2020,,,,6/3/2020
270,No,Sargramostim,Sargramostim,Leukine,Partner Therapeutics Inc.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Other,Repurposed-Approved,University Hospital Ghent; Flanders Institute of Biotechnology,Belgium,Ongoing,,,Phase 4,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,,,,,,,,4,COVID-19,80,No,1,University Hospital Ghent - Ghent - Belgium,,,,,,,,,,,,Gabbie,4/21/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
270,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.partnertx.com/11508-2/,https://www.drugbank.ca/drugs/DB00020,https://www.oncolink.org/cancer-treatment/oncolink-rx/sargramostim-leukine-r-gm-csf,https://www.drugbank.ca/drugs/DB00020,https://www.partnertx.com/11508-2/,https://www.partnertx.com/11508-2/,https://www.partnertx.com/11508-2/,,,,,,,,,https://www.partnertx.com/11508-2/,,,,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE,,,,,,,,,,,6/3/2020,,,,6/3/2020
271,No,Microbiome therapeutic,,Microbiome therapeutic,Persephone Biosciences Inc.,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,,United States,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/21/2020,Anusha Joshi,6/3/2020,,,,6/3/2020
271,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.com/news-releases/persephone-biosciences-announces-ai-driven-microbiome-therapeutic-and-diagnostic-programs-for-covid-19-301033668.html,https://www.prnewswire.com/news-releases/persephone-biosciences-announces-ai-driven-microbiome-therapeutic-and-diagnostic-programs-for-covid-19-301033668.html,https://www.prnewswire.com/news-releases/persephone-biosciences-announces-ai-driven-microbiome-therapeutic-and-diagnostic-programs-for-covid-19-301033668.html,https://www.nbcsandiego.com/news/local/microbiome-targeted-therapeutics-may-have-role-in-covid-19-fight/2306310/,,https://www.nbcsandiego.com/news/local/microbiome-targeted-therapeutics-may-have-role-in-covid-19-fight/2306310/,https://www.nbcsandiego.com/news/local/microbiome-targeted-therapeutics-may-have-role-in-covid-19-fight/2306310/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
272,No,PMZ-2010,PMZ-2010,Centhaquine,Pharmazz INc.,Therapeutic,ARDS,Small molecule,Other,Repurposed-Not Approved,,India,Ongoing,,,Phase 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/22/2020,Arshy,5/28/2020,,,,5/28/2020
272,Yes,https://www.pharmazz.com/pmz-2010-h.php,https://www.pharmazz.com/pmz-2010-h.php,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.pharmiweb.com/press-release/2020-04-09/centhaquine-can-provide-hemodynamic-stability-improve-tissue-oxygenation-reduce-pulmonary-edema-a,https://pubchem.ncbi.nlm.nih.gov/compound/Centhaquine#section=Related-Compounds-with-Annotation,https://www.pharmiweb.com/press-release/2020-04-09/centhaquine-can-provide-hemodynamic-stability-improve-tissue-oxygenation-reduce-pulmonary-edema-a,https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Pharmazz%2C+Inc.&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=,,https://clinicaltrials.gov/ct2/show/NCT04045327,https://www.pharmiweb.com/press-release/2020-04-09/centhaquine-can-provide-hemodynamic-stability-improve-tissue-oxygenation-reduce-pulmonary-edema-a,,,https://www.pharmiweb.com/press-release/2020-04-09/centhaquine-can-provide-hemodynamic-stability-improve-tissue-oxygenation-reduce-pulmonary-edema-a,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04045327,https://clinicaltrials.gov/ct2/show/NCT04045327,https://clinicaltrials.gov/ct2/show/NCT04045327,https://clinicaltrials.gov/ct2/show/NCT04045327,https://clinicaltrials.gov/ct2/show/NCT04045327,https://clinicaltrials.gov/ct2/show/NCT04045327,https://clinicaltrials.gov/ct2/show/NCT04045327,https://clinicaltrials.gov/ct2/show/NCT04045327,https://clinicaltrials.gov/ct2/show/NCT04045327,https://clinicaltrials.gov/ct2/show/NCT04045327,,,,,,,,,,,,,,,
273,No,Sp2CBMTD,Sp2CBMTD,Neumifil,Pneumagen Ltd.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,,Scotland,Ongoing,Carbohydrate bonding module (CBM40) blocks sialic acid receptors in respiratory tract and prevents virus from entering host cells,,Pre-Clinical Testing,,,,,,,,,,,,,Pre-clinical,,,,,,,,,,,,,,,,,Gabbie,4/23/2020,Arshy,5/28/2020,,,,5/28/2020
273,Yes,https://www.pneumagen.com/uploads/images/publications/Antimicrob.%20Agents%20Chemother.-2015-Govorkova-1495-504.pdf,https://www.pneumagen.com/uploads/images/publications/Antimicrob.%20Agents%20Chemother.-2015-Govorkova-1495-504.pdf,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.co.uk/news-releases/pneumagen-leverages-its-novel-glycan-approach-to-target-coronavirus-covid-19-infections-840930671.html,https://www.pneumagen.com/science.html,https://www.pneumagen.com/science.html,https://www.pneumagen.com/pipeline/respiratory-tract-infection.html,,https://www.linkedin.com/company/pneumagen-limited/,https://www.prnewswire.co.uk/news-releases/pneumagen-leverages-its-novel-glycan-approach-to-target-coronavirus-covid-19-infections-840930671.html,https://www.pneumagen.com/science.html,,https://www.pneumagen.com/pipeline.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
274,No,Umbilical Cord Mesenchymal Stem Cells (UC-MSCs),Umbilical Cord Mesenchymal Stem Cells (UC-MSCs),CoreCyte; Others,Predictive Biotech; Predictive Technology,Therapeutic,ARDS,Cell therapies,Other,Repurposed-Approved,Wuhan Union Hospital- China; Wuhan Hamilton Bio-technology Co. Ltd  - China.; ZhiYong Peng; Tuohua Biological Technology Co. Ltd,United States,Ongoing,Umbilical Cord Mesenchymal Stem Cells isolated from Wharton's Jelly; Applied for FDA approval for immediate use for Covid-19 on 04/09/2020,,Manufacturing,,,,,,,,,,APPLIED 04/09/2020,,,,,,,,,,,,,,,,,,,,Gabbie,4/23/2020,Arshy,5/28/2020,,,,5/28/2020
274,Yes,https://www.biospace.com/article/releases/predictive-submits-emergency-use-authorization-application-for-treatment-of-acute-respiratory-distress-syndrome-secondary-to-covid-19-with-umbilical-cord-mesenchymal-stem-cells/,https://www.biospace.com/article/releases/predictive-submits-emergency-use-authorization-application-for-treatment-of-acute-respiratory-distress-syndrome-secondary-to-covid-19-with-umbilical-cord-mesenchymal-stem-cells/,https://www.biospace.com/article/releases/predictive-submits-emergency-use-authorization-application-for-treatment-of-acute-respiratory-distress-syndrome-secondary-to-covid-19-with-umbilical-cord-mesenchymal-stem-cells/,https://www.bioworld.com/COVID19products; https://www.predictivebiotech.com/company/,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/predictive-submits-emergency-use-authorization-application-for-treatment-of-acute-respiratory-distress-syndrome-secondary-to-covid-19-with-umbilical-cord-mesenchymal-stem-cells/,https://clinicaltrials.gov/ct2/show/NCT04269525,https://clinicaltrials.gov/ct2/show/NCT04273646,https://www.predictivebiotech.com/wp-content/uploads/2019/05/CC_Product_Snapshot_v3_2019.pdf,https://clinicaltrials.gov/ct2/show/NCT04269525 ; https://clinicaltrials.gov/ct2/show/NCT04273646,https://www.predictivebiotech.com/company/,https://www.biospace.com/article/releases/predictive-submits-emergency-use-authorization-application-for-treatment-of-acute-respiratory-distress-syndrome-secondary-to-covid-19-with-umbilical-cord-mesenchymal-stem-cells/,https://www.predictivebiotech.com/products/,,https://www.biospace.com/article/releases/predictive-submits-emergency-use-authorization-application-for-treatment-of-acute-respiratory-distress-syndrome-secondary-to-covid-19-with-umbilical-cord-mesenchymal-stem-cells/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
275,No,PRTX-007,PRTX-007,,Primmune Therapeutics,Therapeutic,COVID-19,Small molecule,Other,New,,United States,Ongoing,Activates TLR7 to stimulate innate immune system,,Pre-Clinical Testing,,,,3/31/2020,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/23/2020,Arshy,5/28/2020,,,,5/28/2020
275,Yes,https://www.primmunerx.com/press-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications/,https://www.primmunerx.com/press-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,,https://www.primmunerx.com/#contact,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,,,,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
276,No,SARS-CoV-2 neutralizing antibody,SARS-CoV-2 neutralizing antibody,,Proteona Pte. Ltd.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Heidelberg University Hospital; Tübingen University Hospital; the German Cancer Research Center (DKFZ); the NMI Natural and Medical Sciences Institute; NUS Enterprise; 10x Genomics; NovogeneAIT,Singapore,Ongoing,No candidate yet. Still at discovery stage.,,Discovery,,3/25/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/23/2020,Arshy,5/28/2020,,,,5/28/2020
276,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html,https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html,https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html,https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html,https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html,https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html,https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html,,,https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html,,https://proteona.com/Proteona-leads-international-consortium-to-develop-SARS-CoV-2-neutralizing-antibody-to-help-vulnerable-immunocompromised-individuals.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
277,No,Opaganib,Opaganib,Yeliva,Redhill Biopharma Ltd.; Apogee Biotechnology Group Corp.,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Israel,Ongoing,Phase 2 trial IND application made,,Pre-Clinical Testing,,,,,,5/8/2020,,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/23/2020,Arshy,5/29/2020,,,,5/29/2020
277,Yes,https://www.redhillbio.com/yeliva,https://www.redhillbio.com/yeliva,https://www.redhillbio.com/yeliva,https://www.redhillbio.com/yeliva,https://www.bioworld.com/COVID19products,https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/redhill-seeks-us-fda-approval-to-begin-clinical-study-of-yeliva-for-covid-19-58087112,https://pubchem.ncbi.nlm.nih.gov/compound/abc294640#section=Pharmacology-and-Biochemistry,https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/redhill-seeks-us-fda-approval-to-begin-clinical-study-of-yeliva-for-covid-19-58087112,https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/redhill-seeks-us-fda-approval-to-begin-clinical-study-of-yeliva-for-covid-19-58087112,,https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/redhill-seeks-us-fda-approval-to-begin-clinical-study-of-yeliva-for-covid-19-58087112,https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/redhill-seeks-us-fda-approval-to-begin-clinical-study-of-yeliva-for-covid-19-58087112,https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/redhill-seeks-us-fda-approval-to-begin-clinical-study-of-yeliva-for-covid-19-58087112,,https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/redhill-seeks-us-fda-approval-to-begin-clinical-study-of-yeliva-for-covid-19-58087112,,,,,http://apogee-biotech.com/index.php/news/,https://www.globenewswire.com/news-release/2020/05/08/2030275/0/en/RedHill-Biopharma-Receives-FDA-Approval-for-COVID-19-Clinical-Study-with-Opaganib-in-the-U-S.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
278,No,RHB-107,RHB-107,Upamostat,Redhill Biopharma Ltd.; Link Health Group,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Not Approved,NIAID,Israel,Ongoing,Passed phase 1 and 2 clinical trials for other diseases currently being tested in-vitro for Covid-19,,Pre-Clinical Testing,,,,,,,4/20/20202,,,,,,Pre-clinical,,,,,,,,,,,,,,,,,Gabbie,4/23/2020,Arshy,5/29/2020,,,,5/29/2020
278,Yes,https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15260,https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15260,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.pharmaceutical-technology.com/news/redhill-biopharma-covid-19-drug-candidate/,https://www.drugbank.ca/drugs/DB13052,https://www.pharmaceutical-technology.com/news/redhill-biopharma-covid-19-drug-candidate/,https://www.redhillbio.com/rhb-107,https://www.pharmaceutical-technology.com/news/redhill-biopharma-covid-19-drug-candidate/,https://www.redhillbio.com/contact,https://www.pharmaceutical-technology.com/news/redhill-biopharma-covid-19-drug-candidate/,https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15260,,https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15260,,,,,,,https://www.thepharmaletter.com/article/wilex-wx-671-enters-clinic,https://clinicaltrials.gov/ct2/show/NCT00615940?spons=Wilex&draw=2&rank=4,,,,,https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15260,,,,,,,,,,,,,,,,,,,,,,,,
279,No,2-[4-(2-hydroxyethoxy)-3;5-dimethylphenyl]-5;7-dimethoxy-1;4-dihydroquinazolin-4-one,2-[4-(2-hydroxyethoxy)-3;5-dimethylphenyl]-5;7-dimethoxy-1;4-dihydroquinazolin-4-one,Apabetalone,Resverlogix Corp.,Therapeutic,COVID-19,Small molecule,Unknown,New,Private; NIHR,Canada,Ongoing,,,Phase 3,,2/3/2020,3/24/2020,,,,3/15/2020,3/17/2020,3/23/2020,,,,3,COVID19,,No,,,,,,,,,,,,,,Rebecca Taylor,4/23/2020,Arshy,5/29/2020,,,,5/29/2020
279,Yes,https://www.drugbank.ca/drugs/DB12000,https://www.drugbank.ca/drugs/DB12000,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.drugbank.ca/drugs/DB12000,https://adisinsight.springer.com/drugs/800027698,https://www.resverlogix.com/science-and-programs/apabetalone,http://www.io.nihr.ac.uk/wp-content/uploads/2018/11/11198-Apabetalone-for-MACE-V1.0-OCT18-NON-CONF.pdf,www.resverlogix.com,www.resverlogix.com,,,https://www.resverlogix.com/science-and-programs/clinical,,https://www.resverlogix.com/investors/news.html?article=660,https://adisinsight.springer.com/drugs/800027698,,,,https://www.resverlogix.com/upload/button/3/b9c82f751024/2019-rvx-corp-pres-march-18.pdf,https://www.globenewswire.com/news-release/2020/03/23/2004624/0/en/Resverlogix-Invites-Collaborations-for-use-of-Apabetalone-in-Trials-and-Studies-to-Combat-the-Spread-of-COVID-19-Based-on-New-Research.html,https://www.marketwatch.com/press-release/resverlogix-clinical-candidate-apabetalone-featured-as-a-potential-covid-19-treatment-in-recent-publication-2020-03-24?siteid=bigcharts&dist=bigcharts&tesla=y,,,,,,,,,,,,,,,,,,,,,,,,,,,,
280,No,N-(mercapto-2-methylpropionyl)-l-cysteine,N-(mercapto-2-methylpropionyl)-l-cysteine,Bucillamine,Revive Therapeutics Ltd.,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Canada,Ongoing,Antirheumatic,,Phase 2,,,,,,,,4/9/2020,,,,,2,COVID19,,No,,Novotech: Asia-Pacific,,,,,,,,,,,,Rebecca Taylor,4/24/2020,Arshy,5/29/2020,,,,5/29/2020
280,Yes,https://www.globenewswire.com/news-release/2020/03/20/2003915/0/en/Revive-Therapeutics-Explores-the-Use-of-Bucillamine-as-a-Novel-Treatment-for-Infectious-Diseases-including-COVID-19.html,https://www.globenewswire.com/news-release/2020/03/20/2003915/0/en/Revive-Therapeutics-Explores-the-Use-of-Bucillamine-as-a-Novel-Treatment-for-Infectious-Diseases-including-COVID-19.html,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.drugbank.ca/drugs/DB12160,https://www.mdpi.com/1424-8247/12/4/165,https://www.mdpi.com/1424-8247/12/4/165,,https://www.reuters.com/companies/RVV.CD,,https://www.mdpi.com/1424-8247/12/4/165,,https://clinicaltrials.gov/ct2/show/NCT02942420,,,,,,,,,,,,,,,,https://novotech-cro.com/news/novotech-selected-new-covid-19-clinical-trial-asia-pacific,,https://novotech-cro.com/news/novotech-selected-new-covid-19-clinical-trial-asia-pacific,,,,,,,,,,,,,,,,,,,
281,No,EIDD-2801,,EIDD-2801,Ridgeback Biotherapeutics LP; Merck; Drug Innovations at Emory LLC,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,New,Wayne and Wendy Holman,USA,Ongoing,Oral antiviral,,Phase 1,,,4/7/2020,,,MHRA Clearance,4/10/2020,,,,,,1,COVD19,122,No,4,Covance Daytona Beach Clinical Research Unit; Covance Dallas Clinical Research Unit; Covance Madison Clinical Research Unit	; Covance Leeds Clinical Research Unit,4/10/2020,6/16/2020,6/16/2020,,,,,,,,,Rebecca Taylor,4/24/2020,Arshy,5/29/2020,,,,5/29/2020
281,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.drugbank.ca/drugs/DB15661,https://www.drugbank.ca/drugs/DB15661,https://www.drugbank.ca/drugs/DB15661,https://www.ptcommunity.com/wire/ridgeback-biotherapeutics-announces-mhra-clearance-begin-human-testing-eidd-2801-uk-covid-19,https://www.ridgebackbio.com/,https://www.ptcommunity.com/wire/ridgeback-biotherapeutics-announces-mhra-clearance-begin-human-testing-eidd-2801-uk-covid-19,https://www.drugbank.ca/drugs/DB15661,,https://clinicaltrials.gov/ct2/show/NCT04392219?term=EIDD-2801&draw=2&rank=1,,,https://www.drugtargetreview.com/news/59567/eidd-2801-shows-efficacy-against-covid-19-in-human-cells-and-mice/,,,https://www.ptcommunity.com/wire/ridgeback-biotherapeutics-announces-mhra-clearance-begin-human-testing-eidd-2801-uk-covid-19,https://clinicaltrials.gov/ct2/show/NCT04392219?term=EIDD-2801&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04392219?term=EIDD-2801&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04392219?term=EIDD-2801&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04392219?term=EIDD-2801&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04392219?term=EIDD-2801&draw=2&rank=1,,,,,,,,,,,,,,,,,,,,
282,No,MORAb-022,MORAb-022,Gimsilumab,Roivant Sciences Ltd.; Altasciences Co. Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Switzerland,Ongoing,,,Phase 2,,,,,,,2/19/2020,4/12/2020,,,,,2,COVID19,270,No,14,,4/12/2020,7/2020,10/2020,,,,,,,,,Rebecca Taylor,4/24/2020,Arshy,5/29/2020,,,,5/29/2020
282,Yes,https://www.drugbank.ca/drugs/DB15280,https://www.drugbank.ca/drugs/DB15280,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,https://www.technologynetworks.com/drug-discovery/news/first-us-trial-participant-receives-gimsilumab-for-covid-19-and-acute-respiratory-distress-syndrome-333448,https://www.empr.com/home/news/drugs-in-the-pipeline/pipeline-investigational-therapies-for-covid-19/,https://www.clinicaltrialsarena.com/news/roivant-gimsilumab-covid-19-trial/,,https://roivant.com/,https://roivant.com/,,,,,,,,,,https://pharmaphorum.com/news/roche-begins-phase-3-trial-of-actemra-in-covid-19-pneumonia/,https://www.clinicaltrialsarena.com/news/roivant-gimsilumab-covid-19-trial/,,,,,,,https://www.clinicaltrialsarena.com/news/roivant-gimsilumab-covid-19-trial/,https://www.clinicaltrialsarena.com/news/roivant-gimsilumab-covid-19-trial/,,,,,,,,,,,,,,,,,,,,,
283,No,SAB-185,,SAB-185,Sab Biotherapeutics; CSL Behring LLC,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,BARDA,USA,Ongoing,,,Phase 1,,,,,,,4/1/2020,,,,,,,,,,,,,,,,,,,,,,,Rebecca Taylor,4/25/2020,,,,,,4/25/2020
283,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.medicalcountermeasures.gov/newsroom/2020/sab-185/,https://www.medicalcountermeasures.gov/newsroom/2020/sab-185/,https://www.cslbehring.com/newsroom/2020/sab-covid-19,https://globalbiodefense.com/2020/04/01/jpeo-cbrnd-barda-partner-with-sab-biotherapeutics-to-develop-covid-19-therapeutic/,https://sabbiotherapeutics.com/,https://globalbiodefense.com/2020/04/01/jpeo-cbrnd-barda-partner-with-sab-biotherapeutics-to-develop-covid-19-therapeutic/,,,https://globalbiodefense.com/2020/04/01/jpeo-cbrnd-barda-partner-with-sab-biotherapeutics-to-develop-covid-19-therapeutic/,,,,,,,https://globalbiodefense.com/2020/04/01/jpeo-cbrnd-barda-partner-with-sab-biotherapeutics-to-develop-covid-19-therapeutic/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
284,No,S-Protein/ACE2 Targeted prohylactic polypeptide,,S-Protein/ACE2 Targeted prohylactic polypeptide,Sichuan Kelun Pharmaceutical Co. Ltd.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,New,Apeiron Biologics,USA,Ongoing,,,Phase 2,,,,,,,3/1/2020,4/1/2020,,,,,,,,,,Austria; Germany; Denmark,,,,,,,,,,,,Rebecca Taylor,4/25/2020,,,,,,4/25/2020
284,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.drugtargetreview.com/news/59290/decoy-ace2-receptors-could-be-promising-covid-19-infection-preventing-drug/,https://www.drugtargetreview.com/news/59290/decoy-ace2-receptors-could-be-promising-covid-19-infection-preventing-drug/,https://www.drugtargetreview.com/news/59290/decoy-ace2-receptors-could-be-promising-covid-19-infection-preventing-drug/,https://www.clinicaltrialsarena.com/news/apeiron-biologics-phaseii-covid-19/,https://www.cslbehring.com/,https://www.technologynetworks.com/drug-discovery/news/phase-2-clinical-trial-of-apn01-for-treatment-of-covid-19-inititated-332897,,,,,,,,,,https://www.clinicaltrialsarena.com/news/apeiron-biologics-phaseii-covid-19/,https://www.clinicaltrialsarena.com/news/apeiron-biologics-phaseii-covid-19/,,,,,,,,,,https://www.technologynetworks.com/drug-discovery/news/phase-2-clinical-trial-of-apn01-for-treatment-of-covid-19-inititated-332897,,,,,,,,,,,,,,,,,,,
285,No,Liposomal curcumin,Liposomal curcumin,Lipocurc,Signpath Pharma Inc.,Therapeutic,COVID-19,Other,Antiviral drugs-not specified,Repurposed-Approved,Paracelsus Medical University; Discretionary Research Fund,USA,Ongoing,Cancer Treatment,,Phase 2,,,,,,,3/12/2020,4/1/2020,,,,,2,COVID19,70,No,,Pennysylvania: USA,,,,,,,,,,,,Rebecca Taylor,4/25/2020,,,,,,4/25/2020
285,Yes,https://www.ncbi.nlm.nih.gov/pubmed/30430227,https://www.ncbi.nlm.nih.gov/pubmed/30430227,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.researchgate.net/publication/258347314_Liposomal-formulated_curcumin_Lipocurc_targeting_HDAC_Histone_Deacetylase_prevents_apoptosis_and_improves_motor_deficits_in_Park_7_DJ-1-knockout_rat_model_of_Parkinson's_disease_implications_for_epige,https://www.researchgate.net/publication/258347314_Liposomal-formulated_curcumin_Lipocurc_targeting_HDAC_Histone_Deacetylase_prevents_apoptosis_and_improves_motor_deficits_in_Park_7_DJ-1-knockout_rat_model_of_Parkinson's_disease_implications_for_epige,https://finance.yahoo.com/news/signpath-pharma-focus-coronavirus-disease-132000816.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAMtxCulSHQRqpcWfz5eXklfWPZIxsyEpH3LfUs0lYTGd5XWIzXUfKYIN7lg0efispLMaTlsqNlKlgK0RXT8AEMJCBu_TipsZnVZutbwo1plJidTAfNKK9RxEYjbWGuefhN3x9Q-kMoFP-tPUWbZeHi2005ieCWY6KunPZMA8h7Bx,https://link.springer.com/article/10.1007/s00280-018-3654-0 ;  https://www.researchgate.net/publication/258347314_Liposomal-formulated_curcumin_Lipocurc_targeting_HDAC_Histone_Deacetylase_prevents_apoptosis_and_improves_motor_deficits_in_Park_7_DJ-1-knockout_rat_model_of_Parkinson's_disease_implications_for_epige,http://signpathpharma.com/,http://signpathpharma.com/portfolio/liposomal-curcumin-for-treatment-of-cancer/,http://signpathpharma.com/portfolio/liposomal-curcumin-for-treatment-of-cancer/,,http://signpathpharma.com/portfolio/liposomal-curcumin-for-treatment-of-cancer/,,http://signpathpharma.com/portfolio/liposomal-curcumin-for-treatment-of-cancer/,,,,,https://www.businesswire.com/news/home/20200317005082/en/SignPath-Pharma-Focus-Coronavirus-Disease-COVID-19-Developing,http://signpathpharma.com/pipeline/#details,,,,,http://signpathpharma.com/portfolio/liposomal-curcumin-for-treatment-of-cancer/,,http://signpathpharma.com/portfolio/liposomal-curcumin-for-treatment-of-cancer/,http://signpathpharma.com/portfolio/liposomal-curcumin-for-treatment-of-cancer/,,http://signpathpharma.com/pipeline/#details,,,,,,,,,,,,,,,,,,,
286,No,Interferon Alpha,Interferon Alpha,Antiviral,Sinopharm Group,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,Repurposed-Approved,NIHR,China,Ongoing,,,Phase1/2,,,,,,,4/26/2020,4/26/2020,,,,,,,,,,,,,,,,,,,,,,Rebecca Taylor,4/26/2020,,,,,,4/26/2020
286,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.drugbank.ca/drugs/DB05258,https://www.bioworld.com/COVID19products,https://www.drugbank.ca/drugs/DB05258,https://www.thenews.com.pk/print/648623-chinese-healthcare-group-invites-nih-for-covid-19-vaccine-test,http://www.sinopharm.com/1156.html,http://www.sinopharm.com/1156.html,,,,,,,,,,https://www.thenews.com.pk/print/648623-chinese-healthcare-group-invites-nih-for-covid-19-vaccine-test,https://www.thenews.com.pk/print/648623-chinese-healthcare-group-invites-nih-for-covid-19-vaccine-test,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
287,No,Glycosides,Glycosides,Antiviral,Sirona Biotechem Corp.,Therapeutic,COVID-19,Unknown,Antiviral drugs-broad spectrum,Repurposed-Approved,Private,Canada,Ongoing,,,Pre-Clinical Testing,,,4/1/2020,,,,,,,,,,,COVID19,,,,TFChem: France,,,,,,,,,,,,Rebecca Taylor,4/26/2020,,,,,,4/26/2020
287,Yes,https://www.barrons.com/press-release/PR-CO-20200331-902751?tesla=y,https://www.barrons.com/press-release/PR-CO-20200331-902751?tesla=y,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.barrons.com/press-release/PR-CO-20200331-902751?tesla=y,https://www.barrons.com/press-release/PR-CO-20200331-902751?tesla=y,https://www.sironabiochem.com/sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program/,https://www.sironabiochem.com/sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program/,https://www.sironabiochem.com/,https://www.sironabiochem.com/,,,https://www.sironabiochem.com/sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program/,,,https://www.sironabiochem.com/sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program/,,,,,,,,,,,,,,,https://www.sironabiochem.com/sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program/,,,,,,,,,,,,,,,,,,,
288,No,Compounds that block the activity of the SARS-CoV-2 MPro protease,Compounds that block the activity of the SARS-CoV-2 MPro protease,Therapeutic,Sosei Group Corp.,Therapeutic,COVID-19,,,,,Japan,Ongoing,,,Discovery,,4/14/2020,,,,,,,,,,,,COVID19,,,,,,,,,,,,,,,,Rebecca Taylor,4/26/2020,,,,,,4/26/2020
288,Yes,https://soseiheptares.com/news/599/129/Sosei-Heptares-to-apply-its-Structure-based-Drug-Design-Expertise-in-New-COVID-19-RD-Program.html,https://soseiheptares.com/news/599/129/Sosei-Heptares-to-apply-its-Structure-based-Drug-Design-Expertise-in-New-COVID-19-RD-Program.html,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,https://www.sironabiochem.com/sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program/,https://soseiheptares.com/news/599/129/Sosei-Heptares-to-apply-its-Structure-based-Drug-Design-Expertise-in-New-COVID-19-RD-Program.html,,,https://soseiheptares.com/news/599/129/Sosei-Heptares-to-apply-its-Structure-based-Drug-Design-Expertise-in-New-COVID-19-RD-Program.html,,https://soseiheptares.com/news/599/129/Sosei-Heptares-to-apply-its-Structure-based-Drug-Design-Expertise-in-New-COVID-19-RD-Program.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
289,No,Lung airway cells,,Lung airway cells,Stemcell Technologies Inc.,Therapeutic,COVID-19,Other,Other,New,CDC - China,Canada; China,Ongoing,Neither a treatment nor a prophylactic; mainly used to propagate the SARS-CoV-2 which allowed scientists at China's CDC to isolate the virus and obtain the gene sequence; clinical milestones and studies will not be filled out for this reason; development was finished before 03/25/2020 (which is when article about this breakthrough was published),,Manufacturing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/22/2020,,,,,,4/22/2020
289,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Other,Other,New,https://www.stemcell.com/canadian-biotechnology-company-stemcell-technologies-provides-critical-support-to-sequence-the-covid-19-virus-accelerating-vaccine-development.html,https://www.stemcell.com/canadian-biotechnology-company-stemcell-technologies-provides-critical-support-to-sequence-the-covid-19-virus-accelerating-vaccine-development.html,Ongoing,https://www.bioworld.com/COVID19products https://www.stemcell.com/canadian-biotechnology-company-stemcell-technologies-provides-critical-support-to-sequence-the-covid-19-virus-accelerating-vaccine-development.html,,Manufacturing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
290,No,Epaspire,,Epaspire,The KD Pharma Group SA; SLA Pharma AG,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United Kingdom,Ongoing,Purified EPA in a capsule currently in a Phase 3 clinical trial in Europe for treatment of FAP; well established safety profile and observed suppression of inflammatory cytokines that may contribute to COVID-19 progression; this allowed the quick initiation of Phase 3 COVID-19 trials and led to the goal of using EPAspire to reduce the complications of COVID-19,,Phase 3,,Completed,,,,4/14/2020,,,4/13/2020,,,,3,COVID-19,240,No,Undisclosed,Undisclosed,04/13/2020,07/13/2020,07/31/2020,https://clinicaltrials.gov/ct2/show/NCT04335032,,,,,,Not yet recruiting,,Andy Zhou,4/22/2020,,,,,,4/22/2020
290,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,https://www.kdpharmagroup.com/en/news/kd-pharma-group-sla-pharma-initiate-clinical-trial-covid-19,Ongoing,https://www.kdpharmagroup.com/en/news/kd-pharma-group-sla-pharma-initiate-clinical-trial-covid-19,,Phase 3,,https://www.kdpharmagroup.com/en/news/kd-pharma-group-sla-pharma-initiate-clinical-trial-covid-19,,,,https://www.kdpharmagroup.com/en/news/kd-pharma-group-sla-pharma-initiate-clinical-trial-covid-19,,,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,,,,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,No,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04335032?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=EPA&draw=2&rank=1,,,,,,,,,
291,No,TD-0903,,TD-0903,Theravance,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,New,,United States,Ongoing,Lung-selective inhaled JAK inhibitor that has the potential to block cytokines and chemokines associated with ALI and ARDS; shown to have effective and broad inhibition of JAK-STAT signaling in rodent models; CTA was submitted in the UK on 04/09/2020 - approval pending and phase 1 will begin immediately after,,Phase 1,,Completed,Completed,,,,,,,,,,1,COVID-19,54,Yes,1,Manchester - United Kingdom,04/2020,06/2020,06/2020,https://clinicaltrials.gov/ct2/show/NCT04350736,,1-855-633-8479,medinfo@theravance.com,,COMPLETED,,,Andy Zhou,4/22/2020,,,,,,4/22/2020
291,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Small molecule,Kinase inhibitors,New,,https://www.prnewswire.com/news-releases/theravance-biopharma-responds-to-covid-19-pandemic-by-advancing-td-0903-to-treat-hospitalized-patients-with-acute-lung-injury-301038037.html,Ongoing,https://www.prnewswire.com/news-releases/theravance-biopharma-responds-to-covid-19-pandemic-by-advancing-td-0903-to-treat-hospitalized-patients-with-acute-lung-injury-301038037.html,,Pre-Clinical Testing,,https://www.prnewswire.com/news-releases/theravance-biopharma-responds-to-covid-19-pandemic-by-advancing-td-0903-to-treat-hospitalized-patients-with-acute-lung-injury-301038037.html,https://www.prnewswire.com/news-releases/theravance-biopharma-responds-to-covid-19-pandemic-by-advancing-td-0903-to-treat-hospitalized-patients-with-acute-lung-injury-301038037.html,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04350736,https://clinicaltrials.gov/ct2/show/NCT04350736,https://clinicaltrials.gov/ct2/show/NCT04350736,Yes,https://clinicaltrials.gov/ct2/show/NCT04350736,https://clinicaltrials.gov/ct2/show/NCT04350736,https://clinicaltrials.gov/ct2/show/NCT04350736,https://clinicaltrials.gov/ct2/show/NCT04350736,https://clinicaltrials.gov/ct2/show/NCT04350736,https://clinicaltrials.gov/ct2/show/NCT04350736,,,,,,https://clinicaltrials.gov/ct2/show/NCT04350736,,,,,,,,,
292,No,ARMS-I,,ARMS-I,Cleveland University Hospitals,Vaccine - Prophylactic,COVID-19,Other,Other antiviral drugs,Repurposed-Not Approved,ARMS Pharmaceutical LLC; Cleveland Foundation; Case Western Reserve University,United States,Ongoing,ARMS-I is a microbe-impermeable barrier with anti-viral action designed to prevent upper respiratory infections; currently holds an IND as a potential flu prophylaxis; clinical trial (unspecified phase but characteristics inmply phase 2) to investigate whether ARMS-I will help protect against COVID-19 in frontline health workers; no entry in clinicaltrials.gov yet,,Phase 2,,Completed,,,,,,Target: 05/01/2020,,,,,2,COVID-19,,Yes,,University Hospitals - Cleveland - Ohio; Northeast Ohio health systems - Ohio,05/01/2020,,,,,,,,,,,Andy Zhou,4/24/2020,,,,,,4/24/2020
292,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Other,Other antiviral drugs,Repurposed-Not Approved,https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19 https://www.trialsitenews.com/university-hospitals-cleveland-launch-clinical-trial-assessing-arms-i-to-protect-clinicians-from-covid-19/,https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19,Ongoing,https://www.armspharmaceutical.com/arms-i-science https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19,,Phase 2,,https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19,,,,,,https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19,,,,,https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19,https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19,,Yes,https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19,https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19,https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2020/04/uh-to-launch-clinical-trial-in-the-fight-to-protect-clinicians-against-covid19,,,,,,,,,,,,,,,,,,
293,No,Tradipitant,,Tradipitant,Vanda Pharmaceuticals Inc.,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Not Approved,University of Illinois at Chicago,United States,Ongoing,Tradipitant is currently undergoing clinical trials for other conditions such as gastroparesis; tradipitant is an NK-1R antagonist that is being tested to see if it can treat inflammatory lung injury associated with COVID-19,,Phase 3,,Completed,,,,,,,4/13/2020,,,,3,COVID-19,300,No,1,Lenox Hill Hospital Northwell Health - New York City - New York,04/13/2020,08/01/2020,08/31/2020,https://clinicaltrials.gov/ct2/show/NCT04326426,,,,,,By Invitation ,,Andy Zhou,4/23/2020,,,,,,4/23/2020
293,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Small molecule,Other,Repurposed-Not Approved,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,Ongoing,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2 https://vandapharmaceuticalsinc.gcs-web.com/node/14066/pdf,,Phase 3,,https://vandapharmaceuticalsinc.gcs-web.com/node/14066/pdf,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,,,,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,No,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,,,,,,https://clinicaltrials.gov/ct2/show/NCT04326426?intr=tradipitant&draw=2&rank=2,,,,,,,,,
294,No,Monoclonal antibodies,,Monoclonal antibodies,Vanderbilt University; AstraZeneca,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Twist Bioscience Corp.; DARPA; NIAID; Ology Bioservices Inc.,United States,Ongoing,$14 million contract from US Department of Defense for Ology Bioservices and Vanderbilt to collaborate on antibody discovery against COVID-19; Twist to build a synthetic antibody discovery library based on sequences from a recovered COVID-19 patient from Vandebilt,,Discovery,,3/24/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/24/2020,,,,,,4/24/2020
294,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://news.vanderbilt.edu/2020/05/14/the-front-lines-vanderbilt-physicians-researchers-join-worldwide-fight-against-covid-19/,https://www.bioworld.com/COVID19products,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-partners-vanderbilt-university-medical-center,https://www.bioworld.com/COVID19products,Ongoing,https://www.pharmaceutical-technology.com/news/covid-19-allovir-ology-drugs/ https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-partners-vanderbilt-university-medical-center,,Discovery,,https://www.pharmaceutical-technology.com/news/covid-19-allovir-ology-drugs/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
295,No,VIR-7832,,VIR-7832,Vir Biotechnology Inc.; Biogen Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Wuxi Biologics; National Institute of Allergy and Infectious Diseases; Xencor Inc.; Glaxosmithkline plc; Samsung Biologics Co. Ltd.,United States,Ongoing,VIR-7831 and VIR-7832 are leading antibody candidates that have demonstrated high affinity for the SARS-CoV-2 spike protein; companies aim to directly enter phase 2 clinical trial within the next three to five months; currently still in the development phase,,Discovery,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/24/2020,,,,,,4/24/2020
295,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,https://www.bioworld.com/COVID19products,https://www.vir.bio/contact/,Ongoing,https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/,,Discovery,,https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
296,No,elsafavirine,elsafavirine,Elpida,Viriom Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,,United States,Ongoing,Elpida is a non-nucleoside reverse transcriptase inhibitor that received market approval from the Russian Ministry of Health to treat HIV on 06/30/2017; initated Phase 2 clinical study to evaluate efficacy of Elpida in adults with COVID-19 on 04/08/2020 but currently has no entry on clinicaltrials.gov,,Phase 2,,Completed,,,,,,4/8/2020,,,,,2,COVID-19,240,No,,Russia; Eastern EU Countries,05/01/2020,,,,,,,,,Not yet recruiting,,Andy Zhou,4/24/2020,,,,,,4/24/2020
296,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,,https://www.viriom.com/contact,Ongoing,https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19 https://www.viriom.com/news/2017/11/30/viriom-obtains-first-market-approval-of-elsulfavirine-elpida-for-treatment-of-hiv-1-infection-in-russia,,Phase 2,,https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19,,,,,,https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19,,,,,https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19,https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19,https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19,No,https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19,https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19,https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19,,,,,,,,,https://www.viriom.com/news/2020/4/8/viriom-initiates-phase-2-clinical-study-of-elsulfavirine-for-treatment-of-covid-19,,,,,,,,,
297,No,Viscient Therapeutic,,Viscient Therapeutic,Viscient Biosciences Inc.,Therapeutic,COVID-19,Other,Other,New,,United States,Ongoing,"Viscient is using 3D bioprinting tech to create lung tissue to support research efforts on finding and testing COVID-19 therapies - ""clinical trial in a dish;"" as of 04/20/2020 - still working on a way to develop infected lung tissue",,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/24/2020,,,,,,4/24/2020
297,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,COVID-19,Other,Other,New,,https://www.10news.com/news/coronavirus/biotechs-3d-models-could-lead-to-coronavirus-treatments,Ongoing,https://www.scienceboard.net/index.aspx?sec=sup&sub=can&pag=dis&ItemID=610 https://www.kusi.com/san-diego-biotech-company-fighting-coronavirus-through-3d-bioprinting/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
298,No,CB1 antagonist,,CB1 antagonist,Viripharm Biopharmaceuticals LLC,Therapeutic,COVID-19,Other,Antiviral drugs-broad spectrum,Repurposed-Not Approved,,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,4/22/2020,,,,,,4/22/2020
298,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
299,No,Sinapultide,Sinapultide,KL4 surfactant,Windtree Therapeutics Inc.,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,4/22/2020,,,,,,4/22/2020
299,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
300,No,UC-MSCs,UC-MSCs,Mesenchymal stem cells,Wuhan Hamilton Biotechnology Co. Ltd.,Therapeutic,COVID-19,Unknown,Other,Repurposed-Approved,,China,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,COVID-19,48,No,1,"Union Hospital - Tongji Medical College - Huazhong University of Science and Technology        
Wuhan - Hubei - China",4/20/20,6/30/20,2/15/22,https://clinicaltrials.gov/ct2/show/NCT04273646,,,,,,,,A. Burnett,4/22/2020,,,,,,4/22/2020
300,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
301,No,Antibody,,Antibody,VIB-UGent Center for Medical Biotechnology,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Belgium,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,4/22/2020,,,,,,4/22/2020
301,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
302,No,Plasma treatment,,Plasma treatment,Xbiotech Inc.; Biobridge Global,Therapeutic,COVID-19,Small molecule,Monoclonal antibodies,New,,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,4/22/2020,,,,,,4/22/2020
302,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
303,No,Oxypurinol,Oxypurinol,XRx-101,Xortx Therapeutics Inc.,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,,Canada,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,4/23/2020,,,,,,4/23/2020
303,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
304,No,Antiviral,,Antiviral,Xphyto Therapeutics Corp,Therapeutic,COVID-19,Unknown,Antiviral drugs-broad spectrum,New,,Canada,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,4/23/2020,,,,,,4/23/2020
304,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
305,No,Vaccine,,Vaccine,Axon Neuroscience SE,Vaccine - Prophylactic,COVID-19,Cell therapies,Vaccine,New,,Slovakia,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,4/23/2020,,,,,,4/23/2020
305,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
306,No,Dendritic cell vaccine,,Dendritic cell vaccine,Betta Pharmaceuticals Co. Ltd.; Beijing Dingcheng Taiyuan Biotechnology,Vaccine - Prophylactic,COVID-19,Cell therapies,Vaccine,New,,China,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,4/23/2020,,,,,,4/23/2020
306,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
307,No,Vaccine,,Vaccine,Chongqing Zhifei Biological Products Co. Ltd.,Vaccine - Prophylactic,COVID-19,Unknown,Vaccine,New,,China,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A. Burnett,4/23/2020,,,,,,4/23/2020
307,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
308,No,Fusogenix DNA Vaccine,,Fusogenix DNA Vaccine,Entos Pharmaceuticals,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,,Canada,Ongoing,Direct introduction of a plasmid encoding the antigen(s) against which an immune response is sought and relies on the production of the target antigen in the patient’s own cells,,Discovery,,,,,,,,,,,,,Discovery,COVID-19,,,,,,,,,,,,,,,,Natalie Tang,4/21/2020,,,,,,4/21/2020
308,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.entospharma.com/news/entos-pharmaceuticals-is-developing-a-dna-vaccine-against-covid-19-using-its-fusogenix-nanomedicine-platform,https://www.entospharma.com/news/entos-pharmaceuticals-is-developing-a-dna-vaccine-against-covid-19-using-its-fusogenix-nanomedicine-platform,https://www.entospharma.com/news/entos-pharmaceuticals-is-developing-a-dna-vaccine-against-covid-19-using-its-fusogenix-nanomedicine-platform,https://www.pharmaceutical-business-review.com/news/entos-pharmaceuticals-fusogenix-covid-19/,,https://www.entospharma.com/about,https://www.entospharma.com/news/entos-pharmaceuticals-is-developing-a-dna-vaccine-against-covid-19-using-its-fusogenix-nanomedicine-platform,https://www.entospharma.com/news/entos-pharmaceuticals-is-developing-a-dna-vaccine-against-covid-19-using-its-fusogenix-nanomedicine-platform,,https://www.entospharma.com/news/entos-pharmaceuticals-is-developing-a-dna-vaccine-against-covid-19-using-its-fusogenix-nanomedicine-platform,,,,,,,,,,,,,https://www.entospharma.com/news/entos-pharmaceuticals-is-developing-a-dna-vaccine-against-covid-19-using-its-fusogenix-nanomedicine-platform,COVID-19,,,,,,,,,,,,,,,,,,,,,,,
309,No,ERC’s SARS-Cov-2 Vaccine,,ERC’s SARS-Cov-2 Vaccine,Epitopoietic Research Corp.,Vaccine - Prophylactic,COVID-19,Other,Antiviral drugs-antiretrovirals,Repurposed-Not Approved,,Belgium,Ongoing,Vaccine containing virions; viral proteins at different stages of viral replication; whole human cells and cellular fragments; composing all elements of viral replication,,Discovery,,4/9/2020,,,,,,,,,,,Discovery,COVID-19,,,,,,,,,,,,,,,,Natalie Tang,4/21/2020,,,,,,4/21/2020
309,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/04/09/2014261/0/en/ERC-Launches-Development-Program-for-Novel-Cell-Based-Therapeutic-and-Prophylactic-SARS-CoV-2-Vaccine.html,,https://www.erc-immunotherapy.com/,https://www.erc-immunotherapy.com/media/news/latest-situation-%E2%80%93-ceo-statement,,https://www.erc-immunotherapy.com/,https://www.erc-immunotherapy.com/,https://www.erc-immunotherapy.com/,,https://www.erc-immunotherapy.com/,,https://www.globenewswire.com/news-release/2020/04/09/2014261/0/en/ERC-Launches-Development-Program-for-Novel-Cell-Based-Therapeutic-and-Prophylactic-SARS-CoV-2-Vaccine.html,,,,,,,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,
310,No,Coroflu,,Coroflu,Flugen Inc.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Antiviral drugs-broad spectrum,Repurposed-Not Approved,Flugen Inc; Bharat Biotech International Ltd - India; University of Wisconsin-Madison,India; United States,Ongoing,Modification of M2SR by adding part of the coding region for the coronavirus spike protein,,Discovery,,,,,,,,,,,,,Discovery,COVID-19,,,,,,,,,,,,,,,,Natalie Tang,4/21/2020,,,,,,4/21/2020
310,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://news.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/,https://news.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/,https://news.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/,https://news.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/,https://www.bioworld.com/COVID19products,https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-in-tie-up-to-develop-a-covid-vaccine/articleshow/74977030.cms?from=mdr,https://news.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/,https://news.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/,,http://flugen.com/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/,,,,,,,,,,,,,https://news.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/,COVID-19,,,,,,,,,,,,,,,,,,,,,,,
311,No,Ii-Key-SARS 2 peptide vaccine,,Ii-Key-SARS 2 peptide vaccine,Generex Biotechnology Group,Vaccine - Prophylactic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Approved,China Technology Exchange; Beijing Zhonghua Investment Fund Management Co. LTD; Biology Institute of Shandong Academy of Sciences; Sinotek-Advocates International Industry Development (Shenzhen) Co. LTD,United States,Ongoing,,,Discovery,,2/27/2020,,,,,,,,,,,Discovery,COVID-19,,,,,,,,,,,,,,,,Natalie Tang,4/21/2020,,,,,,4/21/2020
311,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://pipelinereview.com/index.php/2020022973919/Vaccines/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html,https://generex.com/covid-19,https://pipelinereview.com/index.php/2020022973919/Vaccines/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html,https://pipelinereview.com/index.php/2020022973919/Vaccines/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html,https://pipelinereview.com/index.php/2020022973919/Vaccines/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html,https://pipelinereview.com/index.php/2020022973919/Vaccines/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html,,,https://pipelinereview.com/index.php/2020022973919/Vaccines/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html,,https://pipelinereview.com/index.php/2020022973919/Vaccines/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html,,,,,,,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,
312,No,Z-VacciRNA,,Z-VacciRNA,Guanhao Biotech Co. Ltd.; Zy Therapeutics Inc.,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,,,,,,,,Discovery,,,,,,,,,,,,,Discovery,COVID-19,,,,,,,,,,,,,,,,Natalie Tang,4/24/2020,,,,,,4/24/2020
312,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,
313,No,Vaccine,,Vaccine,Hualan Biological Engineering,Vaccine - Prophylactic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Natalie Tang,4/24/2020,,,,,,4/24/2020
313,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
314,No,Vaccine,,Vaccine,ID Pharma Co. Ltd.; Fudan University,Vaccine - Prophylactic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Natalie Tang,4/24/2020,,,,,,4/24/2020
314,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
315,No,HzVSFv13,HzVSFv13,Virus Suppressing Factor,Immunemed,Therapeutic,Pneumonia,,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Korea,Ongoing,,,Phase 1,,,,,,,3/28/2020,,,2/21/2020,,,,,,,,,,,,,,,,,,,,Natalie Tang,4/24/2020,,,,,,4/24/2020
315,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://www.koreabiomed.com/news/articleView.html?idxno=7596,,https://www.prnewswire.com/news-releases/immunemeds-hzvsf-used-for-treatment-of-covid-19-pneumonia-patients-301031662.html,http://www.immunemed.co.kr/eng/news/news.asp?look_url=%2Feng%2Fnews%2Fnews.asp&BPart=news&SPart=eng&sno=4328&mode=read&page_no=1&search_field=&search_text=,,http://www.koreabiomed.com/news/articleView.html?idxno=7596,http://www.immunemed.co.kr/eng/news/news.asp?look_url=%2Feng%2Fnews%2Fnews.asp&BPart=news&SPart=eng&sno=4328&mode=read&page_no=1&search_field=&search_text=,,,http://www.immunemed.co.kr/eng/news/news.asp?look_url=%2Feng%2Fnews%2Fnews.asp&BPart=news&SPart=eng&sno=4328&mode=read&page_no=1&search_field=&search_text=,,,,,,,http://www.immunemed.co.kr/eng/news/news.asp?look_url=%2Feng%2Fnews%2Fnews.asp&BPart=news&SPart=eng&sno=4328&mode=read&page_no=1&search_field=&search_text=,,,http://www.koreabiomed.com/news/articleView.html?idxno=7596,,,,,,,,,,,,,,,,,,,,,,,,,,,
316,No,Nucleic Acid Vaccine,,Nucleic Acid Vaccine,Immunomic Therapeutics Inc.; Epivax Inc.; Pharmajet,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Antiviral drugs-broad spectrum,New,,United States,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Natalie Tang,4/24/2020,,,,,,4/24/2020
316,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://epivax.com/featured/press-release-immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform,https://epivax.com/featured/press-release-immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform,https://epivax.com/featured/press-release-immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform,https://www.hospimedica.com/covid-19/articles/294781719/immunomic-epivax-and-pharmajet-jointly-developing-covid-19-vaccine.html,,https://epivax.com/news/press-release-pharmajet-partners-with-immunomic-therapeutics-and-epivax-to-develop-and-deliver-covid-19-vaccine,https://epivax.com/featured/press-release-immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
317,No,DPX-COVID-19,,DPX-COVID-19,IMV Inc.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,,,,Canada,Ongoing,Epitope based vaccine; Design of a Phase 1 clinical study in 48 healthy subjects completed; clinical sites identified in Nova Scotia and Quebec,,Discovery,,3/18/2020,,,,,,,,,,,Discovery,COVID-19,,,,,,,,,,,,,,,,Natalie Tang,4/24/2020,,,,,,4/24/2020
317,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.ondrugdelivery.com/imv-development-of-dpx-covid-19-vaccine-its-ongoing-business-and-clinical-operations/,https://ir.imv-inc.com/press-releases/detail/635/imv-inc-launches-plans-to-advance-clinical-development-of,,,,https://www.ondrugdelivery.com/imv-development-of-dpx-covid-19-vaccine-its-ongoing-business-and-clinical-operations/,https://www.ondrugdelivery.com/imv-development-of-dpx-covid-19-vaccine-its-ongoing-business-and-clinical-operations/,https://ir.imv-inc.com/press-releases/detail/638/imv-inc-provides-updates-on-the-development-of,,https://www.ondrugdelivery.com/imv-development-of-dpx-covid-19-vaccine-its-ongoing-business-and-clinical-operations/,,https://www.ondrugdelivery.com/imv-development-of-dpx-covid-19-vaccine-its-ongoing-business-and-clinical-operations/,,,,,,,,,,,https://ir.imv-inc.com/press-releases/detail/638/imv-inc-provides-updates-on-the-development-of,https://www.ondrugdelivery.com/imv-development-of-dpx-covid-19-vaccine-its-ongoing-business-and-clinical-operations/,,,,,,,,,,,,,,,,,,,,,,,
318,No,peptide vaccine,peptide vaccine,IPT-001,Intellistem Technologies Inc.,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,,Canada,Ongoing,,,Pre-Clinical Testing,,Completed,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum,4/20/2020,,,,,,4/20/2020
318,Yes,https://bioinformant.com/covid-19-vaccine-intellistem/,https://bioinformant.com/covid-19-vaccine-intellistem/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://bioinformant.com/covid-19-vaccine-intellistem/,https://bioinformant.com/covid-19-vaccine-intellistem/,https://bioinformant.com/covid-19-vaccine-intellistem/,https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=IPT-001&searcher=drugs,,https://www.intellistemtech.com/contact,https://bioinformant.com/covid-19-vaccine-intellistem/,,,https://bioinformant.com/covid-19-vaccine-intellistem/,,https://bioinformant.com/covid-19-vaccine-intellistem/,https://bioinformant.com/covid-19-vaccine-intellistem/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
319,No,Polypeptide vaccine,,Polypeptide vaccine,Liaoning Chengda Biotechnology; Tsinghua University,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,,China,Ongoing,,,Discovery,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum,4/20/2020,,,,,,4/20/2020
319,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.marketwatch.com/press-release/nucleic-acid-vaccine-market-report-covers-top-countries-data-2020-regional-analysis-by-top-key-players-development-size-global-industry-share-forecast-to-2026-2020-04-23,https://www.marketwatch.com/press-release/nucleic-acid-vaccine-market-report-covers-top-countries-data-2020-regional-analysis-by-top-key-players-development-size-global-industry-share-forecast-to-2026-2020-04-23,,,could not find this information so assuming this is in its earliest stages,,could not find this information so assuming this is in its earliest stages,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
320,No,peptide mini-scaffold,peptide mini-scaffold,,Ligandal Inc.,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,New,,United States,Ongoing,High-affinity peptide scaffold that blocks interactions of SARS-CoV-2 to ACE2 receptor,,Pre-Clinical Testing,,Completed,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum,4/20/2020,,,,,,4/20/2020
320,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.ligandal.com/,https://www.ligandal.com/,https://www.ligandal.com/,https://www.ligandal.com/,,https://www.ligandal.com/,https://www.ligandal.com/,,,https://www.ligandal.com/,,https://www.ligandal.com/,https://www.ligandal.com/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
321,No,Medigen Vaccine,,Medigen Vaccine,Medigen Biotechnology Corp.,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,National Institutes of Health,Taiwan,Ongoing,,,Pre-Clinical Testing,,Completed,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum,4/20/2020,,,,,,4/20/2020
321,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,I could not find this anywhere,I could not find this anywhere,https://www.malaysiakini.com/news/511154,https://www.malaysiakini.com/news/511154,http://www.medigen.com.tw/en/home/,https://www.malaysiakini.com/news/511154,,,https://www.malaysiakini.com/news/511154,,https://www.malaysiakini.com/news/511154,https://www.malaysiakini.com/news/511154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
322,No,Mologic Vaccine,,Mologic Vaccine,Mologic Ltd,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,UK Government COVID-19 research funding package,United Kingdom,Ongoing,,,Discovery,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum,4/20/2020,,,,,,4/20/2020
322,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://mologic.co.uk/mologic-awarded-c-1-million-by-uk-government-to-develop-rapid-diagnostic-test-for-covid-19/,I could not find this information anywhere,I could not find this information anywhere,https://mologic.co.uk/mologic-awarded-c-1-million-by-uk-government-to-develop-rapid-diagnostic-test-for-covid-19/,https://mologic.co.uk/mologic-awarded-c-1-million-by-uk-government-to-develop-rapid-diagnostic-test-for-covid-19/,https://mologic.co.uk/mologic-awarded-c-1-million-by-uk-government-to-develop-rapid-diagnostic-test-for-covid-19/,https://mologic.co.uk/mologic-awarded-c-1-million-by-uk-government-to-develop-rapid-diagnostic-test-for-covid-19/,,,https://mologic.co.uk/mologic-awarded-c-1-million-by-uk-government-to-develop-rapid-diagnostic-test-for-covid-19/,,https://mologic.co.uk/mologic-awarded-c-1-million-by-uk-government-to-develop-rapid-diagnostic-test-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
323,No,second-generation AD5 platform,second-generation AD5 platform,NantKwest vaccine,Nantkwest Inc.; Immunitybio Inc.,Vaccine - Prophylactic,COVID-19,Unknown,Antiviral drugs-broad spectrum,New,,United States,Ongoing,Clinical trials expected to start this quarter,,Discovery,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum,4/20/2020,,,,,,4/20/2020
323,Yes,https://immunitybio.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,https://immunitybio.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,https://immunitybio.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://nantkwest.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,https://immunitybio.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,https://immunitybio.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,https://nantkwest.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,,https://nantkwest.com/contact/,,https://immunitybio.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,,https://nantkwest.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,,https://nantkwest.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
324,No,Soligenix Vaccine,,Soligenix Vaccine,Soligenix Inc.,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,University if Hawai'i at Manoa,United States,Ongoing,,,Discovery,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum,4/20/2020,,,,,,4/20/2020
324,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19,http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19,http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19,http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19,http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19,http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19,http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19,,,Seems implied in this article: http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19,,seems implied in this article: http://ir.soligenix.com/2020-03-23-Soligenix-and-University-of-Hawai-i-at-Manoa-Initiate-Work-on-Novel-Coronavirus-Vaccine-for-COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
325,No,S Protein Vaccine,,S Protein Vaccine,U.S. Army Medical Research and Development Command; Walter Reed Army Institute of Research,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,New,,United States,Ongoing,,,Pre-Clinical Testing,,Completed,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum,4/20/2020,,,,,,4/20/2020
325,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806,https://www.bioworld.com/COVID19products,https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806,https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806,,https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806,https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806,,,"this source says ""the initial stages of clinical trials"" but I am not positive this means pre-clinical trials: https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806",,"this source says ""the initial stages of clinical trials"" but I am not positive this means pre-clinical trials: https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806","this source says ""the initial stages of clinical trials"" but I am not positive this means pre-clinical trials: https://www.nbcnews.com/news/us-news/walter-reed-researchers-join-global-search-coronavirus-vaccine-n1165806",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
326,No,truncated S-protein,truncated S-protein,COVID-19 XWG-03,Xiamen Innovax Biotech Co. Ltd; Xiamen University,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,Repurposed-Not Approved,GlaxoSmithKline,China,Ongoing,Originally started being developed to treat HPV,,Pre-Clinical Testing,,Completed,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum,4/20/2020,,,,,,4/20/2020
326,Yes,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.chinadaily.com.cn/a/201909/07/WS5d734d85a310cf3e3556a43c.html,https://www.chinadaily.com.cn/a/201909/07/WS5d734d85a310cf3e3556a43c.html,https://www.reuters.com/article/brief-gsk-says-to-collaborate-with-xiame-idUSFWN2BR07C,https://www.chinadaily.com.cn/a/201909/07/WS5d734d85a310cf3e3556a43c.html,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.chinadaily.com.cn/a/201909/07/WS5d734d85a310cf3e3556a43c.html,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
327,No,ZIP-1642,,ZIP-1642,Ziphius Therapeutics NV,Vaccine - Prophylactic,COVID-19,Unknown,Vaccine,New,,Belgium,Ongoing,,,Discovery,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tatum,4/20/2020,,,,,,4/20/2020
327,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/articles/433873-other-news-to-note-for-march-23-2020,https://www.bioworld.com/articles/433873-other-news-to-note-for-march-23-2020,https://www.bioworld.com/articles/433873-other-news-to-note-for-march-23-2020,https://www.bioworld.com/articles/433873-other-news-to-note-for-march-23-2020,,https://www.bioworld.com/articles/433873-other-news-to-note-for-march-23-2020,https://www.bioworld.com/articles/433873-other-news-to-note-for-march-23-2020,,,https://www.bioworld.com/articles/433873-other-news-to-note-for-march-23-2020,,https://www.bioworld.com/articles/433873-other-news-to-note-for-march-23-2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
328,No,AG0302-COVID19; AG0301-COVID19,,AG0302-COVID19; AG0301-COVID19,AnGes; Osaka University,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Takara Bio Inc.,Japan,Ongoing,,,Phase 3,,Completed,Upcoming,,,,6/30/2020,,,,,,Phase 3,COVID-19,500,Yes,8,UHW Narita Hospital - Chiba - Japan; Medical Corporation Heishinkai OCROM Clinic - Osaka - Japan; Medical Corporation Tsurukamekai Shinjuku Tsurukame C linic - Tokyo - Japan; Medical Corporation Heishinkai ToCROM Clinic - Tokyo - Japan; Medical Corporation Shinanokai Shinanozaka Clinic - Tokyo - Japan; Sekino Clinical Pharmacology Clinic - Tokyo - Japan; NISHI-UMEDA Clinic for Asian Medical Collaboration - Osaka - Japan; Medical Corporation Heishinkai OPHAC Hospital - Osaka - Japan; ,6/30/2020,9/26/2020,7/31/2021,https://clinicaltrials.gov/ct2/show/NCT04655625   https://www.clinicaltrials.gov/ct2/show/NCT04527081,,81-3-5730-2488,anges-cr@anges.co.jp,,,,,Anna,4/22/2020,,,,,,4/22/2020
328,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.anges.co.jp/en/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf,https://www.anges.co.jp/en/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf,https://www.anges.co.jp/en/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf,https://www.anges.co.jp/en/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf,https://ir.takara-bio.co.jp/en/news_all/news_Release/news_Release201889409321505118082820200306.html,https://www.anges.co.jp/en/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf,https://www.anges.co.jp/en/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf,,,https://www.japantimes.co.jp/news/2020/06/30/national/science-health/japan-first-coronavirus-vaccine-clinical-test-starts/#.XxXF5yhKgdU,,https://www.reuters.com/article/us-health-coronavirus-japan-anges/pharma-firm-anges-and-osaka-university-to-begin-testing-coronavirus-vaccine-on-animals-idUSKBN21B019,https://japantoday.com/category/national/update-1-pharma-firm-anges-and-osaka-university-to-begin-testing-coronavirus-vaccine-on-animals,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/22/2020,,,,,,4/22/2020
329,No,canakinumab,canakinumab,Ilaris,Novartis,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,,Switzerland,Ongoing,"Not yet recruiting for observational study; Very limited information on Novartis website about using Ilaris for COVID; just listed as one of numerous drugs ""under investigation for people with COVID infection""",,,,,,,,,,,,,,,,COVID-19 Pneumonia,100,No,,,04/2020,07/2020,09/2020,https://clinicaltrials.gov/ct2/show/NCT04348448,,,,,,,,Anna,4/22/2020,,,,,,4/22/2020
329,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.drugbank.ca/drugs/DB06168,https://www.drugbank.ca/drugs/DB06168,https://www.drugbank.ca/drugs/DB06168,,https://www.novartis.com/news/novartis-corporate-fact-sheet/major-facilities,https://www.novartis.com/coronavirus/response,https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1; https://www.novartis.com/coronavirus/response,,,,,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,,,https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04348448?term=ilaris&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,,,,,,,,Anna,4/22/2020,,,,,,4/22/2020
330,No,emapalumab,emapalumab,Gamifant,Swedish Orphan Biovitrum (Sobi),Therapeutic,Other,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,,Sweden,Ongoing,,,Phase 2,,,,,,,,4/2/2020,,,,,2,Hyperinflammation and respiratory distress in COVID-19 patients,54,No,4,ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica - Brescia - Italy; Ospedale Maggiore Policlinico - Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza - Milan - Italy; Azienda Ospedaliero-Universitaria di Parma - Dipartimento di Malattie infettive ed epatologia - Parma - Italy; Ospedale Lazzaro Spallanzani - Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose - Rome - Italy,04/02/2020,07/2020,09/2020,https://clinicaltrials.gov/ct2/show/NCT04324021,Cristina de Min,,sobi.immuno@sobi.com,,,,,Anna,4/22/2020,,,,,,4/22/2020
330,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.sobi.com/index.php/en/press-releases/sobi-initiate-clinical-study-evaluate-whether-anakinra-and-emapalumab-may-relieve,https://www.sobi.com/en/products,https://www.sobi.com/en/products,https://www.drugbank.ca/drugs/DB14724,,https://www.sobi.com/en/about,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,,,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04324021?term=emapalumab&draw=2&rank=3#contacts,,Anna,4/22/2020,,,,,,4/22/2020
331,No,Antibody,,Antibody,"Distributed Bio, Centivax",Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Crowdsourcing,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/22/2020,,,,,,4/22/2020
331,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,https://www.distributedbio.com/covid19,,,https://www.distributedbio.com/covid19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/22/2020,,,,,,4/22/2020
332,No,Antibodies,,Antibodies,Chelsea and Westminster Hospital; Imperial College London,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,UK Government; University of Kent; Hong Kong University; National Institute for Biological Standards and Control,United Kingdom,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/26/2020,,,,,,4/26/2020
332,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/,https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/,https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/,https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/,https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment; https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/,https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment,https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/,,,https://www.imperial.ac.uk/news/196413/fighting-coronavirus-imperial-researchers-secure-funds/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/26/2020,,,,,,4/26/2020
333,No,Antibody Therapeutic Innovent Biologics,,Antibody Therapeutic Innovent Biologics,Innovent Biologics,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,China,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/22/2020,,,,,,4/22/2020
333,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.scmp.com/business/companies/article/3078085/chinese-cancer-drugs-developer-innovent-joins-crowded-field,https://www.scmp.com/business/companies/article/3078085/chinese-cancer-drugs-developer-innovent-joins-crowded-field,https://www.scmp.com/business/companies/article/3078085/chinese-cancer-drugs-developer-innovent-joins-crowded-field,https://www.scmp.com/business/companies/article/3078085/chinese-cancer-drugs-developer-innovent-joins-crowded-field,,https://www.scmp.com/business/companies/article/3078085/chinese-cancer-drugs-developer-innovent-joins-crowded-field,https://www.scmp.com/business/companies/article/3078085/chinese-cancer-drugs-developer-innovent-joins-crowded-field,,,https://www.btimesonline.com/articles/129691/20200403/chinese-drug-maker-innovent-biologics-developing-antibody-treatment-for-covid-19.htm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/22/2020,,,,,,4/22/2020
334,No,IC14,IC14,recombinant chimeric monoclonal antibody,Implicit Bioscience,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,,Australia,Ongoing,Expanded access available,,,,,,,,Expanded Access available,,,,,,,Expanded access,COVID-19; ARDS,,No,1,IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University - Milan - Italy,,,,https://clinicaltrials.gov/ct2/show/NCT04346277,Lorenzo Dagna,,dagna.lorenzo@unisr.it,,,,,Anna,4/24/2020,,,,,,4/24/2020
334,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://clinicaltrials.gov/ct2/show/NCT04346277,https://clinicaltrials.gov/ct2/show/NCT04346277,https://clinicaltrials.gov/ct2/show/NCT04346277,https://clinicaltrials.gov/ct2/show/NCT04346277,,https://implicitbioscience.com/home/,https://clinicaltrials.gov/ct2/show/NCT04346277,https://clinicaltrials.gov/ct2/show/NCT04346277,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04346277,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04346277,https://clinicaltrials.gov/ct2/show/NCT04346277,,https://clinicaltrials.gov/ct2/show/NCT04346277,https://clinicaltrials.gov/ct2/show/NCT04346277,,,,,https://clinicaltrials.gov/ct2/show/NCT04346277,,,,,,https://clinicaltrials.gov/ct2/show/NCT04346277,,Anna,4/24/2020,,,,,,4/24/2020
335,No,merimepodib,merimepodib,Vicromax,ViralClear Pharmaceuticals; BioSig Technologies,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,,United States,Ongoing,Submitted IND to FDA for Phase 2 trial for COVID-19 patients; Three Phase 2 trials completed in other idications; completed animal testing and phase 1 trials for other indications,,,,,,,,Submitted,,Plan to start with Phase 2 trials,,,,,,,,,,,,,,,,,,,,,,Anna,4/24/2020,,,,,,4/24/2020
335,Yes,https://www.biospace.com/article/releases/mayo-clinic-preparing-to-commence-phase-ii-fda-clinical-trial-for-the-treatment-of-covid-19-with-vicromax-/,https://www.biospace.com/article/releases/mayo-clinic-preparing-to-commence-phase-ii-fda-clinical-trial-for-the-treatment-of-covid-19-with-vicromax-/,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf; https://www.biosig.com/viralclear,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.biosig.com/viralclear,https://www.drugbank.ca/drugs/DB04862,https://www.biosig.com/viralclear,https://www.biosig.com/viralclear,,https://www.biosig.com/contact-biosig,https://www.biosig.com/viralclear,https://www.biosig.com/viralclear; https://www.biosig.com/news-media/press-releases/detail/194/biosig-to-host-conference-call-on-recent-developments-of,,,,,,,,https://www.biosig.com/news-media/press-releases/detail/194/biosig-to-host-conference-call-on-recent-developments-of,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/24/2020,,,,,,4/24/2020
336,No,ISR-50,,ISR-50,ISR Immune System Regulation; TCER AB,Therapeutic,COVID-19,,Vaccine,New,,Sweden,Ongoing,Hope to have animal testing done in 2nd quarter and human testing complete in 4th quarter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/26/2020,,,,,,4/26/2020
336,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf; http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0,,http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0,http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0,,http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0,http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0,http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/26/2020,,,,,,4/26/2020
337,No,antiviral Fc conjugates,,antiviral Fc conjugates,Cidara Therapeutics,Therapeutic,COVID-19,,Other,New,,United States,Ongoing,Uses Antiviaral Fc Conjugates (AVCs),,Pre-Clinical Testing,,Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/26/2020,,,,,,4/26/2020
337,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.cidara.com/cloudbreak/,,https://www.cidara.com/cloudbreak/,https://www.cidara.com/cloudbreak/,,https://www.cidara.com/cloudbreak/,https://www.cidara.com/cloudbreak/,https://www.cidara.com/cloudbreak/,,https://www.cidara.com/cloudbreak/,,https://www.cidara.com/pipeline/,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,4/26/2020,,,,,,4/26/2020
338,No,Antiviral combination,,Antiviral combination,SCORE Consortium; Helmholtz Centre for Infection Research; Janssen Pharmaceutica NV,Therapeutic,COVID-19,Unknown,Antiviral drugs-not specified,Repurposed-Approved,European Union's Horizon 2020 program,Netherlands,Ongoing,It is indicted that combinations of FDA-approved drugs will be teste but unknown as to which ones.,,Pre-Clinical Testing,,Skipped,4/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,4/20/2020,,,,,,4/20/2020
338,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://cordis.europa.eu/project/id/101003627,,https://cordis.europa.eu/project/id/101003627,https://cordis.europa.eu/project/id/101003627,https://www.lumc.nl/over-het-lumc/nieuws/2020/Maart/lumc-doet-onderzoek-naar-coranavirus-remmers/?setlanguage=English&setcountry=en,https://cordis.europa.eu/project/id/101003627,https://cordis.europa.eu/project/id/101003627,,,https://cordis.europa.eu/project/id/101003627,,https://cordis.europa.eu/project/id/101003627,https://cordis.europa.eu/project/id/101003627,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
339,No,Multistem,,Multistem,Athersys,Therapeutic,ARDS,Cell therapies,Other,New,,United States,Ongoing,"The Multistem cells ""express a range of therapeutically-relevant proteins that act like drugs"" ;  Planning to start Phase 2/3 Clinical Trial by 06/30/2020 ; Completed Phase 1/2 Clinical Trial on July 2019 ; Fast-Track Designation by the FDA",,Phase 3,,Completed,Completed,Completed,Completed,Completed,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,4/20/2020,,,,,,4/20/2020
339,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.biospace.com/article/barda-says-athersys-cell-therapy-highly-relevant-for-covid-19/,https://www.biospace.com/article/barda-says-athersys-cell-therapy-highly-relevant-for-covid-19/,https://www.biospace.com/article/barda-says-athersys-cell-therapy-highly-relevant-for-covid-19/,https://www.biospace.com/article/barda-says-athersys-cell-therapy-highly-relevant-for-covid-19/,,https://www.athersys.com/our-company/contact-us/default.aspx,https://www.athersys.com/clinical-trials/clinical-pipeline/default.aspx,https://www.biospace.com/article/barda-says-athersys-cell-therapy-highly-relevant-for-covid-19/ ; https://www.businesswire.com/news/home/20200413005160/en/FDA-Authorizes-Athersys-Initiate-Pivotal-Clinical-Trial,,,,,,,https://www.businesswire.com/news/home/20200413005160/en/FDA-Authorizes-Athersys-Initiate-Pivotal-Clinical-Trial,https://www.businesswire.com/news/home/20200413005160/en/FDA-Authorizes-Athersys-Initiate-Pivotal-Clinical-Trial,https://clinicaltrials.gov/ct2/show/study/NCT02611609?term=MultiStem&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/study/NCT02611609?term=MultiStem&draw=2&rank=4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
340,No,Inhalded mRNA,,Inhalded mRNA,Neurimmune; Ethris,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Monoclonal antibodies,New,,Switzerland;Germany,Ongoing,Manufacturing intended to initiate summer 2020; Expected clinical testing in 4th quarter of 2020 pending regulatory approval,,Discovery,,1/4/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,4/20/2020,,,,,,4/20/2020
340,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,Therapeutic,,https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19,https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19,,,https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19,,https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19,,,,https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19,,,https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
341,No,Novaferon,,Novaferon,The First Hospital of Changsha; The Second Xiangya Hospital of Central South University ; First Affiliated Hospital of Zhejiang University Medical School,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,Repurposed-Approved,,China,Ongoing,Currently licensed in China for treatment of Hepatitis B ; Started recruiting for Phase 4 Clinical Trial(Hu'nan) for COVID-19 patients; Also in testing in another Phase 4 Clinical Trail (Zhejiang) for COVID-19 patients,,Phase 4,,,,,,,,,,,,,4,COVID-19,240,No,2,The First Hospital of Changsha - Changsha - Hu'nan - China ; The Second Xiangya Hospital of Central South University - Changsha - Hu'nan - China,01/29/2020,,,http://www.chictr.org.cn/showprojen.aspx?proj=48809,,,,,,,,Joshuah,4/21/2020,,,,,,4/21/2020
341,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,http://www.chictr.org.cn/showprojen.aspx?proj=48809,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976097/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976097/,http://en.people.cn/n3/2018/0529/c90000-9465205.html,,http://en.people.cn/n3/2018/0529/c90000-9465205.html,,https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1 ; http://en.people.cn/n3/2018/0529/c90000-9465205.html,,http://www.chictr.org.cn/showprojen.aspx?proj=48809 ;  http://www.chictr.org.cn/showproj.aspx?proj=49065,,,,,,,,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,https://www.medrxiv.org/content/10.1101/2020.03.04.20031401v1.full.pdf,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,,,http://www.chictr.org.cn/showprojen.aspx?proj=48809,,,,,,,,,,,,,,,
342,No,BIO-11006,,BIO-11006,Biomarck Pharmaceuticals,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Kinase inhibitors,New,,United States,Ongoing,Currently tested in a pilot Phase 2a clinical trial,,Phase 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,4/21/2020,,,,,,4/21/2020
342,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,http://www.biomarck.com/pipeline/,https://www.ptcommunity.com/wire/biomarck-announces-statistically-significant-results-phase-2-controlled-clinical-study-non,https://www.ptcommunity.com/wire/biomarck-announces-statistically-significant-results-phase-2-controlled-clinical-study-non,,,https://www.ptcommunity.com/wire/biomarck-announces-statistically-significant-results-phase-2-controlled-clinical-study-non,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,,,,,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,,,https://clinicaltrials.gov/ct2/show/NCT03202394?term=BIO-11006&draw=2&rank=3,,,,,,,,,,,,,,,
343,No,nafamostat mesylate,nafamostat mesylate,Nafamostat,University of Tokyo; Ensysce Biosciences; National Center for Global Health Medicine; University Hospital Padova,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,,Japan,Ongoing,Currently recruiting for Phase 2/3 clinical trial in Padova-Italy ; Set to start a unknown phase clinical trial at National Center for Global Health and Medicine in April 2020 ; Requested EUA from FDA with planned Phase 1/2 clinical trial in United States at unknown start time,,Phase 2,,,,,,,,4/20/2020,4/20/2020,,,,2,COVID-19,256,No,,,04/20/2020,12/1/21,12/1/21,https://clinicaltrials.gov/ct2/show/NCT04352400,Gian Paolo Rossi,,gianpaolo.rossi@unipd.it,,,,,Joshuah,4/21/2020,,,,,,4/21/2020
343,Yes,https://www.drugbank.ca/drugs/DB12598,https://www.drugbank.ca/drugs/DB12598,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.businesswire.com/news/home/20200415005156/en/Ensysce-California-Based-Biotech-Company-Mission-Solve,https://www.drugbank.ca/drugs/DB12598,https://www.drugbank.ca/drugs/DB12598,https://www.drugbank.ca/drugs/DB12598,,https://www.drugbank.ca/drugs/DB12598,,https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1 ; https://www.businesswire.com/news/home/20200415005156/en/Ensysce-California-Based-Biotech-Company-Mission-Solve ; https://www.trialsitenews.com/university-of-tokyo-institute-of-medical-science-considers-nafamostat-for-clinical-trial-assessing-potential-to-treat-covid-19-clinical/,,https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1,,,,https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04352400?term=Nafamostat&draw=2&rank=1,,,,,,,,,,,,,,,
344,No,alteplase,alteplase,Activase,Beth Israel Deaconess; University of Colorado Anschultz Medical Campus; Denver Health; Genentech,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Other,Repurposed-Approved,National Institutes of Health ; Department of Defense Peer Reviewed Medical Research Program,United States,Ongoing,"FDA-approved for treating blood clots but currently in Phase 2 clinical trial for COVID-19 patients ; Therapeutic Approach is ""human tissue plasminogen activator""",,Phase 2,,,,,,,,4/22/2020,,,,,2,ARDS,60,No,3,University of Colorado Anschultz Medical Campus - Aurora - Colorado - United States ; Denver Health - Denver-Colorado - United States ; Beth Israel Deaconess Medical Center - Boston - Massachusetts - United States,04/22/2020,9/1/20,11/1/20,https://clinicaltrials.gov/ct2/show/NCT04357730,Ernest E Moore,(303) 602-1820,ernest.moore@dhha.org,,,,,Joshuah,4/22/2020,,,,,,4/22/2020
344,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,http://news.mit.edu/2020/covid-19-treat-respiratory-patients-plasminogen-0324,http://news.mit.edu/2020/covid-19-treat-respiratory-patients-plasminogen-0324,https://www.drugbank.ca/drugs/DB00009,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,http://news.mit.edu/2020/covid-19-treat-respiratory-patients-plasminogen-0324,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6 ; https://www.drugbank.ca/drugs/DB00009,,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6,,,,,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6,http://news.mit.edu/2020/covid-19-treat-respiratory-patients-plasminogen-0324,http://news.mit.edu/2020/covid-19-treat-respiratory-patients-plasminogen-0324,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6,,,https://clinicaltrials.gov/ct2/show/NCT04357730?term=Alteplase&draw=4&rank=6,,,,,,,,,,,,,,,
345,No,anakinra,anakinra,Kineret,Swedish Orphan Biovitrum; Fundacion Miguel Servet,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Netherlands,Ongoing,Currently testing in Phase 4 clinical trial named REMAP-CAP that was updated to include a sub-platform  REMAP-COVID for COVID-19 patients ; Also testing in numerous other Phase 2/3 clinical trials,,Phase 4,,,,,,,,,,,,,4,COVID-19,7100,No,89,Australia ; Belgium ; Canada ; Croatia ; Germany ; Hungary ; Ireland ; Netherlands ; New Zealand ; Portugal ; Romania ; Spain ; United Kingdom,04/11/2016,12/1/21,12/1/23,https://clinicaltrials.gov/ct2/show/NCT02735707,Cameron Green,,info@remapcap.org,,,,,Joshuah,4/22/2020,,,,,,4/22/2020
345,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://clinicaltrials.gov/ct2/show/NCT02735707,https://www.drugbank.ca/drugs/DB00026,https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/interleukin-1-receptor-antagonist,https://www.drugbank.ca/drugs/DB00026,,https://clinicaltrials.gov/ct2/show/NCT02735707,https://clinicaltrials.gov/ct2/show/NCT02735707,https://clinicaltrials.gov/ct2/show/NCT02735707 ; https://clinicaltrials.gov/ct2/show/NCT04330638 ; https://clinicaltrials.gov/ct2/show/NCT04324021 ; https://clinicaltrials.gov/ct2/show/NCT04341584 ; https://clinicaltrials.gov/ct2/show/NCT04339712 ; https://clinicaltrials.gov/ct2/show/NCT04357366,,https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6,https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6,https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6,https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6,https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6,https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6,https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6,,,https://clinicaltrials.gov/ct2/show/NCT02735707?term=anakinra+COVID-19&draw=2&rank=6,,,,,,,,,,,,,,,
346,No,PP-001,,PP-001,Panoptes Pharma GmbH,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,New,,Austria,Ongoing,"Drug has just completed a Phase 2 clinical trial for treatment of severe eye disesases; Article states that clinical trials for COVID-19 ""could begin shortly"".",,Phase 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,4/23/2020,,,,,,4/23/2020
346,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.lisavienna.at/news/the-austrian-biotech-company-panoptes-pharma-gmbh-has-a-promising-candidate-against-covid-19/,https://www.4sc.com/product-pipeline/out-licensed-products/pp-001/,https://www.lisavienna.at/news/the-austrian-biotech-company-panoptes-pharma-gmbh-has-a-promising-candidate-against-covid-19/,https://www.lisavienna.at/news/the-austrian-biotech-company-panoptes-pharma-gmbh-has-a-promising-candidate-against-covid-19/,,https://www.lisavienna.at/news/the-austrian-biotech-company-panoptes-pharma-gmbh-has-a-promising-candidate-against-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
347,No,tofacitinib,tofacitinib,Xeljanz,Pfizer,Therapeutic,Pneumonia,Small molecule,Kinase inhibitors,Repurposed-Approved,,United States,Ongoing,FDA approved to treat arthritis and colitis ; Currently testing in Phase 2 clinical trial for COVID-19 related pneuomia,,Phase 2,,,,,,,,,,,,,2,Pneumonia,50,No,1,Ospediali Riuniti di Ancona - Ancona - Marche - Italy,04/02/2020,6/20/20,7/10/20,https://clinicaltrials.gov/ct2/show/NCT04332042,,,,,,,,Joshuah,4/23/2020,,,,,,4/23/2020
347,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_advances_battle_against_covid_19_on_multiple_fronts,https://www.drugbank.ca/drugs/DB08895,https://www.drugbank.ca/drugs/DB08895,https://www.drugbank.ca/drugs/DB08895,,https://www.pfizer.com/contact,,https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1 ; https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04332042?term=tofacitinib&cntry=IT&draw=2&rank=1,,,,,,,,,,,,,,,
348,No,BLD-2660,,BLD-2660,Blade Therapeutics,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Not Approved,,United States,Ongoing,Caplain (protease) inhibitor; used to be a drug to treat fibrosis,,Phase 2,,,,,,,,,,,,,2,COVID-19,120,No,,,May 2020,August 2020,September 2020,https://clinicaltrials.gov/ct2/show/NCT04334460,,,,,,,,Andrew Chen,4/20/2020,,,,,,4/20/2020
348,Yes,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://clinicaltrials.gov/ct2/show/record/NCT04334460,https://clinicaltrials.gov/ct2/show/record/NCT04334460,https://clinicaltrials.gov/ct2/show/record/NCT04334460,https://adisinsight.springer.com/drugs/800052329,,https://www.blademed.com/contact/,https://clinicaltrials.gov/ct2/show/record/NCT04334460,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/record/NCT04334460,https://clinicaltrials.gov/ct2/show/record/NCT04334460,https://clinicaltrials.gov/ct2/show/record/NCT04334460,https://clinicaltrials.gov/ct2/show/record/NCT04334460,,,https://clinicaltrials.gov/ct2/show/record/NCT04334460,https://clinicaltrials.gov/ct2/show/record/NCT04334460,https://clinicaltrials.gov/ct2/show/record/NCT04334460,https://clinicaltrials.gov/ct2/show/record/NCT04334460,,,,,,,,,,,,,,,
349,No,PREVENT,,PREVENT,PREVENT-nCoV consortium,,,,,,,,,this consortium includes many different groups that are making different drugs; one main group involved is AdaptVac (line 79),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,4/26/2020,,,,,,4/26/2020
349,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
350,No,Biological Vaccine,,Biological Vaccine,Biological E Ltd,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,India,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,4/26/2020,,,,,,4/26/2020
350,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,,,https://www.livemint.com/news/india/covid-19-six-indian-companies-working-on-coronavirus-vaccine-11587016987400.html,,,,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
351,No,COVAX19,COVAX19,Vaxine Vaccine,Vaxine Pty Ltd; Flinders University,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,Australia,Ongoing,,,Phase 1,,,,,,,,,,,,,1,COVID-19,40,Yes,1,Adelaide  - Australia,6/20/20,7/1/21,7/1/21,https://clinicaltrials.gov/ct2/show/NCT04453852,Nikolai Petrovsky,For Australia: +61413131635,nikolai.petrovsky@flinders.edu.au;  d.gordon@flinders.edu.au,,,,,Andrew Chen,4/26/2020,,,Priya Kaur,6/2/2020,,6/2/2020
351,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.eurekalert.org/pub_releases/2020-04/fu-cio040220.php,https://www.eurekalert.org/pub_releases/2020-04/fu-cio040220.php,,,,,https://news.flinders.edu.au/blog/2020/04/03/flinders-targets-covid-19-vaccine/,https://news.flinders.edu.au/blog/2020/04/03/flinders-targets-covid-19-vaccine/,,,https://www.eurekalert.org/pub_releases/2020-04/fu-cio040220.php,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
352,No,University of Cambridge Vaccine,,University of Cambridge Vaccine,University of Cambridge; DIOSynVax,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,United Kingdom,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,4/26/2020,,,,,,4/26/2020
352,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19,https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19,https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19,https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19,https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19,,https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19,https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
353,No,St. Petersburg Vaccine,,St. Petersburg Vaccine,St. Petersburg Scientific Research Institute of Vaccines and Serums,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,Russia,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,4/26/2020,,,,,,4/26/2020
353,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://tass.com/society/1136863,,https://www.corona24.news/c/2020/04/12/st-petersburg-scientists-will-take-part-in-the-development-of-a-standard-against-covid-19-news-news.html,https://www.corona24.news/c/2020/04/12/st-petersburg-scientists-will-take-part-in-the-development-of-a-standard-against-covid-19-news-news.html,,,https://interfax.com/newsroom/top-stories/68233/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
354,No,VBI Vaccine,,VBI Vaccine,VBI Vaccines,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,United States,Ongoing,in collaboration with the National Research Council of Canada (NRC); advances on VBI's enveloped virus-like particle vaccines (eVLP vaccines),,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,4/26/2020,,,,,,4/26/2020
354,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.vbivaccines.com/wire/nrc-pan-coronavirus-vaccine-collaboration/,https://www.vbivaccines.com/wire/nrc-pan-coronavirus-vaccine-collaboration/,https://www.vbivaccines.com/wire/nrc-pan-coronavirus-vaccine-collaboration/,https://www.vbivaccines.com/wire/nrc-pan-coronavirus-vaccine-collaboration/,,https://www.vbivaccines.com/wire/nrc-pan-coronavirus-vaccine-collaboration/,https://www.vbivaccines.com/wire/nrc-pan-coronavirus-vaccine-collaboration/,,,https://www.vbivaccines.com/wire/nrc-pan-coronavirus-vaccine-collaboration/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
355,No,BIOCAD Vaccine,,BIOCAD Vaccine,BIOCAD; IEM,Vaccine - Prophylactic,COVID-19,,Vaccine,New,,Russia,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,4/26/2020,,,,,,4/26/2020
355,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,,https://biocadglobal.com/index.php?posts&post=45,https://biocadglobal.com/index.php?posts&post=45,,https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/,https://gmpnews.net/2020/03/biocad-begins-developing-covid-19-vaccine/,,,https://biocadglobal.com/index.php?posts&post=45,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
356,No,IAVI Vaccine,,IAVI Vaccine,Merck; IAVI; Batavia,Vaccine - Prophylactic,COVID-19,,,,,United States,Ongoing,intends to help lower the cost for producing vaccines for Covid-19,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,4/26/2020,,,,,,4/26/2020
356,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,https://www.bataviabiosciences.com/news/iavi-vsv-vector-epidemic-preparedness-vaccines/,https://www.bataviabiosciences.com/news/iavi-vsv-vector-epidemic-preparedness-vaccines/,,,,,https://www.iavi.org/contact-us,,,,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
357,No,Saiba Vaccine,,Saiba Vaccine,Saiba GmbH,Vaccine - Prophylactic,COVID-19,Other,Antiviral drugs-not specified,New,,Switzerland,Ongoing,Has been able to induce high levels of antibodies within a week in animals,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Hanna,5/9/2020,,,,,,5/9/2020
357,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,,Virus-like particles; https://biorender.com/covid-vaccine-tracker,https://www.saiba-biotech.com/Latest,,,https://www.saiba-biotech.com/contact,,https://www.saiba-biotech.com/Latest,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,,https://www.saiba-biotech.com/Latest,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
358,No,Imophoron Vaccine,,Imophoron Vaccine,Imophoron Ltd; University of Bristol,Vaccine - Prophylactic,COVID-19,Other,Unknown,New,University of Bristol's Emergency Research Group,United Kingdom,Ongoing,Vaccines require no refrigeration,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hanna,5/9/2020,,,,,,5/9/2020
358,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,http://www.pharmatimes.com/news/imophoron_develops_covid-19_vaccine_candidates_1337851,https://www.thepharmaletter.com/article/imophoron-to-begin-preclinical-tests-on-covid-19-vaccines,"VLP; ADDomerTM multiepitope
display; https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf",,,http://www.pharmatimes.com/news/imophoron_develops_covid-19_vaccine_candidates_1337851,http://www.pharmatimes.com/news/imophoron_develops_covid-19_vaccine_candidates_1337851,https://www.thepharmaletter.com/article/imophoron-to-begin-preclinical-tests-on-covid-19-vaccines,https://www.thepharmaletter.com/article/imophoron-to-begin-preclinical-tests-on-covid-19-vaccines,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
359,No,PRTX-007,,PRTX-007,Primmune Therapeutics,Vaccine - Prophylactic,COVID-19,Small molecule,Other,New,,United States,Ongoing,Activates TLR7 to stimulate innate immune system,,Pre-Clinical Testing,,,,3/31/2020,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/23/2020,,,,,,4/23/2020
359,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,,https://www.primmunerx.com/#contact,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,,,,https://www.prnewswire.com/news-releases/primmune-therapeutics-announces-the-selection-of-prtx007-as-its-clinical-development-candidate-for-covid-19-and-oncology-indications-301032274.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
360,No,AB00-1,,AB00-1,Agastiya Biotech LLC,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Not Approved,,United States,Ongoing,Acts on ACE-2 to inhibit the entry of the virus into the cell and workds on NSP15 to prevent its replication; Intends to begin human clinical trials this year,,Pre-Clinical Testing,,,,,,,,,,,,,Pre-Clinical,,,,,,,,,,,,,,,,,Hanna,5/5/2020,,,,,,5/5/2020
360,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.agastiyabiotech.com/covid19/,https://www.agastiyabiotech.com/covid19/,,,https://www.agastiyabiotech.com/contact/,,https://www.agastiyabiotech.com/covid19/;https://www.manchestertimes.com/news/business/agastiya-biotech-proceeding-with-drug-candidate-for-covid-19/article_52279711-3ec6-5087-a02f-e43158a68929.html,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,
361,No,ravulizumab-cwvz,ravulizumab-cwvz,Ultomiris,Alexion Pharmaceuticals Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,,United States,Ongoing,A terminal complement inhibitor of C5,,Phase 3,,,,,,,Assume Completed,Assume Completed,Estimated May 2020,,,,3,COVID 19 Severe Pneumonia; Acute Lung Injury; or Acute Respiratory Distress Syndrome,270,No,,,May 2020,November 2020,February 2021,https://clinicaltrials.gov/ct2/show/NCT04369469,,,clinicaltrials@alexion.com,,,,,Hanna,5/5/2020,,,,,,5/5/2020
361,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/alexion-announces-plans-to-initiate-phase-3-study-of-ultomiris-ravulizumab-cwvz-in-hospitalized-patients-with-severe-covid-19/,https://www.drugbank.ca/drugs/DB11580,https://alexion.com/our-medicines/medicines/ultomiris,,https://clinicaltrials.gov/ct2/show/NCT04369469?term=Ravulizumab&draw=2&rank=5,https://alexion.com/our-company/about-us,https://clinicaltrials.gov/ct2/show/NCT04369469?term=Ravulizumab&draw=2&rank=5,https://www.drugbank.ca/drugs/DB11580,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04369469?term=Ravulizumab&draw=2&rank=5,,,,https://www.biospace.com/article/releases/alexion-announces-plans-to-initiate-phase-3-study-of-ultomiris-ravulizumab-cwvz-in-hospitalized-patients-with-severe-covid-19/,https://clinicaltrials.gov/ct2/show/NCT04369469?term=Ravulizumab&draw=2&rank=5,https://www.biospace.com/article/releases/alexion-announces-plans-to-initiate-phase-3-study-of-ultomiris-ravulizumab-cwvz-in-hospitalized-patients-with-severe-covid-19/,https://www.biospace.com/article/releases/alexion-announces-plans-to-initiate-phase-3-study-of-ultomiris-ravulizumab-cwvz-in-hospitalized-patients-with-severe-covid-19/,,,https://clinicaltrials.gov/ct2/show/NCT04369469?term=Ravulizumab&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04369469?term=Ravulizumab&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04369469?term=Ravulizumab&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04369469?term=Ravulizumab&draw=2&rank=5,,,,,,,,,,,,,,,
362,No,Metablok,,Metablok,Arch Biopartners Inc.,Therapeutic,COVID-19,Other,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Canada,Ongoing,The primary endpoint is to prevent acute respiratory distress syndrome in patients infected with COVID19; DPEP-1 inhibitor treating inflammation in the lungs liver and kidneys,,Phase 2,,,,,,,Finalized: 03/17/2020,04/27/2020 Submitted CTA to health Canada for Phase II; expected to start Summer 2020,,,,,,,,,,,,,,,,,,,,,,Hanna,5/5/2020,,,,,,5/5/2020
362,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/157-arch-biopartners-submits-application-to-health-canada-to-conduct-covid19-phase-ii-human-trial-for-metablok-to-prevent-lung-and-kidney-inflammation,https://www.precisionvaccinations.com/vaccines/metablok-lsalt-peptide,https://www.precisionvaccinations.com/vaccines/metablok-lsalt-peptide,https://www.precisionvaccinations.com/vaccines/metablok-lsalt-peptide,,https://www.precisionvaccinations.com/vaccines/metablok-lsalt-peptide,,https://archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/157-arch-biopartners-submits-application-to-health-canada-to-conduct-covid19-phase-ii-human-trial-for-metablok-to-prevent-lung-and-kidney-inflammation,,,,,,,,,https://archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/152-arch-biopartners-safely-completes-expanded-dosing-of-metablok-in-phase-i-human-trial-and-begins-focus-on-phase-ii-trial,https://www.biospace.com/article/releases/arch-biopartners-releases-new-video-showing-metablok-reducing-lung-inflammation-in-an-animal-model-/,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT03772678?term=LSALT+peptide&draw=2&rank=1,,,,,,,,,,,,,,,
363,No,MEDI-3506,,MEDI-3506,Aztrazeneca plc,Therapeutic,COVID-19,,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,Medimmune; ACCORd,,Ongoing,Targeting Interluekin 33,,Phase 2,,,,,,,Completed 09/30/2019,,,,,,,,,,,,,,,,,,,,,,,Hanna,5/9/2020,,,,,,5/9/2020
363,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,https://www.astrazeneca.com/media-centre/articles/2020/investigating-an-existing-medicine-as-a-potential-treatment-for-covid-19.html,https://adisinsight.springer.com/drugs/800049222; https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,,,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,,https://www.bioworld.com/COVID19products,,,,,,,https://clinicaltrials.gov/ct2/show/NCT03096795,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
364,No,dapagliflozin,dapagliflozin,Farxiga,Aztrazeneca plc,Therapeutic,COVID-19,Small molecule,,Repurposed-Approved,Saint Luke's Health System; AstraZeneca; George Clinical Pty Ltd,United States,Ongoing,A sodium glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2; currently recruiting; estimated completion date October 2020,,Phase 3,,,,,,,,,4/15/2020,,,,3,COVID19,900,No,1,Saint Luke's Mid America Heart Institute Kansas City - Missouri - United States,04/22/2020,October 2020,December 2020,https://clinicaltrials.gov/ct2/show/NCT04350593,Sheryl Windsor,816-932-9858,swindsor@saint-lukes.org,,,,,Hanna,5/9/2020,,,,,,5/9/2020
364,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.drugbank.ca/drugs/DB06292,,https://www.drugbank.ca/drugs/DB06292,https://clinicaltrials.gov/ct2/show/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,,https://www.drugbank.ca/drugs/DB06292,,https://clinicaltrials.gov/ct2/show/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,,,,,,,,,https://clinicaltrials.gov/ct2/show/record/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,,,,https://clinicaltrials.gov/ct2/show/record/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,https://clinicaltrials.gov/ct2/results?cond=&term=Dapagliflozin&cntry=&state=&city=&dist=,https://clinicaltrials.gov/ct2/results?cond=&term=Dapagliflozin&cntry=&state=&city=&dist=,https://clinicaltrials.gov/ct2/results?cond=&term=Dapagliflozin&cntry=&state=&city=&dist=,https://clinicaltrials.gov/ct2/show/study/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/study/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/study/NCT04350593?term=Dapagliflozin&cond=COVID19&draw=2&rank=1,,,,,,,,,,,,,,,
365,No,IgM Antibodies; IgA Antibodies,,IgM Antibodies; IgA Antibodies,Atreca Inc.; Beigene Ltd.; IGM Biosciences Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Atreca - United States; BeiGene-China; IGMBiosciences - United States,Ongoing,Idenitfying the sequeneces of antibodies made by B cells found in blood from acutely infected COVID-19 patients and engineering IgM and IgA antibodies (from the identified sequence) with greater binding power per antibody.,,Discovery,,Announced collaboration on 04/29/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hanna,5/4/2020,,,,,,5/4/2020
365,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://ir.beigene.com/static-files/e62cb49b-21dd-40d0-b305-60946431c587,http://ir.beigene.com/static-files/e62cb49b-21dd-40d0-b305-60946431c587,http://ir.beigene.com/static-files/e62cb49b-21dd-40d0-b305-60946431c587,,,https://www.atreca.com/about/; https://www.beigene.com/about/our-story; https://igmbio.com/,,http://ir.beigene.com/static-files/e62cb49b-21dd-40d0-b305-60946431c587,,,,http://ir.beigene.com/static-files/e62cb49b-21dd-40d0-b305-60946431c587,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
366,No,Audax Therapeutic,,Audax Therapeutic,Audax Medical Inc.,Therapeutic,COVID-19,Small molecule,Other,New,,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
366,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.northeastern.edu/cri/news/northeastern-professor-partners-with-audax-medical-inc-to-combat-covid-19/,https://www.northeastern.edu/cri/news/northeastern-professor-partners-with-audax-medical-inc-to-combat-covid-19/,https://news.northeastern.edu/2020/03/04/heres-how-nanoparticles-could-help-us-get-closer-to-a-treatment-for-covid-19/,https://news.northeastern.edu/2020/03/04/heres-how-nanoparticles-could-help-us-get-closer-to-a-treatment-for-covid-19/,,https://news.northeastern.edu/2020/03/04/heres-how-nanoparticles-could-help-us-get-closer-to-a-treatment-for-covid-19/,https://news.northeastern.edu/2020/03/04/heres-how-nanoparticles-could-help-us-get-closer-to-a-treatment-for-covid-19/,,,https://news.northeastern.edu/2020/03/04/heres-how-nanoparticles-could-help-us-get-closer-to-a-treatment-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
367,No,Bemcentinib,,Bemcentinib,Bergenbio ASA,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,Department of Health and Social Care (DHSC); UK Research and Innovation (UKRI),Norway,Ongoing,,,Phase 2,,,,,,,,,,,,,2,COVID-19,120,No,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
367,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/,https://www.bioworld.com/articles/434740-bergenbios-bemcentinib-joins-fast-tracked-accord-program-targeting-covid-19,https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/,https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/,https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/,https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/,https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/,,,https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/,,,,,,,,,,,,,https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/,https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/,https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
368,No,COVID-19 treatments,,COVID-19 treatments,Biovista Inc.,Therapeutic,COVID-19,Other,Other,New,,United States,Ongoing,AI company that helps identify drugs (Project Prodigy AI),,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
368,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biovista.com/artificial-intelligence-firm-biovista-repositions-four-promising-therapeutics-against-covid-19/,https://www.biovista.com/artificial-intelligence-firm-biovista-repositions-four-promising-therapeutics-against-covid-19/,https://www.biovista.com/artificial-intelligence-firm-biovista-repositions-four-promising-therapeutics-against-covid-19/,https://www.biovista.com/artificial-intelligence-firm-biovista-repositions-four-promising-therapeutics-against-covid-19/,,https://www.biovista.com/solutions/project-prodigy-vs-covid-19/,https://www.biovista.com/solutions/project-prodigy-vs-covid-19/,https://www.biovista.com/solutions/project-prodigy-vs-covid-19/,,https://www.biovista.com/solutions/project-prodigy-vs-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
369,No,CLBS-119,,CLBS-119,Caladrius Biosciences Inc.,Therapeutic,COVID-19,Cell therapies,Other,New,,United States,Ongoing,Repairs lung damage,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
369,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/caladrius-biosciences-plans-to-assess-its-clbs119-cell-therapy-for-repair-of-covid-19-induced-lung-damage/,https://www.biospace.com/article/releases/caladrius-biosciences-plans-to-assess-its-clbs119-cell-therapy-for-repair-of-covid-19-induced-lung-damage/,https://www.biospace.com/article/releases/caladrius-biosciences-plans-to-assess-its-clbs119-cell-therapy-for-repair-of-covid-19-induced-lung-damage/,https://www.biospace.com/article/releases/caladrius-biosciences-plans-to-assess-its-clbs119-cell-therapy-for-repair-of-covid-19-induced-lung-damage/,,https://www.biospace.com/article/releases/caladrius-biosciences-plans-to-assess-its-clbs119-cell-therapy-for-repair-of-covid-19-induced-lung-damage/,,,,https://www.biospace.com/article/releases/caladrius-biosciences-plans-to-assess-its-clbs119-cell-therapy-for-repair-of-covid-19-induced-lung-damage/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
370,No,Dociparstat sodium,,Dociparstat sodium,Chimerix Inc.,Therapeutic,COVID-19,Other,Other,Repurposed-Not Approved,,United States,Ongoing,,,Phase 2,,,,,,,,,,,,,2,COVID-19,74,No,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
370,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-initiation-phase-23-study-dstat-acute-lung,https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-initiation-phase-23-study-dstat-acute-lung,https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-initiation-phase-23-study-dstat-acute-lung,https://www.globenewswire.com/news-release/2019/12/10/1958467/0/en/Chimerix-Presents-Updated-Results-from-Phase-2-Clinical-Trial-of-DSTAT-in-Refractory-Myelodysplastic-Syndrome-and-Acute-Myeloid-Leukemia-at-American-Society-of-Hematology-Annual-Me.html,,https://www.chimerix.com/contact-us/,https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-initiation-phase-23-study-dstat-acute-lung,,,https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-initiation-phase-23-study-dstat-acute-lung,,,,,,,,,,,,,https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-initiation-phase-23-study-dstat-acute-lung,https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-initiation-phase-23-study-dstat-acute-lung,https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-initiation-phase-23-study-dstat-acute-lung,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
371,No,Itanapraced,,Itanapraced,Cerespir Inc.,Therapeutic,ARDS,Small molecule,Other,Repurposed-Not Approved,,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
371,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/cerespir-incorporated-identifies-possible-link-between-covid-19-induced-brain-inflammation-and-acute-respiratory-stress-syndrome-via-breakdown-of-the-blood-brain-barrier/,https://drugs.ncats.io/drug/C35RF1MWQZ,https://www.globenewswire.com/news-release/2020/04/16/2017370/0/en/CERESPIR-INCORPORATED-Identifies-Possible-Link-Between-COVID-19-Induced-Brain-Inflammation-and-Acute-Respiratory-Stress-Syndrome-Via-Breakdown-of-the-Blood-Brain-Barrier.html,https://www.biospace.com/article/releases/cerespir-incorporated-identifies-possible-link-between-covid-19-induced-brain-inflammation-and-acute-respiratory-stress-syndrome-via-breakdown-of-the-blood-brain-barrier/,,https://www.biospace.com/article/releases/cerespir-incorporated-identifies-possible-link-between-covid-19-induced-brain-inflammation-and-acute-respiratory-stress-syndrome-via-breakdown-of-the-blood-brain-barrier/,https://www.biospace.com/article/releases/cerespir-incorporated-identifies-possible-link-between-covid-19-induced-brain-inflammation-and-acute-respiratory-stress-syndrome-via-breakdown-of-the-blood-brain-barrier/,,,https://www.biospace.com/article/releases/cerespir-incorporated-identifies-possible-link-between-covid-19-induced-brain-inflammation-and-acute-respiratory-stress-syndrome-via-breakdown-of-the-blood-brain-barrier/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
372,No,nicotinamide riboside,nicotinamide riboside,Niagen,Chromadex Corp.,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
372,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.businesswire.com/news/home/20200420005265/en/ChromaDex-Commits-COVID-19-Research-Promising-Initial-Preclinical,https://www.businesswire.com/news/home/20200420005265/en/ChromaDex-Commits-COVID-19-Research-Promising-Initial-Preclinical,https://www.businesswire.com/news/home/20200420005265/en/ChromaDex-Commits-COVID-19-Research-Promising-Initial-Preclinical,https://www.businesswire.com/news/home/20200420005265/en/ChromaDex-Commits-COVID-19-Research-Promising-Initial-Preclinical,,https://www.businesswire.com/news/home/20200420005265/en/ChromaDex-Commits-COVID-19-Research-Promising-Initial-Preclinical,https://www.businesswire.com/news/home/20200420005265/en/ChromaDex-Commits-COVID-19-Research-Promising-Initial-Preclinical,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,,,,,,,
373,No,Pacritinib,,Pacritinib,CTI Biopharma Corp.,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,,United States,Ongoing,,,Phase 3,,,,,,,,,,,,,3,COVID-19,358,No,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
373,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19/,http://lincs.hms.harvard.edu/db/sm/10381-101/,https://www.biospace.com/article/releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19/,https://www.ctibiopharma.com/pacritinib/,,https://www.ctibiopharma.com/,https://www.biospace.com/article/releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19/,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,https://www.biospace.com/article/releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19/,https://www.biospace.com/article/releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19/,https://www.biospace.com/article/releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19/,,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
374,No,Fadraciclib,Fadraciclib,CYC-065,Cyclacel Pharmaceuticals Inc.,Therapeutic,COVID-19,Unknown,Kinase inhibitors,Repurposed-Not Approved,University of Edinburgh; LifeArc,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
374,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,https://www.bioworld.com/articles/434562-cyclacel-pharming-repurpose-drugs-to-fight-severe-respiratory-symptoms-of-covid-19,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
375,No,Seliciclib,Seliciclib,CYC-202; R-roscovitine,Cyclacel Pharmaceuticals Inc.,Therapeutic,COVID-19,Unknown,Kinase inhibitors,Repurposed-Not Approved,University of Edinburgh; LifeArc,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andrew Chen,5/19/2020,,,,,,5/19/2020
375,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,https://www.bioworld.com/articles/434562-cyclacel-pharming-repurpose-drugs-to-fight-severe-respiratory-symptoms-of-covid-19,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,https://www.globenewswire.com/news-release/2020/04/20/2018510/0/en/Cyclacel-Pharmaceuticals-Announces-Collaboration-With-the-University-of-Edinburgh-to-Study-Its-CDK-Inhibitors-to-Reduce-Runaway-Inflammation-in-COVID-19-Disease.html,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
376,No,dantrolene sodium,dantrolene sodium,Ryanodex,Eagle Pharmaceuticals Inc.,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,Repurposed-Approved,,United States,Ongoing,Growth inhibitor by modulating free intracellular calcium levels in host cells,,Phase 2,,,completed,,,submitted 04/14/2020,Assumed completed,Target: 05/2020,,,,,,,,,,,,,,,,,,,,,,Ivanna Leon,5/9/2020,,,,,,5/9/2020
376,Yes,https://www.eagleus.com/eagle-pharmaceuticals-corporate-website-statement/,https://www.eagleus.com/eagle-pharmaceuticals-corporate-website-statement/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx,https://www.drugbank.ca/drugs/DB01219,https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx,https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx,,https://www.eagleus.com/contact/,https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx,https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx,,https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx,,,https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx,,,https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx,https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx,https://investor.eagleus.com/press-releases/news-details/2020/Eagle-Pharmaceuticals-Announces-Laboratory-Test-Results-Demonstrating-In-Vitro-Antiviral-Activity-of-RYANODEX-dantrolene-sodium-Against-Coronavirus-SARS-CoV-2/default.aspx,,,,,,,,,,,,,,,,,,,,,,Ivanna Leon,5/10/2020,,,,,,5/10/2020
377,No,EB05 and EB06,,EB05 and EB06,Edesa Biotech Inc.; Light Chain Bioscience; Novimmune SA,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Canada,Ongoing,NI-0101 and NI-0801 programs at lightchain bioscience work as TLR4 and CXCL10 antagonists respectively - being licensed to Edesa Biotech Inc,,Phase 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna Leon,5/10/2020,,,,,,5/10/2020
377,Yes,https://www.accesswire.com/585646/Edesa-Biotech-and-Light-Chain-Bioscience-Sign-License-Agreement-to-Develop-Treatments-for-COVID-19-Pneumonia-and-Other-Disorders,,https://www.accesswire.com/585646/Edesa-Biotech-and-Light-Chain-Bioscience-Sign-License-Agreement-to-Develop-Treatments-for-COVID-19-Pneumonia-and-Other-Disorders,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.accesswire.com/585646/Edesa-Biotech-and-Light-Chain-Bioscience-Sign-License-Agreement-to-Develop-Treatments-for-COVID-19-Pneumonia-and-Other-Disorders,https://www.accesswire.com/585646/Edesa-Biotech-and-Light-Chain-Bioscience-Sign-License-Agreement-to-Develop-Treatments-for-COVID-19-Pneumonia-and-Other-Disorders,https://www.accesswire.com/585646/Edesa-Biotech-and-Light-Chain-Bioscience-Sign-License-Agreement-to-Develop-Treatments-for-COVID-19-Pneumonia-and-Other-Disorders,https://www.lightchainbio.com/our-focus/pipeline.html,,https://www.edesabiotech.com/about/contact-us/,https://www.accesswire.com/585646/Edesa-Biotech-and-Light-Chain-Bioscience-Sign-License-Agreement-to-Develop-Treatments-for-COVID-19-Pneumonia-and-Other-Disorders,https://www.lightchainbio.com/our-focus/pipeline.html,,https://www.edesabiotech.com/clinical-pipeline/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
378,No,eFT226,eFT226,Zotatifin,Effector Therapeutics Inc.,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,Repurposed-Not Approved,,United States,Ongoing,Eukaryotic initiation factor 4A inhibitor which is used by the virus for replication,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna Leon,5/10/2020,,,,,,5/10/2020
378,Yes,https://effector.com/pipeline/#zotatifin,https://effector.com/pipeline/#zotatifin,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/04/30/2025303/0/en/eFFECTOR-s-Zotatifin-Demonstrates-in-vitro-Anti-SARS-CoV-2-Activity-in-Independent-International-Study-Reported-in-Peer-Reviewed-Journal-Nature.html,https://www.globenewswire.com/news-release/2020/04/30/2025303/0/en/eFFECTOR-s-Zotatifin-Demonstrates-in-vitro-Anti-SARS-CoV-2-Activity-in-Independent-International-Study-Reported-in-Peer-Reviewed-Journal-Nature.html,https://www.globenewswire.com/news-release/2020/04/30/2025303/0/en/eFFECTOR-s-Zotatifin-Demonstrates-in-vitro-Anti-SARS-CoV-2-Activity-in-Independent-International-Study-Reported-in-Peer-Reviewed-Journal-Nature.html,https://www.globenewswire.com/news-release/2020/04/30/2025303/0/en/eFFECTOR-s-Zotatifin-Demonstrates-in-vitro-Anti-SARS-CoV-2-Activity-in-Independent-International-Study-Reported-in-Peer-Reviewed-Journal-Nature.html,,https://effector.com/contact/,https://www.globenewswire.com/news-release/2020/04/30/2025303/0/en/eFFECTOR-s-Zotatifin-Demonstrates-in-vitro-Anti-SARS-CoV-2-Activity-in-Independent-International-Study-Reported-in-Peer-Reviewed-Journal-Nature.html,https://www.globenewswire.com/news-release/2020/04/30/2025303/0/en/eFFECTOR-s-Zotatifin-Demonstrates-in-vitro-Anti-SARS-CoV-2-Activity-in-Independent-International-Study-Reported-in-Peer-Reviewed-Journal-Nature.html,,https://www.globenewswire.com/news-release/2020/04/30/2025303/0/en/eFFECTOR-s-Zotatifin-Demonstrates-in-vitro-Anti-SARS-CoV-2-Activity-in-Independent-International-Study-Reported-in-Peer-Reviewed-Journal-Nature.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
379,No,Antibodies,,Antibodies,Fairjourney Biologics SA; Iontas Ltd.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Portugal and England,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna Leon,5/10/2020,,,,,,5/10/2020
379,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.businesswire.com/news/home/20200416005046/en/Leading-Global-Antibody-Discovery-Companies-FairJourney-Biologics,https://www.businesswire.com/news/home/20200416005046/en/Leading-Global-Antibody-Discovery-Companies-FairJourney-Biologics,https://www.businesswire.com/news/home/20200416005046/en/Leading-Global-Antibody-Discovery-Companies-FairJourney-Biologics,https://www.businesswire.com/news/home/20200416005046/en/Leading-Global-Antibody-Discovery-Companies-FairJourney-Biologics,,https://www.businesswire.com/news/home/20200416005046/en/Leading-Global-Antibody-Discovery-Companies-FairJourney-Biologics,https://www.businesswire.com/news/home/20200416005046/en/Leading-Global-Antibody-Discovery-Companies-FairJourney-Biologics,,,https://www.businesswire.com/news/home/20200416005046/en/Leading-Global-Antibody-Discovery-Companies-FairJourney-Biologics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
380,No,Antibodies,,Antibodies,Fusion Antibodies plc,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Northern Ireland,Ongoing,Part of the Northern Ireland Coronavirus Antibody Development Alliance (“NICADA”),,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna Leon,5/10/2020,,,,,,5/10/2020
380,Yes,https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/,,https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/,https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/,https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/,https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/,,https://www.fusionantibodies.com/contact-us/,https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/,https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/,,https://www.fusionantibodies.com/news/research-alliance-with-queens-university-belfast/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
381,No,Antibodies,,Antibodies,Hemogenyx Pharmaceuticals plc,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United Kingdom,Ongoing,Company is using its proprietary humanized mice called Advanced peripheral blood Hematopoietic Chimera,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna Leon,5/10/2020,,,,,,5/10/2020
381,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://hemogenyx.com/investors/investors/announcements/announcement/2020/covid-19-project-initiated/,https://hemogenyx.com/investors/investors/announcements/announcement/2020/covid-19-project-initiated/,https://hemogenyx.com/investors/investors/announcements/announcement/2020/covid-19-project-initiated/,https://hemogenyx.com/investors/investors/announcements/announcement/2020/covid-19-project-initiated/,,https://hemogenyx.com/contact/,https://www.thearmchairtrader.com/hemogenyx-stock-price/,https://hemogenyx.com/investors/investors/announcements/announcement/2020/covid-19-project-initiated/,,https://hemogenyx.com/investors/investors/announcements/announcement/2020/covid-19-project-initiated/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
382,No,vidofludimus calcium,vidofludimus calcium,IMU-838,Immunic Inc.,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,Repurposed-Not Approved,,United States,Ongoing,Inhibitor of dihydroorotate dehydrogenase- an enzyme of pyrimidine de novo biosynthesis,,Phase 2,,Completed,Assumed completed,,,Assumed completed,Completed,Target: 05/2020,,,,,2,COVID-19,600,No,4,"Military Medical Academy, Clinic of Infectious Diseases - Sofia - Bulgaria; UMHATEM N.I.Pirogov - Sofia - Bulgaria; University Hospital Frankfurt - Frankfurt - Germany; Clinic of the Hannover Medical School - Hannover - Germany",06/2020,9/2020,10/1/20,https://clinicaltrials.gov/ct2/show/NCT04379271,Andreas Muehler,,andreas.muehler@imux.com,,,,,Ivanna Leon,5/10/2020,,,,,,5/10/2020
382,Yes,https://www.immunic-therapeutics.com/imu838/,https://www.immunic-therapeutics.com/imu838/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.immunic-therapeutics.com/2020/04/21/immunic-inc-reports-that-imu-838-a-selective-oral-dhodh-inhibitor-has-demonstrated-preclinical-activity-against-sars-cov-2-and-explores-plans-for-a-phase-2-clinical-trial-in-covid-19-patients/,https://www.immunic-therapeutics.com/imu838/,https://www.immunic-therapeutics.com/imu838/,https://www.immunic-therapeutics.com/imu838/,,https://www.immunic-therapeutics.com/contact/,https://www.immunic-therapeutics.com/imu838/,https://www.immunic-therapeutics.com/imu838/,,https://clinicaltrials.gov/ct2/show/record/NCT04379271?term=imu-838&draw=2&rank=3,,https://www.immunic-therapeutics.com/imu838/,https://clinicaltrials.gov/ct2/show/record/NCT04379271?term=imu-838&draw=2&rank=3,,,https://clinicaltrials.gov/ct2/show/record/NCT04379271?term=imu-838&draw=2&rank=3,https://www.immunic-therapeutics.com/imu838/,,,,,,https://clinicaltrials.gov/ct2/show/NCT04379271?term=imu-838&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04379271?term=imu-838&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04379271?term=imu-838&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04379271?term=imu-838&draw=2&rank=3,,,https://clinicaltrials.gov/ct2/show/record/NCT04379271?term=imu-838&draw=2&rank=3,,,https://clinicaltrials.gov/ct2/show/record/NCT04379271?term=imu-838&draw=2&rank=3,,,,,,,,,,,,,,,
383,No,dominant-negative TNF Inhibitor,dominant-negative TNF Inhibitor,Xpro-1595 ,Inmune Bio Inc.,Therapeutic,Other,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,,United States,Ongoing,Supposed to treat respiratory symptoms without being immunosuppressive-TNF has been linked to cytokine storm in COVID-19 patients,,Phase 2,,,,,,Assumed Completed,,Target 06/2020,,,,,2,COVID-19,150,No,,,06/2020,02/2021,2/1/2021,https://clinicaltrials.gov/ct2/show/NCT04370236,Christopher Barnum,1 (858) 964-3720,trials@inmunebio.com,,,,,Ivanna Leon,5/10/2020,,,,,,5/10/2020
383,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.inmunebio.com/index.php/en/news-2/2020/321-muneioncnnouncesnitiationoflinicalrogram20200420,https://www.inmunebio.com/index.php/en/science/xpro1595/overview,https://www.inmunebio.com/index.php/en/news-2/2020/321-muneioncnnouncesnitiationoflinicalrogram20200420,https://www.inmunebio.com/index.php/en/news-2/2020/321-muneioncnnouncesnitiationoflinicalrogram20200420,,https://www.inmunebio.com/index.php/en/contact-2/contact-us,https://www.inmunebio.com/index.php/en/news-2/2020/321-muneioncnnouncesnitiationoflinicalrogram20200420,https://www.inmunebio.com/index.php/en/news-2/2020/321-muneioncnnouncesnitiationoflinicalrogram20200420,,https://clinicaltrials.gov/ct2/show/NCT04370236?term=inmune&draw=2&rank=3,,,,,,https://clinicaltrials.gov/ct2/show/NCT04370236?term=inmune&draw=2&rank=3,,https://clinicaltrials.gov/ct2/show/record/NCT04370236?term=inmune&draw=2&rank=3&view=record,,,,,https://clinicaltrials.gov/ct2/show/NCT04370236?term=inmune&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04370236?term=inmune&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04370236?term=inmune&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04370236?term=inmune&draw=2&rank=3,,,https://clinicaltrials.gov/ct2/show/NCT04370236?term=inmune&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04370236?term=inmune&draw=2&rank=3,,https://clinicaltrials.gov/ct2/show/record/NCT04370236?term=inmune&draw=2&rank=3&view=record,,,,,,,,,,,,,,,
384,No,Cannabidiol-loaded exosomes,,Cannabidiol-loaded exosomes,Innocan Pharma Corp.,Therapeutic,Other,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,Israel,Ongoing,Aim is to use exosome as a targeted delivery sytem to release cannabidiol into the lungs for anti-inflammatory effects,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivanna Leon,5/10/2020,,,,,,5/10/2020
384,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.newsfilecorp.com/release/54575/InnoCan-Pharma-Collaborates-with-Tel-Aviv-University-to-Develop-a-New-Revolutionary-Approach-to-Treat-the-COVID19-Corona-Virus-with-ExosomesLoaded-CBD,https://innocanpharma.com/cell-therapy/,https://innocanpharma.com/cell-therapy/,https://www.newsfilecorp.com/release/54575/InnoCan-Pharma-Collaborates-with-Tel-Aviv-University-to-Develop-a-New-Revolutionary-Approach-to-Treat-the-COVID19-Corona-Virus-with-ExosomesLoaded-CBD,,https://innocanpharma.com/our-story/,https://www.newsfilecorp.com/release/54575/InnoCan-Pharma-Collaborates-with-Tel-Aviv-University-to-Develop-a-New-Revolutionary-Approach-to-Treat-the-COVID19-Corona-Virus-with-ExosomesLoaded-CBD,https://www.newsfilecorp.com/release/54575/InnoCan-Pharma-Collaborates-with-Tel-Aviv-University-to-Develop-a-New-Revolutionary-Approach-to-Treat-the-COVID19-Corona-Virus-with-ExosomesLoaded-CBD,,https://www.euroweeklynews.com/2020/04/27/israeli-scientists-begin-trials-into-the-effectiveness-of-cannabis-in-treating-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
385,No,Brensocatib,Brensocatib,INS-1007,University of Dundee; Insmed Inc.,Therapeutic,ARDS,Small molecule,Other,Repurposed-Approved,Insmed Inc.,Scotland,Ongoing,Multi-center Investigator Initiated Trial; Drug is a Dipeptidyl Peptidase 1 inhibitor which ultimately aims to reduce neutrophil-mediated damage via serine proteases in the lungs,,Phase 3,,Assumed completed,Assumed completed,,,Assumed completed,Completed,Completed,,,,,3,COVID-19,300,No,10,United Kingdom,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB,James Chalmers,,j.chalmers@dundee.ac.uk,,,,,Ivanna Leon,5/10/2020,,,,,,5/10/2020
385,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial,https://www.drugbank.ca/drugs/DB15638,https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial,https://www.drugbank.ca/drugs/DB15638,https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial,https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial,https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial,https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB,,https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial,https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial,,,https://insmed.com/science/pipeline/,https://insmed.com/science/pipeline/,https://insmed.com/science/pipeline/,,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB,https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial,https://investor.insmed.com/2020-04-23-Brensocatib-Formerly-INS1007-to-be-Studied-in-Patients-with-Severe-COVID-19-in-Investigator-Initiated-Trial,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB,,,,,,,,,,,,,,,
386,No,Sonlicromanol,,Sonlicromanol,Khondrion BV,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Netherlands,Ongoing,Currently in Phase 2b clinical trial for mitochondrial diseases ; Sponsor looking for partners to start trial in COVID-19 patients as of April 15th,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,Joshuah,5/8/2020,,,,,,5/8/2020
386,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/04/15/2016163/0/en/Khondrion-highlights-potential-role-of-inflammatory-lipid-modulator-prostaglandin-E2-in-COVID-19-disease-and-proposes-potential-treatment-pathway-with-sonlicromanol.html,https://mitochondrialdiseasenews.com/2020/01/31/khondrion-doses-first-patient-phase-2b-trial-testing-sonlicromanol-mitochondrial-diseases/,https://www.globenewswire.com/news-release/2020/04/15/2016163/0/en/Khondrion-highlights-potential-role-of-inflammatory-lipid-modulator-prostaglandin-E2-in-COVID-19-disease-and-proposes-potential-treatment-pathway-with-sonlicromanol.html,https://www.globenewswire.com/news-release/2020/04/15/2016163/0/en/Khondrion-highlights-potential-role-of-inflammatory-lipid-modulator-prostaglandin-E2-in-COVID-19-disease-and-proposes-potential-treatment-pathway-with-sonlicromanol.html,,https://www.globenewswire.com/news-release/2020/04/15/2016163/0/en/Khondrion-highlights-potential-role-of-inflammatory-lipid-modulator-prostaglandin-E2-in-COVID-19-disease-and-proposes-potential-treatment-pathway-with-sonlicromanol.html,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,,,,,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04165239?term=Sonlicromanol&draw=2&rank=1,,,,,,,,Joshuah,,,,,,,
387,No,VAP-1 Inhibitors,,VAP-1 Inhibitors,Kubota Vision Inc.; Leo Pharma A/S,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,,Ongoing,Currently in Discovery Phase; Screening for novel VAP-1 inhibitor compounds for inflammatory conditions,,Discovery,,4/16/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,5/8/2020,,,,,,5/8/2020
387,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases,https://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases,https://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases,https://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases,,,https://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases,https://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases,,https://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases,,https://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,,,,,,,
388,No,XAV-19,,XAV-19,LFB SA; Kenothera SAS,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,New,,France,Ongoing,Agreetment signed for first clinical batch of drug as of April 15th,,Manufacturing,,Assume Completed,Assume Completed,Assume Completed,4/15/2020,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,5/8/2020,,,,,,5/8/2020
388,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections,https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections,https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections,https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections,,https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections,https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections,https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections,,https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections,,,,,https://www.thepharmaletter.com/article/lfb-inks-deal-with-xenothera-for-xab-19-for-treatment-of-coronavirus-infections,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,,,,,,,
389,No,Carragelose Inhalation therapy,,Carragelose Inhalation therapy,Marinomed Biotech AG,Therapeutic,COVID-19,Other,Antiviral drugs-broad spectrum,Repurposed-Approved,Austrian Research Promotion Agency,Austria,Ongoing,Inhalation solution based on iota-carrageenan polymers derived from red seaweed with physical mode of action; Currently approved OTC in EU/Asia & other markets (non-US) ; Recieved funding for Phase 1 clinical trial and then a proof-of-concept study on viral pneumonia patients,,Phase 1,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,5/8/2020,,,,,,5/8/2020
389,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/,https://media.marinomed.com/22/ea/2a/carragelose-teaser-new-072019.pdf,https://media.marinomed.com/22/ea/2a/carragelose-teaser-new-072019.pdf,https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/,https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/,https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/,https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/,https://media.marinomed.com/22/ea/2a/carragelose-teaser-new-072019.pdf ; https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/,,https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,,,,,,,
390,No,Antiviral,,Antiviral,Molecular Partners AG,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-antiretrovirals,New,,Switzerland,Ongoing,"Engineered trispecific antiviral proteins therapeutic that targets epitopes of viral ""spike""protein needed for infection ; Currently undergoing expedited preclinical testing for lead candidate ; Target of manufactured drug product in Q3 2020",,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,5/8/2020,,,,,,5/8/2020
390,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.molecularpartners.com/molecular-partners-initiates-anti-covid-19-therapeutic-program-leveraging-multi-target-binding-of-darpin-proteins-to-neutralize-sars-cov-2-virus/,https://www.molecularpartners.com/molecular-partners-initiates-anti-covid-19-therapeutic-program-leveraging-multi-target-binding-of-darpin-proteins-to-neutralize-sars-cov-2-virus/,https://www.molecularpartners.com/molecular-partners-initiates-anti-covid-19-therapeutic-program-leveraging-multi-target-binding-of-darpin-proteins-to-neutralize-sars-cov-2-virus/,https://www.molecularpartners.com/molecular-partners-initiates-anti-covid-19-therapeutic-program-leveraging-multi-target-binding-of-darpin-proteins-to-neutralize-sars-cov-2-virus/,,https://www.molecularpartners.com/contact-us/,https://www.molecularpartners.com/molecular-partners-initiates-anti-covid-19-therapeutic-program-leveraging-multi-target-binding-of-darpin-proteins-to-neutralize-sars-cov-2-virus/,https://www.molecularpartners.com/molecular-partners-initiates-anti-covid-19-therapeutic-program-leveraging-multi-target-binding-of-darpin-proteins-to-neutralize-sars-cov-2-virus/,,https://www.molecularpartners.com/molecular-partners-initiates-anti-covid-19-therapeutic-program-leveraging-multi-target-binding-of-darpin-proteins-to-neutralize-sars-cov-2-virus/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,,,,,,,
391,No,idronoxil,idronoxil,Veyonda,Noxopharm Co.,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Austrialia,Ongoing,Currently has IND approval as anti-cancer agent ; Currently trying to get FDA approval to pursue clinical study for COVID-19 patients.,,Manufacturing,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,5/9/2020,,,,,,5/9/2020
391,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/noxopharm-investigating-potential-covid-19-treatment/,https://www.drugbank.ca/drugs/DB04915,https://www.biospace.com/article/releases/noxopharm-investigating-potential-covid-19-treatment/,https://www.biospace.com/article/releases/noxopharm-investigating-potential-covid-19-treatment/,,https://www.biospace.com/employer/545349/noxopharm/,https://www.biospace.com/employer/545349/noxopharm/,https://www.biospace.com/employer/545349/noxopharm/,,https://www.pharmashots.com/31369/noxopharm-anticipates-the-us-fdas-approval-for-evaluating-veyonda-in-a-clinical-study-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,,,,,,,
392,No,Peptides,,Peptides,Nuritas Ltd.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,New,,Ireland,Ongoing,Curently using AI platform screen for peptide candidates (Takes 4-5 months),,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,5/9/2020,,,,,,5/9/2020
392,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/using-ai-to-find-peptide-therapeutics-for-covid-19/,https://www.biospace.com/article/using-ai-to-find-peptide-therapeutics-for-covid-19/,https://www.biospace.com/article/using-ai-to-find-peptide-therapeutics-for-covid-19/,https://www.biospace.com/article/using-ai-to-find-peptide-therapeutics-for-covid-19/,,https://www.biospace.com/article/using-ai-to-find-peptide-therapeutics-for-covid-19/,https://www.biospace.com/article/using-ai-to-find-peptide-therapeutics-for-covid-19/,https://www.biospace.com/article/using-ai-to-find-peptide-therapeutics-for-covid-19/,,https://www.biospace.com/article/using-ai-to-find-peptide-therapeutics-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,,,,,,,
393,No,2X-121,,2X-121,Oncology Ventures A/S,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Not Approved,,Denmark,Ongoing,Currently in Phase 2 clinical trial for ovarian cancer; Started pre-clinical testing at Northern Arizona University as of 04/24/2020,,Pre-Clinical Testing,,Assume Completed,4/24/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,5/10/2020,,,,,,5/10/2020
393,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://oncologyventure.com/pipeline/2x-121/,https://oncologyventure.com/pipeline/2x-121/,https://oncologyventure.com/pipeline/2x-121/,https://oncologyventure.com/pipeline/2x-121/,,https://oncologyventure.com/about-us/,https://oncologyventure.com/pipeline/2x-121/,https://www.technologynetworks.com/drug-discovery/news/covid-19-testing-service-center-to-evaluate-promising-drugs-333864 ; https://oncologyventure.com/pipeline/2x-121/,,https://oncologyventure.com/pipeline/2x-121/,,,https://www.technologynetworks.com/drug-discovery/news/covid-19-testing-service-center-to-evaluate-promising-drugs-333864,,,,,,,,,,,,,,,,,,,,,,,,,,,Joshuah,,,,,,,
394,No,Camostat mesylate,Camostat mesylate,Foipan,Ono Pharmaceuticals Inc.; Yale University; Liebniz Institute for Primate Research,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,Repurposed-Approved,,Japan,Ongoing,Currently approved in Japan to treat pancreatic inflammation ; Currently in Phase 2a clinical trial for COVID-19 patients ; Anti-inflammatory properties and shown in vitro virus inhibitory ability,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,2,COVID-19,114,No,1,Yale University - New Haven - Connecticut,06/19/2020,5/31/21,5/31/21,https://clinicaltrials.gov/ct2/show/NCT04353284,Joseph Vinetz,(203) 737-9730,joseph.vinetz@yale.edu,,,,,Joshuah,5/10/2020,,,,,,5/10/2020
394,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,"https://www.thailandmedical.news/news/coronavirus-drug-research-german-researchers-identify-japanese-drug,-camostat-mesylate-that-could-be-repurposed-to-treat-covid-19","https://www.thailandmedical.news/news/coronavirus-drug-research-german-researchers-identify-japanese-drug,-camostat-mesylate-that-could-be-repurposed-to-treat-covid-19",https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04353284#contacts,https://www.drugbank.ca/drugs/DB13729,https://clinicaltrials.gov/ct2/show/NCT04353284,https://clinicaltrials.gov/ct2/show/NCT04353284,,https://www.ono.co.jp/eng/about/business_locations.html,https://clinicaltrials.gov/ct2/show/NCT04353284,https://clinicaltrials.gov/ct2/show/NCT04353284,,https://clinicaltrials.gov/ct2/show/NCT04353284,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04353284#contacts,https://clinicaltrials.gov/ct2/show/NCT04353284#contacts,https://clinicaltrials.gov/ct2/show/NCT04353284#contacts,https://clinicaltrials.gov/ct2/show/NCT04353284#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04353284#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04353284#contacts,,,,,,,,,,,,,,,
395,No,Vafidemstat,,Vafidemstat,Oryzon Genomics SA,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Spain,Ongoing,Currently in a Phase 2 clinical trial,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,4/27/2020,,,,,2,ARDS,40,No,3,,04/27/2020,,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001618-39,,,,,,,,Joshuah,5/10/2020,,,,,,5/10/2020
395,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,https://www.biospace.com/article/releases/oryzon-to-initiate-escape-a-phase-ii-clinical-trial-to-test-efficacy-of-vafidemstat-in-severely-ill-covid-19-patients/,https://www.biospace.com/article/releases/oryzon-to-initiate-escape-a-phase-ii-clinical-trial-to-test-efficacy-of-vafidemstat-in-severely-ill-covid-19-patients/,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,,,,,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES,,,,,,,,,,,,,,,
396,No,Q Biomed Therapeutic,,Q Biomed Therapeutic,Q Biomed Inc.; Mannin Research,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,New,Mannin Research; Cyclica,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/10/2020,,,,,,5/10/2020
396,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://qbiomed.com/news-and-media/news-2020/191-q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics,https://qbiomed.com/news-and-media/news-2020/191-q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics,https://qbiomed.com/news-and-media/news-2020/191-q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics,https://qbiomed.com/news-and-media/news-2020/191-q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics,https://qbiomed.com/news-and-media/news-2020/191-q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics,https://qbiomed.com/news-and-media/news-2020/191-q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics,https://qbiomed.com/news-and-media/news-2020/191-q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics,,,https://qbiomed.com/news-and-media/news-2020/191-q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/11/2020,,,,,,5/11/2020
397,No,Recursion Therapeutic,,Recursion Therapeutic,Recursion Pharmaceuticals Inc.,Therapeutic,,,,,,,,"this is a dataset, not a therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/10/2020,,,,,,5/10/2020
397,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,https://www.recursionpharma.com/news/rxrx19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/11/2020,,,,,,5/11/2020
398,No,RTB-101,,RTB-101,Restorbio Inc.; Adicet Bio Inc.,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Not Approved,Restorbio stockholders will receive net proceeds from the commercialization,United States,Ongoing,candidate is an inhibitor of target of rapamycin complex 1 (TORC-1),,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/10/2020,,,,,,5/10/2020
398,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/articles/434734-other-news-to-note-for-april-29-2020,https://www.bioworld.com/articles/434734-other-news-to-note-for-april-29-2020,https://www.bioworld.com/articles/434734-other-news-to-note-for-april-29-2020,https://www.restorbio.com/pipeline/,https://www.bioworld.com/articles/434734-other-news-to-note-for-april-29-2020,https://www.restorbio.com/contact/,https://www.bioworld.com/articles/434734-other-news-to-note-for-april-29-2020,https://www.bioworld.com/articles/434734-other-news-to-note-for-april-29-2020,,https://www.bioworld.com/articles/434734-other-news-to-note-for-april-29-2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/13/2020,,,,,,5/13/2020
399,No,RT-001,,RT-001,Retrotope Inc.,Therapeutic,COVID-19,Other,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,RT-001 is a chemically stabilized fatty acid,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/10/2020,,,,,,5/10/2020
399,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.retrotope.com/,,https://www.retrotope.com/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/15/2020,,,,,,5/15/2020
400,No,Nitazoxanide,Nitazoxanide,NT-300,Romark Laboratories LC,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,New,,United States,Ongoing,,,Phase 3,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Target: 04/30/2020,,,,3,,600,No,,,05/12/2020,12/1/20,12/01/2020,https://clinicaltrials.gov/ct2/show/NCT04343248,Matthew Bardin,813-282-8544,matthew.bardin@romark.com,,,,,Meg,5/10/2020,,,,,,5/10/2020
400,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.romark.com/research-development/clinical-trials-covid/,https://www.drugbank.ca/drugs/DB00507,https://www.drugbank.ca/drugs/DB00507,https://www.romark.com/research-development/clinical-trials-covid/,,https://www.romark.com/research-development/clinical-trials-covid/,https://www.romark.com/research-development/clinical-trials-covid/,,,https://www.bioworld.com/COVID19products,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,,https://clinicaltrials.gov/ct2/show/study/NCT04343248?recrs=b&cond=nitazoxanide&draw=2&rank=5#contacts,,,,https://clinicaltrials.gov/ct2/show/study/NCT04343248?recrs=b&cond=nitazoxanide&draw=2&rank=5#contacts,Skipped,https://clinicaltrials.gov/ct2/show/study/NCT04343248?recrs=b&cond=nitazoxanide&draw=2&rank=5#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04343248?recrs=b&cond=nitazoxanide&draw=2&rank=5#contacts,,,https://clinicaltrials.gov/ct2/show/study/NCT04343248?recrs=b&cond=nitazoxanide&draw=2&rank=5#contacts,,https://clinicaltrials.gov/ct2/show/study/NCT04343248?recrs=b&cond=nitazoxanide&draw=2&rank=5#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04343248?recrs=b&cond=nitazoxanide&draw=2&rank=5#contacts,,,,,,,,Meg,5/17/2020,,,,,,5/17/2020
401,No,olokizumab; RPH-104,,olokizumab; RPH-104,R-Pharm JSC; Cromos Pharma LLC,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Cocktail,Repurposed-Not Approved,,Russia;United States,Ongoing,in phase 2/3,,Phase 2,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,,,,,,2,,180,No,,,,,,,,,,,,,,Meg,5/10/2020,,,,,,5/10/2020
401,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html,https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html,https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html,https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html,,https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html,https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html,https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html,,https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html,,,,,,,,,,,,,https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html,,https://www.globenewswire.com/news-release/2020/04/28/2022958/0/en/Cromos-Pharma-Supports-R-Pharm-in-Initiation-of-a-Global-Program-to-Test-Two-of-its-Leading-Candidates-in-Patients-with-Severe-COVID-19-Infection-First-Patients-Have-Been-Recruited.html,,,,,,,,,,,,,,,Meg,5/19/2020,,,,,,5/19/2020
402,No,Ionodelestat,Ionodelestat,POL-6014,Santhera Pharmaceuticals Holding AG,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,Cold Spring Harbor Laboratory (CSHL),Switzerland,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/10/2020,,,,,,5/10/2020
402,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://www.santhera.com/assets/files/press-releases/2020-04-27_CSHL_lono_covid_e_final.pdf,http://www.santhera.com/assets/files/press-releases/2020-04-27_CSHL_lono_covid_e_final.pdf,http://www.santhera.com/assets/files/press-releases/2020-04-27_CSHL_lono_covid_e_final.pdf,http://www.santhera.com/assets/files/press-releases/2020-04-27_CSHL_lono_covid_e_final.pdf,http://www.santhera.com/assets/files/press-releases/2020-04-27_CSHL_lono_covid_e_final.pdf,http://www.santhera.com/,http://www.santhera.com/assets/files/press-releases/2020-04-27_CSHL_lono_covid_e_final.pdf,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/21/2020,,,,,,5/21/2020
403,No,Antisense oligonucleotides,,Antisense oligonucleotides,Sarepta Therapeutics Inc.,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Antiviral drugs-not specified,New,,United States,Ongoing,will be using Sarepta’s RNA technology to identify the antisense oligonucleotides,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/10/2020,,,,,,5/10/2020
403,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/sarepta-therapeutics-announces-research-agreement-with-u-s-department-of-defense-to-evaluate-multiple-constructs-from-its-proprietary-rna-platform-as-treatments-for-covid-19/,https://www.biospace.com/article/releases/sarepta-therapeutics-announces-research-agreement-with-u-s-department-of-defense-to-evaluate-multiple-constructs-from-its-proprietary-rna-platform-as-treatments-for-covid-19/,https://www.biospace.com/article/releases/sarepta-therapeutics-announces-research-agreement-with-u-s-department-of-defense-to-evaluate-multiple-constructs-from-its-proprietary-rna-platform-as-treatments-for-covid-19/,https://www.biospace.com/article/releases/sarepta-therapeutics-announces-research-agreement-with-u-s-department-of-defense-to-evaluate-multiple-constructs-from-its-proprietary-rna-platform-as-treatments-for-covid-19/,,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/sarepta-therapeutics-announces-research-agreement-with-u-s-department-of-defense-to-evaluate-multiple-constructs-from-its-proprietary-rna-platform-as-treatments-for-covid-19/,https://www.biospace.com/article/releases/sarepta-therapeutics-announces-research-agreement-with-u-s-department-of-defense-to-evaluate-multiple-constructs-from-its-proprietary-rna-platform-as-treatments-for-covid-19/,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/23/2020,,,,,,5/23/2020
404,No,Shionogi Therapeutic,,Shionogi Therapeutic,Shionogi & Co. Ltd.,Therapeutic,COVID-19,Unknown,Unknown,New,Hokkaido University Research Center for Zoonosis Control,Japan,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/10/2020,,,,,,5/10/2020
404,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.americanpharmaceuticalreview.com/1315-News/563823-Shionogi-Accelerates-Development-of-Potential-COVID-19-Treatments-Vaccine/?catid=6262,https://www.americanpharmaceuticalreview.com/1315-News/563823-Shionogi-Accelerates-Development-of-Potential-COVID-19-Treatments-Vaccine/?catid=6262,https://www.americanpharmaceuticalreview.com/1315-News/563823-Shionogi-Accelerates-Development-of-Potential-COVID-19-Treatments-Vaccine/?catid=6262,https://www.americanpharmaceuticalreview.com/1315-News/563823-Shionogi-Accelerates-Development-of-Potential-COVID-19-Treatments-Vaccine/?catid=6262,https://www.americanpharmaceuticalreview.com/1315-News/563823-Shionogi-Accelerates-Development-of-Potential-COVID-19-Treatments-Vaccine/?catid=6262,http://www.shionogi.co.jp/en/,https://www.americanpharmaceuticalreview.com/1315-News/563823-Shionogi-Accelerates-Development-of-Potential-COVID-19-Treatments-Vaccine/?catid=6262,,,https://www.americanpharmaceuticalreview.com/1315-News/563823-Shionogi-Accelerates-Development-of-Potential-COVID-19-Treatments-Vaccine/?catid=6262,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/25/2020,,,,,,5/25/2020
405,No,Cynarine,,Cynarine,Som Biotech SL,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,,Spain,Ongoing,"The company’s artificial intelligence (AI)-based screening technology, SOMAIPRO, was used to discover the inhibitors of 3CL proteases",,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meg,5/10/2020,,,,,,5/10/2020
405,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://sombiotech.com/category/news/,https://sombiotech.com/category/news/,https://www.pharmaceutical-technology.com/news/som-biotech-covid-19-candidates/,https://sombiotech.com/category/news/,,https://sombiotech.com/category/news/,https://sombiotech.com/category/news/,https://www.pharmaceutical-technology.com/news/som-biotech-covid-19-candidates/,,https://sombiotech.com/category/news/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
406,No,prexasertib,prexasertib,,Som Biotech SL,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,Ewha Woman's University,Spain,Ongoing,SOM Biotech used artificial intelligence (called SOMAIPRO) to find molecules that could act as inihibitors of 3CL which could potentially treat COVID-19. They are waiting on an IND before proceeding with Phase 1 Clinical Trials.,,Phase 1,,Complete,Completed in vitro,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane,5/5/2020,,,,,,5/5/2020
406,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.drugbank.ca/drugs/DB12008,https://www.medchemexpress.com/LY2606368.html,https://sombiotech.com/new-therapies-for-covid-19/,https://sombiotech.com/new-therapies-for-covid-19/,https://sombiotech.com/new-therapies-for-covid-19/,https://sombiotech.com/new-therapies-for-covid-19/,https://sombiotech.com/new-therapies-for-covid-19/,,https://sombiotech.com/new-therapies-for-covid-19/,,https://sombiotech.com/new-therapies-for-covid-19/,https://sombiotech.com/new-therapies-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
407,No,eravacycline,eravacycline,Xerava,Som Biotech SL; Tetraphase Pharmaceuticals Inc.,Therapeutic,COVID-19,Small molecule,Antibiotics and antiparasitics,Repurposed-Approved,Ewha Woman's University,Spain,Ongoing,SOM Biotech used artificial intelligence (called SOMAIPRO) to find molecules that could act as inihibitors of 3CL which could potentially treat COVID-19. They are waiting on an IND before proceeding with Phase 1 Clinical Trials.,,Phase 1,,2/2/2020,Completed in vitro,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane,5/5/2020,,,,,,5/5/2020
407,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.drugbank.ca/drugs/DB12329,https://www.drugbank.ca/drugs/DB12329,https://www.drugbank.ca/drugs/DB12329,https://sombiotech.com/new-therapies-for-covid-19/,https://sombiotech.com/new-therapies-for-covid-19/,https://sombiotech.com/new-therapies-for-covid-19/,https://sombiotech.com/new-therapies-for-covid-19/,,https://sombiotech.com/new-therapies-for-covid-19/,,https://chemrxiv.org/articles/Fast_Identification_of_Possible_Drug_Treatment_of_Coronavirus_Disease_-19_COVID-19_Through_Computational_Drug_Repurposing_Study/11875446,https://www.pharmaceutical-technology.com/news/som-biotech-covid-19-candidates/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
408,No,Llama-derived antibodies,,Llama-derived antibodies,Sysvax Inc.,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Quacell Biotechnology Co. LTD,China,Ongoing,Sysvax Inc. is investigating several different COVID-19 vaccine approaches.,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane,5/8/2020,,,,,,5/8/2020
408,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,,https://www.bioworld.com/COVID19products,,,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
409,No,PPP-003,,PPP-003,Tetra Bio-Pharma Inc.,Therapeutic,ARDS,,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,Canada,Ongoing,Tetra BioPharma aims to have completed pre-clinical stuudies by fall of 2020 and begin human clinical trials in Montreal.,,Pre-Clinical Testing,,Complete,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane,5/5/2020,,,,,,5/5/2020
409,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Provides-PPP003-Inflammatory-Cytokine-Reduction-Drug-Program/default.aspx,,https://stockdaymedia.com/tetra-bio-pharma-discusses-development-of-ppp003-drug-for-cytokine-reduction-with-the-stock-day-podcast-tbpmf-may-7-2020/,https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Provides-PPP003-Inflammatory-Cytokine-Reduction-Drug-Program/default.aspx,,https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Provides-PPP003-Inflammatory-Cytokine-Reduction-Drug-Program/default.aspx,https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Provides-PPP003-Inflammatory-Cytokine-Reduction-Drug-Program/default.aspx,https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Provides-PPP003-Inflammatory-Cytokine-Reduction-Drug-Program/default.aspx,,https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Provides-PPP003-Inflammatory-Cytokine-Reduction-Drug-Program/default.aspx,,https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Announces-Drug-Candidate-as-Potential-Therapy-for-Managing-Cytokine-Release-Syndrome/default.aspx,https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2020/Tetra-Bio-Pharma-Announces-Drug-Candidate-as-Potential-Therapy-for-Managing-Cytokine-Release-Syndrome/default.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
410,No,Allorx stem cells,,Allorx stem cells,Vitro Diagnostics Inc.,Therapeutic,COVID-19,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,Vitro Biopharma has submitted an IND application and is waiting on results before beginning Phase I human clinical trials.,,Phase 1,,Complete,Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane,5/7/2020,,,,,,5/7/2020
410,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/,https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/,https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/,https://vitrobiopharma.com/vitro-biopharma-2019-ceo-shareholder-letter-record-revenues-leading-to-further-growth-into-2020/,,https://vitrobiopharma.com/contact/,https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/,https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/,,https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/,,https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/,https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
411,No,VBI-S,,VBI-S,Vivacelle Bio Inc.,Therapeutic,Other,Small molecule,Other,New,Ascendia Pharmaceuticals,United States,Ongoing,"VBI-S aims to lower blood pressure and oxygenation from septic shock, which is a common cause of death in COVID patients",,Phase 2,,Complete,Assumed Complete,,,,Skipped,2/1/2020,,,,,,,,,,,,,,,,,,,,,,Sloane,5/7/2020,,,,,,5/7/2020
411,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.com/news-releases/vivacelle-bio-announces-compassionate-use-for-covid-19-patients-with-its-sepsis-treatment-vbi-s-301044045.html,https://clinicaltrials.gov/ct2/show/NCT04257136,https://clinicaltrials.gov/ct2/show/NCT04257136,https://www.prnewswire.com/news-releases/vivacelle-bio-announces-compassionate-use-for-covid-19-patients-with-its-sepsis-treatment-vbi-s-301044045.html,https://www.prnewswire.com/news-releases/vivacelle-bio-announces-compassionate-use-for-covid-19-patients-with-its-sepsis-treatment-vbi-s-301044045.html,https://www.prnewswire.com/news-releases/vivacelle-bio-announces-compassionate-use-for-covid-19-patients-with-its-sepsis-treatment-vbi-s-301044045.html,https://clinicaltrials.gov/ct2/show/NCT04257136?lead=Vivacelle+Bio&draw=2&rank=1,https://www.prnewswire.com/news-releases/vivacelle-bio-announces-compassionate-use-for-covid-19-patients-with-its-sepsis-treatment-vbi-s-301044045.html,,https://clinicaltrials.gov/ct2/show/NCT04257136?lead=Vivacelle+Bio&draw=2&rank=1,,https://www.businesswire.com/news/home/20190708005192/en/Vivacelle-Bio-Announces-FDA-Clearance-Enroll-Patients,https://www.businesswire.com/news/home/20190708005192/en/Vivacelle-Bio-Announces-FDA-Clearance-Enroll-Patients,,,https://www.businesswire.com/news/home/20190708005192/en/Vivacelle-Bio-Announces-FDA-Clearance-Enroll-Patients,https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1,,,,,https://www.prnewswire.com/news-releases/vivacelle-bio-announces-compassionate-use-for-covid-19-patients-with-its-sepsis-treatment-vbi-s-301044045.html,https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1&view=record,https://clinicaltrials.gov/ct2/show/record/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1&view=record,,https://clinicaltrials.gov/ct2/show/record/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1&view=record,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04257136?cond=septic+shock&cntry=US&state=US%3AIN&draw=2&rank=1,,,,,,,,,
412,No,Vyripharm Biopharmaceuticals LLC therapeutic,,Vyripharm Biopharmaceuticals LLC therapeutic,Vyripharm Biopharmaceuticals LLC,Therapeutic,COVID-19,Unknown,Antiviral drugs-not specified,Repurposed-Not Approved,,United States,Ongoing,The drug will combine anti-viral and anti-CB1 antagonist analogues for nuclear medicine imaging applications,,Discovery,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane,5/7/2020,,,,,,5/7/2020
412,Yes,https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/,,https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/,https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/,https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/,,https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/,https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/,https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/,,https://www.biospace.com/article/releases/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/,,https://www.pharmaceuticaldaily.com/vyripharm-biopharmaceuticals-is-in-the-development-stage-of-a-novel-integrated-theranostic-approach-for-the-treatment-of-viral-infections-such-as-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
413,No,Mesencure,,Mesencure,Wize Pharma Inc.; Bonus Biogroup Ltd.,Therapeutic,Pneumonia,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,New,BONUS BioGroup,Israel,Ongoing,,,Pre-Clinical Testing,,,4/19/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane,5/7/2020,,,,,,5/7/2020
413,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://www.bonusbiogroup.com/index.php/news-media/press-releases/item/32-bonus-biogroup-has-initiated-a-preclinical-study-of-a-unique-drug-developed-for-the-treatment-of-life-threatening-respiratory-distress-in-corona-covid-19-patients-and-pneumonia,http://www.bonusbiogroup.com/index.php/news-media/press-releases/item/32-bonus-biogroup-has-initiated-a-preclinical-study-of-a-unique-drug-developed-for-the-treatment-of-life-threatening-respiratory-distress-in-corona-covid-19-patients-and-pneumonia,http://www.bonusbiogroup.com/index.php/news-media/press-releases/item/32-bonus-biogroup-has-initiated-a-preclinical-study-of-a-unique-drug-developed-for-the-treatment-of-life-threatening-respiratory-distress-in-corona-covid-19-patients-and-pneumonia,https://www.bonusbiogroup.com/,http://www.bonusbiogroup.com/index.php/news-media/press-releases/item/32-bonus-biogroup-has-initiated-a-preclinical-study-of-a-unique-drug-developed-for-the-treatment-of-life-threatening-respiratory-distress-in-corona-covid-19-patients-and-pneumonia,,,http://www.bonusbiogroup.com/index.php/news-media/press-releases/item/32-bonus-biogroup-has-initiated-a-preclinical-study-of-a-unique-drug-developed-for-the-treatment-of-life-threatening-respiratory-distress-in-corona-covid-19-patients-and-pneumonia,,,biogroup.com/index.php/news-media/press-releases/item/32-bonus-biogroup-has-initiated-a-preclinical-study-of-a-unique-drug-developed-for-the-treatment-of-life-threatening-respiratory-distress-in-corona-covid-19-patients-and-pneumonia,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
414,No,MAPS vaccine,,MAPS vaccine,Affinivax Inc.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Astellas Pharma Inc.,United States,Ongoing,,,Phase 2,,Complete,Assumed Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane,5/7/2020,,,,,,5/7/2020
414,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://affinivax.com/maps-platform/,https://affinivax.com/maps-platform/,https://affinivax.com/vaccine-pipeline/,https://www.bioworld.com/articles/434616-affinivax-raises-120m-series-b-to-advance-maps-vaccines-and-immunotherapies,https://labcentral.org/resident-companies/affinivax,https://affinivax.com/about/,,,https://www.bioworld.com/articles/434616-affinivax-raises-120m-series-b-to-advance-maps-vaccines-and-immunotherapies,,https://affinivax.com/vaccine-pipeline/,https://affinivax.com/vaccine-pipeline/,,,,https://www.clinicaltrials.gov/ct2/show/study/NCT03803202?term=ASP3772,,,,,,https://www.clinicaltrials.gov/ct2/show/record/NCT03803202?term=ASP3772,https://www.clinicaltrials.gov/ct2/show/study/NCT03803202?term=ASP3772,https://www.clinicaltrials.gov/ct2/show/record/NCT03803202?term=ASP3772,https://www.clinicaltrials.gov/ct2/show/record/NCT03803202?term=ASP3772,https://www.clinicaltrials.gov/ct2/show/record/NCT03803202?term=ASP3772,https://www.clinicaltrials.gov/ct2/show/study/NCT03803202?term=ASP3772#contacts,https://www.clinicaltrials.gov/ct2/show/record/NCT03803202?term=ASP3772,,,https://www.clinicaltrials.gov/ct2/show/study/NCT03803202?term=ASP3772,,,,,,https://www.clinicaltrials.gov/ct2/show/study/NCT03803202?term=ASP3772#contacts,,,,,,,,,
415,No,Chimigen vaccine,,Chimigen vaccine,Akshaya Bio Inc.; Cytovance Biologics; Shenzhen Hepalink Pharmaceutical Group Co. Ltd.,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,Repurposed-Not Approved,Cytovance Biologics,United States,Ongoing,Akshaya's Chimigen vaccine platform is being reappropriated for COVID-19 in combination with Cytovance's GMP insect cell microbial manufacturing platform,,Pre-Clinical Testing,,,Assumed started,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane,5/7/2020,,,,,,5/7/2020
415,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/04/23/2020621/0/en/Cytovance-Biologics-and-Akshaya-Bio-Announce-Collaboration-Agreement-of-Therapeutics-for-Treatment-of-Coronavirus-and-Hepatitis-B-Virus-Infections.html,http://www.akshayabio.com/technology.html,http://www.akshayabio.com/technology.html,http://www.akshayabio.com/pdf/Akshaya_Overview.pdf,https://www.cytovance.com/news-articles/cytovance-biologics-and-akshaya-bio-announce-collaboration-agreement-of-therapeutics-for-treatment-of-coronavirus-and-hepatitis-b-virus-infections,https://www.globenewswire.com/news-release/2020/04/23/2020621/0/en/Cytovance-Biologics-and-Akshaya-Bio-Announce-Collaboration-Agreement-of-Therapeutics-for-Treatment-of-Coronavirus-and-Hepatitis-B-Virus-Infections.html,https://www.globenewswire.com/news-release/2020/04/23/2020621/0/en/Cytovance-Biologics-and-Akshaya-Bio-Announce-Collaboration-Agreement-of-Therapeutics-for-Treatment-of-Coronavirus-and-Hepatitis-B-Virus-Infections.html,https://www.globenewswire.com/news-release/2020/04/23/2020621/0/en/Cytovance-Biologics-and-Akshaya-Bio-Announce-Collaboration-Agreement-of-Therapeutics-for-Treatment-of-Coronavirus-and-Hepatitis-B-Virus-Infections.html,,https://www.cytovance.com/news-articles/cytovance-biologics-and-akshaya-bio-announce-collaboration-agreement-of-therapeutics-for-treatment-of-coronavirus-and-hepatitis-b-virus-infections,,http://www.akshayabio.com/pdf/Akshaya_Overview.pdf,https://www.cytovance.com/news-articles/cytovance-biologics-and-akshaya-bio-announce-collaboration-agreement-of-therapeutics-for-treatment-of-coronavirus-and-hepatitis-b-virus-infections,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
416,No,Brilacidin,,Brilacidin,Innovation Pharmaceuticals Inc.,Vaccine - Prophylactic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Not Approved,,United States,Ongoing,A defense Protein (HDP)/Defensin-Mimetic drug candidate previously being investigated for inflammatory bowel disease and oral mucositis and Acute Bacterial Skin and Skin Structure Infection; Has antiviral and immunomodulatory/anti-inflammatory and antimicrobial properties; Phase 2 trial completed for other indications,,Pre-Clinical Testing,,Started,3/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,5/9/2020,,,,,,5/9/2020
416,Yes,https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e9cebd48660e44c2754fa00/1587342453349/Brilacidin+for+COVID-19+Overview+-+MOA%2C+PreClinical+Data%2C+Academic+Literature+-+4.20.20.pdf,,https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e9cebd48660e44c2754fa00/1587342453349/Brilacidin+for+COVID-19+Overview+-+MOA%2C+PreClinical+Data%2C+Academic+Literature+-+4.20.20.pdf,https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e9cebd48660e44c2754fa00/1587342453349/Brilacidin+for+COVID-19+Overview+-+MOA%2C+PreClinical+Data%2C+Academic+Literature+-+4.20.20.pdf,https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e9cebd48660e44c2754fa00/1587342453349/Brilacidin+for+COVID-19+Overview+-+MOA%2C+PreClinical+Data%2C+Academic+Literature+-+4.20.20.pdf,,,,,,,,https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e9cebd48660e44c2754fa00/1587342453349/Brilacidin+for+COVID-19+Overview+-+MOA%2C+PreClinical+Data%2C+Academic+Literature+-+4.20.20.pdf,,,,http://www.ipharminc.com/stages-of-development,https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e9cebd48660e44c2754fa00/1587342453349/Brilacidin+for+COVID-19+Overview+-+MOA%2C+PreClinical+Data%2C+Academic+Literature+-+4.20.20.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,5/9/2020,,,,,,5/9/2020
417,No,PDS02023,,PDS02023,PDS Biotechnology Corp,Vaccine - Prophylactic,COVID-19,Unknown,Vaccine,New,,United States,Ongoing,Leveraging existing Versamune® platform,,Pre-Clinical Testing,,4/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,5/9/2020,,,,,,5/9/2020
417,Yes,https://www.pdsbiotech.com/pipeline/overview,,https://www.pdsbiotech.com/pipeline/overview,https://www.pdsbiotech.com/pipeline/overview,https://www.bioworld.com/COVID19products,,,,,,https://www.pdsbiotech.com/pipeline/overview,,https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/377-iotechnologynitiatesovelaccineevelopmentrogr20200416,,,,https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/377-iotechnologynitiatesovelaccineevelopmentrogr20200416,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,5/9/2020,,,,,,5/9/2020
418,No,Adenoviral vector vaccine,,Adenoviral vector vaccine,Reithera Srl,Vaccine - Prophylactic,COVID-19,Unknown,Vaccine,New,Leukocare AG; Univercells SA,Italy,Ongoing,Vaccine candidate expected to target the spike protein of SARS-CoV-2; Vaccine technology is based on a novel ReiThera-proprietary simian adenoviral vector with strong immunological potency and low pre-existing immunity in humans,,Discovery,,Started,,,,,Anticipated Summer 2020,,,,,,,,,,,,,,,,,,,,,,,Okezi,5/9/2020,,,,,,5/9/2020
418,Yes,https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/,,https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/,https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/,https://www.bioworld.com/COVID19products,,,,,https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/,https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/,,https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/,,,,https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/,,,,,https://www.univercells.com/newsroom/reithera-leukocare-and-univercells-announce-fast-track-development-of-a-covid-19-vaccine/,,,,,,,,,,,,,,,,,,,,,,,Okezi,5/9/2020,,,,,,5/9/2020
419,No,DNA Vaccine,,DNA Vaccine,Scancell Holdings plc,Vaccine - Prophylactic,COVID-19,Unknown,Vaccine,New,,United Kingdom,Ongoing,Candidate to target the SARS-CoV-2 nucleocapsid (N) protein and the key receptor-binding domain of the spike (S) protein to generate both T cell responses and virus neutralizing antibodies,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,5/9/2020,,,,,,5/9/2020
419,Yes,https://www.scancell.co.uk/product-pipeline,,https://www.scancell.co.uk/product-pipeline,https://www.scancell.co.uk/product-pipeline,https://www.bioworld.com/COVID19products,,,,,,https://www.scancell.co.uk/product-pipeline,,https://www.scancell.co.uk/Data/Sites/1/media/publications/news/covid-19-vaccine-programme.pdf,,,,,https://www.scancell.co.uk/product-pipeline,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,5/9/2020,,,,,,5/9/2020
420,No,Pathogen-specific aAPC,,Pathogen-specific aAPC,Shenzhen Geno-Immune Medical Institute,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,,Shenzhen Third People's Hospital; Shenzhen Second People's Hospital,China,Ongoing,Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes to the artificial antigen presenting cells,,Phase 1,,,Assume completed,,,,Started,,,,,,1,COVID 19,100,No,1,Shenzhen - China,02/15/2020,07/31/2023,12/31/2024,https://clinicaltrials.gov/ct2/show/NCT04299724,Lung-Ji Chang,For China: +86(755)8672 5195,c@szgimi.org,,,,,Okezi,4/26/2020,,,,,,4/26/2020
420,Yes,https://www.nature.com/articles/d41573-020-00073-5,,https://www.nature.com/articles/d41573-020-00073-5,https://www.nature.com/articles/d41573-020-00073-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04299724,,https://clinicaltrials.gov/ct2/show/NCT04299724,https://clinicaltrials.gov/ct2/show/NCT04299724,https://clinicaltrials.gov/ct2/show/NCT04299724,https://clinicaltrials.gov/ct2/show/NCT04299724,,,,,,,,,,,,,,,
421,No,OraPro-COVID-19,,OraPro-COVID-19,Stabilitech Biopharma Ltd.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,United Kingdom,Ongoing,It is a viral vectored adenovirus 5 containing the spike protein DNA from SARS-CoV-2; As of 04/30/2020 they announced successful completion of initial animal safety trials. Website says they'll soon be raising funds for clinical trials and manufacturing. Clinical trials are expected to start in June,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,5/6/2020,,,,,,5/6/2020
421,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://invest.stabilitech.com/,https://invest.stabilitech.com/,https://invest.stabilitech.com/,https://invest.stabilitech.com/,,https://www.stabilitech.com/,https://invest.stabilitech.com/,https://www.stabilitech.com/orapro-covid-19/; https://invest.stabilitech.com/; https://www.stabilitech.com/news/,,https://www.bioworld.com/COVID19products,,,https://www.stabilitech.com/orapro-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,5/6/2020,,,,,,5/6/2020
422,No,Vivagel; SPL-7013,,Vivagel; SPL-7013,Starpharma Ltd,Vaccine - Prophylactic,COVID-19,,Antiviral drugs-not specified,Repurposed-Approved,,Australia,Ongoing,Uses dendrimers--not sure how to classify the molecule type; Repurposing the active ingredient (SPL7013) but would come up with new products/formulations for COVID-19 application,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,5/6/2020,,,,,,5/6/2020
422,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://starpharma.com/news/473,https://starpharma.com/news/473,https://starpharma.com/news/473,https://starpharma.com/news/473,,https://starpharma.com/about_us,https://starpharma.com/news/473,https://starpharma.com/news/473,,https://starpharma.com/news/473,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,5/6/2020,,,,,,5/6/2020
423,No,VLP Vaccine,,VLP Vaccine,Sysvax Inc.,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,Quacell Biotechnology Co. Ltd.,China,Ongoing,Company is developing recombinant protein vaccine (detailed in this row) as well as a nanobody therapeutic and working to increase the half-life of COVID treatments; CEO says he expects vaccine will be IND-ready in the end of 2020 or early 2021,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,5/7/2020,,,,,,5/7/2020
423,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,,https://www.bioworld.com/articles/434585-nanobody-startup-sysvax-aims-covid-19-cures-with-three-approaches,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,5/7/2020,,,,,,5/7/2020
424,No,Baculovirus Expression Vector System vaccine,,Baculovirus Expression Vector System vaccine,UMN Pharma Inc.; Shionogi & Co. Ltd.,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,Japan Agency for Medical Research and Development (AMED),Japan,Ongoing,,,Discovery,,3/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,5/7/2020,,,,,,5/7/2020
424,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.shionogi.com/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine/,https://www.shionogi.com/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine/,https://www.shionogi.com/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine/,https://www.shionogi.com/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine/,shionogi.com/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine/,https://www.umnpharma.com/en/aboutus/,https://www.shionogi.com/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine/,,,shionogi.com/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine/,,shionogi.com/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine/,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,5/7/2020,,,,,,5/7/2020
425,No,Ixiaro,,Ixiaro,Valneva SE; Dynavax Technologies Corp.,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,,,,,I don't think they would be using Ixiaro --at least not as-is-- as a COVID vaccine -- change Product Name? Also why I left the New/Repurposed column blank,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,5/7/2020,,,,,,5/7/2020
425,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://valneva.com/press-release/valneva-and-dynavax-announce-collaboration-to-advance-vaccine-development-for-covid-19/,https://valneva.com/press-release/valneva-and-dynavax-announce-collaboration-to-advance-vaccine-development-for-covid-19/,https://valneva.com/press-release/valneva-and-dynavax-announce-collaboration-to-advance-vaccine-development-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anna,5/7/2020,,,,,,5/7/2020
426,No,Pepticrad vaccine,,Pepticrad vaccine,Valo Therapeutics Ltd,Vaccine - Prophylactic,Other,Subunit Vaccines,Combination,Repurposed-Not Approved,Valo Therapeutics,Finland,Ongoing,It seems to be focused on tumor immunity rather virus immunity,,Pre-Clinical Testing,,,4/22/2020,Completed,,,,,,,Target: 06/30/2021,,,,,,,,,,,,,,,,,,,Bill,5/14/2020,,,,,,5/14/2020
426,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.valotx.com/what-pepticrad,https://www.valotx.com/what-pepticrad,https://www.valotx.com/what-pepticrad,https://www.valotx.com/what-pepticrad,https://www.valotx.com/what-pepticrad,https://www.valotx.com/what-pepticrad,https://cordis.europa.eu/project/id/681219/reporting,,,https://www.targovax.com/en/targovax-and-valo-therapeutics-enter-collaboration-to-develop-ras-neoantigen-coating-of-oncos-viruses-using-pepticrad-technology/ ; https://www.bioworld.com/COVID19products,,https://cordis.europa.eu/project/rcn/204117/reporting/en?rcn=4155,https://www.bioworld.com/COVID19products,https://www.prnewswire.com/news-releases/targovax-and-valo-therapeutics-enter-collaboration-to-develop-ras-neoantigen-coating-of-oncos-viruses-using-pepticrad-technology-301044964.html,,,,,,,https://cordis.europa.eu/project/id/681219/reporting,,,,,,,,,,,,,,,,,,,,,,,,,,
427,No,Vaxipatch vaccine,,Vaxipatch vaccine,Verndari Inc.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Other,New,Verndari Inc.,United States,Ongoing,The product is a combination of a new COVID-19 vaccine and new delivery system,,Pre-Clinical Testing,,Completed,5/1/2020,Completed,,Started,Target: 10/01/20,,,,,,,,,,,,,,,,,,,,,,,Bill,5/16/2020,,,,,,5/16/2020
427,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.verndariinc.com/news/4,https://www.businesswire.com/news/home/20200429005243/en/Verndari-Begins-Preclinical-Testing-COVID-19-Vaccine-University,https://www.businesswire.com/news/home/20200429005243/en/Verndari-Begins-Preclinical-Testing-COVID-19-Vaccine-University,https://www.ucdavis.edu/coronavirus/news/covid-19-vaccine-patch-delivery-technology-enters-preclinical-testing-uc-davis/,https://www.verndariinc.com/news/4,https://www.verndariinc.com/,https://www.verndariinc.com/news/4,,,https://www.bioworld.com/COVID19products,,https://www.verndariinc.com/news/4,https://www.verndariinc.com/news/4,https://www.verndariinc.com/news/4,,https://www.verndariinc.com/news/4,https://www.businesswire.com/news/home/20200429005243/en/Verndari-Begins-Preclinical-Testing-COVID-19-Vaccine-University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
428,No,Viravaxx Vaccine,,Viravaxx Vaccine,Viravaxx AG,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Antiviral drugs-not specified,New,Viravaxx - Medical University of Vienna,Austria,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/16/2020,,,,,,5/16/2020
428,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.genomeweb.com/immunoassays/viravaxx-medical-university-vienna-partnering-covid-19-dx-vaccine-work#.XsAfSGhKg2w,https://www.pharmiweb.com/press-release/2020-04-22/viravaxx-ag-and-the-medical-university-of-vienna-have-launched-a-project-for-an-integrated-platform-for-immune-diagnosis-and-vaccination-for-covid-19,https://www.pharmiweb.com/press-release/2020-04-22/viravaxx-ag-and-the-medical-university-of-vienna-have-launched-a-project-for-an-integrated-platform-for-immune-diagnosis-and-vaccination-for-covid-19,https://www.pharmiweb.com/press-release/2020-04-22/viravaxx-ag-and-the-medical-university-of-vienna-have-launched-a-project-for-an-integrated-platform-for-immune-diagnosis-and-vaccination-for-covid-19,https://www.genomeweb.com/immunoassays/viravaxx-medical-university-vienna-partnering-covid-19-dx-vaccine-work#.XsAfSGhKg2w,https://www.lisavienna.at/news/viravaxx-ag-and-the-medical-university-of-vienna-have-launched-a-project-for-an-integrated-platform/,http://www.viravaxx.eu/company/covid-19/,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
429,No,Masitinib,,Masitinib,AB Science SA,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Kinase inhibitors,New,AB Science SA,France,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,5/4/2020,,,,,2,COVID-19,200,No,1,AB Science-Paris-France,05/04/20,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR,,,DL_MEDICALWRITERS@ab-science.com,,,,,Bill,5/16/2020,,,,,,5/16/2020
429,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,http://www.ab-science.com/pipeline/masitinib,http://www.ab-science.com/pipeline/masitinib,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,,,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,https://www.reuters.com/article/brief-ab-science-initiates-phase-2-study/brief-ab-science-initiates-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-treatment-of-covid-19-idUSASN0006G7,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001635-27-FR,,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR,,,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001635-27/FR,,,,,,,,,
430,No,MRx-4DP0004,,MRx-4DP0004,4D Pharma plc,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,4D pharma plc,United Kingdom,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,5/1/2020,,,,,2,COVID-19,90,No,1,Bradford Royal Infirmary-Bradford-England,05/01/20,08/01/20,09/01/20,https://clinicaltrials.gov/ct2/show/NCT04363372,,,clinicaltrials@4dpharmaplc.com,,,,,Bill,5/16/2020,,,,,,5/16/2020
430,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.4dpharmaplc.com/en/developing-science/pipeline,https://clinicaltrials.gov/ct2/show/NCT04363372,https://clinicaltrials.gov/ct2/show/NCT04363372,https://clinicaltrials.gov/ct2/show/NCT04363372,https://clinicaltrials.gov/ct2/show/NCT04363372,https://clinicaltrials.gov/ct2/show/NCT04363372,https://clinicaltrials.gov/ct2/show/NCT04363372,,,https://www.bioworld.com/COVID19products,,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,,,,,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04363372,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04363372,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04363372,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04363372,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04363372,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT04363372,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04363372#contacts,,,,,,,,,
431,No,ATYR-1923,,ATYR-1923,Atyr Pharma Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,aTyr Pharma Inc.,United States,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,4/21/2020,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,Bill,5/16/2020,,,,,,5/16/2020
431,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-phase-2-study-atyr1923-covid-19-patients,https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-phase-2-study-atyr1923-covid-19-patients,https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,https://pipelinereview.com/index.php/2020042274397/Antibodies/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,,,https://www.bioworld.com/COVID19products,,https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,https://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
432,No,PH-94B,,PH-94B,Vistagen Therapeutics Inc.,Therapeutic,Other,Small molecule,Other,Repurposed-Not Approved,VistaGen Therapeutics,United States,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Started,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,Bill,5/16/2020,,,,,,5/16/2020
432,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,https://www.vistagen.com/,https://www.vistagen.com/,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,,,https://www.bioworld.com/COVID19products,,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,https://www.vistagen.com/news-media/press-releases/detail/138/vistagen-expands-ph94b-clinical-development-to-include,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
433,No,Cymerus,,Cymerus,Cynata Therapeutics Ltd.,Therapeutic,ARDS,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,New,Cynata Therapeutics,Australia,Ongoing,,,Phase 1,,Assume Completed,Completed,Assume Completed,Assume Completed,5/8/2020,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/16/2020,,,,,,5/16/2020
433,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.clinicaltrialsarena.com/news/cynata-therapeutics-covid-19-trial/,https://www.cynata.com/about-cymerus,https://www.cynata.com/about-cymerus,https://www.clinicaltrialsarena.com/news/cynata-therapeutics-covid-19-trial/,https://www.clinicaltrialsarena.com/news/cynata-therapeutics-covid-19-trial/,https://www.cynata.com/,https://www.clinicaltrialsarena.com/news/cynata-therapeutics-covid-19-trial/,,,https://www.bioworld.com/COVID19products,,https://www.atsjournals.org/doi/abs/10.1164/rccm.201911-2143OC,https://www.atsjournals.org/doi/abs/10.1164/rccm.201911-2143OC,https://www.clinicaltrialsarena.com/news/cynata-therapeutics-covid-19-trial/,https://www.clinicaltrialsarena.com/news/cynata-therapeutics-covid-19-trial/,https://www.clinicaltrialsarena.com/news/cynata-therapeutics-covid-19-trial/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
434,No,7HP-349,,7HP-349,7 Hills Pharma,Therapeutic,Other,Small molecule,Combination,Repurposed-Not Approved,7 Hills Pharma,United States,Ongoing,,,Pre-Clinical Testing,,Assume Completed,Completed,Assume Completed,Assume Completed,4/14/2020,TARGET: 9/1/2020,,,,,,,,,,,,,,,,,,,,,,,Bill,5/16/2020,,,,,,5/16/2020
434,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://drug-dev.com/7-hills-pharma-announces-covid-19-vaccine-program-targeting-at-risk-elderly/,https://drug-dev.com/7-hills-pharma-announces-covid-19-vaccine-program-targeting-at-risk-elderly/,https://drug-dev.com/7-hills-pharma-announces-covid-19-vaccine-program-targeting-at-risk-elderly/,https://www.bio.org/events/bio-digital/sessions/677987,http://www.7hillspharma.com/,http://www.7hillspharma.com/,https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html/,,,https://www.bioworld.com/COVID19products,,https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html,https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html,https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html,https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html,https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html,https://www.globenewswire.com/news-release/2020/04/14/2015589/0/en/7-Hills-Pharma-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-7HP349-a-First-in-Class-Immune-Stimulant.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
435,No,Plasma therapy,,Plasma therapy,Adma Biologics Inc.; Biopharma Plasma LLC; GC Pharma; Sanquin,Therapeutic,COVID-19,Cell therapies,Antibiotics and antiparasitics,New,CoVIg-19 Plasma Alliance,United States; Japan; Ukraine; Netherlands; South Korea,Ongoing,,,Pre-Clinical Testing,,Assume Completed,Skipped,Assume Completed,Assume Completed,,Target: 06/01/20,,,,,,,,,,,,,,,,,,,,,,,Bill,5/16/2020,,,,,,5/16/2020
435,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.pharmashots.com/32740/covig-19-plasma-alliance-to-initiate-clinical-study-evaluating-hyperimmune-therapy-for-covid-19-by-summer-2020/,https://www.pharmashots.com/32740/covig-19-plasma-alliance-to-initiate-clinical-study-evaluating-hyperimmune-therapy-for-covid-19-by-summer-2020/,https://www.pharmashots.com/32740/covig-19-plasma-alliance-to-initiate-clinical-study-evaluating-hyperimmune-therapy-for-covid-19-by-summer-2020/,https://www.pharmashots.com/32740/covig-19-plasma-alliance-to-initiate-clinical-study-evaluating-hyperimmune-therapy-for-covid-19-by-summer-2020/,https://www.covig-19plasmaalliance.org/en-us#recruitment,https://www.pharmashots.com/32740/covig-19-plasma-alliance-to-initiate-clinical-study-evaluating-hyperimmune-therapy-for-covid-19-by-summer-2020/,https://www.pharmashots.com/32740/covig-19-plasma-alliance-to-initiate-clinical-study-evaluating-hyperimmune-therapy-for-covid-19-by-summer-2020/,,,https://www.bioworld.com/COVID19products,,https://www.gatesfoundation.org/TheOptimist/Articles/coronavirus-interview-toni-hoover-covig-alliance,https://www.gatesfoundation.org/TheOptimist/Articles/coronavirus-interview-toni-hoover-covig-alliance,https://www.gatesfoundation.org/TheOptimist/Articles/coronavirus-interview-toni-hoover-covig-alliance,https://www.gatesfoundation.org/TheOptimist/Articles/coronavirus-interview-toni-hoover-covig-alliance,,https://www.gatesfoundation.org/TheOptimist/Articles/coronavirus-interview-toni-hoover-covig-alliance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
436,No,rintatolimod,rintatolimod,Ampligen,Aim Immunotech Inc.; GP Pharma SA;,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Other antiviral drugs,Repurposed-Not Approved,,United States,Ongoing,,,Phase 1,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Skipped,Target: 05/30/2020,,,,,1,SARS Coronavirus 2 Infection; Malignant Neoplasm,80,No,1,Roswell Park Cancer Institute - Buffalo - New York,09/04/2020,09/04/2021,09/04/2021,https://clinicaltrials.gov/ct2/show/NCT04379518,,,brahm.segal@roswellpark.org,,,NOT YET RECRUITING,,Purab Patel,5/17/2020,,,,,,5/17/2020
436,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://adisinsight.springer.com/drugs/800001203,https://adisinsight.springer.com/drugs/800001203,https://aidsinfo.nih.gov/drugs/530/rintatolimod/0/professional,https://adisinsight.springer.com/drugs/800001203,,https://adisinsight.springer.com/drugs/800001203,https://www.bioworld.com/COVID19products,,,https://www.bioworld.com/COVID19products,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04379518?term=rintatolimod&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04379518?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Rintatolimod&draw=2&rank=1#contacts,,,,,,,,,
437,No,NK1R; MSC,,NK1R; MSC,Biocardia Inc.,Therapeutic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,5/17/2020,,,,,,5/17/2020
437,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
438,No,CB-5064,,CB-5064,Cohbar Inc.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,,,Pre-Clinical Testing,,Assume Completed,5/5/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,5/17/2020,,,,,,5/17/2020
438,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ir.cohbar.com/press-releases/detail/106/cohbar-to-target-covid-19-associated-acute-respiratory,https://www.biospace.com/article/releases/cohbar-to-target-covid-19-associated-acute-respiratory-distress-syndrome-ards-with-its-apelin-receptor-agonist-peptidespreclinical-testing-of-cb5064-analogs-initiated-in-ards/,https://ir.cohbar.com/press-releases/detail/106/cohbar-to-target-covid-19-associated-acute-respiratory,https://ir.cohbar.com/press-releases/detail/106/cohbar-to-target-covid-19-associated-acute-respiratory,,https://ir.cohbar.com/press-releases/detail/106/cohbar-to-target-covid-19-associated-acute-respiratory,https://ir.cohbar.com/press-releases/detail/106/cohbar-to-target-covid-19-associated-acute-respiratory,,,https://ir.cohbar.com/press-releases/detail/106/cohbar-to-target-covid-19-associated-acute-respiratory,,,https://ir.cohbar.com/press-releases/detail/106/cohbar-to-target-covid-19-associated-acute-respiratory,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
439,No,DW-2008,,DW-2008,Dongwha Pharmaceutical Co. Ltd.,Therapeutic,COVID-19,Other,Antiviral drugs-not specified,Repurposed-Not Approved,,South Korea,Ongoing,,,Pre-Clinical Testing,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Skipped,Target: 06/01/2020,,,,,,,,,,,,,,,,,,,,,,Purab Patel,5/17/2020,,,,,,5/17/2020
439,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.businesswire.com/news/home/20200506005403/en/DongWha-Pharm%E2%80%99s-DW2008-Shows-Excellent-Antiviral-Activity,https://www.businesswire.com/news/home/20200506005403/en/DongWha-Pharm%E2%80%99s-DW2008-Shows-Excellent-Antiviral-Activity,https://www.businesswire.com/news/home/20200506005403/en/DongWha-Pharm%E2%80%99s-DW2008-Shows-Excellent-Antiviral-Activity,https://www.businesswire.com/news/home/20200506005403/en/DongWha-Pharm%E2%80%99s-DW2008-Shows-Excellent-Antiviral-Activity,,https://www.businesswire.com/news/home/20200506005403/en/DongWha-Pharm%E2%80%99s-DW2008-Shows-Excellent-Antiviral-Activity,https://www.businesswire.com/news/home/20200506005403/en/DongWha-Pharm%E2%80%99s-DW2008-Shows-Excellent-Antiviral-Activity,,,https://www.businesswire.com/news/home/20200506005403/en/DongWha-Pharm%E2%80%99s-DW2008-Shows-Excellent-Antiviral-Activity,,,,,,,,https://www.businesswire.com/news/home/20200506005403/en/DongWha-Pharm%E2%80%99s-DW2008-Shows-Excellent-Antiviral-Activity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
440,No,EDP-1815,,EDP-1815,Evelo Biosciences Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,,United States,Ongoing,,,Phase 2,,Assume Completed,Completed,,,,,8/26/2020,,,,,,,,,,,,,,,,,,,,,,Purab Patel,5/17/2020,,,,,,5/17/2020
440,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://evelobio.com/portfolio/,https://evelobio.com/portfolio/,https://evelobio.com/portfolio/,https://evelobio.com/portfolio/,,https://evelobio.com/portfolio/,https://evelobio.com/portfolio/,,,https://clinicaltrials.gov/ct2/show/NCT04488575,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04488575,,,,,https://clinicaltrials.gov/ct2/show/NCT04488575,https://clinicaltrials.gov/ct2/show/NCT04488575,https://clinicaltrials.gov/ct2/show/NCT04488575,https://clinicaltrials.gov/ct2/show/NCT04488575,https://clinicaltrials.gov/ct2/show/NCT04488575,https://clinicaltrials.gov/ct2/show/NCT04488576,https://clinicaltrials.gov/ct2/show/NCT04488577,https://clinicaltrials.gov/ct2/show/NCT04488578,https://clinicaltrials.gov/ct2/show/NCT04488579,https://clinicaltrials.gov/ct2/show/NCT04488580,https://clinicaltrials.gov/ct2/show/NCT04488581,https://clinicaltrials.gov/ct2/show/NCT04488582,https://clinicaltrials.gov/ct2/show/NCT04488583,,,,,,,,,,,,
441,No,Nucleic Acid Therapy,,Nucleic Acid Therapy,Aligos Therapeutics Inc.; Luxna Biotech Co. Ltd.,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Other antiviral drugs,New,,United States,Ongoing,,,Discovery,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,5/17/2020,,,,,,5/17/2020
441,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/04/15/2016577/0/en/Aligos-Therapeutics-Expands-Licensing-Agreement-with-Luxna-Biotech-in-Oligonucleotide-Technology-to-Include-Novel-Coronavirus-Targets.html,https://www.globenewswire.com/news-release/2020/04/15/2016577/0/en/Aligos-Therapeutics-Expands-Licensing-Agreement-with-Luxna-Biotech-in-Oligonucleotide-Technology-to-Include-Novel-Coronavirus-Targets.html,https://www.globenewswire.com/news-release/2020/04/15/2016577/0/en/Aligos-Therapeutics-Expands-Licensing-Agreement-with-Luxna-Biotech-in-Oligonucleotide-Technology-to-Include-Novel-Coronavirus-Targets.html,https://www.globenewswire.com/news-release/2020/04/15/2016577/0/en/Aligos-Therapeutics-Expands-Licensing-Agreement-with-Luxna-Biotech-in-Oligonucleotide-Technology-to-Include-Novel-Coronavirus-Targets.html,,https://www.globenewswire.com/news-release/2020/04/15/2016577/0/en/Aligos-Therapeutics-Expands-Licensing-Agreement-with-Luxna-Biotech-in-Oligonucleotide-Technology-to-Include-Novel-Coronavirus-Targets.html,https://www.globenewswire.com/news-release/2020/04/15/2016577/0/en/Aligos-Therapeutics-Expands-Licensing-Agreement-with-Luxna-Biotech-in-Oligonucleotide-Technology-to-Include-Novel-Coronavirus-Targets.html,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
442,No,Antibodies,,Antibodies,Amgen Inc.; Adaptive Biotechnologies Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,,,Discovery,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,5/17/2020,,,,,,5/17/2020
442,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19/,https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19/,https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19/,https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19/,,https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19/,https://www.amgen.com/media/news-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19/,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
443,No,Antiviral,,Antiviral,Anixa Bioscience Inc.; Ontochem GmbH,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,New,,United States,Ongoing,,,Discovery,,4/20/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,5/17/2020,,,,,,5/17/2020
443,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ir.anixa.com/press-releases/detail/949/anixa-biosciences-and-ontochem-announce-discovery-of-first,https://ir.anixa.com/press-releases/detail/949/anixa-biosciences-and-ontochem-announce-discovery-of-first,https://ir.anixa.com/press-releases/detail/949/anixa-biosciences-and-ontochem-announce-discovery-of-first,https://ir.anixa.com/press-releases/detail/949/anixa-biosciences-and-ontochem-announce-discovery-of-first,,https://ir.anixa.com/press-releases/detail/949/anixa-biosciences-and-ontochem-announce-discovery-of-first,https://ir.anixa.com/press-releases/detail/949/anixa-biosciences-and-ontochem-announce-discovery-of-first,,,https://ir.anixa.com/press-releases/detail/949/anixa-biosciences-and-ontochem-announce-discovery-of-first,,https://ir.anixa.com/press-releases/detail/947/anixa-biosciences-and-ontochem-announce-collaboration-to,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
444,No,Knockdown Coronavirus,,Knockdown Coronavirus,Aum Lifetech Inc.; Aum Biotech LLC,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Other antiviral drugs,New,,United States,Ongoing,,,Discovery,,5/6/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,5/17/2020,,,,,,5/17/2020
444,Yes,https://www.newswire.ca/news-releases/aum-lifetech-and-aum-biotech-launch-knockdown-coronavirus-research-program-879512340.html,,https://www.newswire.ca/news-releases/aum-lifetech-and-aum-biotech-launch-knockdown-coronavirus-research-program-879512340.html,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.newswire.ca/news-releases/aum-lifetech-and-aum-biotech-launch-knockdown-coronavirus-research-program-879512340.html,https://www.newswire.ca/news-releases/aum-lifetech-and-aum-biotech-launch-knockdown-coronavirus-research-program-879512340.html,https://www.newswire.ca/news-releases/aum-lifetech-and-aum-biotech-launch-knockdown-coronavirus-research-program-879512340.html,https://www.newswire.ca/news-releases/aum-lifetech-and-aum-biotech-launch-knockdown-coronavirus-research-program-879512340.html,,https://www.newswire.ca/news-releases/aum-lifetech-and-aum-biotech-launch-knockdown-coronavirus-research-program-879512340.html,https://www.newswire.ca/news-releases/aum-lifetech-and-aum-biotech-launch-knockdown-coronavirus-research-program-879512340.html,,,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
445,No,bacTRL-Spike,,bacTRL-Spike,Symvivo Corp.,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,Canada,Ongoing,,,Phase 1,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,7/1/2020,,,,,,1,COVID-19,24,Yes,1,Melbourne - Australia,11/02/2020,02/08/2022,2/28/2022,https://clinicaltrials.gov/ct2/show/NCT04334980,"Alexander Graves, PhD, MBA ; Michelle Jones, RN, M.Sc., MBA",(604) 428-7474 ; 604-428-7474,bd@symvivo.com,https://www.symvivo.com/,,NOT YET RECRUITING,,Purab Patel,5/17/2020,,,,,,5/17/2020
445,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.symvivo.com/covid-19,https://www.symvivo.com/covid-19,https://www.symvivo.com/covid-19,https://www.symvivo.com/covid-19,,https://www.symvivo.com/covid-19,https://www.symvivo.com/covid-19,,,https://www.bioworld.com/COVID19products,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04334980?term=symvivo&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,,,,,,,,,
446,No,Recombinant vaccine,,Recombinant vaccine,Autonomous University of Mexico,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,Repurposed-Approved,Laboratorios Liomont,Mexico,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,5/11/2020,,,,,,5/11/2020
446,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/articles/435076-mexican-university-basing-covid-19-vaccine-on-zika-dengue,https://www.bioworld.com/articles/435076-mexican-university-basing-covid-19-vaccine-on-zika-dengue,https://www.bioworld.com/articles/435076-mexican-university-basing-covid-19-vaccine-on-zika-dengue,https://www.bioworld.com/articles/435076-mexican-university-basing-covid-19-vaccine-on-zika-dengue,https://www.bioworld.com/articles/435076-mexican-university-basing-covid-19-vaccine-on-zika-dengue,https://www.bioworld.com/articles/435076-mexican-university-basing-covid-19-vaccine-on-zika-dengue,https://www.bioworld.com/articles/435076-mexican-university-basing-covid-19-vaccine-on-zika-dengue,,,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
447,No,Queretero Vaccine,,Queretero Vaccine,Autonomous University of Queretero,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,National Council of Science and Technology,Mexico,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,5/12/2020,,,,,,5/12/2020
447,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/articles/434931-mexican-team-lead-by-vets-racing-to-develop-covid-19-vaccine,https://www.bioworld.com/articles/434931-mexican-team-lead-by-vets-racing-to-develop-covid-19-vaccine,https://www.bioworld.com/articles/434931-mexican-team-lead-by-vets-racing-to-develop-covid-19-vaccine,https://www.bioworld.com/articles/434931-mexican-team-lead-by-vets-racing-to-develop-covid-19-vaccine,https://www.bioworld.com/articles/434931-mexican-team-lead-by-vets-racing-to-develop-covid-19-vaccine,https://www.bioworld.com/articles/434931-mexican-team-lead-by-vets-racing-to-develop-covid-19-vaccine,https://www.bioworld.com/articles/434931-mexican-team-lead-by-vets-racing-to-develop-covid-19-vaccine,,,https://www.bioworld.com/articles/434931-mexican-team-lead-by-vets-racing-to-develop-covid-19-vaccine,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
448,No,CpG 1018,,CpG 1018,Dynavax Technologies Corp.,Vaccine - Prophylactic,COVID-19,Combination,Vaccine,Repurposed-Approved,Dynavax;Sinovac Biotech Ltd.,United States; China,Ongoing,,,Phase 1,,4/16/2020,Skipped,Assume Completed,Assume Completed,Assume Completed,4/16/2020,,,,,,1,COVID-19,744,Yes,1,Suining County Center for Disease Control and Prevention-Xuzhou-China,04/16/20,08/13/20,12/13/20,https://clinicaltrials.gov/ct2/show/NCT04352608,Fengcai Zhu,,jszfc@vip.sina.com,,,,,Lisa,5/15/2020,,,,,,5/15/2020
448,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-sinovac-announce-collaboration-develop-coronavirus,https://www.dynavax.com/science/cpg-1018/,http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-sinovac-announce-collaboration-develop-coronavirus,http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-sinovac-announce-collaboration-develop-coronavirus,http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-sinovac-announce-collaboration-develop-coronavirus,https://www.dynavax.com/,https://www.bioworld.com/COVID19products,,,https://www.bioworld.com/COVID19products,,https://www.fiercebiotech.com/biotech/dynavax-sinovac-latest-to-ally-a-covid-19-vaccine,https://www.fdanews.com/articles/196715-sinovac-begins-phase-1-trial-of-its-covid-19-vaccine-candidate,https://www.fdanews.com/articles/196715-sinovac-begins-phase-1-trial-of-its-covid-19-vaccine-candidate,https://www.fdanews.com/articles/196715-sinovac-begins-phase-1-trial-of-its-covid-19-vaccine-candidate,https://www.fdanews.com/articles/196715-sinovac-begins-phase-1-trial-of-its-covid-19-vaccine-candidate,https://clinicaltrials.gov/ct2/show/NCT04352608,,,,,,https://clinicaltrials.gov/ct2/show/NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,,,,,,https://clinicaltrials.gov/ct2/show/NCT04352608,,,,,,,,,
449,No,mRNA Vaccine,,mRNA Vaccine,Daiichi Sankyo; University of Tokyo,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Daiichi Sankyo; University of Tokyo,Japan,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,5/17/2020,,,,,,5/17/2020
449,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.daiichisankyo.com/about_us/responsibility/csr/support/index.html,https://www.daiichisankyo.com/about_us/responsibility/csr/support/index.html,https://www.daiichisankyo.com/about_us/responsibility/csr/support/index.html,https://www.daiichisankyo.com/about_us/responsibility/csr/support/index.html,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,https://www.daiichisankyo.com/,https://www.bioworld.com/COVID19products,,,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
450,No,Viral Vector Vaccine,,Viral Vector Vaccine,German Center for Infection Research,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Combination,Repurposed-Not Approved,German Center for Infection Research,Germany,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,Assume Completed,Started,,Target: 09/01/20,,,,,,,,,,,,,,,,,,,,,,,Lisa,5/17/2020,,,,,,5/17/2020
450,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines,https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines,https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines,https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines,https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines,https://www.dzif.de/en/sars-cov-2-dzif-scientists-and-development-vaccines,https://www.bioworld.com/COVID19products,,,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,,https://www.dzif.de/en/dzif-focuses-sars-cov-2-research,https://www.dzif.de/en/dzif-focuses-sars-cov-2-research,,https://www.dzif.de/en/dzif-focuses-sars-cov-2-research,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
451,No,TerraCoV2,,TerraCoV2,Noachis Terra Inc.; Oragenics Inc.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Oragenics Inc.,United States,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,5/20/2020,,,,,,5/20/2020
451,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.businesswire.com/news/home/20200504005255/en/Oragenics-Acquires-Noachis-Terra-Develop-TerraCoV2-NIH-Generated,https://www.businesswire.com/news/home/20200504005255/en/Oragenics-Acquires-Noachis-Terra-Develop-TerraCoV2-NIH-Generated,https://www.businesswire.com/news/home/20200504005255/en/Oragenics-Acquires-Noachis-Terra-Develop-TerraCoV2-NIH-Generated,https://www.businesswire.com/news/home/20200504005255/en/Oragenics-Acquires-Noachis-Terra-Develop-TerraCoV2-NIH-Generated,https://www.businesswire.com/news/home/20200504005255/en/Oragenics-Acquires-Noachis-Terra-Develop-TerraCoV2-NIH-Generated,https://www.businesswire.com/news/home/20200504005255/en/Oragenics-Acquires-Noachis-Terra-Develop-TerraCoV2-NIH-Generated,https://www.businesswire.com/news/home/20200504005255/en/Oragenics-Acquires-Noachis-Terra-Develop-TerraCoV2-NIH-Generated,,,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
452,No,CORVax12,,CORVax12,Oncosec Medical Inc.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Combination,New,OncoSec,United States,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,Completed,,Started,,,,,,,,,,,,,,,,,,,,,,,,Lisa,5/21/2020,,,,,,5/21/2020
452,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.cancernetwork.com/news/researchers-plan-evaluate-corvax12-vaccine-phase-i-clinical-trial-covid-19,https://www.cancernetwork.com/news/researchers-plan-evaluate-corvax12-vaccine-phase-i-clinical-trial-covid-19,https://www.cancernetwork.com/news/researchers-plan-evaluate-corvax12-vaccine-phase-i-clinical-trial-covid-19,https://www.cancernetwork.com/news/researchers-plan-evaluate-corvax12-vaccine-phase-i-clinical-trial-covid-19,https://www.cancernetwork.com/news/researchers-plan-evaluate-corvax12-vaccine-phase-i-clinical-trial-covid-19,https://www.cancernetwork.com/news/researchers-plan-evaluate-corvax12-vaccine-phase-i-clinical-trial-covid-19,https://www.cancernetwork.com/news/researchers-plan-evaluate-corvax12-vaccine-phase-i-clinical-trial-covid-19,,,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,,https://idataresearch.com/oncosec-and-inovio-pursuing-phase-1-clinical-trials/,,https://www.cancernetwork.com/news/researchers-plan-evaluate-corvax12-vaccine-phase-i-clinical-trial-covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
453,No,Ose Vaccine,,Ose Vaccine,Ose Immunotherapeutics SA,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,OSE Immunotherapeutics,France,Ongoing,,,Pre-Clinical Testing,,5/5/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,5/21/2020,,,,,,5/21/2020
453,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ose-immuno.com/wp-content/uploads/2020/05/EN_200505_COVID_VF.pdf,https://ose-immuno.com/wp-content/uploads/2020/05/EN_200505_COVID_VF.pdf,https://ose-immuno.com/wp-content/uploads/2020/05/EN_200505_COVID_VF.pdf,https://ose-immuno.com/wp-content/uploads/2020/05/EN_200505_COVID_VF.pdf,https://ose-immuno.com/wp-content/uploads/2020/05/EN_200505_COVID_VF.pdf,https://ose-immuno.com/en/,https://ose-immuno.com/wp-content/uploads/2020/05/EN_200505_COVID_VF.pdf,,,https://www.bioworld.com/COVID19products,,https://ose-immuno.com/wp-content/uploads/2020/05/EN_200505_COVID_VF.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
454,No,Lineage Vaccine,,Lineage Vaccine,Lineage Cell Therapeutics Inc.,Vaccine - Prophylactic,COVID-19,Cell therapies,Vaccine,New,California Institute for Regenerative Medicine,United States,Ongoing,,,Discovery,,5/5/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,5/21/2020,,,,,,5/21/2020
454,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.businesswire.com/news/home/20200505005296/en/Lineage-Cell-Therapeutics-Apply-Allogeneic-Dendritic-Cell,https://www.businesswire.com/news/home/20200505005296/en/Lineage-Cell-Therapeutics-Apply-Allogeneic-Dendritic-Cell,https://www.businesswire.com/news/home/20200505005296/en/Lineage-Cell-Therapeutics-Apply-Allogeneic-Dendritic-Cell,https://www.businesswire.com/news/home/20200505005296/en/Lineage-Cell-Therapeutics-Apply-Allogeneic-Dendritic-Cell,https://www.businesswire.com/news/home/20200505005296/en/Lineage-Cell-Therapeutics-Apply-Allogeneic-Dendritic-Cell,https://lineagecell.com/,https://www.businesswire.com/news/home/20200505005296/en/Lineage-Cell-Therapeutics-Apply-Allogeneic-Dendritic-Cell,,,https://www.bioworld.com/COVID19products,,http://www.pharmaceuticaldaily.com/lineage-cell-therapeutics-to-apply-allogeneic-dendritic-cell-therapy-program-to-covid-19-vaccine-development-2/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
455,No,Zyus Vaccine,,Zyus Vaccine,Zyus Life Sciences Inc.; VIDO-Intervac,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,ZYUS Life Sciences Inc.; VIDO-InterVac,Canada,Ongoing,,,Discovery,,5/7/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,5/21/2020,,,,,,5/21/2020
455,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.zyus.com/news-and-events/news/news-details/2020/ZYUS-Collaborates-with-USasks-VIDO-InterVac-to-Develop-a-Plant-Based-Vaccine-for-COVID-19/default.aspx,https://www.zyus.com/news-and-events/news/news-details/2020/ZYUS-Collaborates-with-USasks-VIDO-InterVac-to-Develop-a-Plant-Based-Vaccine-for-COVID-19/default.aspx,https://www.zyus.com/news-and-events/news/news-details/2020/ZYUS-Collaborates-with-USasks-VIDO-InterVac-to-Develop-a-Plant-Based-Vaccine-for-COVID-19/default.aspx,https://www.zyus.com/news-and-events/news/news-details/2020/ZYUS-Collaborates-with-USasks-VIDO-InterVac-to-Develop-a-Plant-Based-Vaccine-for-COVID-19/default.aspx,https://www.zyus.com/news-and-events/news/news-details/2020/ZYUS-Collaborates-with-USasks-VIDO-InterVac-to-Develop-a-Plant-Based-Vaccine-for-COVID-19/default.aspx,https://www.vido.org/,https://www.zyus.com/news-and-events/news/news-details/2020/ZYUS-Collaborates-with-USasks-VIDO-InterVac-to-Develop-a-Plant-Based-Vaccine-for-COVID-19/default.aspx,,,https://www.bioworld.com/COVID19products,,https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/zyus-collaborates-with-usasks-vido-intervac-to-develop-a-plant-based-vaccine-for-covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
456,No,COVID-19 Immunoglobulin,,COVID-19 Immunoglobulin,CSL Behring Australia; CSL Limited,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Austrailia,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/27/2020,,,,,,5/27/2020
456,Yes,,,,https://www.csl.com/news/2020/20200506-csl-behring-australia-commences-development-of-treatment-for-serious-cases-of-covid-19,Therapeutic,https://www.csl.com/news/2020/20200506-csl-behring-australia-commences-development-of-treatment-for-serious-cases-of-covid-19,https://www.csl.com/news/2020/20200506-csl-behring-australia-commences-development-of-treatment-for-serious-cases-of-covid-19,https://www.csl.com/news/2020/20200506-csl-behring-australia-commences-development-of-treatment-for-serious-cases-of-covid-19,https://www.csl.com/news/2020/20200506-csl-behring-australia-commences-development-of-treatment-for-serious-cases-of-covid-19,,https://www.csl.com/news/2020/20200506-csl-behring-australia-commences-development-of-treatment-for-serious-cases-of-covid-19,https://www.csl.com/news/2020/20200506-csl-behring-australia-commences-development-of-treatment-for-serious-cases-of-covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
457,No,nivolumab,nivolumab,Opdivo,University of Hong Kong; BMS,Therapeutic,COVID-19,Small molecule,Monoclonal antibodies,Repurposed-Approved,,Hong Kong,Ongoing,,,Phase 2,,4/22/2020,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,,2,COVID-19,15,No,1,The University of Hong Kong,4/22/20,6/30/20,8/31/21,https://clinicaltrials.gov/ct2/show/NCT04356508,Gerry Gin Wai Kwok,,gggjerry@gmail.com,,,NOT YET RECRUITING,,Priya Kaur,5/27/2020,,,,,,5/27/2020
457,Yes,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#,Therapeutic,https://clinicaltrials.gov/ct2/show/NCT04356508,https://www.drugbank.ca/drugs/DB09035,https://www.drugbank.ca/drugs/DB09035,https://www.drugbank.ca/drugs/DB09035,,https://clinicaltrials.gov/ct2/show/NCT04356508,https://clinicaltrials.gov/ct2/show/NCT04356508,,,https://clinicaltrials.gov/ct2/show/NCT04356508,,https://clinicaltrials.gov/ct2/show/NCT04356508,https://clinicaltrials.gov/ct2/show/NCT04356508,https://clinicaltrials.gov/ct2/show/NCT04356508,https://clinicaltrials.gov/ct2/show/NCT04356508,https://clinicaltrials.gov/ct2/show/NCT04356508,https://clinicaltrials.gov/ct2/show/NCT04356508,,,,,,https://clinicaltrials.gov/ct2/show/NCT04356508,COVID-20,,https://clinicaltrials.gov/ct2/show/NCT04356508#contacts,https://clinicaltrials.gov/ct2/show/NCT04356508#contacts,https://clinicaltrials.gov/ct2/show/NCT04356508#contacts,https://clinicaltrials.gov/ct2/show/NCT04356508#contacts,https://clinicaltrials.gov/ct2/show/NCT04356508#contacts,https://clinicaltrials.gov/ct2/show/NCT04356508#contacts,https://clinicaltrials.gov/ct2/show/NCT04356508#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04356508#contacts,,Priya Kaur,,,,,,,
458,No,camrelizumab,camrelizumab,AiRuiKa,Wuhan Jinyintan Hospital; Jiangsu HengRui Medicine Co.,Therapeutic,COVID-19,Small molecule,Monoclonal antibodies,Repurposed-Approved,,China,Ongoing,,,Phase 2,,2/10/2020,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,,2,COVID-19,120,No,,,2/10/20,4/30/20,10/31/20,https://clinicaltrials.gov/ct2/show/NCT04268537,,,,,,NOT YET RECRUITING,,Priya Kaur,5/27/2020,,,,,,5/27/2020
458,Yes,https://www.hrs.com.cn/hren/products_pipeline_oncology.html,https://www.hrs.com.cn/hren/products_pipeline_oncology.html,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#,https://www.hrs.com.cn/hren/products_pipeline_oncology.html,Therapeutic,https://www.drugbank.ca/drugs/DB14776,https://clinicaltrials.gov/ct2/show/NCT04268537,https://www.drugbank.ca/drugs/DB14776,https://www.drugbank.ca/drugs/DB14776,,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,,,https://clinicaltrials.gov/ct2/show/NCT04268537,,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,https://clinicaltrials.gov/ct2/show/NCT04268537,,,,,,,,Priya Kaur,,,,,,,
459,No,Antibodies,,Antibodies,Chelsea and Westminster Hospital,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,United Kindom  Government,United Kingdom,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/27/2020,,,,,,5/27/2020
459,Yes,https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment,,https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment,https://www.gov.uk/government/news/vaccine-trials-among-recipients-of-20-million-coronavirus-research-investment,Therapeutic,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-8-20-KR%5B1%5D.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-8-20-KR%5B1%5D.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-8-20-KR%5B1%5D.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-8-20-KR%5B1%5D.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-8-20-KR%5B1%5D.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-8-20-KR%5B1%5D.pdf,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-8-20-KR%5B1%5D.pdf,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-8-20-KR%5B1%5D.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
460,No,Antibodies,,Antibodies,Prellis Biologics Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,,,Pre-Clinical Testing,,4/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/27/2020,,,,,,5/27/2020
460,Yes,https://www.businesswire.com/news/home/20200519005826/en/Prellis-Biologics-Generates-300-Human-Antibodies-Bind,,https://www.businesswire.com/news/home/20200519005826/en/Prellis-Biologics-Generates-300-Human-Antibodies-Bind,https://www.businesswire.com/news/home/20200519005826/en/Prellis-Biologics-Generates-300-Human-Antibodies-Bind,Therapeutic,https://www.prellisbio.com/covid,https://www.prellisbio.com/covid,https://www.prellisbio.com/covid,https://www.prellisbio.com/covid,,https://www.prellisbio.com/covid,https://www.prellisbio.com/covid,,,https://www.prellisbio.com/covid,,https://www.prellisbio.com/covid,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
461,No,Antibodies,,Antibodies,Ligand Pharmaceuticals,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/27/2020,,,,,,5/27/2020
461,Yes,https://www.businesswire.com/news/home/20200406005284/en/Ligand-Corporate-Update-Announces-6th-Date-Quarter,,https://www.businesswire.com/news/home/20200406005284/en/Ligand-Corporate-Update-Announces-6th-Date-Quarter,https://www.businesswire.com/news/home/20200406005284/en/Ligand-Corporate-Update-Announces-6th-Date-Quarter,Therapeutic,https://investor.ligand.com/press-releases/detail/403/ligands-technologies-support-and-enable-potential,https://investor.ligand.com/press-releases/detail/403/ligands-technologies-support-and-enable-potential,https://investor.ligand.com/press-releases/detail/403/ligands-technologies-support-and-enable-potential,https://investor.ligand.com/press-releases/detail/403/ligands-technologies-support-and-enable-potential,,https://investor.ligand.com/press-releases/detail/403/ligands-technologies-support-and-enable-potential,https://investor.ligand.com/press-releases/detail/403/ligands-technologies-support-and-enable-potential,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
462,No,Antibodies,,Antibodies,Costa Rican Social Security Fund; University of Cost Rica; Clodomiro Picado Institute,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Costa Rica,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/27/2020,,,,,,5/27/2020
462,Yes,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#,Therapeutic,https://www.presidencia.go.cr/comunicados/2020/04/costa-rica-to-develop-its-own-covid-19-detection-tests/,https://www.presidencia.go.cr/comunicados/2020/04/costa-rica-to-develop-its-own-covid-19-detection-tests/,https://www.presidencia.go.cr/comunicados/2020/04/costa-rica-to-develop-its-own-covid-19-detection-tests/,https://www.presidencia.go.cr/comunicados/2020/04/costa-rica-to-develop-its-own-covid-19-detection-tests/,,https://www.presidencia.go.cr/comunicados/2020/04/costa-rica-to-develop-its-own-covid-19-detection-tests/,https://www.presidencia.go.cr/comunicados/2020/04/costa-rica-to-develop-its-own-covid-19-detection-tests/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
463,No,MEDI3506,,MEDI3506,AstraZeneca,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,,United Kingdom,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,4/28/2020,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/27/2020,,,,,,5/27/2020
463,Yes,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,Therapeutic,https://adisinsight.springer.com/drugs/800049222,https://adisinsight.springer.com/drugs/800049222,https://adisinsight.springer.com/drugs/800049222,https://adisinsight.springer.com/drugs/800049222,,https://adisinsight.springer.com/drugs/800049222,https://adisinsight.springer.com/drugs/800049222,,,https://adisinsight.springer.com/drugs/800049222,,https://adisinsight.springer.com/drugs/800049222,https://adisinsight.springer.com/drugs/800049222,https://adisinsight.springer.com/drugs/800049222,https://adisinsight.springer.com/drugs/800049222,https://adisinsight.springer.com/drugs/800049222,https://adisinsight.springer.com/drugs/800049222,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,,,,,2,COVID-19,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
464,No,BTK inhibitor,,BTK inhibitor,AstraZeneca,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Approved,,United Kingdom,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/27/2020,,,,,,5/27/2020
464,Yes,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,Therapeutic,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,https://www.drugbank.ca/drugs/DB11703,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,https://www.drugbank.ca/drugs/DB11703,,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-joins-uk-governments-accord-trial-platform.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
465,No,Octagam,,Octagam,Octapharma USA,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Approved,,United States,Ongoing,,,Phase 3,,,,,,,,,6/1/2020,,,,3,COVID-19,54,No,11,,6/1/20,12/30/20,12/30/20,https://clinicaltrials.gov/ct2/show/NCT04400058,Mikaela Raymond,8663371868,ctgov@clinicalresearchmgt.com,,,,,Priya Kaur,5/27/2020,,,,,,5/27/2020
465,Yes,https://www.businesswire.com/news/home/20200416005144/en/New-COVID-19-Clinical-Trial-Supported-Octapharma-USA,,https://www.businesswire.com/news/home/20200416005144/en/New-COVID-19-Clinical-Trial-Supported-Octapharma-USA,https://www.businesswire.com/news/home/20200416005144/en/New-COVID-19-Clinical-Trial-Supported-Octapharma-USA,Therapeutic,https://www.drugbank.ca/drugs/DB00028,https://www.drugbank.ca/drugs/DB00028,https://www.drugbank.ca/drugs/DB00028,https://www.drugbank.ca/drugs/DB00028,,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts,,,,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04400058?term=octagam&cond=covid&draw=2&rank=1#contacts,,,,,,,,Priya Kaur,,,,,,,
466,No,Immunoglobulin from Immunized Sheep,,Immunoglobulin from Immunized Sheep,Public Health England,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,,United Kingdom,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/27/2020,,,,,,5/27/2020
466,Yes,https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710,,https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710,https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710,Therapeutic,https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710,https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710,https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710,https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710,,https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710,https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2020/04/uk-covid19--april-2020.pdf?la=en&hash=63468870BA4F02331409F42AC9061BD6182C7710,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
467,No,Antibodies,,Antibodies,Ablexis; AlivaMab Discovery Services; Berkeley Lights Collaborative,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/27/2020,,,,,,5/27/2020
467,Yes,https://www.prnewswire.com/news-releases/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies-301045039.html,,https://www.prnewswire.com/news-releases/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies-301045039.html,https://www.prnewswire.com/news-releases/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies-301045039.html,Therapeutic,https://www.ablexis.com/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies/,https://www.ablexis.com/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies/,https://www.ablexis.com/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies/,https://www.ablexis.com/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies/,,https://www.ablexis.com/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies/,https://www.ablexis.com/ablexis-alivamab-discovery-services-and-berkeley-lights-collaborate-to-identify-a-diverse-panel-of-anti-sars-cov-2-human-antibodies/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
468,No,monoclonal antibodies,,monoclonal antibodies,Abcore,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/28/2020,,,,,,5/28/2020
468,Yes,https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single,,https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single,https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single,Therapeutic,https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single,https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single,https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single,https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single,,https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single,https://www.businesswire.com/news/home/20200518005113/en/Abcore-Announces-Panel-Patent-Pending-Functional-Single,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
469,No,darunavir,darunavir,Prezista,Johnson & Johnson; Janssen,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,,United States,Ongoing,,,Phase 3,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,3,COVID-19,30,No,1,Shanghai Public Health Clinical Center - Shanghai - China,1/30/20,8/31/20,12/31/20,https://clinicaltrials.gov/ct2/show/NCT04252274,Hongzhou Lu,,luhongzhou@fudan.edu.cn,,,,,Priya Kaur,5/28/2020,,,,,,5/28/2020
469,Yes,https://medcitynews.com/2020/04/jj-hiv-drug-already-in-covid-19-clinical-trials-flunks-in-vitro-study/,https://medcitynews.com/2020/04/jj-hiv-drug-already-in-covid-19-clinical-trials-flunks-in-vitro-study/,https://medcitynews.com/2020/04/jj-hiv-drug-already-in-covid-19-clinical-trials-flunks-in-vitro-study/,https://medcitynews.com/2020/04/jj-hiv-drug-already-in-covid-19-clinical-trials-flunks-in-vitro-study/,Therapeutic,https://www.drugbank.ca/drugs/DB01264,https://www.drugbank.ca/drugs/DB01264,https://www.drugbank.ca/drugs/DB01264,https://www.drugbank.ca/drugs/DB01264,,https://www.drugbank.ca/drugs/DB01264,https://www.drugbank.ca/drugs/DB01264,,,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1,,,,,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04252274?term=darunavir&cond=Covid&draw=2&rank=1#contacts,,Priya Kaur,5/28/2020,,,,,,5/28/2020
470,No,clevudine,clevudine,Levovir,Bukwang Pharm,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Approved,,South Korea,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,4/14/2020,,,,,2,COVID-19,60,No,1,Korea University Guro Hospital - Seoul - Korea,5/6/20,9/30/20,12/31/30,https://clinicaltrials.gov/ct2/show/NCT04347915,Bukwang Bukwang,,bk.E106@bukwang.co.kr,,,,,Priya Kaur,5/28/2020,,,,,,5/28/2020
470,Yes,http://www.koreabiomed.com/news/articleView.html?idxno=8010,http://www.koreabiomed.com/news/articleView.html?idxno=8010,http://www.koreabiomed.com/news/articleView.html?idxno=8010,http://www.koreabiomed.com/news/articleView.html?idxno=8010,Therapeutic,https://en.yna.co.kr/view/AEN20200414006700320,https://www.drugbank.ca/drugs/DB06683,https://en.yna.co.kr/view/AEN20200414006700320,https://en.yna.co.kr/view/AEN20200414006700320,,https://en.yna.co.kr/view/AEN20200414006700320,https://en.yna.co.kr/view/AEN20200414006700320,,,https://en.yna.co.kr/view/AEN20200414006700320,,http://www.koreabiomed.com/news/articleView.html?idxno=8010,http://www.koreabiomed.com/news/articleView.html?idxno=8010,http://www.koreabiomed.com/news/articleView.html?idxno=8010,http://www.koreabiomed.com/news/articleView.html?idxno=8010,http://www.koreabiomed.com/news/articleView.html?idxno=8010,http://www.koreabiomed.com/news/articleView.html?idxno=8010,http://www.koreabiomed.com/news/articleView.html?idxno=8010,,,,,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04347915?term=clevudine&cond=Covid&draw=2&rank=1,,,,,,,,,
471,No,BTL-tml,,BTL-tml,Beech Tree Labs,Therapeutic,COVID-19,Other,Antiviral drugs-not specified,Repurposed-Not Approved,,United States,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/28/2020,,,,,,5/28/2020
471,Yes,https://www.beechtreelabs.com/,,https://www.beechtreelabs.com/,https://www.beechtreelabs.com/,Therapeutic,https://www.clinicaltrialsarena.com/contractors/contract_research/ncra/pressreleases/press7-5/,https://www.clinicaltrialsarena.com/contractors/contract_research/ncra/pressreleases/press7-5/,https://www.news10.com/news/local-news/president-ceo-of-beech-tree-labs-seeks-fda-approval-for-tml-covid-19-treatment/,https://www.news10.com/news/local-news/president-ceo-of-beech-tree-labs-seeks-fda-approval-for-tml-covid-19-treatment/,,https://www.clinicaltrialsarena.com/contractors/contract_research/ncra/pressreleases/press7-5/,https://www.news10.com/news/local-news/president-ceo-of-beech-tree-labs-seeks-fda-approval-for-tml-covid-19-treatment/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
472,No,emetine hydrochloride,emetine hydrochloride,,Acer Therapeutics Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,,United States,Ongoing,,,Phase 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/28/2020,,,,,,5/28/2020
472,Yes,https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/,https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/,,https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/,Therapeutic,https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/,https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/,https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/,https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/,,https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/,https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/,,,https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
473,No,AT-527,,AT-527,Atea Pharmaceuticals Inc.,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Antiviral drugs-not specified,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,5/20/2020,,,,,,,2,COVID-19,180,No,10,Sacramento - California; San Diego - California; Chicago - Illinois; Baltimore - Maryland; Boston- Massachusetts; Saint Louis - Missouri; Cincinnati - Ohio; Cleveland - Ohio; Columbus - Ohio; Charleston - South Carolina,5/2020,12/2020,1/2021,https://clinicaltrials.gov/ct2/show/NCT04396106,,888-481-1607,AteaClinicalTrials@ateapharma.com,,,,,Priya Kaur,5/28/2020,,,,,,5/28/2020
473,Yes,https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html,,https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html,https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html,Therapeutic,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1,https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html,https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1,,https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html,https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html,https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html,https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html,https://www.ateapharma.com/news/atea-pharmaceuticals-announces-ind-clearance-of-at-527-for-covid-19.html,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04396106?term=AT-527&cond=COVID&draw=2&rank=1#contacts,,Priya Kaur,,,,,,,
474,No,Astrotem-V,,Astrotem-V,Naturecell,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,,South Korea,Ongoing,,,Phase 1,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,4/17/2020,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/28/2020,,,,,,5/28/2020
474,Yes,http://www.theasian.asia/archives/107878,,http://www.theasian.asia/archives/107878,http://www.theasian.asia/archives/107878,Therapeutic,http://www.theasian.asia/archives/107878,http://en.kabar.kg/news/stem-cell-treatment-to-become-legal-in-south-korea/,http://en.kabar.kg/news/stem-cell-treatment-to-become-legal-in-south-korea/,http://en.kabar.kg/news/stem-cell-treatment-to-become-legal-in-south-korea/,,http://www.theasian.asia/archives/107878,http://www.theasian.asia/archives/107878,,,http://www.theasian.asia/archives/107878,,http://www.theasian.asia/archives/107878,http://www.theasian.asia/archives/107878,http://www.theasian.asia/archives/107878,http://www.theasian.asia/archives/107878,http://en.kabar.kg/news/stem-cell-treatment-to-become-legal-in-south-korea/,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
475,No,Duke-NUS Therapeutic,,Duke-NUS Therapeutic,Duke-NUS Medical School,Therapeutic,COVID-19,Other,Monoclonal antibodies,New,,Singapore,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/28/2020,,,,,,5/28/2020
475,Yes,,,,https://www.duke-nus.edu.sg/allnews/using-own-immune-cells-to-target-infectious-diseases-including-covid-19,Therapeutic,https://www.duke-nus.edu.sg/allnews/using-own-immune-cells-to-target-infectious-diseases-including-covid-19,https://www.duke-nus.edu.sg/allnews/using-own-immune-cells-to-target-infectious-diseases-including-covid-19,https://www.duke-nus.edu.sg/allnews/using-own-immune-cells-to-target-infectious-diseases-including-covid-19,https://www.duke-nus.edu.sg/allnews/using-own-immune-cells-to-target-infectious-diseases-including-covid-19,,https://www.duke-nus.edu.sg/allnews/using-own-immune-cells-to-target-infectious-diseases-including-covid-19,https://www.duke-nus.edu.sg/allnews/using-own-immune-cells-to-target-infectious-diseases-including-covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
476,No,Dexamethasone,Dexamethasone,,University of Oxford,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United Kingdom,Ongoing,,,Phase 3,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/29/2020,,,,,,5/29/2020
476,Yes,https://www.recoverytrial.net/,https://www.recoverytrial.net/,,https://www.recoverytrial.net/,Therapeutic,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://www.drugbank.ca/drugs/DB01234,https://www.drugbank.ca/drugs/DB01234,https://www.drugbank.ca/drugs/DB01234,,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,,,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,,,,,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,,,https://clinicaltrials.gov/ct2/show/NCT04381936?term=dexamethasone&cond=COVID&draw=2&rank=9,,,,,Priya Kaur,,,,,,,
477,No,ciclesonide,ciclesonide,Alvesco,Covis Pharma B.V.,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United States,Ongoing,,,Phase 3,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,3,COVID-19,400,No,,,5/26/20,9/1/20,12/1/20,https://clinicaltrials.gov/ct2/show/NCT04377711,,,,,,,,Priya Kaur,5/29/2020,,,,,,5/29/2020
477,Yes,https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html,https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html,https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html,https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html,Therapeutic,https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html,https://www.drugbank.ca/drugs/DB01410,https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html,https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html,,https://www.biospace.com/article/releases/covis-pharma-b-v-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19/,https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html,,,https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html,,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,,,,,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,,,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04377711?term=ciclesonide&cond=COVID&draw=2&rank=2,,,,,,,,Priya Kaur,,,,,,,
478,No,Pegylated Interferon alpha-2b,Pegylated Interferon alpha-2b,PegiHep,Zydus Cadila,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,Repurposed-Not Approved,,India,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/29/2020,,,,,,5/29/2020
478,Yes,https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf,Therapeutic,https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf,,https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus-announces-treatment-with-Interferon-alpha%20.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
479,No,Novaferon; Nova,,Novaferon; Nova,First Affiliated Hosptial of Zhejiang University Medical School,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,Repurposed-Approved,,China,Ongoing,,,Phase 4,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,4,COVID-19,30,No,2,The First Hospital of Changsha - Hu'nan - Changsa - China; The Second Xiangya Hospital of Cental South University - Hu'nan - Changsa - China,2/3/20,,,http://www.chictr.org.cn/showprojen.aspx?proj=48809,,,gongguozhong@csu.edu.cn,,,,,Priya Kaur,5/29/2020,,,,,,5/29/2020
479,Yes,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.f7ta2pb1z0as,Therapeutic,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,,,http://www.chictr.org.cn/showprojen.aspx?proj=48809,,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,,,,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,http://www.chictr.org.cn/showprojen.aspx?proj=48809,,,http://www.chictr.org.cn/showprojen.aspx?proj=48809,,,http://www.chictr.org.cn/showprojen.aspx?proj=48809,,,,,Priya Kaur,,,,,,,
480,No,interferon beta-1a,interferon beta-1a,Rebif,Merck kGaA; French Institut National de la Sante et de la Recherche Medicale; INSERM,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,Repurposed-Approved,,France,Ongoing,,,Phase 3,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,3,COVID-19,3100,No,34,Centre Hospitalier Universitaire Amiens-Picardie - Amiens - France; Centre Hospitalier Regional Metz-Thionville - Ars-Laquenexy - France; Centre Hospitalier Régional Universitaire de Besançon - Besançon - France; Centre Hospitalier Universitaire de Bordeaux - Bordeaux - France; APHP - hôpital Henri-Mondor - Créteil - France; Centre Hospitalier Universitaire Dijon-Bourgogne - Dijon - France; Centre Hospitalier Universitaire de Martinique - Fort De France - France - AP-HP Hôpital Bicêtre - Kremlin-Bicêtre - France; Centre Hospitalo-Universitaire de Grenoble - La Tronche - France; Centre Hospitalier Régional Universitaire de Lille - Lille - France; Hospices Civils de Lyon - Lyon - France; Centre Hospitalier Universitaire de Montpellier - Montpellier - France; Groupe Hospitalier de la Région de Mulhouse Sud Alsace - Mulhouse - France; Centre Hospitalier Régional et Universitaire de Nancy - Nancy - France; Centre Hospitalier Universitaire de Nantes - Nantes - France; Centre Hospitalo-Universitaire de Nice - Nice - France; APHP - Hôpital Saint Antoine - Paris - France; APHP - Hôpital Universitaire Pitié Salpêtrière - Paris - France; APHP - Hôpital Cochin - Paris - France; Hôpital Paris Saint-Joseph et Marie Lannelongue - Paris - France; APHP- Hôpital Européen Georges-Pompidou - Paris - France; APHP - Hôpital Bichat Claude Bernard - Paris - France; Centre Hospitalier Universitaire de Rennes - Rennes - France; Hopital DELAFONTAINE- Saint Denis - France; Hôpital d'Instruction des Armées BEGIN - Saint-Mandé - France; Centre Hospitalier Universitaire de Saint Etienne - Saint-Étienne - France; Centre Hospitalier Régional Universitaire de Strasbourg - Strasbourg- France; Centre Hospitalier Universitaire de Toulouse - Toulouse - France; Centre Hospitalier de Tourcoing - Tourcoing - Centre Hospitalier Universitaire de Tours - Tours - France; Centre Hospitalier Annecy Genevois -Épagny - France,3/22/20,3/2023,3/2023,https://clinicaltrials.gov/ct2/show/NCT04315948,Florence Ader,,florence.ader@chu-lyon.fr; helene.esperou@inserm.fr,,,,,Priya Kaur,5/29/2020,,,,,,5/29/2020
480,Yes,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,Therapeutic,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,https://www.emdgroup.com/en/news/rebif-company-statement-19-03-2020.html,,,,,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04315948?term=Rebif&cond=covid&draw=2&rank=6#contacts,,,,,Priya Kaur,,,,,,,
481,No,telmisartan,telmisartan,Micardis,Boehringer Ingelheim; University of Hawaii,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,,,,,,,,,,,,2,COVID-19,40,No,1,University of Hawaii - Manoa - Honolulu - Hawaii - United States,7/1/20,6/30/21,6/30/21,https://clinicaltrials.gov/ct2/show/NCT04360551,Cecilia M Shikuma,,shikuma@hawaii.edu; ogataara@hawaii.edu,,,,,Priya Kaur,5/29/2020,,,,,,5/29/2020
481,Yes,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36,Therapeutic,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://www.drugbank.ca/drugs/DB00966,https://www.drugbank.ca/drugs/DB00966,https://www.drugbank.ca/drugs/DB00966,,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,,,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04360551?term=Micardis&cond=covid&draw=2&rank=2,,,,,,,,Priya Kaur,,,,,,,
482,No,Heparin,,Heparin,Union Hospital; Tongji Medical College; Huazhong University of Science and Technology,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,China,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,,,,449,No,,,,,,,,,,,,,,Priya Kaur,5/29/2020,,,,,,5/29/2020
482,Yes,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.a49g7p85hz36,Therapeutic,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103696/,https://www.drugbank.ca/drugs/DB01109,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103696/,https://www.drugbank.ca/drugs/DB01109,,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,,,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,,,,https://onlinelibrary.wiley.com/doi/10.1111/jth.14817,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
483,No,ST-001; nanoFenretinide,,ST-001; nanoFenretinide,"SciTech Development, LLC",Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Not Approved,,United States,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/29/2020,,,,,,5/29/2020
483,Yes,https://www.scitechdevelopment.com/covid-19,,https://www.scitechdevelopment.com/covid-19,https://www.scitechdevelopment.com/covid-19,Therapeutic,https://www.scitechdevelopment.com/covid-19,https://www.scitechdevelopment.com/covid-19,https://www.scitechdevelopment.com/covid-19,https://www.scitechdevelopment.com/,,https://www.scitechdevelopment.com/,https://www.scitechdevelopment.com/,,,https://www.scitechdevelopment.com/,,https://www.scitechdevelopment.com/,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
484,No,Ruconest,,Ruconest,Pharming,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,The Netherlands,Ongoing,,,,,,,,,,,,,,,,,,150,No,,,,,,,,,,,,,,Priya Kaur,5/29/2020,,,,,,5/29/2020
484,Yes,https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf,,https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf,https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf,Therapeutic,https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf,https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf,https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf,https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf,,https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf,https://www.pharming.com/sites/default/files/imce/Press%20releases/Ruconest%20Covid%20compassionate%20use%2021%20April%202020.pdf,,,,,,,,,,,,,,,,,,https://www.fdanews.com/articles/196751-pharming-reports-positive-results-from-compassionate-use-of-ruconest-in-covid-19-patients,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
485,No,DIBI,,DIBI,Chelation Partners,Therapeutic,COVID-19,Other,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,Canada,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/30/2020,,,,,,5/30/2020
485,Yes,https://www.chelationpartners.com/novel-covid-19-therapeutic,,https://www.chelationpartners.com/novel-covid-19-therapeutic,https://www.chelationpartners.com/novel-covid-19-therapeutic,Therapeutic,https://www.chelationpartners.com/novel-covid-19-therapeutic,https://www.chelationpartners.com/novel-covid-19-therapeutic,https://www.chelationpartners.com/novel-covid-19-therapeutic,https://www.chelationpartners.com/novel-covid-19-therapeutic,,https://www.chelationpartners.com/novel-covid-19-therapeutic,https://www.chelationpartners.com/novel-covid-19-therapeutic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
486,No,GP-1681,,GP-1681,Quotient Sciences; CytoAgents Inc.,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,NIH’s National Institute of Allergy and Infectious Diseases,United Kingdom,Ongoing,,,Phase 1,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Accepted,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/30/2020,,,,,,5/30/2020
486,Yes,https://www.businesswire.com/news/home/20200428005176/en/Quotient-Sciences-CytoAgents-Accelerate-Potential-Treatment-COVID-19,,https://www.businesswire.com/news/home/20200428005176/en/Quotient-Sciences-CytoAgents-Accelerate-Potential-Treatment-COVID-19,https://www.businesswire.com/news/home/20200513005097/en/CytoAgents-Receives-NIH-Funding-Accelerate-Treatment-Cytokine,Therapeutic,https://www.businesswire.com/news/home/20200428005176/en/Quotient-Sciences-CytoAgents-Accelerate-Potential-Treatment-COVID-19,https://www.businesswire.com/news/home/20200428005176/en/Quotient-Sciences-CytoAgents-Accelerate-Potential-Treatment-COVID-19,https://www.businesswire.com/news/home/20200428005176/en/Quotient-Sciences-CytoAgents-Accelerate-Potential-Treatment-COVID-19,https://www.cytoagents.com,https://www.pharmaceutical-technology.com/news/cytoagents-nih-funding/,https://www.businesswire.com/news/home/20200428005176/en/Quotient-Sciences-CytoAgents-Accelerate-Potential-Treatment-COVID-19,https://www.businesswire.com/news/home/20200428005176/en/Quotient-Sciences-CytoAgents-Accelerate-Potential-Treatment-COVID-19,,,https://www.businesswire.com/news/home/20200428005176/en/Quotient-Sciences-CytoAgents-Accelerate-Potential-Treatment-COVID-19,,https://www.cytoagents.com,https://www.cytoagents.com,https://www.cytoagents.com,https://www.cytoagents.com,https://www.cytoagents.com,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
487,No,nebulized alkaline,,nebulized alkaline,pHbarrier,Therapeutic,COVID-19,Other,Antiviral drugs-not specified,Repurposed-Not Approved,,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/30/2020,,,,,,5/30/2020
487,Yes,https://www.phbarrier.com/,,https://www.phbarrier.com/,https://www.phbarrier.com/,Therapeutic,https://www.phbarrier.com/media/4143/ph-barrier-process-overview-brief-v19.pdf,https://www.allrecipes.com/recipe/19247/soft-oatmeal-cookies/,https://www.phbarrier.com/media/4143/ph-barrier-process-overview-brief-v19.pdf,https://www.allrecipes.com/recipe/19247/soft-oatmeal-cookies/,,https://www.allrecipes.com/recipe/19247/soft-oatmeal-cookies/,https://www.allrecipes.com/recipe/19247/soft-oatmeal-cookies/,,,https://www.allrecipes.com/recipe/19247/soft-oatmeal-cookies/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
488,No,Coronzot,,Coronzot,Silkim Pharma,Therapeutic,COVID-19,Other,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,Israel,Ongoing,,,Pre-Clinical Testing,,,4/22/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/30/2020,,,,,,5/30/2020
488,Yes,https://www.silkim.com/covid-19,,https://www.silkim.com/covid-19,https://www.silkim.com/covid-19,Therapeutic,https://www.silkim.com/covid-19,https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071,https://www.silkim.com/covid-19,https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071,,https://www.silkim.com/covid-19,https://www.silkim.com/covid-19,,,https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=2075421071,,,https://www.silkim.com/covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
489,No,Lysteda; Cyklokapron,,Lysteda; Cyklokapron,University of Alabama at Birmingham,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,,2,COVID-19,60,No,1,University of Alabama at Birmingham - Birmingham - Alabama,9/30/20,12/15/20,12/31/20,https://clinicaltrials.gov/ct2/show/NCT04338126,Timothy J Ness,,tness@uabmc.edu,,,,,Priya Kaur,5/31/2020,,,,,,5/31/2020
489,Yes,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.ifp099y9gyv,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.ifp099y9gyv,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#heading=h.ifp099y9gyv,Therapeutic,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://www.drugbank.ca/drugs/DB00302,https://www.drugbank.ca/drugs/DB00302,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04338126?term=Lysteda&cond=covid&draw=2&rank=1,,,,,,,,Priya Kaur,,,,,,,
490,No,senicapoc,,senicapoc,Aarhus University,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,Denmark,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/31/2020,,,,,,5/31/2020
490,Yes,http://www.pharmafile.com/news/548588/researchers-denmark-testing-if-senicapoc-drug-can-reduce-lung-damage-covid-19-patients,,http://www.pharmafile.com/news/548588/researchers-denmark-testing-if-senicapoc-drug-can-reduce-lung-damage-covid-19-patients,http://www.pharmafile.com/news/548588/researchers-denmark-testing-if-senicapoc-drug-can-reduce-lung-damage-covid-19-patients,Therapeutic,http://www.pharmafile.com/news/548588/researchers-denmark-testing-if-senicapoc-drug-can-reduce-lung-damage-covid-19-patients,https://www.drugbank.ca/drugs/DB06280,http://www.pharmafile.com/news/548588/researchers-denmark-testing-if-senicapoc-drug-can-reduce-lung-damage-covid-19-patients,http://www.pharmafile.com/news/548588/researchers-denmark-testing-if-senicapoc-drug-can-reduce-lung-damage-covid-19-patients,,http://www.pharmafile.com/news/548588/researchers-denmark-testing-if-senicapoc-drug-can-reduce-lung-damage-covid-19-patients,http://www.pharmafile.com/news/548588/researchers-denmark-testing-if-senicapoc-drug-can-reduce-lung-damage-covid-19-patients,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,,,,,,,
491,No,fluvoxamine,fluvoxamine,Luvox,Washington University School of Medicine in St. Louis,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,,2,COVID-19,152,No,2,BJC - Belleville - Illinois; Washington University School of Medicine - Saint Louis - Missouri,4/10/20,8/20/20,10/1/20,https://clinicaltrials.gov/ct2/show/NCT04342663,Angela Stevens,,stevens.a@wustl.edu; marissa@wustl.edu,,,,,Priya Kaur,5/31/2020,,,,,,5/31/2020
491,Yes,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit#,https://medicine.wustl.edu/news/study-to-evaluate-antidepressant-as-potential-covid-19-treatment/,https://medicine.wustl.edu/news/study-to-evaluate-antidepressant-as-potential-covid-19-treatment/,Therapeutic,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://www.drugbank.ca/drugs/DB00176,https://medicine.wustl.edu/news/study-to-evaluate-antidepressant-as-potential-covid-19-treatment/,https://www.drugbank.ca/drugs/DB00176,,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04342663?term=fluvoxamine&cond=covid&draw=2&rank=1,,,,,Priya Kaur,,,,,,,
492,No,imatinib,imatinib,Gleevac,Exvastat Ltd,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Ireland,Ongoing,,,Phase 3,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,3,COVID-19,204,No,,,5/20/20,6/1/22,6/1/23,https://clinicaltrials.gov/ct2/show/NCT04394416,Ashkan Emadi,,aemadi@umm.edu,,,,,Priya Kaur,5/31/2020,,,,,,5/31/2020
492,Yes,https://www.imi.europa.eu/news-events/press-releases/imi-announces-covid-projects-boosts-funding-pot-eur-72-million,https://www.imi.europa.eu/news-events/press-releases/imi-announces-covid-projects-boosts-funding-pot-eur-72-million,https://www.imi.europa.eu/news-events/press-releases/imi-announces-covid-projects-boosts-funding-pot-eur-72-million,https://www.imi.europa.eu/news-events/press-releases/imi-announces-covid-projects-boosts-funding-pot-eur-72-million,Therapeutic,https://www.imi.europa.eu/news-events/press-releases/imi-announces-covid-projects-boosts-funding-pot-eur-72-million,https://www.drugbank.ca/drugs/DB00619,https://www.imi.europa.eu/news-events/press-releases/imi-announces-covid-projects-boosts-funding-pot-eur-72-million,https://www.drugbank.ca/drugs/DB00619,,https://www.imi.europa.eu/news-events/press-releases/imi-announces-covid-projects-boosts-funding-pot-eur-72-million,https://www.imi.europa.eu/news-events/press-releases/imi-announces-covid-projects-boosts-funding-pot-eur-72-million,,,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,,,,,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04394416?term=imatinib&cond=covid&draw=2&rank=1,,,,,Priya Kaur,,,,,,,
493,No,ABX464,,ABX464,Abivax,Therapeutic,COVID-19,Small molecule,Combination,Repurposed-Approved,,France,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,,,,,,2,COVID-19,1034,No,1,Centre Hospitalier Universitaire de Nice - Nice - France,5/1/20,12/30/20,4/30/21,https://clinicaltrials.gov/ct2/show/NCT04393038,Paul Gineste,,paul.gineste@abivax.com,,,,,Priya Kaur,5/31/2020,,,,,,5/31/2020
493,Yes,https://abivax.gcs-web.com/news-releases/news-release-details/abx464-inhibits-replication-sars-cov-2-covid-19-reconstituted,,https://abivax.gcs-web.com/news-releases/news-release-details/abx464-inhibits-replication-sars-cov-2-covid-19-reconstituted,https://abivax.gcs-web.com/news-releases/news-release-details/abx464-inhibits-replication-sars-cov-2-covid-19-reconstituted,Therapeutic,https://abivax.gcs-web.com/news-releases/news-release-details/abx464-inhibits-replication-sars-cov-2-covid-19-reconstituted,https://www.drugbank.ca/drugs/DB14828,https://abivax.gcs-web.com/news-releases/news-release-details/abx464-inhibits-replication-sars-cov-2-covid-19-reconstituted,https://www.drugbank.ca/drugs/DB14828,,https://abivax.gcs-web.com/news-releases/news-release-details/abx464-inhibits-replication-sars-cov-2-covid-19-reconstituted,https://abivax.gcs-web.com/news-releases/news-release-details/abx464-inhibits-replication-sars-cov-2-covid-19-reconstituted,,,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04393038?term=ABX464&cond=covid&draw=2&rank=1,,,,,,,,,Priya Kaur,5/31/2020,,,,,,5/31/2020
494,No,sPIF,,sPIF,BioIncept,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United States,Ongoing,,,Phase 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Priya Kaur,5/31/2020,,,,,,5/31/2020
494,Yes,https://bioincept.com/,,https://bioincept.com/,https://bioincept.com/,https://bioincept.com,https://bioincept.com,https://bioincept.com,https://bioincept.com,https://bioincept.com,,https://bioincept.com,https://bioincept.com,,,https://bioincept.com,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
495,No,DNA Vaccine,,DNA Vaccine,University of Waterloo,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,Canada,Ongoing,,,Discovery,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,6/4/2020,,,,,,6/4/2020
495,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine,https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine,https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine,https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine,,https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine,https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine,,,https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine,,https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
496,No,Inactivated Vaccine,,Inactivated Vaccine,Chinese Academy of Medical Sciences; Institute of Medical Biology; ,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,China,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,5/15/2020,6/20/2020,,,,,2,COVID-19,35433,Yes,3,West China Second University Hospital -Chengdu- China; São Paulo - Brazil; Selangor - Malaysia,7/10/2020,11/1/2020,11/1/2021,https://clinicaltrials.gov/ct2/show/NCT04412538 https://clinicaltrials.gov/ct2/show/NCT04470609  https://www.clinicaltrials.gov/ct2/show/NCT04659239?term=Inactivated+SARS-CoV-2+Vaccine+AND+Chinese+Academy+of+Medical+Sciences&draw=2&rank=3,Qihan Li,For China: 86-0871-68335905; For Brazil:  +55(11) 49304243; For Malaysia: +6013-4528200 ,liqihan@imbcams.com,,,,,Purab Patel,6/4/2020,,,,,,6/4/2020
496,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,,,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-198cf6037313a140ce89905bdd05b50332.pdf?sfvrsn=c457438f_2&download=true,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
497,No,Inactivated + CpG 1018 Vaccine,,Inactivated + CpG 1018 Vaccine,Sinovac; Dynavax,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,China,Ongoing,,,Phase 2,,Assume Completed,Assume Completed,Assume Completed,Assume Completed,Assume Completed,4/16/2020,4/16/2020,,,,,,,,,,,,,,,,,,,,,,Purab Patel,6/4/2020,,,,,,6/4/2020
497,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.genengnews.com/covid-19-candidates/sinovac-biotech-and-dynavax/,https://www.genengnews.com/covid-19-candidates/sinovac-biotech-and-dynavax/,https://www.genengnews.com/covid-19-candidates/sinovac-biotech-and-dynavax/,https://www.genengnews.com/covid-19-candidates/sinovac-biotech-and-dynavax/,,https://www.genengnews.com/covid-19-candidates/sinovac-biotech-and-dynavax/,https://www.genengnews.com/covid-19-candidates/sinovac-biotech-and-dynavax/,,,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04352608#contacts,,,,,,,,,
498,No,Inactivated Vaccine,,Inactivated Vaccine,Osaka University; BIKEN; NIBIOHN,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,Japan,Ongoing,,,Pre-Clinical Testing,,Assume Completed,3/19/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,6/4/2020,,,,,,6/4/2020
498,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,,,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://pj.jiho.jp/article/241725,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
499,No,VLP-recombinant protein + Adjuvant Vaccine,,VLP-recombinant protein + Adjuvant Vaccine,Osaka University; BIKEN; National Institutes of Biomedical Innovation,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,Japan,Ongoing,,,Pre-Clinical Testing,,Assume Completed,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,6/4/2020,,,,,,6/4/2020
499,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,,,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
500,No,Inactivated Vaccine,,Inactivated Vaccine,Research Institute for Biological Safety Problems,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,Kazakhstan,Ongoing,,,Pre-Clinical Testing,,Assume Completed,5/15/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,6/4/2020,,,,,,6/4/2020
500,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://astanatimes.com/2020/05/who-approves-kazakh-covid-19-vaccine-for-preclinical-trials/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
501,No,Codon deoptimized live attenuated virus,,Codon deoptimized live attenuated virus,Indian Immunologicals Ltd; Griffith University,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,Australia,Ongoing,,,Pre-Clinical Testing,,Assume Completed,4/23/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,6/4/2020,,,,,,6/4/2020
501,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://news.griffith.edu.au/2020/04/23/griffith-university-researchers-on-the-road-to-covid-19-vaccine/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
502,No,Non-replicating viral vector MVA expressing structural proteins,,Non-replicating viral vector MVA expressing structural proteins,Centro Nacional Biotecnologia; CNB-CSIC,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,Spain,Ongoing,,,Pre-Clinical Testing,,Assume Completed,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,6/4/2020,,,,,,6/4/2020
502,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
503,No,Non-replicating viral vector vaccine,,Non-replicating viral vector vaccine,University of Manitoba,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,,Canada,Ongoing,,,Pre-Clinical Testing,,Assume Completed,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Purab Patel,6/4/2020,,,,,,6/4/2020
503,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
504,No,BBV152,,BBV152,Bharat Biotech,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,Thomas Jefferson University,India,Ongoing,,,Phase 3,,Assume Completed,Started,Assume Completed,Assume Completed,Assume Completed,7/13/2020,7/13/2020,11/25/2020,,,,3,COVID-19,27680,Yes,12,Rohtak - Haryana - India; Visakhapatnam - Andhra Pradesh - India; Patna - Bihar - India; Belgaum - Karnataka - India; Nagpur - Maharastra - India; Delhi - New Delhi - India; Bhubaneswar - Orissa - India; Chennai - Tamilnadu - India; Hyderabad - Telangana - India; Gorakhpur - Uttar Pradesh - India; Kanpur - Uttar Pradesh - India; Goa - India,7/13/2020,6/30/21,3/1/22,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152  https://clinicaltrials.gov/ct2/show/NCT04471519?term=BBV152&draw=2&rank=1  https://clinicaltrials.gov/ct2/show/NCT04641481?term=BBV152&draw=2&rank=2,V Krishna Mohan,For India: 04023480567,kmohan@bharatbiotech.com  ,,,,,Purab Patel,6/4/2020,,,,,,6/4/2020
504,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,,,,,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,,,,,,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152,,,,,,,,,,,,
505,No,Protein subunit S Protein + adjuvant,,Protein subunit S Protein + adjuvant,"National Institute of Infectious Disease, Japan",Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,National Institute of Infectious Disease-Japan,Japan,Ongoing,,,Pre-Clinical Testing,,3/4/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sara,5/27/2020,Enoch,5/27/2020,,,,5/27/2020
505,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://vpmthane.org/web2/assets/files/Dr.-SandeepKahandal-ArticleonCovid-19.pdf,https://vpmthane.org/web2/assets/files/Dr.-SandeepKahandal-ArticleonCovid-19.pdf,https://vpmthane.org/web2/assets/files/Dr.-SandeepKahandal-ArticleonCovid-19.pdf,https://vpmthane.org/web2/assets/files/Dr.-SandeepKahandal-ArticleonCovid-19.pdf,https://vpmthane.org/web2/assets/files/Dr.-SandeepKahandal-ArticleonCovid-19.pdf,https://www.genengnews.com/a-lists/vanquishing-the-virus-160-covid-19-drug-and-vaccine-candidates-in-development/4/,https://www.genengnews.com/a-lists/vanquishing-the-virus-160-covid-19-drug-and-vaccine-candidates-in-development/4/,,,https://www.genengnews.com/a-lists/vanquishing-the-virus-160-covid-19-drug-and-vaccine-candidates-in-development/4/,,https://covidvax.org/covid19-vaccine/NIIDJapan/S-protein-National-Institute-of-Infectious-Disease-Japan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
506,No,PittCoVacc,,PittCoVacc,University of Pittsburgh,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,University of Pittsburgh School of Medicine,United States,Ongoing,,,Pre-Clinical Testing,,4/1/2020,4/2/2020,Assume Completed,Assume Completed,Started,Target: 06/01/20,,,,,,,,,,,,,,,,,,,,,,,Sara,5/27/2020,Enoch,5/27/2020,,,,5/27/2020
506,Yes,https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php,,https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php,https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php,Vaccine - Prophylactic,https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php,https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php,https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php,https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php,https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php,https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php,https://www.eurekalert.org/pub_releases/2020-04/uop-cvc033120.php,,,https://www.id-hub.com/2020/04/02/covid-19-vaccine-candidate-shows-promise-preclinical-trial/,,https://www.id-hub.com/2020/04/02/covid-19-vaccine-candidate-shows-promise-preclinical-trial/,https://www.id-hub.com/2020/04/02/covid-19-vaccine-candidate-shows-promise-preclinical-trial/,https://www.id-hub.com/2020/04/02/covid-19-vaccine-candidate-shows-promise-preclinical-trial/,https://www.id-hub.com/2020/04/02/covid-19-vaccine-candidate-shows-promise-preclinical-trial/,https://www.id-hub.com/2020/04/02/covid-19-vaccine-candidate-shows-promise-preclinical-trial/,https://covidvax.org/covid19-vaccine/PittsburghUni/PittCoVacc-400-tiny-needles-array-skin-patch-University-of-Pittsburgh,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
507,No,Peptide Vaccine,,Peptide Vaccine,FBRI SRC VB VECTOR,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,Rospotrebnadzor; FBRI SRC VB VECTOR,Russia,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Enoch,5/28/2020,Sara,5/28/2020,,,,5/28/2020
507,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,http://www.istc.int/en/institute/10150,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
508,No,Subunit Vaccine,,Subunit Vaccine,FBRI SRC VB VECTOR,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Rospotrebnadzor; FBRI SRC VB VECTOR,Russia,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Enoch,5/28/2020,Sara,5/28/2020,,,,5/28/2020
508,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
509,No,Protein Subunit Vaccine,,Protein Subunit Vaccine,"LakePharma, Inc.",Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,LakePharma Inc.,United States,Ongoing,,,Pre-Clinical Testing,,3/18/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sara,5/28/2020,Enoch,5/28/2020,,,,5/28/2020
509,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://lakepharma.com/integrated-solutions/covid-19-activities/overview,https://lakepharma.com/integrated-solutions/covid-19-activities/overview,https://lakepharma.com/integrated-solutions/covid-19-activities/overview,,,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,https://covidvax.org/covid19-vaccine/LakePharma/Nanoparticle-vaccine-LakePharma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
510,No,Protein Subunit Vaccine,,Protein Subunit Vaccine,University of Alberta,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Canadian Institutes of Health Research; Alberta Innovates,Canada,Ongoing,,,Pre-Clinical Testing,,3/26/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sara,5/29/2020,Enoch,5/29/2020,,,,5/29/2020
510,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.ualberta.ca/medicine/news/2020/april/university-of-alberta-researchers-in-race-against-time-to-create-covid-19-vaccine,https://www.ualberta.ca/medicine/news/2020/april/university-of-alberta-researchers-in-race-against-time-to-create-covid-19-vaccine,https://www.ualberta.ca/medicine/news/2020/april/university-of-alberta-researchers-in-race-against-time-to-create-covid-19-vaccine,https://www.ualberta.ca/medicine/news/2020/april/university-of-alberta-researchers-in-race-against-time-to-create-covid-19-vaccine,,,https://www.ualberta.ca/medicine/news/2020/april/university-of-alberta-researchers-in-race-against-time-to-create-covid-19-vaccine,,https://www.ualberta.ca/medicine/news/2020/april/university-of-alberta-researchers-in-race-against-time-to-create-covid-19-vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
511,No,Protein Subunit Vaccine,,Protein Subunit Vaccine,AnyGo Technology,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,AnyGo Technology,China,Ongoing,,,Pre-Clinical Testing,,3/17/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sara,5/29/2020,Enoch,5/29/2020,,,,5/29/2020
511,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,http://anygo.sell.everychina.com/aboutus.html,http://anygo.sell.everychina.com/aboutus.html,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,https://covidvax.org/covid19-vaccine/AnyGoTech/S1---Fc-fusion-protein-AnyGo-Technology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
512,No,Protein Subunit Vaccine,,Protein Subunit Vaccine,Yisheng Biopharma,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,Yisheng Biopharma,China,Ongoing,,,Pre-Clinical Testing,,3/8/2020,Started,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,Enoch,5/30/2020,Sara,5/30/2020,,,,5/30/2020
512,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,https://covidvax.org/covid19-vaccine/YishengBiopharma/Recombinant-protein-Yisheng-Biopharma,https://covidvax.org/covid19-vaccine/YishengBiopharma/Recombinant-protein-Yisheng-Biopharma,https://covidvax.org/covid19-vaccine/YishengBiopharma/Recombinant-protein-Yisheng-Biopharma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
513,No,Protein Subunit Vaccine,,Protein Subunit Vaccine,Vabiotech,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,Vabiotech; Bristol University,United Kingdom; Vietnam,Ongoing,,,Pre-Clinical Testing,,Assume Completed,4/26/2020,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,Enoch,5/30/2020,Sara,5/30/2020,,,,5/30/2020
513,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,https://e.vnexpress.net/news/news/vietnam-tests-covid-19-vaccine-on-mice-4093317.html,https://e.vnexpress.net/news/news/vietnam-tests-covid-19-vaccine-on-mice-4093317.html,https://e.vnexpress.net/news/news/vietnam-tests-covid-19-vaccine-on-mice-4093317.html,https://e.vnexpress.net/news/news/vietnam-tests-covid-19-vaccine-on-mice-4093317.html,https://e.vnexpress.net/news/news/vietnam-tests-covid-19-vaccine-on-mice-4093317.html,https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf?ua=1,,,https://e.vnexpress.net/news/news/vietnam-tests-covid-19-vaccine-on-mice-4093317.html,,https://vietnamnews.vn/society/716407/mice-administered-with-vietnamese-covid-19-vaccine-remain-healthy.html,https://vietnamnews.vn/society/716407/mice-administered-with-vietnamese-covid-19-vaccine-remain-healthy.html,https://www.trialsitenews.com/vietnams-state-owned-vabiotech-pursues-a-vaccine-now-in-mice-testing-so-far-so-good/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
514,No,Protein Subunit Vaccine,,Protein Subunit Vaccine,"University of California, San Diego",Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,National Science Foundation,United States,Ongoing,,,Discovery,,4/20/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Enoch,5/30/2020,Sara,5/30/2020,,,,5/30/2020
514,Yes,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,Vaccine - Prophylactic,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,https://covidvax.org/covid19-vaccine/SanDiegoCaliUni/Plant-virus-nanotechnology-University-of-California-San-Diego,,,https://covidvax.org/covid19-vaccine/SanDiegoCaliUni/Plant-virus-nanotechnology-University-of-California-San-Diego,,https://covidvax.org/covid19-vaccine/SanDiegoCaliUni/Plant-virus-nanotechnology-University-of-California-San-Diego,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
515,No,OMV-based Vaccine,,OMV-based Vaccine,Quadram Institute Biosciences,Vaccine - Prophylactic,COVID-19,Small molecule,Vaccine,New,Quadram Institute,United Kingdom,Ongoing,,,Discovery,,5/6/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,6/5/2020,,,,,,6/5/2020
515,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/,https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/,https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/,https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/,https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/,https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/,https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/,,,https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
516,No,OMV-based Vaccine,,OMV-based Vaccine,BiOMVis SR; University of Trento,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,BiOMViS Srl; University of Trento,Italy,Ongoing,,,Pre-Clinical Testing,,4/28/2020,Started,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,6/5/2020,,,,,,6/5/2020
516,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,,,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,https://www.toscanalifesciences.org/it/2020/04/covid-19-piattaforma-di-biomvis-si-dimostra-efficace-nella-ricerca-di-un-possibile-vaccino-2/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
517,No,Subunit Vaccine,,Subunit Vaccine,Applied Biotechnology Institute Inc.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Applied Biotechnology Institute Inc.,United States,Ongoing,,,Pre-Clinical Testing,,Assume Completed,Started,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,6/5/2020,,,,,,6/5/2020
517,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
518,No,Adjucanted recombinant protein,,Adjucanted recombinant protein,Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology; Chinese Academy of Sciences,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology Chinese Academy of Sciences,China,Ongoing,,,Phase 2,,Assume Completed,Started,Assume Completed,Assume Completed,Assume Completed,6/22/2020,7/12/2020,,,,,2,COVID-19,900,Yes,3,Hunan Provincial Center for Disease Control and Prevention - Changsha - China; The Second Affiliated Hospital of Chongqing Medical University  - Chongqing - China; Xiangtan - Changsha - China,7/12/2020,9/15/2021,12/15/2021,https://clinicaltrials.gov/ct2/show/NCT04466085  https://clinicaltrials.gov/ct2/show/NCT04445194  https://clinicaltrials.gov/ct2/show/NCT04550351,fangjun Li,13574109585,646022285@qq.com; dingfan@zhifeishengwu.com        ,,,,,Lisa,6/5/2020,,,,,,6/5/2020
518,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,https://clinicaltrials.gov/ct2/show/NCT04466085,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,https://clinicaltrials.gov/ct2/show/NCT04445194,https://clinicaltrials.gov/ct2/show/NCT04466085,,,,,https://clinicaltrials.gov/ct2/show/NCT04466085,https://clinicaltrials.gov/ct2/show/NCT04466085,https://clinicaltrials.gov/ct2/show/NCT04466085,https://clinicaltrials.gov/ct2/show/NCT04466085,https://clinicaltrials.gov/ct2/show/NCT04466085,https://clinicaltrials.gov/ct2/show/NCT04466085,https://clinicaltrials.gov/ct2/show/NCT04466085,https://clinicaltrials.gov/ct2/show/NCT04466085,https://clinicaltrials.gov/ct2/show/NCT04466085,,,,,,,,,,,,,,,,
519,No,RBD-based,,RBD-based,Neovii; Tel Aviv University,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Tel Aviv University; Neovii,Israel; Switzerland,Ongoing,,,Pre-Clinical Testing,,5/13/2020,Started,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,6/5/2020,,,,,,6/5/2020
519,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,,,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,https://www.prnewswire.com/news-releases/neovii-to-develop-a-novel-vaccine-for-covid-19-in-an-exclusive-partnership-with-tel-aviv-university-301057606.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
520,No,Replicating Viral Vector; YF17D Vector,,Replicating Viral Vector; YF17D Vector,KU Leuven,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,KU Leuven; UZ Leuven,Belgium,Ongoing,,,Pre-Clinical Testing,,3/26/2020,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,6/5/2020,,,,,,6/5/2020
520,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.leuvenmindgate.be/news/support-our-leuven-researchers-in-finding-a-cure-against-corona,,,https://www.leuvenmindgate.be/news/support-our-leuven-researchers-in-finding-a-cure-against-corona,,https://www.leuvenmindgate.be/news/support-our-leuven-researchers-in-finding-a-cure-against-corona,https://www.leuvenmindgate.be/news/support-our-leuven-researchers-in-finding-a-cure-against-corona,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
521,No,Measles Vector Vaccine,,Measles Vector Vaccine,Zydus Cadila,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Zydus Cadila,India,Ongoing,,,Pre-Clinical Testing,,2/17/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,6/5/2020,,,,,,6/5/2020
521,Yes,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,Vaccine - Prophylactic,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.pharmatutor.org/pharma-news/2020/zydus-cadila-accelerates-covid-19-vaccine-research,,https://www.pharmatutor.org/pharma-news/2020/zydus-cadila-accelerates-covid-19-vaccine-research,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
522,No,Measles Vector Vaccine,,Measles Vector Vaccine,FBRI SRC VB VECTOR,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,FBRI SRC VB VECTOR; Rospotrebnadzor,Russia,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,6/5/2020,,,,,,6/5/2020
522,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
523,No,Recombinant Vaccine,,Recombinant Vaccine,FBRI SRC VB VECTOR,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,FBRI SRC VB VECTOR; Rospotrebnadzor,Russia,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,6/5/2020,,,,,,6/5/2020
523,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
524,No,VSV Vector Vaccine,,VSV Vector Vaccine,FBRI SRC VB VECTOR,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,FBRI SRC VB VECTOR; Rospotrebnadzor,Russia,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lisa,6/5/2020,,,,,,6/5/2020
524,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
525,No,mRNA Vaccine,,mRNA Vaccine,FBRI SRC VB VECTOR,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,FBRI SRC VB VECTOR; Rospotrebnadzor,Russia,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
525,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
526,No,VSV-S Vaccine,,VSV-S Vaccine,University of Western Ontario,Vaccine - Prophylactic,COVID-19,Combination,Vaccine,New,Canadian Institutes of Health Research,Canada,Ongoing,,,Pre-Clinical Testing,,3/19/2020,,,,,06/01/2020,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
526,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://covidvax.org/covid19-vaccine/WesternOntarioUni/VSV---S-University-of-Western-Ontario,,,,,https://covidvax.org/covid19-vaccine/WesternOntarioUni/VSV---S-University-of-Western-Ontario,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
527,No,Newcastle Disease Virus Vector Vaccine,,Newcastle Disease Virus Vector Vaccine,Intravacc; Wageningen Bioveterinary Research; Utrecht University,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,WBVR; Intravacc; Utrecht,Netherlands,Ongoing,,,Pre-Clinical Testing,,5/14/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
527,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research/show-bvr/Development-of-an-intranasal-vaccine-against-COVID-19.htm,https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research/show-bvr/Development-of-an-intranasal-vaccine-against-COVID-19.htm,https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research/show-bvr/Development-of-an-intranasal-vaccine-against-COVID-19.htm,https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research/show-bvr/Development-of-an-intranasal-vaccine-against-COVID-19.htm,https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research/show-bvr/Development-of-an-intranasal-vaccine-against-COVID-19.htm,https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research/About-us.htm,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.hollandbio.nl/nieuws/intravacc-to-develop-emergency-and-conventional-covid-19-vaccines/,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,6/1/2020,,,,,,6/1/2020
528,No,Avian paramyxovirus vector vaccine,,Avian paramyxovirus vector vaccine,Lancaster University,Vaccine - Prophylactic,COVID-19,Combination,Vaccine,New,Lancaster University,United Kingdom,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
528,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://dnd.com.pk/pakistani-scientist-dr-muhammad-munir-listed-as-potential-covid-19-vaccine-maker-by-who/189385,,,https://dnd.com.pk/pakistani-scientist-dr-muhammad-munir-listed-as-potential-covid-19-vaccine-maker-by-who/189385,,https://dnd.com.pk/pakistani-scientist-dr-muhammad-munir-listed-as-potential-covid-19-vaccine-maker-by-who/189385,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,6/1/2020,,,,,,6/1/2020
529,No,LNP-encapsulated mRNA cocktail encoding RBD,,LNP-encapsulated mRNA cocktail encoding RBD,Fudan University; Shanghai JiatTong University; RNACure Biopharma,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,Fudan University; Shanghai JiaoTong University; RNACure Biopharma,China,Ongoing,,,Pre-Clinical Testing,,5/7/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
529,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.fudan.edu.cn/en/2020/0307/c344a104281/page.htm,https://www.fudan.edu.cn/en/2020/0307/c344a104281/page.htm,https://www.fudan.edu.cn/en/2020/0307/c344a104281/page.htm,https://www.fudan.edu.cn/en/2020/0307/c344a104281/page.htm,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://covidvax.org/covid19-vaccine/FudanUniRBD/LNP-encapsulated-mRNA-cocktail-encoding-RBD-Fudan-University-Shangai-JiaoTong-University-RNACure-Bio,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,6/1/2020,,,,,,6/1/2020
530,No,Replicating Defective SARS-CoV-2 derived RNAs Vaccine,,Replicating Defective SARS-CoV-2 derived RNAs Vaccine,Centro Nacional biotecnologia; CNB-CSIC,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,Centro Nacional Biotecnología,Spain,Ongoing,,,Pre-Clinical Testing,,5/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
530,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://covidvax.org/covid19-vaccine/CNB-RNA/RNA-defective-SARS-CoV-2-derived-RNAs-Centro-Nacional-Biotecnologia-CNB-CSIC-,,https://covidvax.org/covid19-vaccine/CNB-RNA/RNA-defective-SARS-CoV-2-derived-RNAs-Centro-Nacional-Biotecnologia-CNB-CSIC-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
531,No,mRNA Vaccine,,mRNA Vaccine,RNAImmune Inc.,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,RNAimmune Inc,United States,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
531,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
532,No,mRNA Vaccine,,mRNA Vaccine,GeneOne Life Science; Houston Methodist,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,Inovio Pharmaceuticals,United States; South Korea,Ongoing,,,Pre-Clinical Testing,,3/17/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
532,Yes,https://www.houstonmethodist.org/research/covid19/geneone/,,https://www.houstonmethodist.org/research/covid19/geneone/,https://www.houstonmethodist.org/research/covid19/geneone/,Vaccine - Prophylactic,https://www.houstonmethodist.org/research/covid19/geneone/,https://www.houstonmethodist.org/research/covid19/geneone/,https://www.houstonmethodist.org/research/covid19/geneone/,https://www.houstonmethodist.org/research/covid19/geneone/,https://www.chron.com/neighborhood/woodlands/health/article/Behind-the-scenes-Houston-doctor-preps-for-new-15192520.php,https://www.houstonmethodist.org/research/covid19/geneone/,https://www.houstonmethodist.org/research/covid19/geneone/,,,https://www.houstonmethodist.org/research/covid19/geneone/,,https://www.houstonmethodist.org/research/covid19/geneone/,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,6/3/2020,,,,,,6/3/2020
533,No,mRNA Vaccine,,mRNA Vaccine,Greenligh Biosciences,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,Greenlight Biosciences,United States,Ongoing,,,Pre-Clinical Testing,,5/12/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
533,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/greenlight-raises-17m-for-mrna-vaccine-capacity-hike-citing-covid-19-target/,https://bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/greenlight-raises-17m-for-mrna-vaccine-capacity-hike-citing-covid-19-target/,https://bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/greenlight-raises-17m-for-mrna-vaccine-capacity-hike-citing-covid-19-target/,,,https://bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/greenlight-raises-17m-for-mrna-vaccine-capacity-hike-citing-covid-19-target/,,https://bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/greenlight-raises-17m-for-mrna-vaccine-capacity-hike-citing-covid-19-target/,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,6/3/2020,,,,,,6/3/2020
534,No,VLP Vaccine,,VLP Vaccine,OSIVAX,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,OSIVAX,France,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
534,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,6/3/2020,,,,,,6/3/2020
535,No,VLP Vaccine,,VLP Vaccine,ARTES Biotechnology,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,ARTES Biotechnology,Germany,Ongoing,,,Pre-Clinical Testing,,4/27/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
535,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://pharma-industry-review.com/artes-joins-fight-against-covid-19-vlp-vaccine-platforms,https://pharma-industry-review.com/artes-joins-fight-against-covid-19-vlp-vaccine-platforms,https://pharma-industry-review.com/artes-joins-fight-against-covid-19-vlp-vaccine-platforms,https://www.contractpharma.com/content-microsite/covid-19/2020-04-27/artes-biotech-to-develop-vlp-sars-cov-2-vax-candidates,https://www.contractpharma.com/content-microsite/covid-19/2020-04-27/artes-biotech-to-develop-vlp-sars-cov-2-vax-candidates,https://www.contractpharma.com/content-microsite/covid-19/2020-04-27/artes-biotech-to-develop-vlp-sars-cov-2-vax-candidates,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.contractpharma.com/content-microsite/covid-19/2020-04-27/artes-biotech-to-develop-vlp-sars-cov-2-vax-candidates,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
536,No,VLP; Whole Virus Vaccine,,VLP; Whole Virus Vaccine,Univeristy of Sao Paulo,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,University of Sao Paulo,Brazil,Ongoing,,,Pre-Clinical Testing,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
536,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,Vaccine - Prophylactic,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.efe.com/efe/english/portada/brazil-scientists-using-new-approach-in-search-for-covid-19-vaccine/50000260-4199376,https://www.efe.com/efe/english/portada/brazil-scientists-using-new-approach-in-search-for-covid-19-vaccine/50000260-4199376,https://www.efe.com/efe/english/portada/brazil-scientists-using-new-approach-in-search-for-covid-19-vaccine/50000260-4199376,,,https://www.efe.com/efe/english/portada/brazil-scientists-using-new-approach-in-search-for-covid-19-vaccine/50000260-4199376,,https://www.efe.com/efe/english/portada/brazil-scientists-using-new-approach-in-search-for-covid-19-vaccine/50000260-4199376,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
537,No,SK Vaccine,,SK Vaccine,SK Biosciences; SK Group,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,SK Biosciences; SK Group,South Korea,Ongoing,,,Pre-Clinical Testing,,Assume Completed,3/24/2020,Assume Completed,Assume Completed,,09/01/2020,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
537,Yes,https://www.upi.com/Health_News/2020/03/24/Korean-company-starts-animal-trial-of-coronavirus-vaccine/9671585056981/?sl=11,,https://www.upi.com/Health_News/2020/03/24/Korean-company-starts-animal-trial-of-coronavirus-vaccine/9671585056981/?sl=11,https://www.upi.com/Health_News/2020/03/24/Korean-company-starts-animal-trial-of-coronavirus-vaccine/9671585056981/?sl=11,Vaccine - Prophylactic,http://www.koreabiomed.com/news/articleView.html?idxno=7798,http://www.koreabiomed.com/news/articleView.html?idxno=7798,http://www.koreabiomed.com/news/articleView.html?idxno=7798,https://www.upi.com/Health_News/2020/03/24/Korean-company-starts-animal-trial-of-coronavirus-vaccine/9671585056981/?sl=11,https://www.upi.com/Health_News/2020/03/24/Korean-company-starts-animal-trial-of-coronavirus-vaccine/9671585056981/?sl=11,https://www.upi.com/Health_News/2020/03/24/Korean-company-starts-animal-trial-of-coronavirus-vaccine/9671585056981/?sl=11,https://www.upi.com/Health_News/2020/03/24/Korean-company-starts-animal-trial-of-coronavirus-vaccine/9671585056981/?sl=11,,,https://www.upi.com/Health_News/2020/03/24/Korean-company-starts-animal-trial-of-coronavirus-vaccine/9671585056981/?sl=11,,https://covidvax.org/covid19-vaccine/SK/SK-vaccine-SK-Bioscience,https://covidvax.org/covid19-vaccine/SK/SK-vaccine-SK-Bioscience,https://covidvax.org/covid19-vaccine/SK/SK-vaccine-SK-Bioscience,https://covidvax.org/covid19-vaccine/SK/SK-vaccine-SK-Bioscience,,https://covidvax.org/covid19-vaccine/SK/SK-vaccine-SK-Bioscience,,,,,,,,,,,,,,,,,,,,,,,Bill,6/5/2020,,,,,,6/5/2020
538,No,Vaccine,,Vaccine,Precision Vaccines Program; Boston Children's Hospital,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Precision Vaccines Program; Boston Children's Hospital,United States,Ongoing,,,Discovery,,3/10/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,5/31/2020,,,,,,5/31/2020
538,Yes,https://www.scientificamerican.com/article/coronavirus-vaccines-may-not-work-for-the-elderly-and-this-lab-aims-to-change-that/,,https://www.scientificamerican.com/article/coronavirus-vaccines-may-not-work-for-the-elderly-and-this-lab-aims-to-change-that/,https://www.scientificamerican.com/article/coronavirus-vaccines-may-not-work-for-the-elderly-and-this-lab-aims-to-change-that/,Vaccine - Prophylactic,https://www.scientificamerican.com/article/coronavirus-vaccines-may-not-work-for-the-elderly-and-this-lab-aims-to-change-that/,https://www.scientificamerican.com/article/coronavirus-vaccines-may-not-work-for-the-elderly-and-this-lab-aims-to-change-that/,https://www.scientificamerican.com/article/coronavirus-vaccines-may-not-work-for-the-elderly-and-this-lab-aims-to-change-that/,https://www.scientificamerican.com/article/coronavirus-vaccines-may-not-work-for-the-elderly-and-this-lab-aims-to-change-that/,https://discoveries.childrenshospital.org/coronavirus-vaccine/,https://discoveries.childrenshospital.org/coronavirus-vaccine/,https://discoveries.childrenshospital.org/coronavirus-vaccine/,,,https://discoveries.childrenshospital.org/coronavirus-vaccine/,,https://discoveries.childrenshospital.org/coronavirus-vaccine/,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bill,6/5/2020,,,,,,6/5/2020
539,No,Vaccine,,Vaccine,Kentucky BioProcessing; BAT,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,Kentucky BioProcessing,United States,Ongoing,,,Phase 2,,4/1/2020,Completed,Completed,06/01/2020,COMPLETED,7/20/2020,,,,,,2,COVID-19,180,Yes,2,PMG Research of Wilmington - Wilmington - North Carolina; ICON Early Phase Studies - San Antonio - Texas,12/28/2020,5/6/2021,3/23/2022,https://clinicaltrials.gov/ct2/show/NCT04473690,Oscar Guzman,336-741-5043,guzmano@rjrt.com,,,,,Bill,5/31/2020,,,,,,5/31/2020
539,Yes,https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL,,https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL,https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL,Vaccine - Prophylactic,https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL,https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL,https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL,https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL,https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL,https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL,https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBN8QNL,,,https://clinicaltrials.gov/ct2/show/NCT04473690,,https://www.owensborotimes.com/news/2020/04/kbp-begins-testing-covid-19-vaccine-candidate-on-animals/,https://www.owensborotimes.com/news/2020/04/kbp-begins-testing-covid-19-vaccine-candidate-on-animals/,https://www.owensborotimes.com/news/2020/04/kbp-begins-testing-covid-19-vaccine-candidate-on-animals/,https://www.owensborotimes.com/news/2020/04/kbp-begins-testing-covid-19-vaccine-candidate-on-animals/,https://www.owensborotimes.com/news/2020/04/kbp-begins-testing-covid-19-vaccine-candidate-on-animals/,https://clinicaltrials.gov/ct2/show/NCT04473690,,,,,,https://clinicaltrials.gov/ct2/show/NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,,https://clinicaltrials.gov/ct2/show/NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,,,,,,,,,,,,,
540,No,Vaccine,,Vaccine,University of Laval,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Canadian Institutes of Health Research,Canada,Ongoing,,,Pre-Clinical Testing,,3/6/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane P.,06/01/2020,,,,,,6/1/2020
540,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.ulaval.ca/en/about-us/media-centre/press-releases/press-releases-2020/21-million-better-understand-and-combat-covid-19,https://www.ulaval.ca/en/about-us/media-centre/press-releases/press-releases-2020/21-million-better-understand-and-combat-covid-19,https://www.ulaval.ca/en/about-us/media-centre/press-releases/press-releases-2020/21-million-better-understand-and-combat-covid-19,https://www.ulaval.ca/en/about-us/media-centre/press-releases/press-releases-2020/21-million-better-understand-and-combat-covid-19,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.ulaval.ca/en/about-us/media-centre/press-releases/press-releases-2020/21-million-better-understand-and-combat-covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,06/02/2020,,,,,,6/2/2020
541,No,Vaccine,,Vaccine,"Universidad Catolica, Instituto Milenio de Inmunologia e Inmunoterapia; Consorcio Technologica en Biomedicina Clinico Molecular; IMMII; BMRC",Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Unknown,New,,Chile,Ongoing,Scientists will use respiratory syncytial virus (RSV) and human metapneumovirus (MPVh) vaccine developments and apply them to COVID-19 research.,,Discovery,,3/13/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane P.,06/01/2020,,,,,,6/1/2020
541,Yes,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635448/,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,,,,,,,,,,,,,,,,,,,,,,,,,,,,,06/04/2020,,,,,,6/4/2020
542,No,Vaccine,,Vaccine,Emergex Vaccines Holding Limited; George Mason University's National Center for Biodefense and Infectious Diseases,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,,United Kingdom,Ongoing,Scientists are developing a T-cell-inducing vaccine that produces a strong T cell immune response to help target and kill infected cells. It works by using peptides to stimulate T-cells.,,Discovery,,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane P.,06/01/2020,,,,,,6/1/2020
542,Yes,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,http://emergexvaccines.com/wp-content/uploads/2020/04/31-March-2020-White-Paper-Scientific-Rationale-for-the-Use-of-T-Cell-Priming-to-Reduce-R0-to-Limit-Spread-of-COVID-19-During-Active-Pandemic-FINAL.pdf,http://emergexvaccines.com/wp-content/uploads/2020/04/31-March-2020-White-Paper-Scientific-Rationale-for-the-Use-of-T-Cell-Priming-to-Reduce-R0-to-Limit-Spread-of-COVID-19-During-Active-Pandemic-FINAL.pdf,,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,https://asia.nikkei.com/Business/Startups/Coronavirus-vaccine-set-for-testing-says-startup-backed-by-Singapore-VC,,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,06/06/2020,,,,,,6/6/2020
543,No,AVI-205,,AVI-205,AbVision Inc.,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,,United States,Ongoing,,,Pre-Clinical Testing,,Completed,Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane P.,06/01/2020,,,,,,6/1/2020
543,Yes,https://www.biospace.com/article/first-in-class-active-targeting-vaccine-candidate-for-covid-19/,,https://www.biospace.com/article/first-in-class-active-targeting-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/first-in-class-active-targeting-vaccine-candidate-for-covid-19/,http://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,http://abvisioninc.com/2020/05/03/abvision-announced-a-first-in-class-active-targeting-vaccine-candidate-for-covid-19/,http://abvisioninc.com/2020/05/03/abvision-announced-a-first-in-class-active-targeting-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/first-in-class-active-targeting-vaccine-candidate-for-covid-19/,http://abvisioninc.com/2020/05/03/abvision-announced-a-first-in-class-active-targeting-vaccine-candidate-for-covid-19/,,https://www.biospace.com/article/first-in-class-active-targeting-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/first-in-class-active-targeting-vaccine-candidate-for-covid-19/,,,http://abvisioninc.com/2020/05/03/abvision-announced-a-first-in-class-active-targeting-vaccine-candidate-for-covid-19/,,http://abvisioninc.com/2020/05/03/abvision-announced-a-first-in-class-active-targeting-vaccine-candidate-for-covid-19/,http://abvisioninc.com/2020/05/03/abvision-announced-a-first-in-class-active-targeting-vaccine-candidate-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,06/08/2020,,,,,,6/8/2020
544,No,Recombinant LVS Vaccine,,Recombinant LVS Vaccine,University of California Los Angeles,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Unknown,Repurposed-Not Approved,,United States,Ongoing,"Scientists are attempting to develop a single vector platform vaccine that would protect against many emerging pathogens as well as ""Tier 1 Select Agents.""",,Pre-Clinical Testing,,Completed,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane P.,06/06/2020,,,,,,6/6/2020
544,Yes,http://ucla.technologypublisher.com/techcase/20-0322,,http://ucla.technologypublisher.com/techcase/20-0322,http://ucla.technologypublisher.com/techcase/20-0322,https://www.uclahealth.org/infectious-diseases/Workfiles/infectious-diseases/Marcus-Horwitz-profile-page2.pdf,https://www.uclahealth.org/infectious-diseases/Workfiles/infectious-diseases/Marcus-Horwitz-profile-page2.pdf,http://ucla.technologypublisher.com/techcase/18-1241,http://ucla.technologypublisher.com/techcase/18-1241,http://ucla.technologypublisher.com/techcase/20-0322,,https://www.uclahealth.org/infectious-diseases/Workfiles/infectious-diseases/Marcus-Horwitz-profile-page2.pdf,https://www.uclahealth.org/infectious-diseases/Workfiles/infectious-diseases/Marcus-Horwitz-profile-page2.pdf,https://www.uclahealth.org/infectious-diseases/Workfiles/infectious-diseases/Marcus-Horwitz-profile-page2.pdf,,http://ucla.technologypublisher.com/techcase/20-0322,,http://ucla.technologypublisher.com/techcase/20-0322,http://ucla.technologypublisher.com/techcase/20-0322,,,,,,,,,,,,,,,,,,,,,,,,,,,,06/10/2020,,,,,,6/10/2020
545,No,mRNA Vaccine,,mRNA Vaccine,"eTheRNA, Epivax, Nexelis, Reprocell and the Center for the Evaluation of Vaccination of the University of Antwerp",Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,Belgium,Ongoing,An intranasal delivery system is being explored with this vaccine.,,Pre-Clinical Testing,,Completed,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane P.,06/06/2020,,,,,,6/6/2020
545,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,06/12/2020,,,,,,6/12/2020
546,No,Attenuated Vaccine,,Attenuated Vaccine,Fundacao Oswaldo Cruz; Instituto Butantan,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,Repurposed-Approved,LabWare,Brazil,Ongoing,,,Pre-Clinical Testing,,Completed,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,Sloane P.,06/06/2020,,,,,,6/6/2020
546,Yes,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine,https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,https://www.labware.com/en/p/About-Us/COVID19/Instituto-Butantan,http://www.butantan.gov.br/,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,06/14/2020,,,,,,6/14/2020
547,No,Organicell Flow,,Organicell Flow,Organicell Regenerative Medicine,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,New,,United States,Ongoing,,,Phase 1,,Completed,Completed,,,5/11/2020,5/12/2020,,,,,,1,COVID-19,,No,2,Landmark Hospital - Naples - Florida; Landmark Hospital - Athens - Georgia,09/08/2020,10/31/2020,12/31/2020,https://clinicaltrials.gov/ct2/show/NCT04384445,Maria Ines Mitrani,1-888-963-7881,clinicaltrials@organicell.com,,,NOT YET RECRUITING,,Sloane P.,06/06/2020,,,,,,6/6/2020
547,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,https://organicell.com/organicell-flow/,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,https://organicell.com/clinical-trials/,,https://organicell.com/fda-approves-two-emergency-inds-to-administer-organicell-flow-for-covid-19/,https://organicell.com/fda-approves-two-emergency-inds-to-administer-organicell-flow-for-covid-19/,,,https://organicell.com/fda-approves-two-emergency-inds-to-administer-organicell-flow-for-covid-19/,,https://organicell.com/fda-approves-two-emergency-inds-to-administer-organicell-flow-for-covid-19/,https://organicell.com/fda-approves-two-emergency-inds-to-administer-organicell-flow-for-covid-19/,,,https://organicell.com/fda-approves-two-emergency-inds-to-administer-organicell-flow-for-covid-19/,https://organicell.com/fda-approves-two-emergency-inds-to-administer-organicell-flow-for-covid-19/,,,,,,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04384445?term=Organicell&draw=2&rank=1,,,06/16/2020,,,,,,6/16/2020
548,No,KB-109,,KB-109,Kaleido Biosciences Inc.,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,United States,Ongoing,Scientists are studying outpatients in 2 non-IND clinical studies,,Phase 2,,Assumed Complete,Completed,,,No IND,,5/14/2020,,,,,2,COVID-19,350,No,1,University of Massachusetts Medical School - Boston - Massachusetts,05/14/2020,,,,,,,,,,,Sloane P.,06/06/2020,,,,,,6/6/2020
548,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/05/14/2033339/0/en/Kaleido-Biosciences-Initiates-Controlled-Clinical-Study-of-Microbiome-Metabolic-Therapy-KB109-in-Outpatients-with-Mild-to-Moderate-COVID-19.html,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://kaleido.com/our-pipeline/,,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,,,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,,,,,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,https://www.biospace.com/article/releases/kaleido-biosciences-initiates-controlled-clinical-study-of-microbiome-metabolic-therapy-kb109-in-outpatients-with-mild-to-moderate-covid-19/,,,,,,,,,,,,06/18/2020,,,,,,6/18/2020
549,No,Estradiol patch,,Estradiol patch,Stony Brook University Hospital,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,United States,Ongoing,"Scientists theorize that estrogen may effect angiotensin-converting enzyme 2 (ACE2) proteins which have receptors on cells that are used by COVID-19 as entry-points to the cell. Estrogen has also been shown to improve immune response, espeically in viral infections.",,Phase 2,,Assumed Complete,Assumed Complete,,,IND,Skipped,4/24/2020,,,,,2,COIVD-19,110,No,1,Stony Brook University Hospital - New York - United States,04/24/2020,11/15/2020,11/15/2020,https://clinicaltrials.gov/ct2/show/NCT04359329,Christina Preece,631-371-3309,PatchStudy@stonybrookmedicine.edu,,,,,Sloane P.,06/06/2020,,,,,,6/6/2020
549,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04359329,https://www.drugbank.ca/drugs/DB00783,https://www.nytimes.com/2020/04/27/health/coronavirus-estrogen-men.html,https://www.drugbank.ca/drugs/DB00783,,https://clinicaltrials.gov/ct2/show/NCT04359329,https://clinicaltrials.gov/ct2/show/NCT04359329,https://www.nytimes.com/2020/04/27/health/coronavirus-estrogen-men.html,,https://www.bioworld.com/COVID19products,,,,,,https://clinicaltrials.gov/ct2/show/NCT04359329,https://www.healio.com/news/endocrinology/20200501/study-investigates-estrogen-patch-use-to-lessen-covid19-complications,https://clinicaltrials.gov/ct2/show/NCT04359329,,,,,https://clinicaltrials.gov/ct2/show/NCT04359329,https://clinicaltrials.gov/ct2/show/NCT04359329,https://clinicaltrials.gov/ct2/show/record/NCT04359329,https://clinicaltrials.gov/ct2/show/study/NCT04359329,https://clinicaltrials.gov/ct2/show/study/NCT04359329,https://clinicaltrials.gov/ct2/show/study/NCT04359329,https://clinicaltrials.gov/ct2/show/study/NCT04359329,https://clinicaltrials.gov/ct2/show/study/NCT04359329,https://clinicaltrials.gov/ct2/show/study/NCT04359329,https://clinicaltrials.gov/ct2/show/study/NCT04359329,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04359329,,,,,,,,,
550,No,Anticovir,,Anticovir,Betterlife Pharma Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,New,Altum Pharmaceuticals Inc.,Canada,Ongoing,Drug will be dispensed via Metered Dose Inhaler (MDI).,,Pre-Clinical Testing,,Assumed Complete,Started,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
550,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/betterlife-pharma-enters-into-a-licensing-agreement/,https://www.altumpharma.com/pipeline/ap-003/,https://www.altumpharma.com/pipeline/ap-003/,https://www.altumpharma.com/pipeline/ap-003/,https://www.biospace.com/article/releases/betterlife-pharma-enters-into-a-licensing-agreement/,https://www.thepharmaletter.com/article/betterlife-pharma-inks-licensing-deal-for-anticovir,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/betterlife-pharma-enters-into-a-licensing-agreement/,,https://www.bioworld.com/COVID19products,,https://www.altumpharma.com/pipeline/ap-003/,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
551,No,Apograft-treated stem cells,,Apograft-treated stem cells,Cellect Biotechnology Ltd.,Therapeutic,ARDS,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Israel,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JWC,5/29/2020,,,,,,5/29/2020
551,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,Therapeutic,https://www.prnewswire.com/news-releases/cellect-biotechnologys-apograft-to-empower-cellular-treatment-of-covid-19-related-pulmonary-diseases-301060683.html,https://www.prnewswire.com/news-releases/cellect-biotechnologys-apograft-to-empower-cellular-treatment-of-covid-19-related-pulmonary-diseases-301060683.html,https://www.prnewswire.com/news-releases/cellect-biotechnologys-apograft-to-empower-cellular-treatment-of-covid-19-related-pulmonary-diseases-301060683.html,https://www.cellect.co/solutions,,https://www.cellect.co/,https://www.prnewswire.com/news-releases/cellect-biotechnologys-apograft-to-empower-cellular-treatment-of-covid-19-related-pulmonary-diseases-301060683.html,,,https://www.prnewswire.com/news-releases/cellect-biotechnologys-apograft-to-empower-cellular-treatment-of-covid-19-related-pulmonary-diseases-301060683.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
552,No,Mesenchymal Stem Cells,,Mesenchymal Stem Cells,Citius Pharmaceuticals Inc.; Novellus Inc.,Therapeutic,ARDS,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,Citius Pharmaceuticals Inc.,United States,Ongoing,,,Pre-Clinical Testing,,4/1/2020,4/27/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,JWC,5/29/2020,,,,,,5/29/2020
552,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,Therapeutic,https://ir.citiuspharma.com/press-releases/detail/95/citius-signs-exclusive-option-with-novellus-to-license,https://ir.citiuspharma.com/press-releases/detail/95/citius-signs-exclusive-option-with-novellus-to-license,https://ir.citiuspharma.com/press-releases/detail/95/citius-signs-exclusive-option-with-novellus-to-license,https://ir.citiuspharma.com/press-releases/detail/95/citius-signs-exclusive-option-with-novellus-to-license,https://ir.citiuspharma.com/press-releases/detail/95/citius-signs-exclusive-option-with-novellus-to-license,https://ir.citiuspharma.com/press-releases/detail/95/citius-signs-exclusive-option-with-novellus-to-license,https://ir.citiuspharma.com/press-releases/detail/95/citius-signs-exclusive-option-with-novellus-to-license,,,https://ir.citiuspharma.com/press-releases/detail/98/citius-announces-data-on-novecite-mesenchymal-stem-cells,,https://ir.citiuspharma.com/press-releases/detail/95/citius-signs-exclusive-option-with-novellus-to-license,https://ir.citiuspharma.com/press-releases/detail/96/citius-announces-pre-ind-submission-to-fda-under-the,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
553,No,CAL-02,,CAL-02,Combioxin SA,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,Repurposed-Not Approved,,Switzerland,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JWC,5/29/2020,,,,,,5/29/2020
553,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,Therapeutic,https://www.combioxin.com/pipeline/,https://www.combioxin.com/pipeline/,https://www.mdpi.com/2079-6382/9/2/94,https://www.combioxin.com/pipeline/,,https://www.combioxin.com/news/,https://www.combioxin.com/pipeline/,,,http://www.lascco.com/documents/200504PR-Combioxin-PositivefeedbackfromFDAonPINDforCAL02inCOVID-19patients.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
554,No,e-Therapeutics Therapeutic,,e-Therapeutics Therapeutic,e-Therapeutics plc,Therapeutic,COVID-19,Other,Other,,,United Kingdom,Ongoing,Network-driven Drug Discovery works to determine host mechanisms that are critical for virus replication and spread,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JWC,5/31/2020,,,,,,5/31/2020
554,Yes,,,,https://www.bioworld.com/COVID19products,Therapeutic,https://www.etherapeutics.co.uk/media/1237/covid-19_ndd_overview.pdf,https://www.etherapeutics.co.uk/media/1237/covid-19_ndd_overview.pdf,https://www.etherapeutics.co.uk/media/1237/covid-19_ndd_overview.pdf,,,https://www.etherapeutics.co.uk/what-we-do/covid-19/,https://www.etherapeutics.co.uk/what-we-do/covid-19/,https://www.etherapeutics.co.uk/media/1237/covid-19_ndd_overview.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
555,No,KAND-567,,KAND-567,Kancera AB,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Sweden,Ongoing,Kancera has applied to begin Phase II studies,,Phase 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JWC,5/31/2020,,,,,,5/31/2020
555,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,Therapeutic,http://kancera.com/en/researchportfolio/,http://kancera.com/en/researchportfolio/,http://kancera.com/en/researchportfolio/,http://kancera.com/en/researchportfolio/,,http://kancera.com/en/researchportfolio/,http://kancera.com/en/researchportfolio/,http://kancera.com/en/press/press-releases/#,,http://kancera.com/en/press/press-releases/#,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
556,No,Capton product,,Capton product,Mercaptor Discoveries Inc.,Therapeutic,COVID-19,Unknown,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JWC,5/31/2020,,,,,,5/31/2020
556,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,Therapeutic,https://mercaptor.com/mercaptor-discoveries-uses-its-proprietary-neurotherapeutic-platform-to-develop-treatment-for-covid-19/,https://mercaptor.com/mercaptor-discoveries-uses-its-proprietary-neurotherapeutic-platform-to-develop-treatment-for-covid-19/,https://mercaptor.com/mercaptor-discoveries-uses-its-proprietary-neurotherapeutic-platform-to-develop-treatment-for-covid-19/,https://mercaptor.com/mercaptor-discoveries-uses-its-proprietary-neurotherapeutic-platform-to-develop-treatment-for-covid-19/,,https://mercaptor.com/mercaptor-discoveries-uses-its-proprietary-neurotherapeutic-platform-to-develop-treatment-for-covid-19/,https://mercaptor.com/mercaptor-discoveries-uses-its-proprietary-neurotherapeutic-platform-to-develop-treatment-for-covid-19/,,,https://mercaptor.com/mercaptor-discoveries-uses-its-proprietary-neurotherapeutic-platform-to-develop-treatment-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
557,No,TR-C 19,,TR-C 19,Vsy Biotechnology GmbH,Therapeutic,COVID-19,Unknown,Unknown,,,Germany,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JWC,5/31/2020,,,,,,5/31/2020
557,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,Therapeutic,https://www.vsybiotechnology.com/a-new-drug-to-treat-covid-19-tr-c-19-at-human-testing-phase/,https://www.vsybiotechnology.com/a-new-drug-to-treat-covid-19-tr-c-19-at-human-testing-phase/,https://www.vsybiotechnology.com/a-new-drug-to-treat-covid-19-tr-c-19-at-human-testing-phase/,,,https://www.vsybiotechnology.com/about-us/,https://www.vsybiotechnology.com/a-new-drug-to-treat-covid-19-tr-c-19-at-human-testing-phase/,,,https://www.vsybiotechnology.com/a-new-drug-to-treat-covid-19-tr-c-19-at-human-testing-phase/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
558,No,Antibody,,Antibody,Xavier Saelens,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Belgium,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JWC,5/31/2020,,,,,,5/31/2020
558,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,Therapeutic,http://www.vib.be/en/news/Pages/Towards-antibodies-against-COVID-19.aspx,http://www.vib.be/en/news/Pages/Towards-antibodies-against-COVID-19.aspx,http://www.vib.be/en/news/Pages/Towards-antibodies-against-COVID-19.aspx,http://www.vib.be/en/news/Pages/Towards-antibodies-against-COVID-19.aspx,,http://www.vib.be/en/news/Pages/Towards-antibodies-against-COVID-19.aspx,http://www.vib.be/en/news/Pages/Towards-antibodies-against-COVID-19.aspx,,,http://www.vib.be/en/news/Pages/Towards-antibodies-against-COVID-19.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
559,No,Antibodies,,Antibodies,Proteogenix SA,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,France,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JWC,5/31/2020,,,,,,5/31/2020
559,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,Therapeutic,https://www.proteogenix.science/contact/,https://www.proteogenix.science/contact/,https://www.proteogenix.science/contact/,https://www.proteogenix.science/contact/,,https://www.proteogenix.science/contact/,https://www.proteogenix.science/contact/,,,https://www.proteogenix.science/contact/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
560,No,Antibodies,,Antibodies,Yumab GmbH,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Germany,Ongoing,,,Pre-Clinical Testing,,,5/7/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,JWC,5/31/2020,,,,,,5/31/2020
560,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.yumab.com/wp-content/uploads/2020/05/2020.05.08_PR_SARS-CoV-2_ENG_final.pdf,https://www.yumab.com/wp-content/uploads/2020/05/2020.05.08_PR_SARS-CoV-2_ENG_final.pdf,https://www.yumab.com/wp-content/uploads/2020/05/2020.05.08_PR_SARS-CoV-2_ENG_final.pdf,https://www.yumab.com/wp-content/uploads/2020/05/2020.05.08_PR_SARS-CoV-2_ENG_final.pdf,,https://www.yumab.com/wp-content/uploads/2020/05/2020.05.08_PR_SARS-CoV-2_ENG_final.pdf,https://www.yumab.com/wp-content/uploads/2020/05/2020.05.08_PR_SARS-CoV-2_ENG_final.pdf,,,https://www.yumab.com/wp-content/uploads/2020/05/2020.05.08_PR_SARS-CoV-2_ENG_final.pdf,,,https://www.yumab.com/wp-content/uploads/2020/05/2020.05.08_PR_SARS-CoV-2_ENG_final.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
561,No,TY027,,TY027,Tychan,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Singapore,Ongoing,,,Phase 1,,,,,,,,,,,,,1,COVID-19,25,Yes,1,SingHealth Investigational Medicine Unit - Singapore - Singapore,6/9/20,11/1/20,2/1/21,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,Justin Ng,,justin@tychanltd.com        ,,,,,,,,,,,,
561,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://www.genengnews.com/covid-19-candidates/tychan-ty027/,https://www.genengnews.com/covid-19-candidates/tychan-ty027/,https://www.genengnews.com/covid-19-candidates/tychan-ty027/,,https://www.genengnews.com/covid-19-candidates/tychan-ty027/,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY027&draw=2&rank=1,,,,,,,,,,,,
562,No,IgY-110,,IgY-110,IGY Life Sciences,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Canada,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
562,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.pharmaceutical-business-review.com/news/igy-life-sciences-mms-covid-19-antibody/,https://www.pharmaceutical-business-review.com/news/igy-life-sciences-mms-covid-19-antibody/,https://www.pharmaceutical-business-review.com/news/igy-life-sciences-mms-covid-19-antibody/,https://www.pharmaceutical-business-review.com/news/igy-life-sciences-mms-covid-19-antibody/,,https://www.pharmaceutical-business-review.com/news/igy-life-sciences-mms-covid-19-antibody/,https://www.pharmaceutical-business-review.com/news/igy-life-sciences-mms-covid-19-antibody/,,,https://www.pharmaceutical-business-review.com/news/igy-life-sciences-mms-covid-19-antibody/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
563,No,GC376,,GC376,Anivive Lifesciences,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Approved,,United States,Ongoing,Protease Inhibitor,,Pre-Clinical Testing,,,,,,5/26/2020,By End of 2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
563,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.anivive.com/news/anivive-repurposes-veterinary-drug-gc376-for-covid-19,https://www.anivive.com/news/anivive-repurposes-veterinary-drug-gc376-for-covid-19,https://www.anivive.com/news/anivive-repurposes-veterinary-drug-gc376-for-covid-19,https://www.anivive.com/news/anivive-repurposes-veterinary-drug-gc376-for-covid-19,,https://www.anivive.com/news/anivive-repurposes-veterinary-drug-gc376-for-covid-19,https://www.anivive.com/news/anivive-repurposes-veterinary-drug-gc376-for-covid-19,https://www.anivive.com/news/anivive-repurposes-veterinary-drug-gc376-for-covid-19,,https://www.anivive.com/news/anivive-repurposes-veterinary-drug-gc376-for-covid-19,,,,,,https://www.anivive.com/news/anivive-repurposes-veterinary-drug-gc376-for-covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
564,No,Small Mobile Stem cells,,Small Mobile Stem cells,SMSbiotech,Therapeutic,COVID-19,Cell therapies,Other,Repurposed-Not Approved,,United States,Ongoing,treatment that could repair critically damaged tissues by the coronavirus,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
564,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.smsbiotech.com/covid19_treatment_proposal/,https://www.smsbiotech.com/covid19_treatment_proposal/,,https://www.smsbiotech.com/covid19_treatment_proposal/,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.smsbiotech.com/covid19_treatment_proposal/,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
565,No,valsartan,valsartan,Diovan,Radbound Univeristy,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,Netherlands,Ongoing,,,Phase 4,,,,,,,,,,,,,4,COVID-19,651,No,7,Jeroen Bosch Ziekenhuis - s-Hertogenbosch - Netherlands; Rijnstate - Arnhem - Netherlands; Radboudumc - Nijmegen - Netherlands; Laurentius Ziekenhuis - Roermond - Netherlands; Erasmus MC - Rotterdam - Netherlands; Franciscus Gasthuis - Rotterdam - Netherlands; Ikazia Ziekenhuis - Rotterdam - Netherlands,4/17/20,12/1/20,12/1/21,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,Roland RJ van Kimmenade,,Roland.vanKimmenade@radboudumc.nl,,,,,,,,,,,,
565,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://www.drugbank.ca/drugs/DB00177,https://www.drugbank.ca/drugs/DB00177,https://www.drugbank.ca/drugs/DB00177,,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04335786?term=valsartan&cond=covid&draw=2&rank=1,,,,,,,,,,,,
566,No,famotidine,famotidine,Pepcid,Feinstein Institutes for Medical Research; Northwell Health; Alchem,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United Stated,Ongoing,,,Phase 3,,,,,,,,,,,,,3,COVID-19,942,No,5,Southside Hospital - Bay Shore - New York; North Shore University Hospital - Manhasset - New York; Northern Westchester Hospital - Mount Kisco - New York; Lenox Hill Hospital - New York - New York; Long Island Jewish Medical Center - Queens - New York,4/7/20,9/7/20,4/7/21,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,Julie DiGregorio,(516) 493-7950,jdigregori@northwell.edu	,,,,,,,,,,,,
566,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://www.drugbank.ca/drugs/DB00927,https://www.drugbank.ca/drugs/DB00927,https://www.drugbank.ca/drugs/DB00927,,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,,,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04370262?term=famotidine&cond=covid&draw=2&rank=2,,,,,,,,,,,,
567,No,icosapent ethyl,icosapent ethyl,Vascepa,Amarin Corp,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Canada,Ongoing,,,Phase 2,,,,,,,,,,,,,2,COVID-19,100,No,1,North York Diagnostic and Cardiology Clinic - Ontario - Canada,6/1/20,12/1/20,12/1/20,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,Subodh Verma,1-416-864-5997,subodh.verma@unityhealth.to,,,,,,,,,,,,
567,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://www.drugbank.ca/drugs/DB08887,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://www.drugbank.ca/drugs/DB08887,,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04412018?term=icosapent+ethyl&cond=covid&draw=2&rank=1,,,,,,,,,,,,
568,No,OP-101,,OP-101,Orpheris; Ashvattha Therapeutics,Therapeutic,COVID-19,Other,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,,,,,,,5/28/2020,,,,,2,COVID-19,24,No,1,San Diego - California,7/1/20,10/10/20,11/10/20,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,Jeffrey L. Cleland,1 650 241 1697,cleland@orpheris.com,,,,,,,,,,,,
568,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.fiercebiotech.com/biotech/after-passing-safety-hurdle-orpheris-kickstarts-covid-19-cytokine-storm-efficacy-test,https://www.fiercebiotech.com/biotech/after-passing-safety-hurdle-orpheris-kickstarts-covid-19-cytokine-storm-efficacy-test,,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,,,,,,,,https://www.businesswire.com/news/home/20200528005275/en/Ashvattha-Therapeutics-Subsidiary-Orpheris-Announces-FDA-Agreement,,,,,,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04458298?term=OP-101&cond=covid&draw=2&rank=1,,,,,,,,,,,,
569,No,lipid ibupfofen,lipid ibupfofen,Flarin,King's College London,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United Kingdom,Ongoing,,,Phase 4,,,,,,,,,,,,,4,COVID-19,230,No,1,Guy's and St Thomas' NHS Foundation Trust - London - United Kingdom,5/26/20,9/25/20,5/25/21,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,Ndaba Mazibuko,,ndaba.mazibuko@nhs.net,,,,,,,,,,,,
569,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04334629?term=Flarin&cond=covid&draw=2&rank=1,,,,,,,,,,,,
570,No,almitrine,almitrine,,University of Oxford,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,United Kingdom,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
570,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.ox.ac.uk/news/2020-05-29-covid-19-drug-trial-could-lead-enhanced-respiratory-care-patients,https://www.pulmonologyadvisor.com/home/topics/lung-infection/hypoxemia-related-to-covid-19-may-benefit-from-almitrine-treatment/,https://www.pulmonologyadvisor.com/home/topics/lung-infection/hypoxemia-related-to-covid-19-may-benefit-from-almitrine-treatment/,https://www.ox.ac.uk/news/2020-05-29-covid-19-drug-trial-could-lead-enhanced-respiratory-care-patients,,https://www.ox.ac.uk/news/2020-05-29-covid-19-drug-trial-could-lead-enhanced-respiratory-care-patients,https://www.ox.ac.uk/news/2020-05-29-covid-19-drug-trial-could-lead-enhanced-respiratory-care-patients,,,https://covid-19tracker.milkeninstitute.org/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
571,No,VP01,,VP01,Vicore Pharma,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,LifeArc; University College London,United Kingdom,Ongoing,Small molecule designed to target AT2R to reduce inflammation and treat pulmonary fibrosis; MHRA granted VP01 approval to commence phase 2 to investigate whether it reduced inflammation in COVID-19 patients,,Phase 2,,Assumed Complete,Assumed Complete,,,MHRA,,6/30/2020,,,,,2,COVID-19,100,No,3,Department of Medicine-Civil Hospital and B J Medical College - Ahmadabad - India; Department of Medicine-Noble Hospitals Pvt. Ltd - Pune - India; Respiratory Medicine-University College Hospital - London - United Kingdom,06/30/2020,09/2020,09/2021,https://clinicaltrials.gov/ct2/show/NCT04452435,Mimi Flensburg,45 2210 9950,mimi.flensburg@vicorepharma.com,,COVID-19 requiring hospitalization but not ventilation; only London location is recruiting,,,,,,,,,,
571,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,https://www.lifearc.org/funding/covid-19-funding/attract/,https://www.lifearc.org/funding/covid-19-funding/attract/,Ongoing,https://www.lifearc.org/funding/covid-19-funding/attract/,,Phase 2,,https://www.lifearc.org/funding/covid-19-funding/attract/,https://www.lifearc.org/funding/covid-19-funding/attract/,,,https://www.lifearc.org/funding/covid-19-funding/attract/,,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1,,,,,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1,No,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04452435?lead=vicore&draw=2&rank=1#contacts,,,,,,,,,,,,
572,No,AQCH,,AQCH,Sun Pharmaceutical Industries Ltd,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,,India,Ongoing,Plant derived treatment initially intended for treating dengue but broad-spectrum anti-viral activity shows promise for COVID-19; no detailed entry on clinicaltrials,,Phase 2,,Assumed Complete,Assumed Complete,,,DCGI,,6/8/2020,,,,,2,COVID-19,210,No,12,India,06/08/2020,10/2020,10/2020,,,,,,,,,,,,,,,,
572,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,Ongoing,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,,Phase 2,,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,,,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,,,,,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,No,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,https://www.clinicaltrialsarena.com/news/sun-pharma-covid-19-trial/,,,,,,,,,,,,,,,,
573,No,CIGB-258,,CIGB-258,Genetic Engineering and Biotechnology Center,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,New,Ministry of Public Health - Cuba,Cuba,Ongoing,Immunoregulatory peptide; clinical trial did not have a traditional phase but description appears to indicate phase 2 and was completed in 05/30/2020 and published results on 6/30/2020 https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1,,Phase 2,,Assumed Complete,Assumed Complete,,,3/30/2020,,3/31/2020,,,,,,,,,,,,,,,,,,,TRIAL COMPLETED,,,,,,,,,,
573,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,New,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://rpcec.sld.cu/en/trials/RPCEC00000313-En,Ongoing,https://rpcec.sld.cu/en/trials/RPCEC00000313-En https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1,,Phase 2,,https://rpcec.sld.cu/en/trials/RPCEC00000313-En,https://rpcec.sld.cu/en/trials/RPCEC00000313-En,,,https://rpcec.sld.cu/en/trials/RPCEC00000313-En,,https://rpcec.sld.cu/en/trials/RPCEC00000313-En,,,,,,,,,,,,,,,,,,,https://rpcec.sld.cu/en/trials/RPCEC00000313-En,,,,,,,,,,
574,No,FSD-201,,FSD-201,FSD Pharma,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,Canada,Ongoing,Drug is ultramicronized palmitoylethanolamide intended to reduce COVID-19 inflammation; currently is planning a phase 2a trial after receiving FDA approval; phase 1 results will be published soon,,Phase 1,,Assumed Complete,Assumed Complete,,,6/1/2020,6/1/2020,,,,,,,,,,,,,,,,,,,,TRIAL COMPLETED,,,,,,,,,,
574,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,https://fsdpharma.com/about-us/,Ongoing,https://www.businesswire.com/news/home/20200602005990/en/FSD-Pharma-Receives-U.S.-FDA-Approval-Design,,Phase 2,,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,,,https://www.businesswire.com/news/home/20200602005990/en/FSD-Pharma-Receives-U.S.-FDA-Approval-Design,https://www.businesswire.com/news/home/20200602005990/en/FSD-Pharma-Receives-U.S.-FDA-Approval-Design,,,,,,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,Yes,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,,,,,,,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,,,,,,,,,,
575,No,PB-1046,,PB-1046,PhaseBio,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,Vasoactive intestinal peptide recptor agonist that targets VPAC receptors to have anti-inflammatory effects among others; also in trials for Pulmonary Arterial Hypertension,,Phase 2,,Assumed Complete,Assumed Complete,,,5/27/2020,,6/26/2020,,,,,2,COVID-19,210,No,,,06/26/2020,12/18/2020,12/18/2020,https://clinicaltrials.gov/ct2/show/NCT04433546,,888 521 2805,Clinicaltrials@phasebio.com,,Male or Female aged 18-85; hospitalized for COVID-19; written or verbal consent; receiving O2 by face mask or nasal cannula and/or elevated markers of cardiac injury or dysfunction,,,,,,,,,,
575,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,https://www.businesswire.com/news/home/20200527005882/en/PhaseBio-Launches-Clinical-Trial-Evaluate-PB1046-Treatment,Ongoing,https://www.businesswire.com/news/home/20200527005882/en/PhaseBio-Launches-Clinical-Trial-Evaluate-PB1046-Treatment,,Phase 2,,https://www.businesswire.com/news/home/20200527005882/en/PhaseBio-Launches-Clinical-Trial-Evaluate-PB1046-Treatment,https://www.businesswire.com/news/home/20200527005882/en/PhaseBio-Launches-Clinical-Trial-Evaluate-PB1046-Treatment,,,https://www.businesswire.com/news/home/20200527005882/en/PhaseBio-Launches-Clinical-Trial-Evaluate-PB1046-Treatment,,https://clinicaltrials.gov/ct2/show/NCT04433546,,,,,https://clinicaltrials.gov/ct2/show/NCT04433546#contacts,https://clinicaltrials.gov/ct2/show/NCT04433546#contacts,https://clinicaltrials.gov/ct2/show/NCT04433546#contacts,No,,,https://clinicaltrials.gov/ct2/show/NCT04433546#contacts,https://clinicaltrials.gov/ct2/show/NCT04433546#contacts,https://clinicaltrials.gov/ct2/show/NCT04433546#contacts,https://clinicaltrials.gov/ct2/show/NCT04433546#contacts,,https://clinicaltrials.gov/ct2/show/NCT04433546#contacts,https://clinicaltrials.gov/ct2/show/NCT04433546#contacts,,https://clinicaltrials.gov/ct2/show/NCT04433546#contacts,,,,,,,,,,
576,No,PTC299,,PTC299,PTC Therapeutics Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,,United States,Ongoing,Currently in evaluation for AML besides COVID19; small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) that reduces SARS-CoV-2 viral replication and selectively modulates immune response,,Phase 2,,Assumed Complete,Assumed Complete,,,CTA,,6/30/2020,6/30/2020,,,,2,COVID-19,380,No,5,Augusta University - Augusta - Georgia; Johns Hopkins Hospital - Baltimore - Maryland; Hospital Del Mar - Barcelona - Spain; Hospital Universitario Infanta Leonor - Madrid - Spain; Hospital 12 de Octubre - Madrid - Spain,06/30/2020,01/30/2021,01/30/2021,https://clinicaltrials.gov/ct2/show/NCT04439071,,866 562 4620,medinfo@ptcbio.com,,Not yet recruiting; 18 or older with signed and dated informed consent; hospitalized for confirmed COVID19,,,,,,,,,,
576,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,,https://www.ptcbio.com/about/contact-us/,Ongoing,https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-the-initiation-of-a-phase-23-clinical-trial-to-evaluate-ptc299-for-the-treatment-of-covid-19-301078337.html,,Phase 3,,https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-the-initiation-of-a-phase-23-clinical-trial-to-evaluate-ptc299-for-the-treatment-of-covid-19-301078337.html,https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-the-initiation-of-a-phase-23-clinical-trial-to-evaluate-ptc299-for-the-treatment-of-covid-19-301078337.html,,,https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-the-initiation-of-a-phase-23-clinical-trial-to-evaluate-ptc299-for-the-treatment-of-covid-19-301078337.html,,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,,,,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,No,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,,https://clinicaltrials.gov/ct2/show/NCT04439071?intr=ptc299&draw=2&rank=4,,,,,,,,,,
577,No,raloxifene,raloxifene,Evista,Dompe farmaceutici; Exscalate4CoV,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,Italy,Ongoing,Currently on market for treatment of osteoporosis as raloxifene; currently in discussions with the EMA; drug intended to be used in clinical trials to observe efficacy against COVID-19,,Pre-Clinical Testing,,Assumed Complete,Assumed Complete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
577,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,COVID-19,Small molecule,Other,Repurposed-Approved,,https://www.dompe.com/en/media/press-releases/eu-supported-private-public-consortium-exscalate4cov-raloxifene-proposed-for-clinical-trials-after-tests-show-it-inhibits-sars-cov-2,Ongoing,https://www.dompe.com/en/media/press-releases/eu-supported-private-public-consortium-exscalate4cov-raloxifene-proposed-for-clinical-trials-after-tests-show-it-inhibits-sars-cov-2,,Pre-Clinical Testing,,https://www.dompe.com/en/media/press-releases/eu-supported-private-public-consortium-exscalate4cov-raloxifene-proposed-for-clinical-trials-after-tests-show-it-inhibits-sars-cov-2,https://www.dompe.com/en/media/press-releases/eu-supported-private-public-consortium-exscalate4cov-raloxifene-proposed-for-clinical-trials-after-tests-show-it-inhibits-sars-cov-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
578,No,losmapimod,,losmapimod,Fulcrum Therapeutics,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,New,,United States,Ongoing,Oral p38 MAPK inhibitor; phase 3 to begin soon - conducted on 400 patients and aims to have topline data by Q1 2020,,Phase 3,,Assumed Complete,Assumed Complete,,,6/24/2020,,,6/24/2020,,,,,,,,,,06/24/2020,12/2020,02/2021,,,,,,,,,,,,,,,,
578,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,COVID-19,Small molecule,Kinase inhibitors,New,,https://www.fulcrumtx.com/contact/,Ongoing,https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-initiation-multi-center-phase-3,,Phase 3,,https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-initiation-multi-center-phase-3,https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-initiation-multi-center-phase-3,,,https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-initiation-multi-center-phase-3,,,https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-initiation-multi-center-phase-3,,,,,,,,,,https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-initiation-multi-center-phase-3,https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-initiation-multi-center-phase-3,https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-initiation-multi-center-phase-3,,,,,,,,,,,,,,,,
579,No,dutasteride,dutasteride,AndroCoV,Applied Biology Inc.,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,United States,Ongoing,AndroCoV is an experimental trial utilizing 3 drugs - dutasteride-ivermectin-azithromycine; dutasteride is FDA approved to treat enlarged prostate; no specific trial phase announced but description resembles phase 2,,Phase 2,,Assumed Complete,Assumed Complete,,,Assumed complete,,6/26/2020,,,,,2,COVID-19,254,No,1,Corpometria Institute - Brasilia - Brazil,06/26/2020,12/31/2020,01/31/2021,https://clinicaltrials.gov/ct2/show/NCT04446429,Flavio A Cadegiani,5561996506111,f.cadegiani@gmail.com,,Not yet recruiting; male; 50 years or older; SARS Cov 2 positive but not hospitalized; informed consent,,,,,,,,,,
579,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,COVID-19,Small molecule,Other,Repurposed-Approved,,https://www.businesswire.com/news/home/20200624005871/en/Applied-Biology-Collaboration-Brown-University-Researchers-Corpometria,Ongoing,https://clinicaltrials.gov/ct2/show/NCT04446429,,Phase 2,,https://www.businesswire.com/news/home/20200624005871/en/Applied-Biology-Collaboration-Brown-University-Researchers-Corpometria,https://www.businesswire.com/news/home/20200624005871/en/Applied-Biology-Collaboration-Brown-University-Researchers-Corpometria,,,https://clinicaltrials.gov/ct2/show/NCT04446429,,https://clinicaltrials.gov/ct2/show/NCT04446429,,,,,https://clinicaltrials.gov/ct2/show/NCT04446429,https://clinicaltrials.gov/ct2/show/NCT04446429,https://clinicaltrials.gov/ct2/show/NCT04446429,No,https://clinicaltrials.gov/ct2/show/NCT04446429,https://clinicaltrials.gov/ct2/show/NCT04446429,https://clinicaltrials.gov/ct2/show/NCT04446429,https://clinicaltrials.gov/ct2/show/NCT04446429,https://clinicaltrials.gov/ct2/show/NCT04446429,https://clinicaltrials.gov/ct2/show/NCT04446429,https://clinicaltrials.gov/ct2/show/NCT04446429,https://clinicaltrials.gov/ct2/show/NCT04446429,https://clinicaltrials.gov/ct2/show/NCT04446429,,,https://clinicaltrials.gov/ct2/show/NCT04446429,,,,,,,,,
580,No,Eritoran,,Eritoran,Eisai,Therapeutic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
580,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
581,No,GX-19,,GX-19,Genexine Consortium; GenNBio; International Vaccine Institute; KAIST; POSTECH; Binex,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,South Korea,Ongoing,,,Phase 1,,Completed,Completed,Completed,Completed,Completed,6/17/2020,,,,,,1,COVID-19,210,Yes,1,Severance Hospital - Seoul - South Korea,06/17/2020,03/17/2021,06/17/2022,https://www.clinicaltrials.gov/ct2/show/NCT04445389,Yoon-Jeong Choi,82-31-628-3233,yoonjeong.choi@genexine.com,,,,,,,,,,,,
581,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.genengnews.com/covid-19-candidates/genexine-gx-19/,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.genengnews.com/covid-19-candidates/genexine-gx-19/,,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,,,https://www.clinicaltrials.gov/ct2/show/NCT04445389,,https://www.genengnews.com/covid-19-candidates/genexine-gx-19/,https://www.genengnews.com/covid-19-candidates/genexine-gx-19/,https://www.genengnews.com/covid-19-candidates/genexine-gx-19/,https://www.genengnews.com/covid-19-candidates/genexine-gx-19/,https://www.genengnews.com/covid-19-candidates/genexine-gx-19/,https://www.clinicaltrials.gov/ct2/show/NCT04445389,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,https://www.clinicaltrials.gov/ct2/show/NCT04445389,,https://www.clinicaltrials.gov/ct2/show/NCT04445389,,,,,,,,,
582,No,DNA with electroporation,,DNA with electroporation,Chula Vaccine Research Center,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,Thailand,Ongoing,Human trials planned for October.,,Pre-Clinical Testing,,Completed,5/26/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
582,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.chula.ac.th/en/clipping/31103/,https://www.chula.ac.th/en/clipping/31103/,https://www.chula.ac.th/en/clipping/31103/,https://www.chula.ac.th/en/clipping/31103/,,https://www.chula.ac.th/en/clipping/31103/,https://www.chula.ac.th/en/clipping/31103/,https://www.chula.ac.th/en/clipping/31103/,,https://www.chula.ac.th/en/clipping/31103/,,https://www.chula.ac.th/en/clipping/31103/,https://www.chula.ac.th/en/clipping/31103/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
583,No,"DNA plasmid vaccine S, S1, S2, RBD & N",,"DNA plasmid vaccine S, S1, S2, RBD & N",National Research Centre,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,Egypt,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
583,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
584,No,MV-014-210,,MV-014-210,Meissa Vaccines,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,United States,Ongoing,,,Pre-Clinical Testing,,Completed,6/30/2020,6/30/2020,6/30/2020,6/30/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
584,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,,,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,https://www.meissavaccines.com/blog/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidatesfor-covid-19-and-rsv,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
585,No,MVA-S,,MVA-S,IDIBAPS Hospital Clinic,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,Repurposed-Approved,GeoVax/BravoVax,Spain,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
585,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program,https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program,https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program,https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program,https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program,https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program,https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program,,,https://www.geovax.com/news/geovax-provides-update-on-coronavirus-covid-19-vaccine-development-program,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
586,No,AAVCOVID,,AAVCOVID,Grousbeck Gene Therapy; AveXis; Viralgen; Aldevron,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,United States,Ongoing,,,Discovery,,5/14/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
586,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.aao.org/eye-health/news/coronavirus-covid-vaccine-gene-therapy-luxturna,https://www.aao.org/eye-health/news/coronavirus-covid-vaccine-gene-therapy-luxturna,https://www.aao.org/eye-health/news/coronavirus-covid-vaccine-gene-therapy-luxturna,https://www.aao.org/eye-health/news/coronavirus-covid-vaccine-gene-therapy-luxturna,,https://www.aao.org/eye-health/news/coronavirus-covid-vaccine-gene-therapy-luxturna,https://www.aao.org/eye-health/news/coronavirus-covid-vaccine-gene-therapy-luxturna,,,https://www.aao.org/eye-health/news/coronavirus-covid-vaccine-gene-therapy-luxturna,,https://www.aao.org/eye-health/news/coronavirus-covid-vaccine-gene-therapy-luxturna,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
587,No,Gam-COVID-Vac Lyo,,Gam-COVID-Vac Lyo,Gamaleya Research Institute,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,Russia,Ongoing,,,Phase 2,,Completed,Completed,Completed,Completed,Completed,6/17/2020,6/17/2020,,,,,,,,,,,,,,,,,,,COMPLETED,,,,,,,,,,
587,Yes,https://clinicaltrials.gov/ct2/show/NCT04437875,,https://clinicaltrials.gov/ct2/show/NCT04437875,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,,,https://clinicaltrials.gov/ct2/show/NCT04436471,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,,,,,,,,,,,,,,,
588,No,Influenza A H1N1 vector,,Influenza A H1N1 vector,National Research Centre,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,,,Egypt,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
588,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,file:///Users/priya/Downloads/novel-coronavirus-landscape-covid-19e7269232504f4ce8bb2fe20709e830bd%20(1).pdf,file:///Users/priya/Downloads/novel-coronavirus-landscape-covid-19e7269232504f4ce8bb2fe20709e830bd%20(1).pdf,file:///Users/priya/Downloads/novel-coronavirus-landscape-covid-19e7269232504f4ce8bb2fe20709e830bd%20(1).pdf,,,file:///Users/priya/Downloads/novel-coronavirus-landscape-covid-19e7269232504f4ce8bb2fe20709e830bd%20(1).pdf,file:///Users/priya/Downloads/novel-coronavirus-landscape-covid-19e7269232504f4ce8bb2fe20709e830bd%20(1).pdf,,,file:///Users/priya/Downloads/novel-coronavirus-landscape-covid-19e7269232504f4ce8bb2fe20709e830bd%20(1).pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
589,No,Structurally modified spherical particles of the tobacco mosaic virus (TMV),,Structurally modified spherical particles of the tobacco mosaic virus (TMV),Lomonosov Moscow State University,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,Repurposed-Not Approved,,Russia,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
589,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
590,No,RBD protein fused with Fc of IgG + Adjuvant,,RBD protein fused with Fc of IgG + Adjuvant,Chulalongkorn University; GPO,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,,,Thailand,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
590,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
591,No,Targeted (Langerhans cell specific) protein subunit,,Targeted (Langerhans cell specific) protein subunit,Max-Planck Institute of Colloids and Interfaces,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,KHAN-I,Germany,Ongoing,Vaccine-delivery technique using Langerhans cells,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
591,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,https://www.mpg.de/en,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
592,No,Plant-based subunit (RBD-Fc + Adjuvant),,Plant-based subunit (RBD-Fc + Adjuvant),Baiya Phytopharm; Chula Vaccine Research Center,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,New,,Thailand,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
592,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,https://baiyaphytopharm.com/wp-content/uploads/2020/07/RBD-Data-sheet-.pdf,https://baiyaphytopharm.com/wp-content/uploads/2020/07/RBD-Data-sheet-.pdf,,https://baiyaphytopharm.com/wp-content/uploads/2020/07/RBD-Data-sheet-.pdf,,,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
593,No,Subunit,,Subunit,Helix Biogen Consult; Ogbomoso & Trinity Immonoefficient Laboratory,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Unknown,New,,Nigeria,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
593,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.today.ng/news/nigeria/nigerian-universities-scientists-vaccine-coronavirus-prevention-302420,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://www.von.gov.ng/covid-19-nigerian-scientists-develop-vaccines/,,https://www.von.gov.ng/covid-19-nigerian-scientists-develop-vaccines/,,,,https://www.von.gov.ng/covid-19-nigerian-scientists-develop-vaccines/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
594,No,VSV-S,,VSV-S,Israel Institute for Biological Research,Vaccine - Prophylactic,COVID-19,Other,Vaccine,Repurposed-Not Approved,,Israel,Ongoing,VSV virus is a virus that doesn't cause diseases in humans; will be used to form antibodies against COVID,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
594,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://nocamels.com/2020/06/israeli-covid-19-vaccine-effective-animal-trial/,https://www.biorxiv.org/content/10.1101/2020.06.18.160655v1.full,https://www.jpost.com/health-science/iibr-coronavirus-vaccine-found-to-work-in-hamsters-632179,https://nocamels.com/2020/06/israeli-covid-19-vaccine-effective-animal-trial/,,https://www.jpost.com/health-science/iibr-coronavirus-vaccine-found-to-work-in-hamsters-632179,https://www.jpost.com/health-science/iibr-coronavirus-vaccine-found-to-work-in-hamsters-632179,,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
595,No,mRNA,,mRNA,IDIBAPS Hospital Clinic,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,Spain,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
595,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.thisistherealspain.com/en/latest-news/spain-10-covid-19-vaccine-projects/,https://www.thisistherealspain.com/en/latest-news/spain-10-covid-19-vaccine-projects/,https://www.thisistherealspain.com/en/latest-news/spain-10-covid-19-vaccine-projects/,https://www.thisistherealspain.com/en/latest-news/spain-10-covid-19-vaccine-projects/,,https://www.thisistherealspain.com/en/latest-news/spain-10-covid-19-vaccine-projects/,https://www.thisistherealspain.com/en/latest-news/spain-10-covid-19-vaccine-projects/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
596,No,mRNA in targeted LPNs (Langerhans cell specific),,mRNA in targeted LPNs (Langerhans cell specific),Max Planck Institute of Colloids and Interfaces,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,KHAN-I,Germany,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
596,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.mpikg.mpg.de/6306915/news_publication_14807464_transferred?c=132305,https://www.mpikg.mpg.de/6306915/news_publication_14807464_transferred?c=132305,https://www.mpikg.mpg.de/6306915/news_publication_14807464_transferred?c=132305,https://www.mpikg.mpg.de/6306915/news_publication_14807464_transferred?c=132305,https://www.mpikg.mpg.de/6306915/news_publication_14807464_transferred?c=132305,https://www.mpikg.mpg.de/6306915/news_publication_14807464_transferred?c=132305,https://www.mpikg.mpg.de/6306915/news_publication_14807464_transferred?c=132305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
597,No,"Virus-like particles, lentivirus, and baculovirus vehicles",,"Virus-like particles, lentivirus, and baculovirus vehicles",Navarrabiomed,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,,Spain,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
597,Yes,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,https://www.navarrabiomed.es/en/navarrabiomed/conocenos,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
598,No,Multitope Peptide-based Vaccine,,,Covaxx,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,,United States,Ongoing,expected to undergo human trials in summer 2020,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
598,Yes,,,,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z,https://www.covaxx.com/,https://www.covaxx.com/vaccine,https://www.covaxx.com/,https://www.covaxx.com/,,https://www.covaxx.com/vaccine,https://www.covaxx.com/vaccine,,,https://www.covaxx.com/vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
599,No,DMX-200,,DMX-200,Dimerix Ltd.,Therapeutic,ARDS,Small molecule,Combination,Repurposed-Not Approved,,Victoria; Australia,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
599,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/articles/435569-dimerixs-lead-candidate-to-enter-global-remap-cap-trial-to-treat-covid-19-ards,https://adisinsight.springer.com/drugs/800041842,"https://www.mdmag.com/medical-news/update-dmx200-treatment-focal-segmental-sclerosis#:~:text=Packham%3A%20DMX%2D200%20is%20a,chemokine%20receptor%20blocker%20(CCR2).",https://www.bioworld.com/articles/435569-dimerixs-lead-candidate-to-enter-global-remap-cap-trial-to-treat-covid-19-ards,,https://dimerix.com/products/,https://www.bioworld.com/articles/435569-dimerixs-lead-candidate-to-enter-global-remap-cap-trial-to-treat-covid-19-ards,,,https://www.bioworld.com/articles/435569-dimerixs-lead-candidate-to-enter-global-remap-cap-trial-to-treat-covid-19-ards,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
600,No,Bivalirudin,,Bivalirudin,Hamad Medical Corp.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,,Qatar,Ongoing,type of anticoagulant,,Phase 4,,,,,,,,,,,,,4,COVID-19,100,No,1,Hamad Medical Corporation,06/28/2020,09/28/2020,03/28/2021,https://clinicaltrials.gov/ct2/show/NCT04445935,Marcus Lance,00974 ext 33530292,mlance@hamad.qa,,,,,,,,,,,,
600,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315936/,https://www.marketwatch.com/press-release/impact-analysis-of-covid-19-on-bivalirudin-and-desmopressin-market-future-forecast-2017-2024-by-global-key-players-size-share-trends-revenue-analysis-and-future-growth-analysis-2020-05-18?tesla=y,https://www.facs.org/-/media/files/covid19/umiami_study_uses_of_coagulopathy.ashx,https://www.facs.org/-/media/files/covid19/umiami_study_uses_of_coagulopathy.ashx,,https://www.hamad.qa/EN/Pages/default.aspx,https://clinicaltrials.gov/ct2/show/NCT04445935,https://www.facs.org/-/media/files/covid19/umiami_study_uses_of_coagulopathy.ashx,,https://clinicaltrials.gov/ct2/show/NCT04445935,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04445935,https://clinicaltrials.gov/ct2/show/NCT04445935,https://clinicaltrials.gov/ct2/show/NCT04445935,https://clinicaltrials.gov/ct2/show/NCT04445935,,,,,,,,,,,,,,,,,,,,,
601,No,Tacrolimus,,Tacrolimus,Hospital Universitari de Bellvitge,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Spain,Ongoing,,,Phase 3,,Assume completed,Assume completed,Assume completed,,,Assume completed,Assume completed,Started,,,,3,COVID-19,84,No,1,Hospital Universitari de Bellvitge - L'Hospitalet de Llobregat - Barcelona - Spain,04/01/2020,06/01/2020,07/01/2020,https://clinicaltrials.gov/ct2/show/NCT04341038,Xavier Solanich,0034 932607500 ext 8946,xsolanich@bellvitgehospital.cat,,,,,Natalie Tang,7/17/2020,,,,,,7/17/2020
601,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~/media/5B83D25935DF43A38FF823E24604AC36.ashx,https://www.drugbank.ca/drugs/DB00864,https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~/media/5B83D25935DF43A38FF823E24604AC36.ashx,https://clinicaltrials.gov/ct2/show/NCT04341038,,https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~/media/5B83D25935DF43A38FF823E24604AC36.ashx,https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~/media/5B83D25935DF43A38FF823E24604AC36.ashx,,,https://clinicaltrials.gov/ct2/show/NCT04341038,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,https://clinicaltrials.gov/ct2/show/NCT04341038,,,,,,,,,,,,
602,No,BACTEK-R (MV130),,BACTEK-R (MV130),Inmunotek SL; Bioclever 2005 SL,Therapeutic,Pneumonia,Other,Nonspecific anti-inflammatory and immunosuppressive drugs,,,Spain,Ongoing,Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome,,Phase 3,,Assume completed,Assume completed,Assume completed,,,Assume completed,Assume completed,Started,,,,3,COVID-19,100,No,1,Hospital Metropolitano Santiago - Santiago De Los Caballeros - Dominican Republic,06/10/2020,07/01/2021,07/31/2021,https://clinicaltrials.gov/ct2/show/NCT04363814,Nicolas Batlle,18299472222,gangeles@gmail.com;mcasanovas@inmunotek.com,,,,,Natalie Tang,7/17/2020,,,,,,7/17/2020
602,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04363814,https://www.inmunotek.com/en/022011-bactek-study/,https://www.inmunotek.com/en/022011-bactek-study/,,,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://www.inmunotek.com/en/022011-bactek-study/,,https://clinicaltrials.gov/ct2/show/NCT04363814,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,https://clinicaltrials.gov/ct2/show/NCT04363814,,,,,Natalie Tang,7/18/2020,,,,,,7/18/2020
603,No,Doxycycline,,Doxycycline,Nantes University Hospital,Therapeutic,COVID-19,Small molecule,Antibiotics and antiparasitics,Repurposed-Approved,,France,Ongoing,,,Phase 3,,Assume completed,Assume completed,Assume completed,,,Assume completed,Assume completed,Started,,,,3,COVID-19,330,No,6,CHU Avicenne - APHP - France; CHU Bordeaux - France; CHU Caen - France; CHU Dijon - France; CHU Grenoble - France; CHU Nantes - France,06/01/2020,12/01/2020,12/01/2020,https://clinicaltrials.gov/ct2/show/NCT04371952,Eve MAUBEC; Fabrice BONNET; Anne DOMPMARTIN-BLANCHERE; Lionel PIROTH; Marie-Thérèse Leccia; Brigitte DRENO PUPH; Amir Khammari,1 48 95 70 90 ext 0033;  5 56 79 58 23 ext 0033; 2 31 27 25 10 ext 0033; 3 30 29 33 05 ext 0033; 476769320 ext 0033; 2 40 08 31 18 ext 0033,eve.maubec@aphp.fr; fabrice.bonnet@chu-bordeaux.fr; dompmartin-a@chu-caen.fr; lionel.piroth@chu-dijon.fr; mtleccia@chu-grenoble.fr; brigitte.dreno@atlanmed.fr; amir.khammari@chu-nantes.fr,,Not yet recruiting,,,Natalie Tang,7/17/2020,,,,,,7/17/2020
603,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04371952,https://www.drugbank.ca/drugs/DB00864,https://www.drugbank.ca/drugs/DB00864,https://www.drugbank.ca/drugs/DB00864,,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,,,https://clinicaltrials.gov/ct2/show/NCT04371952,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,https://clinicaltrials.gov/ct2/show/NCT04371952,,https://clinicaltrials.gov/ct2/show/NCT04371952,,,Natalie Tang,7/20/2020,,,,,,7/20/2020
604,No,Sarconeos (BIO-101),,Sarconeos (BIO-101),Biophytis SA,Therapeutic,ARDS,Small molecule,Other,Repurposed-Not Approved,Biophytis SA,Belgium; United States; United Kingdom,Ongoing,Potential treatment for respiratory failure associated with Covid-19.,,Phase 2,,Assume completed,Assume completed,Assume completed,,7/2/2020,Assume completed,Started,,,,,2,COVID-19,310,No,1,AZ-Sint Maarten - Mechelen - Belgium,6/16/20,7/1,9/1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,Shmuel Agus,16176424891,sam.agus@biophytis.com,,,,,Natalie Tang,7/19/2020,,,,,,7/19/2020
604,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biophytis.com/wp-content/uploads/2020/04/Biophytis-COVA-Launch-EN-PR.pdf,https://www.biophytis.com/wp-content/uploads/2020/04/Biophytis-COVA-Launch-EN-PR.pdf,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://www.biophytis.com/wp-content/uploads/2020/04/Biophytis-COVA-Launch-EN-PR.pdf,https://www.biophytis.com/wp-content/uploads/2020/04/Biophytis-COVA-Launch-EN-PR.pdf,https://www.biospace.com/article/releases/biophytis-receives-fda-ind-clearance-for-cova-a-phase-2-3-clinical-trial-with-sarconeos-bio101-for-the-treatment-of-patients-with-covid-19-related-respiratory-failure/,https://www.biophytis.com/wp-content/uploads/2020/04/Biophytis-COVA-Launch-EN-PR.pdf,https://www.biophytis.com/wp-content/uploads/2020/04/Biophytis-COVA-Launch-EN-PR.pdf,,https://www.biophytis.com/wp-content/uploads/2020/04/Biophytis-COVA-Launch-EN-PR.pdf,,,,,,https://www.biospace.com/article/releases/biophytis-receives-fda-ind-clearance-for-cova-a-phase-2-3-clinical-trial-with-sarconeos-bio101-for-the-treatment-of-patients-with-covid-19-related-respiratory-failure/,,,,,,,https://www.biophytis.com/wp-content/uploads/2020/04/Biophytis-COVA-Launch-EN-PR.pdf,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04472728?term=Sarconeos+%28BIO-101%29&draw=2&rank=1,,,,,Natalie Tang,7/19/2020,,,,,,7/19/2020
605,No,sofosbuvir; daclatasvir; hydroxychloroquine,sofosbuvir; daclatasvir; hydroxychloroquine,,Cairo University,Therapeutic,COVID-19,Combination,Antiviral drugs-broad spectrum,Repurposed-Approved,Sovaldi - Gilead Sciences; Daklinza - Bristol-Myers Squibb; Plaquenil - Sanofi Pharmaceuticals,Egypt; Iran,Ongoing,,,Phase 2,,Assume completed,Assume completed,Assume completed,,,Assume completed,Started,,,,,2,COVID-19,100,No,,,07/2020,10/2020,12/2020,https://clinicaltrials.gov/ct2/show/NCT04443725,,,,,Not yet recruiting,,,Natalie Tang,7/19/2020,,,,,,7/19/2020
605,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.healio.com/news/infectious-disease/20200709/hcv-drugs-sofosbuvir-daclatasvir-show-promise-as-potential-covid19-treatment,https://www.healio.com/news/infectious-disease/20200709/hcv-drugs-sofosbuvir-daclatasvir-show-promise-as-potential-covid19-treatment,https://www.healio.com/news/infectious-disease/20200709/hcv-drugs-sofosbuvir-daclatasvir-show-promise-as-potential-covid19-treatment,https://www.healio.com/news/infectious-disease/20200709/hcv-drugs-sofosbuvir-daclatasvir-show-promise-as-potential-covid19-treatment,https://www.medscape.com/viewarticle/933822,https://clinicaltrials.gov/ct2/show/NCT04443725,https://clinicaltrials.gov/ct2/show/NCT04443725,,,https://clinicaltrials.gov/ct2/show/NCT04443725,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04443725,https://clinicaltrials.gov/ct2/show/NCT04443725,https://clinicaltrials.gov/ct2/show/NCT04443725,https://clinicaltrials.gov/ct2/show/NCT04443725,,,https://clinicaltrials.gov/ct2/show/NCT04443725,https://clinicaltrials.gov/ct2/show/NCT04443725,https://clinicaltrials.gov/ct2/show/NCT04443725,https://clinicaltrials.gov/ct2/show/NCT04443725,,,,,https://clinicaltrials.gov/ct2/show/NCT04443725,,,Natalie Tang,7/24/2020,,,,,,7/24/2020
606,No,pamrevlumab,pamrevlumab,,Fibrogen Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Fibrogen Inc,United States,Ongoing,Anti-connective growth factor monoclonal antibody,,Phase 2,,Assume completed,Assume completed,Assume completed,,,Assume completed,6/21/2020,,,,,2,COVID-19,130,No,,,,,,,,,,,,,,Natalie Tang,7/19/2020,,,,,,7/19/2020
606,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,,,,,,,,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,,,,,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-first-patient-enrolled-pamrevlumab-clinical-0,,,,,,,,,,,,,,,,,,,,,
607,No,atazanavir; dexamethasone,atazanavir; dexamethasone,NA-831,Neuroactiva Inc.,Therapeutic,COVID-19,Combination,Combination,Repurposed-Approved,NeuroActiva Inc.,United States,Ongoing,Anti-retroviral and anti-inflammatory combination therapy,,Phase 2,,Assume completed,Assume completed,Assume completed,,,Assume completed,8/15/2020,,,,,2,COVID-19,525,No,31,Coronavirus Research Institute- Testing Site - Los Angeles - United States - 90095; Coronavirus Research Institute - Orange - United States - 92868; Coronavirus Research Institute-Testing Site - Palo Alto - California - United States - 94304; Coronavirus Research Institute-Testing Site - Sacramento - California - United States - 95817; Coronavirus Research Institute-Testing Site - San Diego - California - United States - 92314; Coronavirus Research Testing Site - San Francisco - California - United States - 94110; Coronavirus Research Institute-Testing Site - Sunnyvale - California - United States - 94086; Coronavirus Research Institute-Testing Site - Washington - District of Columbia - United States - 20007; Coronavirus Research Institute-Testing Site - Washington - District of Columbia - United States - 20010; Coronavirus Research Institute-Testing Site - Fort Lauderdale - Florida - United States - 33308; Coronavirus Research Institute-Testing Site - Tampa - Florida - United States - 33620; Coronavirus Research Institute- Testing Site - Chicago - Illinois - United States - 60612; Coronavirus Research Institute-Testing Site - Naperville - Illinois - United States - 60540; Coronavirus Research Institute-Testing Site - Baltimore - Maryland - United States - 21287; Coronavirus Research Institute-Testing Site - Bethesda - Maryland - United States - 20892; Coronavirus Research Institute-Testing Site - Boston - Massachusetts - United States - 02114; Coronavirus Research Institute-Testing Site - Worcester- Massachusetts - United States - 01655; Coronavirus Research Institute-Testing Site - Ann Arbor - Michigan - United States - 48109;Coronavirus Research Institute-Testing Site - Detroit - Michigan - United States - 48202; Coronavirus Research Institute-Testing Site - Newark - New Jersey - United States - 07102; Coronavirus Research Institute-Testing Site - Bronx - New York - United States - 10467; Coronavirus Research Institute-Testing Site- New York - United States - 10016; Coronavirus Research Institute- Testing Site - Rochester - New York - United States - 14642; Coronavirus Research Institute-Testing Site - Durham - North Carolina - United States - 27704; Coronavirus Research Institute-Testing Site - Philadelphia - Pennsylvania - United States - 19104; Coronavirus Research Institute- Testing Site - Fort Sam Houston - Texas - United States - 78234; Coronavirus Research Institute-Testing Site -Galveston - Texas - United States - 77555; Coronavirus Research Institute-Testing Site - Houston - Texas - United States - 77030; Coronavirus Research Institute-Testing Site - Kirkland - Washington - United States - 98034; Coronavirus Research Institute-Testing Site - Seattle - Washington - United States - 98104; Coronavirus Research Institute-Testing Site - Tacoma - Washington - United States - 98431,08/15/2020,12/31/2020,02/15/2020,https://clinicaltrials.gov/ct2/show/NCT04452565,Brian Tran; Frank Kennedy,14159413133; 14159413133,BTran@neuroactiva.com; FKennedy@neuroactiva.com,,,,,Natalie Tang,7/19/2020,,,,,,7/19/2020
607,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,,,https://clinicaltrials.gov/ct2/show/NCT04452565,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04452565,,,,,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,,https://clinicaltrials.gov/ct2/show/NCT04452565,https://clinicaltrials.gov/ct2/show/NCT04452565,,,,,,,,,,,,
608,No,epoprostenol,epoprostenol,Epoprostenol (Ventoprost),Aerogen Pharma Ltd.,Therapeutic,ARDS,Small molecule,Other,Repurposed-Approved,,United States,Ongoing,A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation.,,Phase 2,,Assume completed,Assume completed,Assume completed,,,Assume completed,,,,,,2,COVID-19,30,No,1,Ohio State University - Columbus - Ohio,7/31/20,12/1/20,2/1/21,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,Judy R Doto,4847165438,judydoto@aerogenpharma.com,,Not yet Recruiting,,,Natalie Tang,7/19/2020,,,,,,7/19/2020
608,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.acc.org/latest-in-cardiology/articles/2020/05/13/08/55/inpatient-use-of-inhaled-pulmonary-vasodilator-therapy-in-patients-infected-with-covid-19,https://www.acc.org/latest-in-cardiology/articles/2020/05/13/08/55/inpatient-use-of-inhaled-pulmonary-vasodilator-therapy-in-patients-infected-with-covid-19,https://www.acc.org/latest-in-cardiology/articles/2020/05/13/08/55/inpatient-use-of-inhaled-pulmonary-vasodilator-therapy-in-patients-infected-with-covid-19,https://www.acc.org/latest-in-cardiology/articles/2020/05/13/08/55/inpatient-use-of-inhaled-pulmonary-vasodilator-therapy-in-patients-infected-with-covid-19,,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04452669?term=epoprostenol&cond=covid&draw=2&rank=1,,,,,,,,,,,,
609,No,razuprotafib,razuprotafib,,Aerpio Pharmaceuticals Inc.,Therapeutic,ARDS,Other,Other,Repurposed-Not Approved,Aerpio Pharmaceuticals Inc; Quantum Leap,United States,Ongoing,"Razuprotafib blocks vascular endothelial protein tyrosine phosphatase, or VE-PTP, that depresses production of Tie2 receptor proteins. Tie2 proteins are receptors on the surface of cells that bind to angiopoietins, which are protein growth factors needed to form blood vessels; Thus, razuprotafib activates Tie2 receptor proteins, allowing for stable blood vessel formation in affected tissue in the eyes and kidneys, which the company is testing in mid-stage clinical trials. Aerpio says it has preclinical evidence showing the drug’s beneficial effects extend to a number of disease states including ARDS resulting from Covid-19 infections.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Natalie Tang,7/19/2020,,,,,,7/19/2020
609,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://sciencebusiness.technewslit.com/?p=39191,https://www.globenewswire.com/news-release/2020/05/27/2039771/0/en/Aerpio-Pharmaceuticals-Inc-and-Quantum-Leap-Healthcare-Collaborative-Announce-the-Selection-of-Razuprotafib-for-Evaluation-in-the-I-SPY-COVID-Trial-for-the-Treatment-of-Acute-Respi.html,https://sciencebusiness.technewslit.com/?p=39191,https://sciencebusiness.technewslit.com/?p=39191,https://www.globenewswire.com/news-release/2020/05/27/2039771/0/en/Aerpio-Pharmaceuticals-Inc-and-Quantum-Leap-Healthcare-Collaborative-Announce-the-Selection-of-Razuprotafib-for-Evaluation-in-the-I-SPY-COVID-Trial-for-the-Treatment-of-Acute-Respi.html,https://www.globenewswire.com/news-release/2020/05/27/2039771/0/en/Aerpio-Pharmaceuticals-Inc-and-Quantum-Leap-Healthcare-Collaborative-Announce-the-Selection-of-Razuprotafib-for-Evaluation-in-the-I-SPY-COVID-Trial-for-the-Treatment-of-Acute-Respi.html,https://www.globenewswire.com/news-release/2020/05/27/2039771/0/en/Aerpio-Pharmaceuticals-Inc-and-Quantum-Leap-Healthcare-Collaborative-Announce-the-Selection-of-Razuprotafib-for-Evaluation-in-the-I-SPY-COVID-Trial-for-the-Treatment-of-Acute-Respi.html,https://www.globenewswire.com/news-release/2020/05/27/2039771/0/en/Aerpio-Pharmaceuticals-Inc-and-Quantum-Leap-Healthcare-Collaborative-Announce-the-Selection-of-Razuprotafib-for-Evaluation-in-the-I-SPY-COVID-Trial-for-the-Treatment-of-Acute-Respi.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
610,No,apilimod,apilimod,LAM-002A,AI Therapeutics Inc.,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Approved,AI Therapeutics Inc.,United States,Ongoing,,,Phase 2,,Assume completed,Assume completed,Assume completed,,,Assume completed,7/15/2020,,,,,2,COVID-19,142,No,1,Yale University - New Haven - Connecticut - United States,07/15/2020,12/31/20,01/31/2021,https://clinicaltrials.gov/ct2/show/NCT04446377,Charles Dela Cruz; Peter Young,4158608370,pyoung@ai-thera.com,,,,,Natalie Tang,7/19/2020,,,,,,7/19/2020
610,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://adisinsight.springer.com/drugs/800043703,https://adisinsight.springer.com/drugs/800043703,https://adisinsight.springer.com/drugs/800043703,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,https://clinicaltrials.gov/ct2/show/NCT04446377#contacts,,,,,,,,,,,,
611,No,DUR-928,,DUR-928,Durect Corp.,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Not Approved,,United States,Ongoing,,,Phase 2,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,6/1/2020,,,,,2,COVID-19,80,No,3,Chicago-Illinois; Detroit- Michigan; Newark-New Jersey,09/21/2020,09/01/2021,10/01/2021,https://clinicaltrials.gov/ct2/show/NCT04447404,Deborah Scott ;Julie Fergus,4087771417,deborah.scott@durect.com ; julie.fergus@durect.com        ,,,,,,,,,,,,
611,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://www.durect.com/dur-928/overview/,http://www.durect.com/dur-928/overview/,http://www.durect.com/dur-928/overview/,http://www.durect.com/dur-928/overview/,,https://www.biospace.com/article/releases/durect-corporation-announces-initiation-of-patient-recruitment-in-phase-2-safety-and-efficacy-study-of-dur-928-in-covid-19-patients-with-acute-liver-or-kidney-injury/,http://www.durect.com/dur-928/overview/,,,,,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=5,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=6,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=7,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=8,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=9,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=10,,,,,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04447404?term=DUR-928&draw=2&rank=4,,,,,,,,,,
612,No,Tecfarin,,Tecfarin,Espero Biopharma Inc.,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Not Approved,,United States,Ongoing,Currently in phase 3 for treating patients with End Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib),,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
612,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://esperobio.com/espero-biopharma-inc-expands-collaboration-effort-for-tecarfarin/,https://esperobio.com/espero-biopharma-inc-expands-collaboration-effort-for-tecarfarin/,https://esperobio.com/espero-biopharma-inc-expands-collaboration-effort-for-tecarfarin/,https://esperobio.com/espero-biopharma-inc-expands-collaboration-effort-for-tecarfarin/,,https://esperobio.com/,https://esperobio.com/,https://esperobio.com/espero-biopharma-inc-expands-collaboration-effort-for-tecarfarin/,,https://esperobio.com/espero-biopharma-inc-expands-collaboration-effort-for-tecarfarin/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
613,No,ILT101,ILT101,Interleukin-2,ILTOO Pharma,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,Assistance Publique - Hôpitaux de Paris,France,Ongoing,,,Phase 2,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,6/1/2020,,,,,2,COVID-19,30,No,1,Paris-France,06/01/2020,07/01/2020,08/01/2020,https://clinicaltrials.gov/ct2/show/NCT04357444,Jean-Michel Constantin,3301421600,Jean-michel.constantin@aphp.fr,,,,,,,,,,,,
613,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,https://clinicaltrials.gov/ct2/show/NCT04357444#contacts,,,,,,,,,,,
614,No,Nangibotide,,Nangibotide,Inotrem,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,France,Ongoing,,,Phase 2,,,,,,,,,,,,,2,COVID-19,60,No,1,Réanimation Médicale Hôpital Central - Nancy - France,6/1,3/1,3/1,https://clinicaltrials.gov/ct2/show/NCT04429334,Jean-Jacques Garaud,,covtrem@inotrem.com,,,,,,,,,,,,
614,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nancy, France",,,,,,,,,,,,,,,,,,,
615,No,Inhibitor of Neutrophil Elastase; Isotretinoin,,Inhibitor of Neutrophil Elastase; Isotretinoin,Kafrelsheikh University,Therapeutic,COVID-19,Combination,Other,Repurposed-Not Approved,Damietta University,Egypt,Ongoing,,,Phase 2,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,6/1/2020,,,,,2,COVID-19,360,Yes,,Egypt,10/01/2020,10/01/2020,12/01/2020,https://clinicaltrials.gov/ct2/show/NCT04396067,Mahmoud Elkazzaz,,	mahmoudramadan2051@yahoo.com,,,,,,,,,,,,
615,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,https://clinicaltrials.gov/ct2/show/NCT04396067#contacts,,,,,,,,,,,,
616,No,Cosentyx,Cosentyx,Secukinumab,Lomonosov Moscow State University Medical Research and Education Center,Therapeutic,COVID-19,Combination,Monoclonal antibodies,Repurposed-Approved,,Russia,Ongoing,Study compares COLchicine Versus Ruxolitinib and Secukinumab,,Phase 2,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,5/8/2020,,,,,2,COVID-19,70,No,1,Moscow-Russia,05/08/2020,07/22/3030,08/23/2020,https://clinicaltrials.gov/ct2/show/NCT04403243,Julia Begrambekova; Yana Orlova,79854679273 ; 791651663002,begrambekova@ossn.ru ; yaorlova@mc.msu.ru,,,,,,,,,,,,
616,Yes,https://www.cosentyx.com/,https://www.cosentyx.com/,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,https://clinicaltrials.gov/ct2/show/NCT04403243#contacts,,,,,,,,,,
617,No,calcifediol,calcifediol,Rayaldee,Opko Health Inc.,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,United States,Ongoing,"Despite information that a phase 2 trial is happening, no information on clinical trials.com",,Phase 2,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,,,,,,2,COVID-19,116,,,,,,,,,,,,,,,,,,,,,,
617,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.opko.com/news-media/press-releases/detail/394/fda-authorizes-opko-health-clinical-trial-evaluating,https://www.drugbank.ca/drugs/DB00146,https://www.drugbank.ca/drugs/DB00147,https://www.opko.com/news-media/press-releases/detail/394/fda-authorizes-opko-health-clinical-trial-evaluating,,https://www.biospace.com/article/releases/fda-authorizes-opko-health-clinical-trial-evaluating-rayaldee-in-covid-19-patients/,https://www.biospace.com/article/releases/fda-authorizes-opko-health-clinical-trial-evaluating-rayaldee-in-covid-19-patients/,https://www.biospace.com/article/releases/fda-authorizes-opko-health-clinical-trial-evaluating-rayaldee-in-covid-19-patients/,,https://www.biospace.com/article/releases/fda-authorizes-opko-health-clinical-trial-evaluating-rayaldee-in-covid-19-patients/,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,,,,,,https://www.biospace.com/article/releases/fda-authorizes-opko-health-clinical-trial-evaluating-rayaldee-in-covid-19-patients/,https://www.biospace.com/article/releases/fda-authorizes-opko-health-clinical-trial-evaluating-rayaldee-in-covid-19-patients/,https://www.biospace.com/article/releases/fda-authorizes-opko-health-clinical-trial-evaluating-rayaldee-in-covid-19-patients/,,,,,,,,,,,,,,,,,,,,,,
618,No,AMY-101,,AMY-101,Amyndas Pharmaceuticals Inc.,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,is a C3 inhibitor,,Phase 2,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,7/1/2020,,,,,2,COVID-19,144,No,,,07/01/2020,01/01/2021,03/01/2021,https://clinicaltrials.gov/ct2/show/NCT04395456,,,,,,,,,,,,,,,
618,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,,https://www.amyndas.com/contact/,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,https://clinicaltrials.gov/ct2/show/NCT04395456#contacts,,,,,,,,,,,,,,,
619,No,RBT-9,,RBT-9,Renibus Therapeutics Inc.,Therapeutic,COVID-19,Unknown,Antiviral drugs-not specified,Repurposed-Not Approved,Frontier Scientific,United States,Ongoing,,,Phase 2,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,6/30/2020,,,,,2,COVID-19,252,No,1,Fort Worth- Texas,06/30/2020,06/30/2020,12/31/2020,https://clinicaltrials.gov/ct2/show/NCT04364763,Austin Keyser; Stacey Ruiz,	6822851733,"covid19trials@renibus.com; sruiz@renibus.com	
",,,,,,,,,,,,
619,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.biospace.com/article/releases/frontier-scientific-develops-and-provides-process-to-produce-active-pharmaceutical-ingredient-for-clinical-trial-of-covid-19-therapeutic-investigational-drug-rbt-9/,https://www.biospace.com/article/releases/frontier-scientific-develops-and-provides-process-to-produce-active-pharmaceutical-ingredient-for-clinical-trial-of-covid-19-therapeutic-investigational-drug-rbt-9/,https://www.biospace.com/article/releases/frontier-scientific-develops-and-provides-process-to-produce-active-pharmaceutical-ingredient-for-clinical-trial-of-covid-19-therapeutic-investigational-drug-rbt-9/,https://www.biospace.com/article/releases/frontier-scientific-develops-and-provides-process-to-produce-active-pharmaceutical-ingredient-for-clinical-trial-of-covid-19-therapeutic-investigational-drug-rbt-9/,https://www.biospace.com/article/releases/frontier-scientific-develops-and-provides-process-to-produce-active-pharmaceutical-ingredient-for-clinical-trial-of-covid-19-therapeutic-investigational-drug-rbt-9/,https://www.biospace.com/article/releases/frontier-scientific-develops-and-provides-process-to-produce-active-pharmaceutical-ingredient-for-clinical-trial-of-covid-19-therapeutic-investigational-drug-rbt-9/,https://www.biospace.com/article/releases/frontier-scientific-develops-and-provides-process-to-produce-active-pharmaceutical-ingredient-for-clinical-trial-of-covid-19-therapeutic-investigational-drug-rbt-9/,,,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04364763?term=RBT-9&draw=2&rank=1#contacts,,,,,,,,,,,,
620,No,SNDX-6352,SNDX-6352,Axatilimab,Syndax Pharmaceuticals,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United Stattes,Ongoing,,,Phase 2,,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,Assumed Completed,5/30/2020,,,,,2,COVID-19,186,No,2,Scottsdale- Arizona; Bronx- New York,05/30/2020,11/15/2020,11/15/2020,https://clinicaltrials.gov/ct2/show/NCT04415073,Sue Fischer,7817959419,sfischer@syndax.com	,,,,,,,,,,,,
620,Yes,https://www.syndax.com/pipeline/,https://www.syndax.com/pipeline/,https://clinicaltrials.gov/ct2/show/NCT04415073?recrs=a&type=Intr&cond=COVID-19&draw=14&rank=606,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://www.syndax.com/pipeline/sndx-6352-cgvhd/?gclid=Cj0KCQjw0rr4BRCtARIsAB0_48NDijYDEjJo1YwUfBkKSxB1uqVGIBraLLcRHE2jiv5TmqFxWz6djYUaAgWyEALw_wcB,http://www.syndax.com/pipeline/sndx-6352-cgvhd/?gclid=Cj0KCQjw0rr4BRCtARIsAB0_48NDijYDEjJo1YwUfBkKSxB1uqVGIBraLLcRHE2jiv5TmqFxWz6djYUaAgWyEALw_wcB,http://www.syndax.com/pipeline/sndx-6352-cgvhd/?gclid=Cj0KCQjw0rr4BRCtARIsAB0_48NDijYDEjJo1YwUfBkKSxB1uqVGIBraLLcRHE2jiv5TmqFxWz6djYUaAgWyEALw_wcB,http://www.syndax.com/pipeline/sndx-6352-cgvhd/?gclid=Cj0KCQjw0rr4BRCtARIsAB0_48NDijYDEjJo1YwUfBkKSxB1uqVGIBraLLcRHE2jiv5TmqFxWz6djYUaAgWyEALw_wcB,,http://www.syndax.com/pipeline/sndx-6352-cgvhd/?gclid=Cj0KCQjw0rr4BRCtARIsAB0_48NDijYDEjJo1YwUfBkKSxB1uqVGIBraLLcRHE2jiv5TmqFxWz6djYUaAgWyEALw_wcB,http://www.syndax.com/pipeline/sndx-6352-cgvhd/?gclid=Cj0KCQjw0rr4BRCtARIsAB0_48NDijYDEjJo1YwUfBkKSxB1uqVGIBraLLcRHE2jiv5TmqFxWz6djYUaAgWyEALw_wcB,,,https://clinicaltrials.gov/ct2/show/NCT04415073,,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,https://clinicaltrials.gov/ct2/show/NCT04415073#contacts,,,,,,,,,,,,
621,No,Zilucoplan,,Zilucoplan,UCB Pharma,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,"University Hospital, Ghent",Belgium,Ongoing,,,Phase 2,,,,,,,5/22/2020,,,,,,2,COVID-19,81,No,9,Aalst - Belgium; Brugge - Belgium; Brussels - Belgium; Gent - Belgium; Leper - Belgium; Liège - Belgium; Roeselare - Belgium; Tongeren - Belgium,05/22/2020,05/2021,09/2021,https://www.clinicaltrials.gov/ct2/show/NCT04382755,Anja Delporte; Bart Lambrech,003293320228,anja.delporte@uzgent.be; bart.lambrecht@ugent.be,,,,,,,,,,,,
621,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.drugbank.ca/drugs/DB15636,https://myastheniagravisnews.com/zilucoplan/,https://www.drugbank.ca/drugs/DB15636,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.ucb.com/our-science/pipeline,,,https://www.ucb.com/our-science/pipeline,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04382755,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,https://www.clinicaltrials.gov/ct2/show/NCT04382755,,,,,,,,,,,,
622,No,Brequinar,,Brequinar,Clear Creek Bio Inc.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Not Approved,,United States,Ongoing,,,Phase 1,,,,,,,6/25/2020,,,,,,1,COVID-19,24,No,3,Hartford Hospital - Hartford - Connecticut; University of South Florida/Tampa General - Tampa - Florida; Temple University - Philadelphia - Pennsylvania,06/25/2020,03/2021,4/2021,https://clinicaltrials.gov/ct2/show/NCT04425252,Barbara L. Powers,(617) 765-2252,clinical@clearcreekbio.com,,,,,,,,,,,,
622,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04425252,https://www.clearcreekbio.com/,https://www.clearcreekbio.com/,https://www.clearcreekbio.com/,,https://www.clearcreekbio.com/,https://www.clearcreekbio.com/,,,https://clinicaltrials.gov/ct2/show/NCT04425252,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04425252,,,,,,https://clinicaltrials.gov/ct2/show/NCT04425252,,https://clinicaltrials.gov/ct2/show/NCT04425252,https://clinicaltrials.gov/ct2/show/NCT04425252,https://clinicaltrials.gov/ct2/show/NCT04425252,https://clinicaltrials.gov/ct2/show/NCT04425252,https://clinicaltrials.gov/ct2/show/NCT04425252,https://clinicaltrials.gov/ct2/show/NCT04425252,https://clinicaltrials.gov/ct2/show/NCT04425252,https://clinicaltrials.gov/ct2/show/NCT04425252,https://clinicaltrials.gov/ct2/show/NCT04425252,https://clinicaltrials.gov/ct2/show/NCT04425252,https://clinicaltrials.gov/ct2/show/NCT04425252,,,,,,,,,,,,
623,No,Lanadelumab,,Lanadelumab,Radbout Univercity; Takeda,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Netherlands,Ongoing,,,Phase 1,,,,,,,Target: 6/25/2020,,,,,,1,COVID-19,80,No,10,s-Hertogenbosch - Netherlands; Amsterdam - Netherlands; Arnhem - Netherlands; Blaricum - Netherlands; Breda - Netherlands; Den Haag - Netherlands; Nijmegen - Netherlands; Tilburg - Netherlands; Utrecht - Netherlands; Zwolle - Netherlands,10/03/2020,08/03/2021,08/03/2021,https://clinicaltrials.gov/ct2/show/NCT04422509,Roger Bruggemann,0031243611111,roger.bruggemann@radboudumc.nl,,,,,,,,,,,,
623,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04422509,https://www.takhzyro.com/,https://www.takhzyro.com/,https://www.takhzyro.com/,,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,,,https://clinicaltrials.gov/ct2/show/NCT04422509,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04422509,,,,,,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,https://clinicaltrials.gov/ct2/show/NCT04422509,,https://www.ru.nl/english/,,,,,,,,,,
624,No,Pentoxifylline,,Pentoxifylline,Sadat City University,Therapeutic,COVID-19,Other,Combination,Repurposed-Approved,,Egypt,Ongoing,,,Phase 1,,,,,,,Target: 08/13/2020,,,,,,1,COVID-19,200,No,1,Shibīn Al Kawn - Egypt,08/13/2020,12/30/2020,12/30/2020,https://clinicaltrials.gov/ct2/show/NCT04433988,Mahmoud S Abdalla,00201063340887,mahmoud.samy@gop.usc.edu.eg,,,,,,,,,,,,
624,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04433988,https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13733?af=R,https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13733?af=R,https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13733?af=R,,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,,,https://clinicaltrials.gov/ct2/show/NCT04433988,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04433988,,,,,,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,https://clinicaltrials.gov/ct2/show/NCT04433988,,,,,,,,,,,,
625,No,SBI-101,,SBI-101,Sentien Biotechnologies Inc.,Therapeutic,COVID-19,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,,,Phase 1,,,,,,,Target: 08/2020,,,,,,1,COVID-19,24,No,,,08/2020,02/2021,07/2021,https://clinicaltrials.gov/ct2/show/NCT04445220,Brian Miller,781-361-9031,brian.miller@sentienbiotech.com,,,,,,,,,,,,
625,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04445220,https://sentienbiotech.com/product/,https://sentienbiotech.com/product/,https://clinicaltrials.gov/ct2/show/NCT04445220,,https://sentienbiotech.com/,https://clinicaltrials.gov/ct2/show/NCT04445220,,,https://clinicaltrials.gov/ct2/show/NCT04445220,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04445220,,,,,,https://clinicaltrials.gov/ct2/show/NCT04445220,https://clinicaltrials.gov/ct2/show/NCT04445220,https://clinicaltrials.gov/ct2/show/NCT04445220,https://clinicaltrials.gov/ct2/show/NCT04445220,,,https://clinicaltrials.gov/ct2/show/NCT04445220,https://clinicaltrials.gov/ct2/show/NCT04445220,https://clinicaltrials.gov/ct2/show/NCT04445220,https://clinicaltrials.gov/ct2/show/NCT04445220,https://clinicaltrials.gov/ct2/show/NCT04445220,https://clinicaltrials.gov/ct2/show/NCT04445220,https://clinicaltrials.gov/ct2/show/NCT04445220,,,,,,,,,,,,
626,No,TL-895,,TL-895,Telios Pharma Inc.,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,,United States,Ongoing,,,Phase 1,,,,,,,Target: 06/2020,,,,,,1,COVID-19,146,No,,,06/2020,7/2021,07/2021,https://www.clinicaltrials.gov/ct2/show/NCT04419623,John Mei,650-542-0136,jmei@teliospharma.com,,,,,,,,,,,,
626,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,,,https://www.clinicaltrials.gov/ct2/show/NCT04419623,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04419623,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,,,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,https://www.clinicaltrials.gov/ct2/show/NCT04419623,,,,,,,,,,,,
627,No,Agent-797,,Agent-797,Agenus Inc.,Therapeutic,COVID-19,Cell therapies,Combination,Repurposed-Not Approved,,United States,Ongoing,,,Pre-Clinical Testing,,,,,,6/2/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
627,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://agenusbio.com/pipeline/,https://agenusbio.com/pipeline/,https://investor.agenusbio.com/2020-06-02-FDA-Clears-IND-for-iNKT-Cells-to-Treat-COVID-19-Patients,https://agenusbio.com/inkt-allogeneic-cell-therapy/,,https://investor.agenusbio.com/2020-06-02-FDA-Clears-IND-for-iNKT-Cells-to-Treat-COVID-19-Patients,https://agenusbio.com/pipeline/,,,https://agenusbio.com/pipeline/,,,,,,https://investor.agenusbio.com/2020-06-02-FDA-Clears-IND-for-iNKT-Cells-to-Treat-COVID-19-Patients,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
628,No,APL-9,,APL-9,Apellis Pharmaceuticals Inc.,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,,,Phase 1,,,,,,,5/26/2020,,,,,,1,COVID-19,66,No,4,Westchester General Hospital - Miami - Florida; Norton Women's and Children's Hospital - Louisville - Kentucky; Audobon Hospital - Louisville - Kentucky; University at Buffalo - Buffalo - New York,05/26/2020,11/2020,11/2020,https://clinicaltrials.gov/ct2/show/NCT04402060,,833-284-6361,clinicaltrials@apellis.com,,,,,,,,,,,,
628,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://investors.apellis.com/news-releases/news-release-details/apellis-initiates-phase-12-study-apl-9-patients-severe-covid-19,https://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-will-commence-apl-9-program-control,https://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-will-commence-apl-9-program-control,http://apellis.com/our-science/our-pipeline,,https://apellis.com/contact-us/,https://investors.apellis.com/news-releases/news-release-details/apellis-initiates-phase-12-study-apl-9-patients-severe-covid-19,,,https://investors.apellis.com/news-releases/news-release-details/apellis-initiates-phase-12-study-apl-9-patients-severe-covid-19,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04402060,,,,,,https://clinicaltrials.gov/ct2/show/NCT04402060,https://clinicaltrials.gov/ct2/show/NCT04402060,https://clinicaltrials.gov/ct2/show/NCT04402060,https://clinicaltrials.gov/ct2/show/NCT04402060,https://clinicaltrials.gov/ct2/show/NCT04402060,https://clinicaltrials.gov/ct2/show/NCT04402060,https://clinicaltrials.gov/ct2/show/NCT04402060,https://clinicaltrials.gov/ct2/show/NCT04402060,https://clinicaltrials.gov/ct2/show/NCT04402060,https://clinicaltrials.gov/ct2/show/NCT04402060,,https://clinicaltrials.gov/ct2/show/NCT04402060,https://clinicaltrials.gov/ct2/show/NCT04402060,,,,,,,,,,,,
629,No,BX-U001,,BX-U001,Baylx Inc.,Therapeutic,COVID-19,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,On Hold,,,Phase 1,,,,,,6/4/2020,Target: 09/01/2020,,,,,,1,COVID-19,9,No,,,12/1/2020,4/30/2021,6/30/2021,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,Vincent Liao,949-308-1952,baylx@baylxinc.com,,,,,,,,,,,,
629,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells,https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells,https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells,https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells,,https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells,https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells,,,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,,,,,,"https://www.baylxinc.com/post/baylx-inc-received-us-fda-clearance-of-ind-application-for-its-cord-tissue-mesenchymal-stem-cells#:~:text=Irvine%2C%20CA%2C%20USA%2C%20June%2004%2C%202020%20--%20Baylx%2C,%28hUC-MSC%29%20product%20in%20patients%20with%20Rheumatoid%20Arthritis%20%28RA%29.",https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,,,,,,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,,,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04452097?term=bx-u001&draw=2&rank=2,,,,,,,,,,,,
630,No,BAT-2020,,BAT-2020,Bio-Thera Solutions,Therapeutic,COVID-19,Unknown,Unknown,New,,United States,Ongoing,,,Phase 1,,,,,,,Target: 07/20/2020,,,,,,1,COVID-19,174,No,,,10/20/2020,01/20/2021,08/18/2021,https://clinicaltrials.gov/ct2/show/NCT04432766,,,,,,,,,,,,,,,
630,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04432766,https://www.biothera.com/,https://www.biothera.com/,https://www.biothera.com/,,https://www.biothera.com/,https://clinicaltrials.gov/ct2/show/NCT04432766,,,https://clinicaltrials.gov/ct2/show/NCT04432766,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04432766,,,,,,https://clinicaltrials.gov/ct2/show/NCT04432766,https://clinicaltrials.gov/ct2/show/NCT04432766,https://clinicaltrials.gov/ct2/show/NCT04432766,https://clinicaltrials.gov/ct2/show/NCT04432766,,,https://clinicaltrials.gov/ct2/show/NCT04432766,https://clinicaltrials.gov/ct2/show/NCT04432766,https://clinicaltrials.gov/ct2/show/NCT04432766,https://clinicaltrials.gov/ct2/show/NCT04432766,,,,,,,,,,,,,,,
631,No,FSD-201,,FSD-201,FSD Pharma Inc.,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,Canada,Ongoing,Phase 1 demonstrated no serious adverse side effects and company plans to advance into a Phase 2a trail for COVID-19 treatment without mention of a start date,,Phase 2,,,,,,6/1/2020,2/21/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
631,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,,,,,,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379084&isReview=true,,,,,,https://www.businesswire.com/news/home/20200621005031/en/FSD-Pharma-Reports-Favorable-Topline-Results-Phase,,,,,,,,,,,,,,,,,,,,,,,,
632,No,TAK-981,,TAK-981,Takeda; Millenium Pharmaceuticals Inc.,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,United States,Ongoing,Intended for studying in subset of cancer patients with COVID-19,,Phase 1,,,,,,,5/22/2020,,,,,,1,COVID-19,80,No,8,University of California San Diego Moores Cancer Center - La Jolla - California; Massachusetts General Hospital - Boston - Massachusetts; Barbara Ann Karmanos Cancer Institute - Detroit - Michigan; HealthPartners Cancer Care Center Regions Hospital - Saint Paul - Minnesota; University Hospitals Seidman Cancer Center - Cleveland - Ohio; Fox Chase Cancer Center - Philadelphia - Pennsylvania; The University of Texas MD Anderson Cancer Center - Houston - Texas; Froedtert and the Medical College of Wisconsin - Milwaukee - Wisconsin,10/01/2018,02/16/2021,10/06/2021,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,,1-844-662-8532,globaloncologymedinfo@takeda.com,,,,,,,,,,,,
632,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,https://cancerres.aacrjournals.org/content/79/13_Supplement/3252,https://cancerres.aacrjournals.org/content/79/13_Supplement/3252,https://cancerres.aacrjournals.org/content/79/13_Supplement/3252,,https://www.fool.com/earnings/call-transcripts/2020/05/15/takeda-pharmaceutical-tak-q4-2019-earnings-call-tr.aspx,https://www.fool.com/earnings/call-transcripts/2020/05/15/takeda-pharmaceutical-tak-q4-2019-earnings-call-tr.aspx,https://www.fool.com/earnings/call-transcripts/2020/05/15/takeda-pharmaceutical-tak-q4-2019-earnings-call-tr.aspx,,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,,,,,,,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT03648372?term=TAK-981&draw=2&rank=3,,,,,,,,,,,,
633,No,PL-8177,,PL-8177,Palatin Technologies Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,New,,United States,Ongoing,Postive results in demonstrated in multiple preclinical inflammatory disease models and a lung injury model. IND is planned to be submitted in third quarter of 2020 and a Phase 2 clinical trial initiation in the fourth quarter of 2020.,,Phase 2,,,,,,,Assume Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
633,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.com/news-releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-301081588.html,https://www.palatin.com/research-focus/inflammatory-disease/,https://www.prnewswire.com/news-releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-301081588.html,https://www.prnewswire.com/news-releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-301081588.html,,https://www.prnewswire.com/news-releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-301081588.html,https://www.prnewswire.com/news-releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-301081588.html,https://www.prnewswire.com/news-releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-301081588.html,,https://www.prnewswire.com/news-releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-301081588.html,,,,,,,https://www.prnewswire.com/news-releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-301081588.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
634,No,deupirfenidone,deupirfenidone,LYT-100,Puretech Health plc,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,United States,Ongoing,A deuterated analogue of pirfenidone -an approved drug for treatment of idiopathic pulmonary fibrosis. Currently in a Phase 1 trial to determine safety in healthy volunteers and patients with breast cancer-related upper limb secondary lumphoedema. There are plans to initiate a trail in third quarter of 2020 for treating non-critical patients with COVID-19,,Phase 1,,,,,,,3/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
634,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.puretechhealth.com/news/23-press-releases/1218-puretech-advances-lyt-100-deupirfenidone-for-treatment-of-serious-respiratory-complications-that-persist-following-resolution-of-covid-19-infection,https://www.puretechhealth.com/news/23-press-releases/1218-puretech-advances-lyt-100-deupirfenidone-for-treatment-of-serious-respiratory-complications-that-persist-following-resolution-of-covid-19-infection,https://www.puretechhealth.com/news/23-press-releases/1218-puretech-advances-lyt-100-deupirfenidone-for-treatment-of-serious-respiratory-complications-that-persist-following-resolution-of-covid-19-infection,https://www.puretechhealth.com/news/23-press-releases/1218-puretech-advances-lyt-100-deupirfenidone-for-treatment-of-serious-respiratory-complications-that-persist-following-resolution-of-covid-19-infection,,https://www.puretechhealth.com/news/23-press-releases/1218-puretech-advances-lyt-100-deupirfenidone-for-treatment-of-serious-respiratory-complications-that-persist-following-resolution-of-covid-19-infection,https://www.puretechhealth.com/news/23-press-releases/1218-puretech-advances-lyt-100-deupirfenidone-for-treatment-of-serious-respiratory-complications-that-persist-following-resolution-of-covid-19-infection,puretechhealth.com/news/23-press-releases/1218-puretech-advances-lyt-100-deupirfenidone-for-treatment-of-serious-respiratory-complications-that-persist-following-resolution-of-covid-19-infection,,https://clinicaltrials.gov/ct2/show/NCT04243837?term=LYT-100&draw=2&rank=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
635,No,TY-027,,TY-027,Tichan Pte Ltd.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Singapore,Ongoing,TY-027 showed full clearance of the virus in lab studies and demonstrated safety in preclincal studies; Currently in a Phase 1 trial with efficacy data expected to be available in the third quarter.,,Phase 1,,,,,,,6/9/2020,,,,,,1,COVID-19,25,Yes,1,SingHealth Investigational Medicine Unit - Singapore,06/09/2020,11/2020,2/1/2021,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,Justin Ng ; Anjali Baglody,65 9002 5606 ; 65 9420 4576,justin@tychanltd.com ; anjalib@tychanltd.com,,,,,,,,,,,,
635,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.genengnews.com/covid-19-candidates/tychan-ty027/,https://www.genengnews.com/covid-19-candidates/tychan-ty027/,https://www.genengnews.com/covid-19-candidates/tychan-ty027/,https://www.genengnews.com/covid-19-candidates/tychan-ty027/,,https://www.tychan.com/,https://www.genengnews.com/covid-19-candidates/tychan-ty027/,https://www.genengnews.com/covid-19-candidates/tychan-ty027/,,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04429529?term=TY-027&draw=2&rank=1,,,,,,,,,,,,
636,No,Decidual stromal cells,,Decidual stromal cells,University Health Network Toronto; Oslo University Hospital,Therapeutic,ARDS,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,Canada,Ongoing,,,Phase 1,,,,,,,6/30/2020,,,,,,1,COVID-19 ,20,No,1,Toronto General Hospital - Toronto - Ontario - Canada,08/24/2020,02/24/2021,02/24/2021,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,John Granton ; Jonas Mattsson,416-340-4485; 416-946-4501,john.granton@uhn.ca ; jonas.mattsson@uhn.ca,,,,,,,,,,,,
636,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://clinicaltrials.gov/ct2/show/NCT04451291,https://clinicaltrials.gov/ct2/show/NCT04451291,https://clinicaltrials.gov/ct2/show/NCT04451291,https://clinicaltrials.gov/ct2/show/NCT04451291,,https://clinicaltrials.gov/ct2/show/NCT04451291,https://clinicaltrials.gov/ct2/show/NCT04451291,,,https://www.bioworld.com/COVID19products,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,https://clinicaltrials.gov/ct2/show/NCT04451291#contacts,,,,,,,,,,,,,
637,No,SARS-CoV-2 main protease inhibitors,,SARS-CoV-2 main protease inhibitors,A2A Pharmaceuticals Inc.; Laxai Life Sciences Pvt. Ltd.,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,New,,India,Ongoing,The molecules were designed computationally using AI and preclinical optimization will lead to selection of lead candidates,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
637,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,prnewswire.com/in/news-releases/a2a-pharmaceuticals-collaborates-with-laxai-life-sciences-to-co-develop-sars-cov-2-main-proteases-inhibitors-for-the-treatment-of-covid-19-821711487.html,prnewswire.com/in/news-releases/a2a-pharmaceuticals-collaborates-with-laxai-life-sciences-to-co-develop-sars-cov-2-main-proteases-inhibitors-for-the-treatment-of-covid-19-821711487.html,prnewswire.com/in/news-releases/a2a-pharmaceuticals-collaborates-with-laxai-life-sciences-to-co-develop-sars-cov-2-main-proteases-inhibitors-for-the-treatment-of-covid-19-821711487.html,prnewswire.com/in/news-releases/a2a-pharmaceuticals-collaborates-with-laxai-life-sciences-to-co-develop-sars-cov-2-main-proteases-inhibitors-for-the-treatment-of-covid-19-821711487.html,,prnewswire.com/in/news-releases/a2a-pharmaceuticals-collaborates-with-laxai-life-sciences-to-co-develop-sars-cov-2-main-proteases-inhibitors-for-the-treatment-of-covid-19-821711487.html,prnewswire.com/in/news-releases/a2a-pharmaceuticals-collaborates-with-laxai-life-sciences-to-co-develop-sars-cov-2-main-proteases-inhibitors-for-the-treatment-of-covid-19-821711487.html,prnewswire.com/in/news-releases/a2a-pharmaceuticals-collaborates-with-laxai-life-sciences-to-co-develop-sars-cov-2-main-proteases-inhibitors-for-the-treatment-of-covid-19-821711487.html,,prnewswire.com/in/news-releases/a2a-pharmaceuticals-collaborates-with-laxai-life-sciences-to-co-develop-sars-cov-2-main-proteases-inhibitors-for-the-treatment-of-covid-19-821711487.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
638,No,Human monoclonal antibodies (mAbCo19),,Human monoclonal antibodies (mAbCo19),Achilles Vaccines srl,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,EU Malaria Fund,Italy,Ongoing,The EU Malaria Fund announced funding for the development of the antibodies on 06/03/2020,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
638,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.covidx.eu/mabco19,https://www.covidx.eu/mabco19,https://www.covidx.eu/mabco19,https://www.covidx.eu/mabco19,https://www.covidx.eu/mabco19,https://www.businesswire.com/news/home/20200619005083/en/Italy-Beneficiary-EU-Malaria-Fund-Siena-Based-Achilles,https://www.businesswire.com/news/home/20200619005083/en/Italy-Beneficiary-EU-Malaria-Fund-Siena-Based-Achilles,https://www.covidx.eu/mabco19,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
639,No,Tempol,,Tempol,Adamis Pharmaceuticals Corp.; Matrix Biomed Inc.,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,United States,Ongoing,Adamis is planning to apply for funding and work with the FDA to expedite testing.  Clinical trial material is curently available since Tempol is being tested in other clinical trials for other purposes.,,Phase 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
639,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,http://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-pharmaceuticals-announces-license-commercialize-tempol,https://www.drugbank.ca/drugs/DB12449,http://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-pharmaceuticals-announces-license-commercialize-tempol,http://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-pharmaceuticals-announces-license-commercialize-tempol,,,http://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-pharmaceuticals-announces-license-commercialize-tempol,http://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-pharmaceuticals-announces-license-commercialize-tempol,,http://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-pharmaceuticals-announces-license-commercialize-tempol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
640,No,AB-201 (rNAPc2),,AB-201 (rNAPc2),Arca Biopharm Inc.,Therapeutic,Other,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,New,,United States,Ongoing,AB-201 is being developed as a potential treatment for COVID-related coagulopathy. It has undergone clinical testing through Phase 2 for anticoagulation. ARCA plans to file an IND application for COVID-19 in the third quarter of 2020 estimating late-stage clinical testing in the second half of 2020. A Phase 2B/3 clinical trial protocol is being developed for COVID-19 patients with elevated D-dimer levels.,,Phase 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
640,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.globenewswire.com/news-release/2020/05/28/2040150/0/en/ARCA-biopharma-Announces-AB201-Development-Program-for-Treatment-of-COVID-19-Associated-Coagulopathy.html,https://www.drugbank.ca/drugs/DB06552,https://www.globenewswire.com/news-release/2020/05/28/2040150/0/en/ARCA-biopharma-Announces-AB201-Development-Program-for-Treatment-of-COVID-19-Associated-Coagulopathy.html,https://www.globenewswire.com/news-release/2020/05/28/2040150/0/en/ARCA-biopharma-Announces-AB201-Development-Program-for-Treatment-of-COVID-19-Associated-Coagulopathy.html,,https://www.globenewswire.com/news-release/2020/05/28/2040150/0/en/ARCA-biopharma-Announces-AB201-Development-Program-for-Treatment-of-COVID-19-Associated-Coagulopathy.html,https://www.globenewswire.com/news-release/2020/05/28/2040150/0/en/ARCA-biopharma-Announces-AB201-Development-Program-for-Treatment-of-COVID-19-Associated-Coagulopathy.html,https://www.globenewswire.com/news-release/2020/05/28/2040150/0/en/ARCA-biopharma-Announces-AB201-Development-Program-for-Treatment-of-COVID-19-Associated-Coagulopathy.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
641,No,gilteritinib,gilteritinib,Xospata,Astellas Pharma Inc.,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,,Tokyo - Japan,Ongoing,tyrosine kinase inhibitor,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
641,Yes,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.drugbank.ca/drugs/DB12141,https://www.drugbank.ca/drugs/DB12141,https://www.bioworld.com/COVID19products,,https://www.astellas.com/en/contact-us,https://www.bioworld.com/COVID19products,,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
642,No,ATR-002,,ATR-002,Atriva Therapeutics GmbH,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Not Approved,,Tübingen - Germany,Ongoing,MEK inhibitor,,Phase 2,,,,,,,,,,,,,2,COVID-19,,,,,,,,,,,,,,,,,,,,,,,
642,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.genengnews.com/covid-19-candidates/atriva-therapeutics-atr-002/,https://www.genengnews.com/covid-19-candidates/atriva-therapeutics-atr-002/,https://www.clinicaltrialsarena.com/news/atriva-therapeutics-covid-19-trial/,https://www.globenewswire.com/news-release/2020/05/28/2039939/0/en/Atriva-Therapeutics-to-Develop-ATR-002-for-Treatment-of-Patients-with-COVID-19-in-Phase-II-Study.html,,https://www.atriva-therapeutics.com/14-news/96-news-phase2-2020,https://www.atriva-therapeutics.com/14-news/96-news-phase2-2020,,,https://www.atriva-therapeutics.com/14-news/96-news-phase2-2020,,,,,,,,,,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,
643,No,TP-508,,TP-508,Chrysalis Biotherapeutics Inc.,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Not Approved,,Galveston - Texas,Ongoing,helps against blood clotting and other cardiovascular problems faced by COVID-19 patients,,Phase 1,,,,,,,,,,,,,1,COVID-19,,,,,,,,,,,,,,,,,,,,,,,
643,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://chrysbio.com/chrysalis-biotherapeutics-receives-funding-from-the-national-institutes-of-health-for-covid-19-therapeutic-development/,https://www.drugbank.ca/drugs/DB05309,https://chrysbio.com/chrysalis-biotherapeutics-receives-funding-from-the-national-institutes-of-health-for-covid-19-therapeutic-development/,https://www.galvnews.com/news/free/article_31c2f715-0467-5348-89ef-fdd3a45b304d.html,,https://chrysbio.com/chrysalis-biotherapeutics-receives-funding-from-the-national-institutes-of-health-for-covid-19-therapeutic-development/,https://chrysbio.com/chrysalis-biotherapeutics-receives-funding-from-the-national-institutes-of-health-for-covid-19-therapeutic-development/,,,https://chrysbio.com/chrysalis-biotherapeutics-receives-funding-from-the-national-institutes-of-health-for-covid-19-therapeutic-development/,,,,,,,,,,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,
644,No,,,,Delta 4 GmbH,Therapeutic,COVID-19,Other,Other,Repurposed-Not Approved,,Vienna - Austria,Ongoing,digital drug discovery platform,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
644,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://delta4.ai/press-release-june-2020/,https://delta4.ai/press-release-june-2020/,https://delta4.ai/press-release-june-2020/,,,https://delta4.ai/press-release-june-2020/,https://delta4.ai/press-release-june-2020/,https://delta4.ai/press-release-june-2020/,,https://delta4.ai/press-release-june-2020/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
645,No,egg immunoglobulins,,egg immunoglobulins,Ignova GmbH,Therapeutic,COVID-19,Other,Monoclonal antibodies,Repurposed-Not Approved,,Visbek - Germany,Ongoing,customized immunoglobulins to inhibit infection,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
645,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.com/in/news-releases/ignova-files-patent-application-on-antibody-against-covid-19-837978500.html,https://ignova.com/ignova-files-patent-application-on-antibody-against-covid-19/,https://ignova.com/ignova-files-patent-application-on-antibody-against-covid-19/,https://ignova.com/ignova-files-patent-application-on-antibody-against-covid-19/,,https://www.prnewswire.com/in/news-releases/ignova-files-patent-application-on-antibody-against-covid-19-837978500.html,https://www.prnewswire.com/in/news-releases/ignova-files-patent-application-on-antibody-against-covid-19-837978500.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
646,No,Antibodies,,Antibodies,Immuncetye Life Sciences Inc.; Thermogenesis Holdings Inc.,Therapeutic,COVID-19,Other,Monoclonal antibodies,Repurposed-Not Approved,,Irvine - California,Ongoing,plans to isolate antibodies from blood that can used to treat COVID-19 patients,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
646,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.hospimedica.com/covid-19/articles/294783005/thermogenesis-announces-publishing-of-results-of-immunecytes-licensed-neutralizing-antibody-therapeutics-for-covid-19.html,https://www.biospace.com/article/releases/thermogenesis-and-immunecyte-joint-venture-developing-several-convalescent-plasma-and-antibody-therapeutic-approaches-against-covid-19-featured-on-fox40-and-other-local-news-outlets/,https://www.biospace.com/article/releases/thermogenesis-and-immunecyte-joint-venture-developing-several-convalescent-plasma-and-antibody-therapeutic-approaches-against-covid-19-featured-on-fox40-and-other-local-news-outlets/,https://www.biospace.com/article/releases/thermogenesis-and-immunecyte-joint-venture-developing-several-convalescent-plasma-and-antibody-therapeutic-approaches-against-covid-19-featured-on-fox40-and-other-local-news-outlets/,,https://www.hospimedica.com/covid-19/articles/294783005/thermogenesis-announces-publishing-of-results-of-immunecytes-licensed-neutralizing-antibody-therapeutics-for-covid-19.html,https://www.hospimedica.com/covid-19/articles/294783005/thermogenesis-announces-publishing-of-results-of-immunecytes-licensed-neutralizing-antibody-therapeutics-for-covid-19.html,,,https://www.hospimedica.com/covid-19/articles/294783005/thermogenesis-announces-publishing-of-results-of-immunecytes-licensed-neutralizing-antibody-therapeutics-for-covid-19.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
647,No,IMS-001,,IMS-001,Imstem Biotechnology Inc.; Agex Therapeutics Inc.,Therapeutic,COVID-19,Cell therapies,Other,Repurposed-Not Approved,,Alameda - California,Ongoing,stem cell therapy; also being used to treat ARDS and pneumonia for COVID-19 patients,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
647,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.pharmaceutical-business-review.com/news/agex-therapeutics-imstem-biotechnology-sign-non-binding-letter-of-intent-regarding-investigational-msc-candidate-ims001-for-covid-19/,https://www.pharmaceutical-business-review.com/news/agex-therapeutics-imstem-biotechnology-sign-non-binding-letter-of-intent-regarding-investigational-msc-candidate-ims001-for-covid-19/,https://www.pharmaceutical-business-review.com/news/agex-therapeutics-imstem-biotechnology-sign-non-binding-letter-of-intent-regarding-investigational-msc-candidate-ims001-for-covid-19/,https://www.bioworld.com/articles/435490-other-news-to-note-for-june-2-2020,,https://www.bioworld.com/articles/435490-other-news-to-note-for-june-2-2020,https://www.bioworld.com/articles/435490-other-news-to-note-for-june-2-2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
648,No,R-107,,R-107,Kalytera Therapeutics Inc.,Therapeutic,COVID-19,Small molecule,Other,New,,San Rafael - California,Ongoing,also being used to treat ARDS,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
648,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://kalytera.co/news/kalytera-announces-data-demonstrating-that-r-107-preserves-organ-function-in-a-murine-study-mimicking-covid-19-lung-disease/,https://kalytera.co/news/kalytera-announces-data-demonstrating-that-r-107-preserves-organ-function-in-a-murine-study-mimicking-covid-19-lung-disease/,https://kalytera.co/news/kalytera-announces-data-demonstrating-that-r-107-preserves-organ-function-in-a-murine-study-mimicking-covid-19-lung-disease/,https://kalytera.co/news/kalytera-announces-data-demonstrating-that-r-107-preserves-organ-function-in-a-murine-study-mimicking-covid-19-lung-disease/,,https://kalytera.co/news/kalytera-announces-data-demonstrating-that-r-107-preserves-organ-function-in-a-murine-study-mimicking-covid-19-lung-disease/,https://kalytera.co/news/kalytera-announces-data-demonstrating-that-r-107-preserves-organ-function-in-a-murine-study-mimicking-covid-19-lung-disease/,,,https://kalytera.co/news/kalytera-announces-data-demonstrating-that-r-107-preserves-organ-function-in-a-murine-study-mimicking-covid-19-lung-disease/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
649,No,carragelose inhalation therapy,,carragelose inhalation therapy,Marinomed Biotech Ag.,Therapeutic,Pneumonia,Other,Antiviral drugs-broad spectrum,Repurposed-Not Approved,,Vienna - Austria,Ongoing,sulfated polymer that comes from red seaweed ; interacts with virus particles,,Phase 1,,,,,,,,,,,,,1,COVID-19,,Yes,,,,,,,,,,,,,,,,,,,,,
649,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.oindpnews.com/2020/04/marinomed-gets-funding-for-development-of-carragelose-inhalation-solution-for-the-treatment-of-covid-19-pneumonia/,https://www.carragelose.com/en/mode-of-action,https://www.pharmiweb.com/press-release/2020-04-28/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose-1,https://www.marinomed.com/en/news/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose,,https://www.marinomed.com/en/news/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose,https://www.marinomed.com/en/news/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose,https://www.carragelose.com/en/mode-of-action,,https://www.expresspharma.in/covid19-updates/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose/,,,,,,,,,,,,,https://www.expresspharma.in/covid19-updates/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose/,https://www.expresspharma.in/covid19-updates/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose/,,https://www.expresspharma.in/covid19-updates/marinomed-receives-ffg-funding-to-research-sars-cov-2-therapy-based-on-carragelose/,,,,,,,,,,,,,,,,,,,,,
650,No,Dinaciclib,,Dinaciclib,Merck Sharp & Dohme Corp.,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,,San Francisco - California,Ongoing,little information about this -- repurposed drug,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
650,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296007/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296007/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296007/,,https://qbi.ucsf.edu/,https://qbi.ucsf.edu/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
651,No,MNPR-101; Radioimmunotherapeutics,,MNPR-101; Radioimmunotherapeutics,Monopar Therapeutics Inc.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,,USA,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
651,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.monopartx.com/pipeline/mnpr-101,https://www.monopartx.com/pipeline/mnpr-101,https://www.monopartx.com/pipeline/mnpr-101,https://www.monopartx.com/pipeline/mnpr-101,,https://www.monopartx.com/contact-us,,,,https://www.monopartx.com/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
652,No,OBP-AI-005,,OBP-AI-005,Oncolys Biopharma Inc.,Therapeutic,COVID-19,Unknown,Antiviral drugs-not specified,New,,USA,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
652,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ssl4.eir-parts.net/doc/4588/tdnet/1850514/00.pdf,https://ssl4.eir-parts.net/doc/4588/tdnet/1850514/00.pdf,https://ssl4.eir-parts.net/doc/4588/tdnet/1850514/00.pdf,https://ssl4.eir-parts.net/doc/4588/tdnet/1850514/00.pdf,,https://www.oncolys.com/en/contact/,https://ssl4.eir-parts.net/doc/4588/tdnet/1850514/00.pdf,,,https://ssl4.eir-parts.net/doc/4588/tdnet/1850514/00.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
653,No,Ranpirnase,,Ranpirnase,Orgenesis Inc.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,Repurposed-Not Approved,,USA,Ongoing,,,Pre-Clinical Testing,,Assumed completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
653,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ir.orgenesis.com/press-releases/detail/159/orgenesis-and-leidos-collaborate-on-potential-treatment-for,https://www.thepharmaletter.com/article/orgenesis-falls-as-it-says-it-will-acquire-tamir-biotechnology-assets,https://ir.orgenesis.com/press-releases/detail/159/orgenesis-and-leidos-collaborate-on-potential-treatment-for,ctepcore.nci.nih.gov/ctepaers/security/login,,ctepcore.nci.nih.gov/ctepaers/security/login,ctepcore.nci.nih.gov/ctepaers/security/login,,,ctepcore.nci.nih.gov/ctepaers/security/login,,ctepcore.nci.nih.gov/ctepaers/security/login,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
654,No,ORP-100S,,ORP-100S,Orpro Therapeutics Inc.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,New,,USA,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
654,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.orprotherapeutics.com/covid-19/,https://www.orprotherapeutics.com/covid-19/,https://www.orprotherapeutics.com/technology/orp-100s-for-inhalation/,https://www.orprotherapeutics.com/technology/orp-100s-for-inhalation/,,https://www.orprotherapeutics.com/2020/05/28/347/,https://www.orprotherapeutics.com/technology/orp-100s-for-inhalation/,,,https://www.orprotherapeutics.com/2020/05/28/347/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
655,No,Neutrophil Extracellular Trap Inhibitor,,Neutrophil Extracellular Trap Inhibitor,Peel Therapeutics Inc.,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,New,,USA,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
655,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.prnewswire.com/news-releases/peel-therapeutics-announces-possible-new-treatment-for-covid-19-301085175.html,https://www.prnewswire.com/news-releases/peel-therapeutics-announces-possible-new-treatment-for-covid-19-301085175.html,https://www.prnewswire.com/news-releases/peel-therapeutics-announces-possible-new-treatment-for-covid-19-301085175.html,https://www.prnewswire.com/news-releases/peel-therapeutics-announces-possible-new-treatment-for-covid-19-301085175.html,,https://www.prnewswire.com/news-releases/peel-therapeutics-announces-possible-new-treatment-for-covid-19-301085175.html,https://www.prnewswire.com/news-releases/peel-therapeutics-announces-possible-new-treatment-for-covid-19-301085175.html,,,https://www.peeltx.com/science,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
656,No,,,,Pharnext SA,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,,France,Ongoing,97 frequently prescribed drugs being re-purposed to treat COVID-19,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
656,Yes,,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.pharnext.com/images/PDF/press_releases/2020.03.23_COVID19_EN.pdf,https://www.pharnext.com/images/PDF/press_releases/2020.03.23_COVID19_EN.pdf,https://www.pharnext.com/images/PDF/press_releases/2020.03.23_COVID19_EN.pdf,https://www.pharnext.com/images/PDF/press_releases/2020.03.23_COVID19_EN.pdf,,https://www.pharnext.com/fr/societe/profil-de-l-entreprise,https://www.pharnext.com/images/PDF/press_releases/2020.03.23_COVID19_EN.pdf,https://www.pharnext.com/images/PDF/press_releases/2020.03.23_COVID19_EN.pdf,,https://www.pharnext.com/images/PDF/press_releases/2020.03.23_COVID19_EN.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
657,No,PTI-129,,PTI-129,Proteostasis Therapeutics Inc.,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,Repurposed-Not Approved,,USA,Ongoing,reduces level of misfolded proteins,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
657,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-vitro-data-pti-129-potential,https://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-vitro-data-pti-129-potential,https://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-vitro-data-pti-129-potential,https://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-vitro-data-pti-129-potential,,http://www.proteostasis.com/contact-us/,https://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-vitro-data-pti-129-potential,https://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-vitro-data-pti-129-potential,,https://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-vitro-data-pti-129-potential,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
658,No,AS-1411,,AS-1411,Qualigen Therapeutics Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,Repurposed-Not Approved,,USA,Ongoing,"DNA aptamer designed to target and bind with nucleolin, a human protein utilized by some viruses to enter a cell.",,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
658,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.genengnews.com/covid-19-candidates/qualigen-therapeutics-as1411/,https://www.genengnews.com/covid-19-candidates/qualigen-therapeutics-as1411/,https://www.genengnews.com/covid-19-candidates/qualigen-therapeutics-as1411/,https://www.genengnews.com/covid-19-candidates/qualigen-therapeutics-as1411/,,https://www.qualigeninc.com/about-us/contact-qualigen/,https://www.genengnews.com/covid-19-candidates/qualigen-therapeutics-as1411/,https://www.genengnews.com/covid-19-candidates/qualigen-therapeutics-as1411/,,https://www.genengnews.com/covid-19-candidates/qualigen-therapeutics-as1411/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
659,No,MAPK13-IN-1,,MAPK13-IN-1,Quantitative Biosceinces Institute UCSF,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Approved,,USA,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
659,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bloomberg.com/press-releases/2020-06-28/ucsf-quantitative-biosciences-institute-cell-publication-elucidates-how-sars-cov-2-dramatically-rewires-important-cell-program,https://www.medchemexpress.com/MAPK13-IN-1.html,https://www.bloomberg.com/press-releases/2020-06-28/ucsf-quantitative-biosciences-institute-cell-publication-elucidates-how-sars-cov-2-dramatically-rewires-important-cell-program,https://www.bloomberg.com/press-releases/2020-06-28/ucsf-quantitative-biosciences-institute-cell-publication-elucidates-how-sars-cov-2-dramatically-rewires-important-cell-program,,http://qbi.ucsf.edu/aboutus,https://www.bloomberg.com/press-releases/2020-06-28/ucsf-quantitative-biosciences-institute-cell-publication-elucidates-how-sars-cov-2-dramatically-rewires-important-cell-program,,,https://www.bloomberg.com/press-releases/2020-06-28/ucsf-quantitative-biosciences-institute-cell-publication-elucidates-how-sars-cov-2-dramatically-rewires-important-cell-program,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
660,No,SB203580,,SB203580,Quantitative Biosceinces Institute UCSF,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Approved,,USA,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
660,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
661,No,Silmitasertib,,Silmitasertib,Senhwa Biosciences Inc.,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,Taiwan headquartered Senhwa Biosciences Inc; The University of California San Francisco’s Quantitative Biosciences Institute,USA,Ongoing,Curbes RNA from proliferating; CK2 inhibitor,,Discovery,,3/31/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
661,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,https://www.biospace.com/article/releases/senhwa-biosciences-silmitasertib-named-as-potential-covid-19-therapy/,https://www.biospectrumasia.com/news/34/15848/senhwa-biosciences-nih-to-co-develop-covid-19-drug.html,https://www.drugbank.ca/drugs/DB15408,https://www.biospectrumasia.com/news/34/15848/senhwa-biosciences-nih-to-co-develop-covid-19-drug.html,,,https://www.biospectrumasia.com/news/34/15848/senhwa-biosciences-nih-to-co-develop-covid-19-drug.html,,,,https://www.biospace.com/article/releases/senhwa-biosciences-silmitasertib-named-as-potential-covid-19-therapy/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
662,No,SFA-005,,SFA-005,SFA Therapeutics Inc.,Therapeutic,ARDS,Other,Other,New,Ben Franklin,USA,Ongoing,Preventing cytokine release syndrome; currently being evaluated in animal model of ARDS,,,,Announced partnership 06/24/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
662,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.businesswire.com/news/home/20200624005197/en/Melior-Discovery-Announces-Partnership-SFA-Grant-Directed,,,,https://www.sep.benfranklin.org/2020/06/18/ben-franklin-backs-founders-fighting-covid-19-and-its-effects/,https://sfatherapeutics.com/,,https://www.sep.benfranklin.org/2020/06/18/ben-franklin-backs-founders-fighting-covid-19-and-its-effects/; https://www.businesswire.com/news/home/20200624005197/en/Melior-Discovery-Announces-Partnership-SFA-Grant-Directed,,,,https://www.businesswire.com/news/home/20200624005197/en/Melior-Discovery-Announces-Partnership-SFA-Grant-Directed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
663,No,Immunotherapy; StemVacs,,Immunotherapy; StemVacs,Therapeutic Solutions International Inc.,Therapeutic,COVID-19,Other,Other,Repurposed-Not Approved,Therapeutic Solutions Intl,USA,Ongoing,Based on activating universal donor immune systems so that upon injection they reprogram the bodies natural killer while also supressing lung inflammation,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
663,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,https://www.biospace.com/article/releases/therapeutic-solutions-international-submits-publication-on-stemvacs-preclinical-data-supporting-covid-19-indication/,https://www.biospace.com/article/releases/therapeutic-solutions-international-submits-publication-on-stemvacs-preclinical-data-supporting-covid-19-indication/,,,https://www.biospace.com/article/releases/therapeutic-solutions-international-submits-publication-on-stemvacs-preclinical-data-supporting-covid-19-indication/,,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
664,No,VAL-201,,VAL-201,Valirx plc,Therapeutic,COVID-19,Other,Kinase inhibitors,Repurposed-Not Approved,Collaboration with Oncolytika and Black Cat Bio,UK,Ongoing,Treatment for hyperimmune response,,Pre-Clinical Testing,,Collaboration announced 6/7/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
664,Yes,https://www.bioworld.com/COVID19products,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,https://www.sharesmagazine.co.uk/news/market/6944114/ValiRx-enters-collaboration-to-develop-SARS-CoV2-treatment,,https://www.sharesmagazine.co.uk/news/market/6944114/ValiRx-enters-collaboration-to-develop-SARS-CoV2-treatment,,https://www.sharesmagazine.co.uk/news/market/6944114/ValiRx-enters-collaboration-to-develop-SARS-CoV2-treatment,https://www.share-talk.com/valirx-plc-val-l-collaboration-agreement-signed/#gs.ae31u3,,https://www.sharesmagazine.co.uk/news/market/6944114/ValiRx-enters-collaboration-to-develop-SARS-CoV2-treatment,,https://www.bioworld.com/COVID19products,,https://www.sharesmagazine.co.uk/news/market/6944114/ValiRx-enters-collaboration-to-develop-SARS-CoV2-treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
665,No,AlloStim,,AlloStim,Immunovative Therapies Ltd.; Mirror Biologics Inc.,Vaccine - Prophylactic,Other,Whole-pathogen vaccines,Antiviral drugs-not specified,New,Immunovative Therapies and Mirror Biologics,USA,Ongoing,Protects against any type of viral infection and is designed for the elderly,,Phase 1,,,,,,,7/6/2020,,,,,,1,COVID-19,40,Yes,1,New York,7/6/2020,12/7/2020,12/31/20,https://clinicaltrials.gov/ct2/show/NCT04441047,Kim Demonte; Thu Bui,1-732-630-9059; 1-619-227-4872,axellaresearch@gmail.com;  thu@immunovative.com,,,,,,,,,,,,
665,Yes,https://clinicaltrials.gov/ct2/show/NCT04441047,,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html,https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html,https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html,https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html,https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html,https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html,,https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html,,Phase 4,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,https://clinicaltrials.gov/ct2/show/NCT04441047,,,,,,,,,,,,
666,No,Oral Polio Vaccine (OPV),,Oral Polio Vaccine (OPV),Bandim Health Project,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,Repurposed-Not Approved,Global Virus Network,,Ongoing,,,Phase 4,,,,,,,,,,,,,4,COVID-19,3400,No,1,Bissau - Guinea-Bissau,July 2020,June 2021,June 2021,https://clinicaltrials.gov/ct2/show/NCT04445428,Ane Fisker,245 966625316 ; 45 50570593,a.fisker@bandim.org,,Enrolling by invitation only,,,,,,,,,,
666,Yes,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6&rank=46,,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6&rank=46,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6&rank=46,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6&rank=46,,,https://biorender.com/covid-vaccine-tracker/details/v-CV15/-34,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,,,,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04445428?recrs=abf&cond=COVID-19&intr=vaccine&draw=6,,,,,,,,,,,,
667,No,IMM-101,,IMM-101,Canadian Cancer Trials Group; Immodulon Therapeutics Ltd.; BioCan Rx; CCSRI; AtGen Canada Inc.; ARCC; Ontario Institute for Cancer Research,Vaccine - Prophylactic,COVID-19,Other,Other,Repurposed-Not Approved,Canadian Cancer Society - BioCanRx - the Ontario Institute for Cancer Research - The Ottawa Hospital Foundation - The Ottawa Hospital Academic Medical Organization - ATGen Canada/NKMax - and Immodulon Therapeutics,Canada,Ongoing,Focused on strenghtening the immune system of cancer patients,,Phase 3,,,,,,,,,8/1/2020,,,,3,COVID-19 ,1500,No,5,Hamilton - Ontario - Canada; London - Ontario - Canada; Ottawa - Ontario - Canada; Toronto - Ontario - Canada; Montreal - Quebec -Canada,7/1/2020,12/31/2020,3/31/2021,https://clinicaltrials.gov/ct2/show/NCT04442048,Chris O'Callaghan,613-533-6430,cocallaghan@ctg.queensu.ca,,,,,,,,,,,,
667,Yes,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5&rank=40,,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5&rank=40,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5&rank=40,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5&rank=40,,,https://ichgcp.net/clinical-trials-registry/NCT04442048,https://ichgcp.net/clinical-trials-registry/NCT04442048,https://medicalxpress.com/news/2020-07-cancer-patients-covid-world-first-trial.html,https://medicalxpress.com/news/2020-07-cancer-patients-covid-world-first-trial.html,,https://medicalxpress.com/news/2020-07-cancer-patients-covid-world-first-trial.html,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,,,,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,,,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04442048?recrs=abf&cond=COVID-19&intr=vaccine&draw=5,,,,,,,,,,,,
668,No,RUTI Vaccine,,RUTI Vaccine,Fundacio Institut Germans Trias i Pujol,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,Repurposed-Not Approved,Collaboration with  University Institute for Primary Health Care Research Jordi Gol; clinical triai financed by The General Directorate of Research and Innovation in Health of the Government of Catalonia,,Ongoing,A therapeutic vaccine for tuberculosis indications,,,,,,,,,,,,,,,,COVID-19,315,Yes,1,Barcelona - Spain,7/30/20,12/1/20,12/1/20,https://clinicaltrials.gov/ct2/show/NCT04453488,Pere-Joan Cardona,34 93 033 0527 ext 6400,pjcardona@igtp.cat,,,,,,,,,,,,
668,Yes,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3&rank=17,,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3&rank=17,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3&rank=17,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3&rank=17,http://biotech-spain.com/en/articles/archivel-s-ruti-vaccine-begins-clinical-trial-to-increase-the-immunity-of-healthcare-professionals-exposed-to-covid-19/,,http://biotech-spain.com/en/articles/archivel-s-ruti-vaccine-begins-clinical-trial-to-increase-the-immunity-of-healthcare-professionals-exposed-to-covid-19/,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,http://biotech-spain.com/en/articles/archivel-s-ruti-vaccine-begins-clinical-trial-to-increase-the-immunity-of-healthcare-professionals-exposed-to-covid-19/,,,http://biotech-spain.com/en/articles/archivel-s-ruti-vaccine-begins-clinical-trial-to-increase-the-immunity-of-healthcare-professionals-exposed-to-covid-19/,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04453488?recrs=abf&cond=COVID-19&intr=vaccine&draw=3,,,,,,,,,,,,
669,No,,,,Helix Nanotechnologies Inc.,Vaccine - Prophylactic,COVID-19,Other,Vaccine,Repurposed-Not Approved,Investment from Sam Altman,,Ongoing,Using personalized vaccine technology previously created to fight cancer; work centered around manipulating mRNA to deliver a message to make parts of the coronavirus visible to the immune system; approach may provide protection against all future corona viruses,,Pre-Clinical Testing,,3/10/2020,4/3/2020 injected first vaccine into mice,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
669,Yes,,,,https://www.helixnano.com/,https://www.helixnano.com/,,,https://www.cnbc.com/2020/04/24/what-it-is-like-to-invent-a-covid-19-vaccine-during-pandemic.html,https://www.cnbc.com/2020/04/24/what-it-is-like-to-invent-a-covid-19-vaccine-during-pandemic.html,https://www.genengnews.com/covid-19-candidates/helix-nanotechnologies/,,,https://www.genengnews.com/covid-19-candidates/helix-nanotechnologies/; https://www.cnbc.com/2020/04/24/what-it-is-like-to-invent-a-covid-19-vaccine-during-pandemic.html,,https://www.cnbc.com/2020/04/24/what-it-is-like-to-invent-a-covid-19-vaccine-during-pandemic.html,,https://www.cnbc.com/2020/04/24/what-it-is-like-to-invent-a-covid-19-vaccine-during-pandemic.html,https://www.cnbc.com/2020/04/24/what-it-is-like-to-invent-a-covid-19-vaccine-during-pandemic.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
670,No,Infliximab,,Infliximab,Tufts Medical Center,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,Tufts Medical Center; NIH,USA,Ongoing,TNFα inhibitor therapy,,Phase 2,,,,,,,,6/1/2020,,,,,2,COVID-19,17,No,1,Boston - Massachusets,6/1/2020,9/1/20,12/20,https://clinicaltrials.gov/ct2/show/NCT04425538,Christian Lawlor,617-636-5000 ext 8897,clawlor3@tuftsmedicalcenter.org,,,,,,,,,,,,
670,Yes,https://clinicaltrials.gov/ct2/show/NCT04425538,,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://www.drugbank.ca/drugs/DB00065,https://biorender.com/covid-vaccine-tracker/details/d-0080/ryoncil-remestemcel-l-allogenic-mesenchymal-stem-cells,https://www.drugbank.ca/drugs/DB00065,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,,https://clinicaltrials.gov/ct2/show/NCT04425538,,https://clinicaltrials.gov/ct2/show/NCT04425538,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04425538,,,,,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,,,,,,,,,,,,
671,No,Infliximab,,Infliximab,Tufts Medical Center,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,Tufts Medical Center; NIH,USA,Ongoing,TNFα inhibitor therapy,,Phase 2,,,,,,,,6/1/2020,,,,,2,COVID-19,17,No,1,Boston - Massachusets,6/1/2020,9/1/20,12/1/20,https://clinicaltrials.gov/ct2/show/NCT04425538,Christian Lawlor,617-636-5000 ext 8897,clawlor3@tuftsmedicalcenter.org,,,,,,,,,,,,
671,Yes,https://clinicaltrials.gov/ct2/show/NCT04425538,,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://www.drugbank.ca/drugs/DB00065,https://biorender.com/covid-vaccine-tracker/details/d-0080/ryoncil-remestemcel-l-allogenic-mesenchymal-stem-cells,https://www.drugbank.ca/drugs/DB00065,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,,https://clinicaltrials.gov/ct2/show/NCT04425538,,https://clinicaltrials.gov/ct2/show/NCT04425538,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04425538,,,,,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,https://clinicaltrials.gov/ct2/show/NCT04425538,,,,,,,,,,,,
672,No,Deferoxamine,,Deferoxamine,Kermanshah University of Medical Sciences,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,Kermanshah University of Medical Sciences,Iran,Ongoing,Acts as a chelating agent that eliminates iron and aluminum in the bloodstream.,,Phase 2,,Assumed Complete,Assumed Complete,,,,6/1/2020,6/1/2020,,,,,2,COVID-19,50,No,1,"Regenerative Medicine Research Center, Kermanshah University of Medical Sciences - Kermanshah - Iran",06/01/2020,09/01/2020,3/1/21,https://clinicaltrials.gov/ct2/show/record/NCT04333550,Alireza Ghaffarieh,16086987334,alirezaghaffariyeh@hotmail.com,,,,,,,,,,,,
672,Yes,https://clinicaltrials.gov/ct2/show/NCT04333550,,https://clinicaltrials.gov/ct2/show/NCT04333550,https://clinicaltrials.gov/ct2/show/NCT04333550,https://clinicaltrials.gov/ct2/show/NCT04333550,https://clinicaltrials.gov/ct2/show/NCT04333550,https://www.drugbank.ca/drugs/DB00746,https://www.drugbank.ca/drugs/DB00746,https://www.drugbank.ca/drugs/DB00746,https://clinicaltrials.gov/ct2/show/NCT04333550,http://gsia.kums.ac.ir/en,https://clinicaltrials.gov/ct2/show/NCT04333550,https://www.drugbank.ca/drugs/DB00746,,https://clinicaltrials.gov/ct2/show/NCT04333550,,https://clinicaltrials.gov/ct2/show/NCT04333550,https://clinicaltrials.gov/ct2/show/NCT04333550,,,,https://clinicaltrials.gov/ct2/show/NCT04333550,https://clinicaltrials.gov/ct2/show/NCT04333550,,,,,https://clinicaltrials.gov/ct2/show/NCT04333550,https://clinicaltrials.gov/ct2/show/NCT04333550,https://clinicaltrials.gov/ct2/show/study/NCT04333550,https://clinicaltrials.gov/ct2/show/study/NCT04333550,https://clinicaltrials.gov/ct2/show/study/NCT04333550,,https://clinicaltrials.gov/ct2/show/record/NCT04333550,https://clinicaltrials.gov/ct2/show/record/NCT04333550,https://clinicaltrials.gov/ct2/show/record/NCT04333550,https://clinicaltrials.gov/ct2/show/record/NCT04333550,https://clinicaltrials.gov/ct2/show/record/NCT04333550,https://clinicaltrials.gov/ct2/show/study/NCT04333550#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04333550#contacts,,,,,,,,,,,,
673,No,Puylmozyme,,Puylmozyme,Acibadem University,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,The Scientific and Technological Research Council of Turkey,Turkey,Ongoing,,,Phase 2,,Assumed Complete,Assumed Complete,,,,Skipped,5/25/2020,,,,,2,COVID-19,60,No,1,Istanbul - Turkey,05/25/20,08/25/2020,09/25/2020,https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts,Ercument Ovalı,905325729174,ercument.ovali@acibadem.com,,,,,,,,,,,,
673,Yes,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2&rank=4,,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,https://www.drugbank.ca/drugs/DB00003,https://www.drugbank.ca/drugs/DB00003,https://www.drugbank.ca/drugs/DB00003,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,,,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,,,,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2&rank=4,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2&rank=4,,,,,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,https://clinicaltrials.gov/ct2/show/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,https://clinicaltrials.gov/ct2/show/record/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,https://clinicaltrials.gov/ct2/show/record/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2,https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04432987?recrs=a&type=Intr&cond=COVID-19&draw=2#contacts,,,,,,,,,,,,
674,No,Aspirin; clopidogrel; rivaroxaban; atorvastatin; omeprazole,,Aspirin; clopidogrel; rivaroxaban; atorvastatin; omeprazole,Imperial College London,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United Kingdom,Ongoing,,,,,2/27/2020,Assumed Complete,,,,,,,,,,,COVID-19,3170,No,1,London - England,04/03/2020,03/30/2021,03/30/2021,https://clinicaltrials.gov/ct2/show/study/NCT04333407#contacts,Alena Marynina,07776 224520,alena.marynina@nhs.net,,,,,,,,,,,,
674,Yes,https://clinicaltrials.gov/ct2/show/study/NCT04333407,,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://www.drugbank.ca/drugs/DB00945,https://docs.google.com/spreadsheets/d/1IUDoUXsEdk_d6FDgXTMVwuSHU_myagwVCEeMf81Tsjg/edit#gid=1988095192,https://clinicaltrials.gov/ct2/show/study/NCT04333407,,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://clinicaltrials.gov/ct2/show/study/NCT04333407,,,,,https://pubmed.ncbi.nlm.nih.gov/32113509/,https://clinicaltrials.gov/ct2/show/study/NCT04333407,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://clinicaltrials.gov/ct2/show/study/NCT04333407,,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://clinicaltrials.gov/ct2/show/study/NCT04333407,https://clinicaltrials.gov/ct2/show/study/NCT04333407#contacts,,https://clinicaltrials.gov/ct2/show/study/NCT04333407#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04333407#contacts,,,,,,,,,,,,
675,No,Prazosin,,Prazosin,John Hopkins University,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,Assumed Complete,4/30/2020,,,,Skipped,5/13/2020,,,,,2,COVID-19,220,No,1,Baltimore - Maryland,05/13/2020,12/1/20,12/1/20,https://clinicaltrials.gov/ct2/show/study/NCT04365257#contacts,Chetan Bettegowda,4109558620,cbetteg1@jhmi.edu,,,,,,,,,,,,
675,Yes,https://clinicaltrials.gov/ct2/show/NCT04365257,,https://clinicaltrials.gov/ct2/show/NCT04365257,https://clinicaltrials.gov/ct2/show/NCT04365257,https://clinicaltrials.gov/ct2/show/NCT04365257,https://clinicaltrials.gov/ct2/show/NCT04365257,https://www.drugbank.ca/drugs/DB00457,https://clinicaltrials.gov/ct2/show/NCT04365257,Prazosin,,https://clinicaltrials.gov/ct2/show/NCT04365257,https://clinicaltrials.gov/ct2/show/NCT04365257,,,https://clinicaltrials.gov/ct2/show/NCT04365257,,https://clinicaltrials.gov/ct2/show/NCT04365257,https://www.hopkinsmedicine.org/news/newsroom/news-releases/researchers-urge-clinical-trial-of-blood-pressure-drug-to-prevent-lethal-complication-of-covid-19,,,,https://clinicaltrials.gov/ct2/show/NCT04365257,https://clinicaltrials.gov/ct2/show/NCT04365257,,,,,https://clinicaltrials.gov/ct2/show/NCT04365257,https://clinicaltrials.gov/ct2/show/NCT04365257,https://clinicaltrials.gov/ct2/show/study/NCT04365257,https://clinicaltrials.gov/ct2/show/NCT04365257,https://clinicaltrials.gov/ct2/show/study/NCT04365257,https://clinicaltrials.gov/ct2/show/study/NCT04365257,https://clinicaltrials.gov/ct2/show/study/NCT04365257,https://clinicaltrials.gov/ct2/show/study/NCT04365257,https://clinicaltrials.gov/ct2/show/study/NCT04365257,https://clinicaltrials.gov/ct2/show/study/NCT04365257#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04365257#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04365257#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04365257#contacts,,,,,,,,,,,,
676,No,Etoposide,,Etoposide,Boston Medical Center,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,Assumed Complete,Assumed Complete,,,5/1/2020,Skipped,5/8/2020,,,,,2,COVID-19,64,No,1,Boston - Massachusets,05/08/2020,12/1/20,12/1/21,https://clinicaltrials.gov/ct2/show/study/NCT04356690#contacts,John Mark Sloan,6176387002,mark.sloan@bmc.org,,,,,,,,,,,,
676,Yes,https://clinicaltrials.gov/ct2/show/NCT04356690,,https://clinicaltrials.gov/ct2/show/NCT04356690,https://clinicaltrials.gov/ct2/show/NCT04356690,https://clinicaltrials.gov/ct2/show/NCT04356690,https://clinicaltrials.gov/ct2/show/NCT04356690,https://www.drugbank.ca/drugs/DB00773,https://www.drugbank.ca/drugs/DB00773,https://www.drugbank.ca/drugs/DB00773,,https://www.drugbank.ca/drugs/DB00773,https://clinicaltrials.gov/ct2/show/NCT04356690,,,https://clinicaltrials.gov/ct2/show/NCT04356690,,https://clinicaltrials.gov/ct2/show/NCT04356690,https://clinicaltrials.gov/ct2/show/NCT04356690,,,https://www.bmc.org/healthcity/research/etoposide-and-other-clinical-trials-covid-19-inflammation,https://clinicaltrials.gov/ct2/show/NCT04356690,https://clinicaltrials.gov/ct2/show/NCT04356690,,,,,https://www.drugbank.ca/drugs/DB00773,https://www.drugbank.ca/drugs/DB00773,https://www.drugbank.ca/drugs/DB00773,https://www.drugbank.ca/drugs/DB00773,https://www.drugbank.ca/drugs/DB00773,https://www.drugbank.ca/drugs/DB00773,https://clinicaltrials.gov/ct2/show/NCT04356690,https://clinicaltrials.gov/ct2/show/NCT04356690,,https://clinicaltrials.gov/ct2/show/study/NCT04356690#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04356690#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04356690#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04356690#contacts,,,,,,,,,,,,
677,No,Cyclosporine,,Cyclosporine,University of Pennsylvania,Therapeutic,COVID-19,Small molecule,Other antiviral drugs,Repurposed-Approved,,United States,Ongoing,,,Phase 1,,Assumed Complete,4/22/2020,,,,6/22/2020,,,,,,1,COVID-19,20,No,1,Philadelphia - Pennsylvania,06/22/2020,9/1/20,12/1/20,https://clinicaltrials.gov/ct2/show/NCT04412785#contacts,Joan Gilmore,2157468902,jgilmore@pennmedicine.upenn.edu,,,,,,,,,,,,
677,Yes,https://clinicaltrials.gov/ct2/show/NCT04412785,,https://clinicaltrials.gov/ct2/show/NCT04412785,https://clinicaltrials.gov/ct2/show/NCT04412785,https://clinicaltrials.gov/ct2/show/NCT04412785,https://clinicaltrials.gov/ct2/show/NCT04412785,https://www.drugbank.ca/drugs/DB00091,https://www.drugbank.ca/drugs/DB00091,https://www.drugbank.ca/drugs/DB00091,,https://clinicaltrials.gov/ct2/show/NCT04412785,https://clinicaltrials.gov/ct2/show/NCT04412785,,,https://clinicaltrials.gov/ct2/show/NCT04412785,,https://clinicaltrials.gov/ct2/show/NCT04412785,https://www.thedp.com/article/2020/04/coronavirus-medicine-drug-therapy-treatment,,,,https://clinicaltrials.gov/ct2/show/NCT04412785,,,,,,https://www.drugbank.ca/drugs/DB00091,https://www.drugbank.ca/drugs/DB00091,https://www.drugbank.ca/drugs/DB00091,https://www.drugbank.ca/drugs/DB00091,https://www.drugbank.ca/drugs/DB00091,https://clinicaltrials.gov/ct2/show/NCT04412785#contacts,https://clinicaltrials.gov/ct2/show/NCT04412785#contacts,https://clinicaltrials.gov/ct2/show/NCT04412785#contacts,https://clinicaltrials.gov/ct2/show/NCT04412785#contacts,https://clinicaltrials.gov/ct2/show/NCT04412785#contacts,https://clinicaltrials.gov/ct2/show/NCT04412785#contacts,https://clinicaltrials.gov/ct2/show/NCT04412785#contacts,https://clinicaltrials.gov/ct2/show/NCT04412785#contacts,,,,,,,,,,,,
678,No,Sirolimus,,Sirolimus,University of Cincinnati; Thomas Jefferson University,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,Assumed Complete,4/15/2020,,,,Skipped,4/24/2020,,,,,2,COVID-19,30,No,2,Chicago - Illinois; Cincinnati - Ohio,04/24/2020,07/01/2020,09/01/2020,https://clinicaltrials.gov/ct2/show/NCT04341675#contacts,Nishant Gupta,5135584831,guptans@ucmail.uc.edu,,,,,,,,,,,,
678,Yes,https://clinicaltrials.gov/ct2/show/NCT04341675,,https://clinicaltrials.gov/ct2/show/NCT04341675,https://clinicaltrials.gov/ct2/show/NCT04341675,https://clinicaltrials.gov/ct2/show/NCT04341675,https://clinicaltrials.gov/ct2/show/NCT04412785#contacts,https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility,https://www.uc.edu/news/articles/2020/05/n20912629.html,https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility,,https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility,https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility,,,https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility,,https://clinicaltrials.gov/ct2/show/NCT04341675,https://www.uc.edu/news/articles/2020/04/n20906921.html,,,,https://clinicaltrials.gov/ct2/show/NCT04341675,https://clinicaltrials.gov/ct2/show/NCT04341675,,,,,https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility,https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility,https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility,https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility,https://clinicaltrials.gov/ct2/show/NCT04341675#eligibility,https://clinicaltrials.gov/ct2/show/NCT04341675#contacts,https://clinicaltrials.gov/ct2/show/NCT04341675#contacts,https://clinicaltrials.gov/ct2/show/NCT04341675#contacts,https://clinicaltrials.gov/ct2/show/NCT04341675#contacts,https://clinicaltrials.gov/ct2/show/NCT04341675#contacts,https://clinicaltrials.gov/ct2/show/NCT04341675#contacts,https://clinicaltrials.gov/ct2/show/NCT04341675#contacts,https://clinicaltrials.gov/ct2/show/NCT04341675#contacts,,,,,,,,,,,,
679,No,Povidone-Iodine,,Povidone-Iodine,Universiti Kebangsaan Malaysia Medical Centre,Therapeutic,COVID-19,Small molecule,Antibiotics and antiparasitics,Repurposed-Approved,,Malaysia,On Hold,,,Phase 2,,Assumed Complete,Assumed Complete,,,,Skipped,6/22/2020,Skipped,,,,complete,COVID-19,20,No,1,Bandar Tun Razak - Wilayah Persekutuan Kuala Lumpur - Malaysia,06/22/2020,06/29/2020,07/06/2020,https://clinicaltrials.gov/ct2/show/record/NCT04410159,Nurul A Mohamed,,drnurul@usim.edu.my,,,,,,,,,,,,
679,Yes,https://clinicaltrials.gov/ct2/show/NCT04410159,,https://clinicaltrials.gov/ct2/show/NCT04410159,https://clinicaltrials.gov/ct2/show/NCT04410159,https://clinicaltrials.gov/ct2/show/NCT04410159,https://clinicaltrials.gov/ct2/show/NCT04410159,https://www.drugbank.ca/drugs/DB06812,https://www.drugbank.ca/drugs/DB06812,https://www.drugbank.ca/drugs/DB06812,,https://clinicaltrials.gov/ct2/show/NCT04410159,https://clinicaltrials.gov/ct2/show/NCT04410159,,,https://clinicaltrials.gov/ct2/show/NCT04410159,,https://clinicaltrials.gov/ct2/show/NCT04410159,https://clinicaltrials.gov/ct2/show/NCT04410159,,,,https://clinicaltrials.gov/ct2/show/NCT04410159,https://clinicaltrials.gov/ct2/show/NCT04410159,https://clinicaltrials.gov/ct2/show/NCT04410159,,,,https://clinicaltrials.gov/ct2/show/NCT04410159,https://clinicaltrials.gov/ct2/show/NCT04410159,https://clinicaltrials.gov/ct2/show/record/NCT04410159,https://clinicaltrials.gov/ct2/show/record/NCT04410159,https://clinicaltrials.gov/ct2/show/record/NCT04410159,https://clinicaltrials.gov/ct2/show/study/NCT04410159,https://clinicaltrials.gov/ct2/show/record/NCT04410159,https://clinicaltrials.gov/ct2/show/record/NCT04410159,https://clinicaltrials.gov/ct2/show/record/NCT04410159,https://clinicaltrials.gov/ct2/show/record/NCT04410159,https://clinicaltrials.gov/ct2/show/study/NCT04410159,,https://clinicaltrials.gov/ct2/show/study/NCT04410159,,,,,,,,,,,,
680,No,Zanubrutinib,,Zanubrutinib,BeiGene,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,Assumed Complete,Assumed Complete,,,5/8/2020,Skipped,6/1/2020,,,,,2,COVID-19,52,No,9,District of Columbia - Washington; Maywood - Illinois; Boston - Massachusetts; Morristown - New Jersey; Newark - New Jersey; Summit - New Jersey; Lubbock - Texas; Milwaukee - Wisconsin,06/01/2020,04/01/2021,4/1/21,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,BeiGene,18778285568,clinicaltrials@beigene.com,,,,,,,,,,,,
680,Yes,https://clinicaltrials.gov/ct2/show/NCT04382586,,https://clinicaltrials.gov/ct2/show/NCT04382586,https://clinicaltrials.gov/ct2/show/NCT04382586,https://clinicaltrials.gov/ct2/show/NCT04382586,https://clinicaltrials.gov/ct2/show/NCT04382586,https://www.drugbank.ca/drugs/DB15035,https://www.drugbank.ca/drugs/DB15035,https://www.drugbank.ca/drugs/DB15035,,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://www.drugbank.ca/drugs/DB15035,,,https://www.drugbank.ca/drugs/DB15035,,https://clinicaltrials.gov/ct2/show/NCT04382586,https://clinicaltrials.gov/ct2/show/NCT04382586,,,https://www.beigene.com/covid-response,https://clinicaltrials.gov/ct2/show/NCT04382586,https://clinicaltrials.gov/ct2/show/NCT04382586,,,,,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,https://clinicaltrials.gov/ct2/show/NCT04382586#contacts,,,,,,,,,,,,
681,No,Azithromycin,,Azithromycin,University of Oxford; Pfizer,Therapeutic,COVID-19,Small molecule,Antibiotics and antiparasitics,Repurposed-Approved,Pfizer,United Kingdom,Ongoing,,,Phase 3,,Assumed Complete,Assumed Complete,,,Skipped,Skipped,5/29/2020,,,,,3,COVID-19,800,No,5,Banbury - Oxfordshire; Oxford - Oxfordshire; Dundee - Scotland; Birmingham - United Kingdom; West Bromwich - United Kingdom,05/29/2020,09/13/2020,10/13/2020,https://clinicaltrials.gov/ct2/show/NCT04381962,Lucy Cureton,01865227374,atomic2@ndorms.ox.ac.uk,,,,,,,,,,,,
681,Yes,https://clinicaltrials.gov/ct2/show/NCT04381962,,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://www.drugbank.ca/drugs/DB00207,https://www.drugbank.ca/drugs/DB00207,https://www.drugbank.ca/drugs/DB00207,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,,,https://clinicaltrials.gov/ct2/show/NCT04381962,,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,,,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,,,,,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,https://clinicaltrials.gov/ct2/show/NCT04381962,,,,,,,,,,,,
682,No,Levamisole; formoterol; budesonide,,Levamisole; formoterol; budesonide,Fasa University of Medical Sciences,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Iran,Ongoing,This combined drug therapy is aimed at treating the ARDS associated with COVID-19 as well as the virus itself,,Phase 2,,,,,,,,4/4/2020,,,,,2,COVID-19,30,No,1,Vali-Asr Hospital - Tehran - Iran,04/04/2020,04/20/2020,05/20/2020,https://clinicaltrials.gov/ct2/show/NCT04331470,Siamack Afazeli ; Mojtaba Farjaam,989121392982 ; 989177104789,Dr.afazeli@gmail.com ; farjam.md@gmail.com,,,,,,,,,,,,
682,Yes,https://clinicaltrials.gov/ct2/show/NCT04331470,,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,,https://www.drugbank.ca/drugs/DB00848 ; https://www.drugbank.ca/drugs/DB00983 ; https://www.drugbank.ca/drugs/DB01222,https://www.drugbank.ca/drugs/DB00848 ; https://www.drugbank.ca/drugs/DB00983 ; https://www.drugbank.ca/drugs/DB01222,https://www.drugbank.ca/drugs/DB00848 ; https://www.drugbank.ca/drugs/DB00983 ; https://www.drugbank.ca/drugs/DB01222,,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,,https://clinicaltrials.gov/ct2/show/NCT04331470,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04331470,,,,,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,https://clinicaltrials.gov/ct2/show/NCT04331470,,,,,,,,,,,,
683,No,MSTT1041A,,MSTT1041A,Genentech Inc.,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,New,,United States,Ongoing,Mechanism of Action is inhibition of interleukin-33,,Phase 2,,,,,,,,6/2/2020,,,,,2,COVID-19,300,No,24,eStudySite - Chula Vista- California ; eStudy Site - La Mesa - California ; Torrance Memorial Medical Center - Torrance - California ; Larkin Community Hospital Palm Psring Campus - Hialeah - Florida ; DM Clinical Research - Alexandria - Lousiana ; MedPharmics - Metairie - Louisiana ; Southeast Lousiana Veterans Health Care System (NAVREF) - New Orleans - Lousiana ; Henry Ford Health System - Detroit - Michigan ; St.Joseph's Regional Medical Center - Paterson - New Jersey ; Albany Medical Center - Albany - New York ; Lincoln Medical Mental Health Center - Bronx - New York ; Jacobi Medical Center Lewis M. Fraad Department of Pediatrics - Bronx - New York ; Staten Island University Hospital Department of Pharmacy - Staten Island - New York ; Cape Fear Valley Health System - Fayetteville - North Carolina ; Mercy St. Vincent Medical Center - Toledo - Ohio ; Providence Portland Medical Center Investigational Drug Service/ Regional Research - Portland - Oregon ; Lehigh Valley Health Network - Allentown - Pennsylvania ; Temple Uni Medical Center Pulmonary & Critical Care Medicine - Philadelphia - Pennsylvania ; Parkland Health & Hospital System - Dallas - Texas ; University of Texas Southwestern Medical Center - Dallas - Texas ; Virginia Commonwealth University - Richmond - Virginia ; Virginia Mason Medical Center - Seattle - Washington ; MultiCare Institute for Research and Innovation Clinic/Outpatient Facility - Tacoma - Washington,06/02/2020,01/29/2021,3/3/2021,https://clinicaltrials.gov/ct2/show/NCT04386616,,888-662-6728,global-roche-genentech-trials@gene.com,,,,,,,,,,,,
683,Yes,https://clinicaltrials.gov/ct2/show/NCT04386616,,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://adisinsight.springer.com/drugs/800038653,https://adisinsight.springer.com/drugs/800038653,https://adisinsight.springer.com/drugs/800038653,,https://www.gene.com/contact-us/visit-us,https://adisinsight.springer.com/drugs/800038653,https://adisinsight.springer.com/drugs/800038653,,https://clinicaltrials.gov/ct2/show/NCT04386616,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04386616,,,,,,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,,,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,,,,,,,,,,,,
684,No,UTTR1147A,,UTTR1147A,Genentech Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,New,,United States,Ongoing,Mechanism of Action is activating IL-22R signaling,,Phase 2,,,,,,,,6/2/2020,,,,,2,COVID-19,300,No,24,eStudySite - Chula Vista- California ; eStudy Site - La Mesa - California ; Torrance Memorial Medical Center - Torrance - California ; Larkin Community Hospital Palm Psring Campus - Hialeah - Florida ; DM Clinical Research - Alexandria - Lousiana ; MedPharmics - Metairie - Louisiana ; Southeast Lousiana Veterans Health Care System (NAVREF) - New Orleans - Lousiana ; Henry Ford Health System - Detroit - Michigan ; St.Joseph's Regional Medical Center - Paterson - New Jersey ; Albany Medical Center - Albany - New York ; Lincoln Medical Mental Health Center - Bronx - New York ; Jacobi Medical Center Lewis M. Fraad Department of Pediatrics - Bronx - New York ; Staten Island University Hospital Department of Pharmacy - Staten Island - New York ; Cape Fear Valley Health System - Fayetteville - North Carolina ; Mercy St. Vincent Medical Center - Toledo - Ohio ; Providence Portland Medical Center Investigational Drug Service/ Regional Research - Portland - Oregon ; Lehigh Valley Health Network - Allentown - Pennsylvania ; Temple Uni Medical Center Pulmonary & Critical Care Medicine - Philadelphia - Pennsylvania ; Parkland Health & Hospital System - Dallas - Texas ; University of Texas Southwestern Medical Center - Dallas - Texas ; Virginia Commonwealth University - Richmond - Virginia ; Virginia Mason Medical Center - Seattle - Washington ; MultiCare Institute for Research and Innovation Clinic/Outpatient Facility - Tacoma - Washington,06/02/2020,01/29/2021,3/3/2021,https://clinicaltrials.gov/ct2/show/NCT04386616,,888-662-6728,global-roche-genentech-trials@gene.com,,,,,,,,,,,,
684,Yes,https://clinicaltrials.gov/ct2/show/NCT04386616,,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://www.gene.com/medical-professionals/pipeline,https://www.gene.com/medical-professionals/pipeline,https://www.gene.com/medical-professionals/pipeline,,https://www.gene.com/contact-us/visit-us,https://clinicaltrials.gov/ct2/show/NCT04386616,https://www.gene.com/medical-professionals/pipeline,,https://clinicaltrials.gov/ct2/show/NCT04386616,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04386616,,,,,,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,,,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,,https://clinicaltrials.gov/ct2/show/NCT04386616,https://clinicaltrials.gov/ct2/show/NCT04386616,,,,,,,,,,,,
685,No,metenkefalin; tridecactide,,metenkefalin; tridecactide,Bosnalijek D.D,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Bosnia and Herzegovina,Ongoing,This combined drug treatment is a immunomodulatory therapy to prevent as much tissue damage associated with COVID-19,,Phase 2,,,,,,,,,,,,,2,COVID-19,120,No,1,Clinical Center University of Sarajevo - Sarajevo - Sarajevo Canton - Bosnia and Herzagovina,05/01/2020,10/31/2020,12/31/2020,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,Jasna Dzananovic,38733560603,Jasna.Dzananovic@Bosnalijek.com,,,,,,,,,,,,
685,Yes,https://clinicaltrials.gov/ct2/show/NCT04374032,,https://clinicaltrials.gov/ct2/show/NCT04374032,https://clinicaltrials.gov/ct2/show/NCT04374032,https://clinicaltrials.gov/ct2/show/NCT04374032,,https://www.drugbank.ca/drugs/DB12668 ; https://www.drugbank.ca/drugs/DB15687,https://www.drugbank.ca/drugs/DB12668 ; https://www.drugbank.ca/drugs/DB15687,https://www.drugbank.ca/drugs/DB12668 ; https://www.drugbank.ca/drugs/DB15687,,http://www.bosnalijek.com/,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04374032?term=Tridecactide&draw=2&rank=2,,,,,,,,,,,,
686,No,Melatonin,,Melatonin,Baqiyatallah Medical Sciences University,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Iran,Ongoing,Melatonin is being investigated for its potential anti-inflammatory effects in treatment of COVID-19,,,,,,,,,,,,,,,,COVID-19,55,No,1,Mohammad Sadegh Bagheri Baghdast - Tehran - Iran,05/12/2020,06/05/2020,09/25/2020,https://clinicaltrials.gov/ct2/show/NCT04409522,Mohammad Sadegh Baheri Bahdasht,0098 9356319204,sadegh.bagheri@gmail.com,,,,,,,,,,,,
686,Yes,https://clinicaltrials.gov/ct2/show/NCT04409522,,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://www.drugbank.ca/drugs/DB01065,https://clinicaltrials.gov/ct2/show/NCT04409522,https://www.drugbank.ca/drugs/DB01065,,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,https://clinicaltrials.gov/ct2/show/NCT04409522,,,,,,,,,,,,
687,No,Iloprost,,Iloprost,Rigshospitalet; Hamad Medical Corporation,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,Denmark ; Qatar,Ongoing,This drug is being investigated for restoring vascular integrity in COVID-19 patients from respiratory failure.,,Phase 2,,,,,,,,6/15/2020,,,,,2,COVID-19,80,No,5,Bispebjerg Hospital (Dept. of Anaethesia and Intensive Care) - Copenhagen - Denmark ; Rigshopitalet (Dept. of Intensive Care) - Copenhagen - Denmark ; Copenhagen University Hospital Herlev (Dept. of Intensive Care) - Herlev - Denmark ; Nordsjaelands Hospital(Dept. of Anaesthesia and Intensive Care) - Hillerød - Denmark ; Hvidovre Hospital (Dept. Anaesthesia and Intensive Care) - Hvidovre - Denmark,06/15/2020,05/31/2021,05/31/2021,https://clinicaltrials.gov/ct2/show/NCT04420741,Pär I Johansson ; Anders Perner,45 3545 2030 ; 45 3545 8333,Per.johansson@regionh.dk ; Anders.Perner@regionh.dk,,,,,,,,,,,,
687,Yes,https://clinicaltrials.gov/ct2/show/NCT04420741,,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://www.drugbank.ca/drugs/DB01088,https://www.drugbank.ca/drugs/DB01088,https://www.drugbank.ca/drugs/DB01088,,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,,https://clinicaltrials.gov/ct2/show/NCT04420741,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04420741,,,,,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,https://clinicaltrials.gov/ct2/show/NCT04420741,,,,,,,,,,,,
688,No,Progesterone,,Progesterone,IBSA Institut Biochimique SA,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Switzerland,Ongoing,This drug is being investigated in men with COVID-19 as an anti-inflammatory drug,,Phase 1,,,,,,,4/27/2020,,,,,,1,COVID-19,40,No,1,Cedars Sinai Medical Center - Los Angeles - California - United States,04/27/2020,09/01/2020,04/17/2021,https://clinicaltrials.gov/ct2/show/NCT04365127,Vanessa Vasco,3109677451,Vanessa.Vasco@csmns.org,,,,,,,,,,,,
688,Yes,https://clinicaltrials.gov/ct2/show/NCT04365127,,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://www.drugbank.ca/drugs/DB00396,healio.com/news/endocrinology/20200507/study-examines-progesterone-to-reduce-inflammation-in-covid19,https://www.drugbank.ca/drugs/DB00396,,https://www.ibsagroup.com/ibsa-group/ibsa-headquarter.html,https://clinicaltrials.gov/ct2/show/NCT04365127,https://www.healio.com/news/endocrinology/20200507/study-examines-progesterone-to-reduce-inflammation-in-covid19,,https://clinicaltrials.gov/ct2/show/NCT04365127,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04365127,,,,,,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,https://clinicaltrials.gov/ct2/show/NCT04365127,,,,,,,,,,,,
689,No,Bacille Calmette-Guérin (BCG),,Bacille Calmette-Guérin (BCG),Murdoch Childrens Research Institute; TASK Applied Science; Texas A&M University; UMC Utrecth; Radboud University,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,Repurposed-Approved,,Australian ; South Africa ; United States ; Netherlands ;,Ongoing,,,Phase 3,,,,,,,,,3/30/2020,,,,3,COVID-19,10078,Yes,6,Sydney - Australia; Breda - Netherlands; Nieuwegein - Netherlands; Barcelona - Spain; Sevilla - Spain; St Leonards - Exeter - United Kingdom,03/30/2020,10/30/2020,03/30/2022,https://clinicaltrials.gov/ct2/show/NCT04327206,Prof Nigel Curtis ; Kaya Gardiner,613 93456366 ; 613 99366461,nigel.curtis@rch.org.au ; kaya.gardiner@mcri.edu.au,,,,,,,,,,,,
689,Yes,https://clinicaltrials.gov/ct2/show/NCT04327206,,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://www.cdc.gov/tb/publications/factsheets/prevention/bcg.htm,https://www.cdc.gov/tb/publications/factsheets/prevention/bcg.htm,https://www.cdc.gov/tb/publications/factsheets/prevention/bcg.htm,,,https://clinicaltrials.gov/ct2/show/NCT04327206,,,https://clinicaltrials.gov/ct2/show/NCT04327206,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04327206,,,,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,https://clinicaltrials.gov/ct2/show/NCT04327206,,,,,,,,,,,,
690,No,Tigerase,,Tigerase,AO GENERIUM,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Russia,Ongoing,This drug is currently approved in Russia for treatment of cystic fibrosis,,Phase 3,,,,,,,,,6/1/2020,,,,3,COVID-19,100,No,6,City Clinical Hospital #15 - Moscow - Russian Federation ; I.M. Sechenov First Moscow State Medical University (Sechenov University) - Moscow - Russian Federation ; City Clinical Hospital #51 - Moscow - Russian Federation ; City Clinical Hospital #52 - Moscow - Russian Federation ; Siberian State Medical University (SibMed) - Moscow - Russian Federation,06/01/2020,07/20/2020,07/20/2020,https://clinicaltrials.gov/ct2/show/NCT04459325,Eugene V. Zuev ; Oksana A. Markova,79466419698 ; 7 9854418959,evzuev@generium.ru ; oamarkova@generium.ru,,,,,,,,,,,,
690,Yes,https://clinicaltrials.gov/ct2/show/NCT04459325,,https://clinicaltrials.gov/ct2/show/NCT04459325,https://clinicaltrials.gov/ct2/show/NCT04459325,https://clinicaltrials.gov/ct2/show/NCT04459325,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
691,No,N-acetylcysteine,,N-acetylcysteine,Memorial Sloan Kettering Cancer Center,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,,,,,,,,,,,,2,COVID-19,86,No,1,Memorial Sloan Kettering Cancer Center - New York - New York,5/1/20,5/1/21,5/1/21,https://clinicaltrials.gov/ct2/show/NCT04374461,Santosha Vardhana,646-888-3285,vardhans@mskcc.org,,,,,,,,,,,,
691,Yes,https://clinicaltrials.gov/ct2/show/NCT04374461,,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://www.drugbank.ca/drugs/DB06151,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261085/,https://www.drugbank.ca/drugs/DB06151,,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,,,https://clinicaltrials.gov/ct2/show/NCT04374461,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,https://clinicaltrials.gov/ct2/show/NCT04374461,,,,,,,,,,,,
692,No,Melphalan,,Melphalan,Federal State Budgetary Institution - Pulmonology Scientific Research Institute,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,Russia,Ongoing,Chemotherapeutic,,Phase 2,,,,,,,,,,,,,2,COVID-19,60,No,1,Moscow - Russian Federation - 125430,4/30/20,10/30/20,10/30/20,https://clinicaltrials.gov/ct2/show/NCT04380376,Kiril A Zykov,,kirillaz@inbox.ru	,,,,,,,,,,,,
692,Yes,https://clinicaltrials.gov/ct2/show/NCT04380376,,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://www.drugbank.ca/drugs/DB01042,https://clinicaltrials.gov/ct2/show/NCT04380376,https://www.drugbank.ca/drugs/DB01042,,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,,,https://clinicaltrials.gov/ct2/show/NCT04380376,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,https://clinicaltrials.gov/ct2/show/NCT04380376,,https://clinicaltrials.gov/ct2/show/NCT04380376,,,,,,,,,,,,
693,No,DFV890,,DFV890,Novartis Pharmaceuticals,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,Denmark,Ongoing,Inhibitor of NLRP3,,Phase 2,,,,,,,,,,,,,2,COVID-19,120,No,10,Copenhagen - Denmark - DK-2400; Hvidovre - Denmark - 2650;  Heidelberg - Baden-Württemberg - Germany - 69126; Regensburg - Bavaria - Germany; Bonn - Germany - 53105; Hannover - Germany - 30625; Wuerzburg - Germany; Budapest - Hungary - 1121; Budapest - Hungary - H-1097; Harderwijk - Netherlands,5/27/20,12/21/20,12/21/20,https://clinicaltrials.gov/ct2/show/NCT04382053,,,novartis.email@novartis.com        ,,,,,,,,,,,,
693,Yes,https://clinicaltrials.gov/ct2/show/NCT04382053,,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://medwatch.dk/Top_picks_in_english/article12214057.ece,https://medwatch.dk/Top_picks_in_english/article12214057.ece,https://medwatch.dk/Top_picks_in_english/article12214057.ece,,https://medwatch.dk/Top_picks_in_english/article12214057.ece,https://medwatch.dk/Top_picks_in_english/article12214057.ece,https://medwatch.dk/Top_picks_in_english/article12214057.ece,,https://clinicaltrials.gov/ct2/show/NCT04382053,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,https://clinicaltrials.gov/ct2/show/NCT04382053,,,https://clinicaltrials.gov/ct2/show/NCT04382053,,,,,,,,,,,,
694,No,Fluoxetine,,Fluoxetine,University of Toledo Health Science Campus,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,United States,Ongoing,Antidepressant,,Phase 4,,,,,,,,,,,,,4,COVID-19,2000,Yes,1,University of Toledo - Toledo - Ohio,5/1/20,4/20/21,10/20/21,https://clinicaltrials.gov/ct2/show/NCT04377308,Cheryl McCullumsmith,4193835651,cheryl.mccullumsmith@utoledo.edu        ,,,,,,,,,,,,
694,Yes,https://clinicaltrials.gov/ct2/show/NCT04377308,,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://www.drugbank.ca/drugs/DB00472,https://medicine.wustl.edu/news/study-to-evaluate-antidepressant-as-potential-covid-19-treatment/,https://www.drugbank.ca/drugs/DB00472,,https://www.drugbank.ca/drugs/DB00472,https://www.drugbank.ca/drugs/DB00472,https://medicine.wustl.edu/news/study-to-evaluate-antidepressant-as-potential-covid-19-treatment/,,https://www.drugbank.ca/drugs/DB00472,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,https://clinicaltrials.gov/ct2/show/NCT04377308,,,,,,,,,,,,
695,No,Clazakizumab,,Clazakizumab,Cedars-Sinai Medical Center; Johns Hopkins University,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,,United States,Ongoing,,,Phase 2,,,,,,,,,,,,,2,COVID-19,60,No,1,Cedars-Sinai Medical Center - Los Angeles - California,4/24/20,12/31/20,3/31/20,https://clinicaltrials.gov/ct2/show/NCT04348500,Noriko Ammerman,310-248-8186,noriko.ammerman@cshs.org	,,,,,,,,,,,,
695,Yes,https://clinicaltrials.gov/ct2/show/NCT04348500,,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://www.drugbank.ca/drugs/DB12849,https://www.drugbank.ca/drugs/DB12849,https://www.drugbank.ca/drugs/DB12849,,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,,,https://clinicaltrials.gov/ct2/show/NCT04348500,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,https://clinicaltrials.gov/ct2/show/NCT04348500,,,,,,,,,,,,
696,No,Defibrotide,,Defibrotide,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Spain,Ongoing,,,Phase 2,,,,,,,,,,,,,2,COVID-19,120,No,1,Virgen de la Arrixaca University Clinical Hospital - Murcia - Spain,4/8/20,1/15/21,1/15/21,https://clinicaltrials.gov/ct2/show/NCT04348383,José M. Moraleda,,jmoraled@um.es        ,,,,,,,,,,,,
696,Yes,https://clinicaltrials.gov/ct2/show/NCT04348383,,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://www.drugbank.ca/drugs/DB04932,https://clinicaltrials.gov/ct2/show/NCT04348383,https://www.drugbank.ca/drugs/DB04932,,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,,,https://clinicaltrials.gov/ct2/show/NCT04348383,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,https://clinicaltrials.gov/ct2/show/NCT04348383,,https://clinicaltrials.gov/ct2/show/NCT04348383,,,,,,,,,,,,
697,No,JS016,,JS016,Shanghai Junshi Bioscience Co. Ltd.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,,China,Ongoing,,,Phase 1,,,,,,,,,,,,,1,COVID-19,40,Yes,1,Huashan Hospital affiliated to Fudan University - Shanghai - China,6/5/20,12/11/20,12/11/20,https://clinicaltrials.gov/ct2/show/NCT04441918,Jing Zhang,,13816357098@163.com,,,,,,,,,,,,
697,Yes,https://clinicaltrials.gov/ct2/show/NCT04441918,,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://www.pharmaceutical-business-review.com/news/eli-lilly-junshi-covid-19-trial/,https://www.pharmaceutical-business-review.com/news/eli-lilly-junshi-covid-19-trial/,https://www.pharmaceutical-business-review.com/news/eli-lilly-junshi-covid-19-trial/,,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,,,https://clinicaltrials.gov/ct2/show/NCT04441918,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,https://clinicaltrials.gov/ct2/show/NCT04441918,,https://clinicaltrials.gov/ct2/show/NCT04441918,,,,,,,,,,,,
698,No,GLS-1200,,GLS-1200,"GeneOne Life Science, Inc.",Vaccine - Prophylactic,COVID-19,Other,Antiviral drugs-not specified,Repurposed-Approved,,United States,Ongoing,Stimulates NO production which reduces coronavirus efficacy,,Phase 2,,,,,,5/6/2020,,,,,,,2,COVID-19,225,Yes,2,University of Pennsylvania - Philadelphia - Pennsylvania; Baton Rouge - Louisiana,6/1/20,2/1/21,3/1/21,https://clinicaltrials.gov/ct2/show/NCT04408183,,610-707-5671,jmaslow@geneonels-us.com,,,,,,,,,,,,
698,Yes,https://clinicaltrials.gov/ct2/show/NCT04408183,,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,https://www.oindpnews.com/2020/05/fda-approves-ind-for-phase-2-study-of-geneone-life-science-nasal-spray-for-the-prevention-of-covid-19/,https://www.oindpnews.com/2020/05/fda-approves-ind-for-phase-2-study-of-geneone-life-science-nasal-spray-for-the-prevention-of-covid-19/,https://www.oindpnews.com/2020/05/fda-approves-ind-for-phase-2-study-of-geneone-life-science-nasal-spray-for-the-prevention-of-covid-19/,https://www.oindpnews.com/2020/05/fda-approves-ind-for-phase-2-study-of-geneone-life-science-nasal-spray-for-the-prevention-of-covid-19/,,https://www.oindpnews.com/2020/05/fda-approves-ind-for-phase-2-study-of-geneone-life-science-nasal-spray-for-the-prevention-of-covid-19/,https://www.oindpnews.com/2020/05/fda-approves-ind-for-phase-2-study-of-geneone-life-science-nasal-spray-for-the-prevention-of-covid-19/,,,https://www.oindpnews.com/2020/05/fda-approves-ind-for-phase-2-study-of-geneone-life-science-nasal-spray-for-the-prevention-of-covid-19/,,,,,,https://www.oindpnews.com/2020/05/fda-approves-ind-for-phase-2-study-of-geneone-life-science-nasal-spray-for-the-prevention-of-covid-19/,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,https://clinicaltrials.gov/ct2/show/NCT04408183,,,https://clinicaltrials.gov/ct2/show/NCT04408183,,,,,,,,,,,,
699,No,Garadacimab,,Garadacimab,CSL Behring,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,,,,,,,,,,,,2,COVID-19,124,No,1,Inspira Health Center Vineland - Vineland - New Jersey,7/1/20,12/1/20,12/1/20,https://clinicaltrials.gov/ct2/show/NCT04409509,,,clinicaltrials@cslbehring.com        ,,,,,,,,,,,,
699,Yes,https://clinicaltrials.gov/ct2/show/NCT04409509,,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,,,https://clinicaltrials.gov/ct2/show/NCT04409509,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,https://clinicaltrials.gov/ct2/show/NCT04409509,,,https://clinicaltrials.gov/ct2/show/NCT04409509,,,,,,,,,,,,
700,No,ArtemiC,,ArtemiC,MGC Pharmaceuticals d.o.o,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Israel,Ongoing,,,Phase 2,,,,,,,,5/5/2020,,,,,2,COVID-19,50,No,3,Hillel Yaffe Medical Center - Hadera - Haifa - Israel; Nazareth Hospital EMMS - Nazareth - Israel; Rambam Health Care Campus - Haifa - Israel,5/8/20,11/1/20,1/1/21,https://clinicaltrials.gov/ct2/show/NCT04382040,Nadia Lisovoder,972529573063,nadyal@galilee-cbr.com,,,,,,,,,,,,
700,Yes,https://clinicaltrials.gov/ct2/show/NCT04382040,,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://www.clinicaltrialsarena.com/news/mgc-phase-ii-artemic-covid-19/,https://www.clinicaltrialsarena.com/news/mgc-phase-ii-artemic-covid-19/,https://www.clinicaltrialsarena.com/news/mgc-phase-ii-artemic-covid-19/,,https://www.clinicaltrialsarena.com/news/mgc-phase-ii-artemic-covid-19/,https://clinicaltrials.gov/ct2/show/NCT04382040,,,https://clinicaltrials.gov/ct2/show/NCT04382040,,,,,,,,https://www.clinicaltrialsarena.com/news/mgc-phase-ii-artemic-covid-19/,,,,,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,https://clinicaltrials.gov/ct2/show/NCT04382040,,,,,,,,,,,,
701,No,CERC-002,,CERC-002,"Aevi Genomic Medicine, LLC; Cerecor",Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Kinase inhibitors,Repurposed-Approved,,United States,Ongoing,,,Phase 2,,Assumed Complete,Assumed Complete,,,6/28/2020,Skipped,6/2/2020,,,,,2,COVID-19,82,No,2,Cape Fear Valley Medical Center - Fayetteville - North Carolina; Carolina Institute for Clinical Research LLC - Fayetteville - North Carolina,06/02/2020,10/01/2020,11/01/2020,https://clinicaltrials.gov/ct2/show/NCT04412057,H. Jeffrey Wilkins,6104575095,jwilkins@cerecor.com,,,,,,,,,,,,
701,Yes,https://clinicaltrials.gov/ct2/show/NCT04412057,,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://ir.cerecor.com/press-releases/detail/94/cerecor-announces-fda-clearance-of-ind-for-cerc-002-in,https://ir.cerecor.com/press-releases/detail/94/cerecor-announces-fda-clearance-of-ind-for-cerc-002-in,https://ir.cerecor.com/press-releases/detail/94/cerecor-announces-fda-clearance-of-ind-for-cerc-002-in,,https://clinicaltrials.gov/ct2/show/study/NCT04412057,https://clinicaltrials.gov/ct2/show/study/NCT04412057,,,https://clinicaltrials.gov/ct2/show/study/NCT04412057,,https://www.cerecor.com/resources/related-publications/cerc-002-publications,https://www.cerecor.com/resources/related-publications/cerc-002-publications,,,https://ir.cerecor.com/press-releases/detail/94/cerecor-announces-fda-clearance-of-ind-for-cerc-002-in,https://www.cerecor.com/pipeline,6/3/2020,,,,,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://ir.cerecor.com/press-releases/detail/94/cerecor-announces-fda-clearance-of-ind-for-cerc-002-in,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,https://clinicaltrials.gov/ct2/show/NCT04412057,,,,,,,,,,,,
702,No,BMS-986253,,BMS-986253,Bristol-Myers Squibb,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Kinase inhibitors,Repurposed-Not Approved,Bristol-Myers Squibb,United States,Ongoing,"Drug indication for solid tumor, COVID-19, and hematological malignancy",,Phase 2,,Assumed Complete,Assumed Complete,,,Completed,Skipped,4/15/2020,,,,,2,COVID-19,138,No,1,Columbia University Irving Medical Center - New York - New York,04/15/2020,09/01/2021,09/01/2022,https://clinicaltrials.gov/ct2/show/record/NCT04347226,Lisa Olmos,2123425162,cancerclinicaltrials@cumc.columbia.edu,,,,,,,,,,,,
702,Yes,https://clinicaltrials.gov/ct2/show/NCT04347226,,https://clinicaltrials.gov/ct2/show/NCT04347226,https://clinicaltrials.gov/ct2/show/NCT04347226,https://clinicaltrials.gov/ct2/show/NCT04347226,https://clinicaltrials.gov/ct2/show/record/NCT04347226,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-il-8-monoclonal-antibody-humax-il8,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-il-8-monoclonal-antibody-humax-il8,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-il-8-monoclonal-antibody-humax-il8,https://clinicaltrials.gov/ct2/show/record/NCT04347226,https://clinicaltrials.gov/ct2/show/record/NCT04347226,https://clinicaltrials.gov/ct2/show/record/NCT04347226,https://clinicaltrials.gov/ct2/show/record/NCT04347226,,https://clinicaltrials.gov/ct2/show/study/NCT04347226,,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-il-8-monoclonal-antibody-humax-il8,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-il-8-monoclonal-antibody-humax-il8,,,https://clinicaltrials.gov/ct2/show/record/NCT04347226,https://clinicaltrials.gov/ct2/show/record/NCT04347226,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04347226,,https://clinicaltrials.gov/ct2/show/study/NCT04347226,https://clinicaltrials.gov/ct2/show/study/NCT04347226,https://clinicaltrials.gov/ct2/show/study/NCT04347226,https://clinicaltrials.gov/ct2/show/study/NCT04347226,https://clinicaltrials.gov/ct2/show/study/NCT04347226,https://clinicaltrials.gov/ct2/show/record/NCT04347226,https://clinicaltrials.gov/ct2/show/study/NCT04347226,https://clinicaltrials.gov/ct2/show/study/NCT04347226,https://clinicaltrials.gov/ct2/show/record/NCT04347226,https://clinicaltrials.gov/ct2/show/record/NCT04347226,https://clinicaltrials.gov/ct2/show/record/NCT04347226,,,,,,,,,,,,
703,No,Anluohuaxian,,Anluohuaxian,Peking University First Hospital,Therapeutic,COVID-19,Unknown,Unknown,Repurposed-Not Approved,,China,Ongoing,,,Phase 1,,Assumed Complete,Assumed Complete,,,,4/1/2020,,,,,,1,COVID-19,750,No,9,The Second People's Hospital of Fuyang - Anhui - China; Ezhou Central Hospital - Wuhan - China; Huoshenshan Hospital of Wuhan - Wuhan - China; Jinyinyan Hospital of Wuhan - Wuhan - China; Tongji Hospital of Huazhong University of Science and Technology - Wuhan - China; West Hospital Union Hospital Huazhong University of Science and Technology - Wuhan - China; Wuhan Pulmonary Hospital - Wuhan - China; Zhongnan Hospital of Wuhan University - Wuhan - China; Wenzhou Medical University Affiliated First Hospital - Wenzhou - China,04/01/2020,06/01/2020,12/01/2020,https://clinicaltrials.gov/ct2/show/record/NCT04334265,Guiqiang Wang,13911405123,john131212@sina.com,,,,,,,,,,,,
703,Yes,https://clinicaltrials.gov/ct2/show/NCT04334265,,https://clinicaltrials.gov/ct2/show/NCT04334265,https://clinicaltrials.gov/ct2/show/NCT04334265,https://clinicaltrials.gov/ct2/show/NCT04334265,https://clinicaltrials.gov/ct2/show/record/NCT04334265,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/,,https://clinicaltrials.gov/ct2/show/study/NCT04334265,https://clinicaltrials.gov/ct2/show/record/NCT04334265,,,https://clinicaltrials.gov/ct2/show/study/NCT04334265,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/,,,,https://clinicaltrials.gov/ct2/show/study/NCT04334265,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04334265,https://clinicaltrials.gov/ct2/show/study/NCT04334265#contacts,https://clinicaltrials.gov/ct2/show/record/NCT04334265,https://clinicaltrials.gov/ct2/show/study/NCT04334265#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04334265#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04334265#contacts,https://clinicaltrials.gov/ct2/show/record/NCT04334265,https://clinicaltrials.gov/ct2/show/record/NCT04334265,https://clinicaltrials.gov/ct2/show/record/NCT04334265,https://clinicaltrials.gov/ct2/show/record/NCT04334265,https://clinicaltrials.gov/ct2/show/record/NCT04334265,https://clinicaltrials.gov/ct2/show/record/NCT04334265,https://clinicaltrials.gov/ct2/show/record/NCT04334265,,,,,,,,,,,,
704,No,azoximer bromide,azoximer bromide,Polyoxidonium,NPO Petrovax,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Approved,,Russian Federation,Ongoing,Azoximer bromide acts as an immune adjuvent.,,Phase 2,,Assumed Complete,Assumed Complete,,,,Skipped,4/29/2020,4/29/2020,,,,2,COVID-19,394,No,12,City hospital No. 5 of Barnaul - Barnaul - Russian Federation; Central rEsearch Institute of Epidemiology of Rospotrebnadzor - Moscow - Russian Federation; City Clinical Hospital No. 15 named after OM Filatov - Moscow - Russian Federation; Infectious Clinical Hospital No. 1 of the Moscow Department of Healthcare - Moscow; City Clinical Hospital No. 24 of the Moscow Department of Healthcare - Moscow - Russian Federation; Research Institute of Emergency Care named after N.V. Sklifosovsky in Department of Health of the city of Moscow - Moscow - Russian Federation; City Clinical Hospital No. 40 of the Moscow Department of Healthcare - Moscow - Russian Federation; Infectious clinical hospital No. 2 of Nizhny Novgorod - Nizhny Novgorod - Russian Federation; Orenburg State Medical University - Orenburg; First St. Petersburg State Medical University named after Academician I.P. Pavlov - Saint Petersburg - Russian Federation; Regional Clinical Hospital - Vladimir - Russian Federation; Yaroslavl State Medical University of Ministry of Health of the Russian Federation - Yaroslavl - Russian Federation,04/29/2020,04/01/2021,04/01/2021,https://clinicaltrials.gov/ct2/show/record/NCT04381377,Nikolay Dodonov,7 (495)7307545 ext 125,dodonovns@petrovax.ru,,,,,,,,,,,,
704,Yes,https://clinicaltrials.gov/ct2/show/NCT04381377,https://clinicaltrials.gov/ct2/show/NCT04381377,https://clinicaltrials.gov/ct2/show/NCT04381377,https://clinicaltrials.gov/ct2/show/NCT04381377,https://clinicaltrials.gov/ct2/show/NCT04381377,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892947/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892947/,http://www.freepatentsonline.com/EP0789586.html,,https://clinicaltrials.gov/ct2/show/NCT04381377,https://clinicaltrials.gov/ct2/show/NCT04381377,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892947/,,https://clinicaltrials.gov/ct2/show/NCT04381377,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892947/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892947/,,,,https://clinicaltrials.gov/ct2/show/record/NCT04381377,https://clinicaltrials.gov/ct2/show/record/NCT04381377,https://clinicaltrials.gov/ct2/show/record/NCT04381377,,,,https://clinicaltrials.gov/ct2/show/NCT04381377,https://clinicaltrials.gov/ct2/show/NCT04381377,https://clinicaltrials.gov/ct2/show/NCT04381377,https://clinicaltrials.gov/ct2/show/NCT04381377,https://clinicaltrials.gov/ct2/show/NCT04381377,https://clinicaltrials.gov/ct2/show/record/NCT04381377,https://clinicaltrials.gov/ct2/show/record/NCT04381377,https://clinicaltrials.gov/ct2/show/record/NCT04381377,https://clinicaltrials.gov/ct2/show/record/NCT04381377,https://clinicaltrials.gov/ct2/show/record/NCT04381377,https://clinicaltrials.gov/ct2/show/record/NCT04381377,https://clinicaltrials.gov/ct2/show/record/NCT04381377,https://clinicaltrials.gov/ct2/show/record/NCT04381377,,,,,,,,,,,,
705,No,Sevoflurane,,Sevoflurane,University of Zurich,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Switzerland,Ongoing,,,Phase 3,,Assumed Complete,Assumed Complete,,,,Skipped,Skipped,4/23/2020,,,,3,COVID-19,64,No,1,University Hospital Zurch - Zurich - Switzerland,04/23/2020,03/31/2021,03/31/2021,https://clinicaltrials.gov/ct2/show/NCT04355962,Martin Schläpfer,41442554690 ext 41442554690,martin.schlaepfer@usz.ch,,,,,,,,,,,,
705,Yes,https://clinicaltrials.gov/ct2/show/NCT04355962,,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://www.drugbank.ca/drugs/DB01236,https://www.drugbank.ca/drugs/DB01236,https://www.drugbank.ca/drugs/DB01236,,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,,,https://clinicaltrials.gov/ct2/show/NCT04355962,,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,,,,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,,,,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,https://clinicaltrials.gov/ct2/show/NCT04355962,,,,,,,,,,,,
706,No,Budesonide,,Budesonide,Fondation Ophtalmologique Adolphe de Rothschild,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,France,Ongoing,"This study specifically investigates treatments for olfaction disorders which may be caused or related to COVID-19.
",,Phase 3,,Assumed Complete,Assumed Complete,,,5/15/2020,Skipped,Skipped,6/18/2020,,,,3,COVID-19,120,No,1,Hopital Lariboisière - Paris - France,05/18/2020,05/18/2021,05/25/2021,https://clinicaltrials.gov/ct2/show/NCT04361474,Mary Daval,0148036870,mdaval@for.paris,,,,,,,,,,,,
706,Yes,https://clinicaltrials.gov/ct2/show/NCT04361474,,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://www.drugbank.ca/drugs/DB01222,https://clinicaltrials.gov/ct2/show/NCT04361474,https://www.drugbank.ca/drugs/DB01222,,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,,https://clinicaltrials.gov/ct2/show/NCT04361474,,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001667-85/FR,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,,,,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,,https://clinicaltrials.gov/ct2/show/NCT04361474,https://clinicaltrials.gov/ct2/show/NCT04361474,,,,,,,,,,,,
707,No,Abidol hydrochloride,,Abidol hydrochloride,Tongji Hospital,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,Repurposed-Not Approved,,China,Ongoing,,,Phase 4,,Complete,Assumed Complete,,,Complete,Skipped,Skipped,2/1/2020,,,,4,COVID-19,100,No,1,Department and Institute of Infectious Disease - Wuhan - China,02/01/2020,06/01/2020,07/01/2020,https://clinicaltrials.gov/ct2/show/NCT04254874,Qin Ning,8613971521450,qning@vip.sina.com,,,,,,,,,,,,
707,Yes,https://clinicaltrials.gov/ct2/show/NCT04254874,,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://www.drugs.com/international/abidol.html,,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,,,https://clinicaltrials.gov/ct2/show/study/NCT04254874,,https://www.drugs.com/international/abidol.html,https://www.drugs.com/international/abidol.html,,,https://www.medrxiv.org/content/10.1101/2020.03.16.20034934v1.full.pdf,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,,,,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,,,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,https://clinicaltrials.gov/ct2/show/NCT04254874,,,,,,,,,,,,
708,No,Veru-111,,Veru-111,Venu Inc.,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,The therapeautic approach of this drug is both antivial and anti-inflammatory,,Phase 2,,Assumed Completed,2/18/2020,,,6/12/2020,Skipped,6/18/2020,,,,,2,COVID-19,40,No,5,HonorHealth - Scottsdale - Arizona; Methodist Hospital - saint Louis Park - Minnesota; Regions Hospital - Saint Paul - Minnesota; WC-CRCN at North Vista Hospital - Las Vegas - Nevada; Inspira Medical Center - Vineland - New Jersey,06/18/2020,11/30/2020,12/18/2020,https://clinicaltrials.gov/ct2/show/NCT04388826,Gary Barnette,9194263611,gbarnette@verupharma.com,,,,,,,,,,,,
708,Yes,https://clinicaltrials.gov/ct2/show/NCT04388826,,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,"https://www.globenewswire.com/news-release/2020/05/05/2027535/0/en/Veru-Reports-Positive-Clinical-Results-from-VERU-111-Phase-1b-2-Trial-in-Men-with-Metastatic-Castration-Resistant-Prostate-Cancer-Advancing-to-Pivotal-Phase-3-Clinical-Program.html#:~:text=VERU%2D111%20is%20an%20oral,agents%20(abiraterone%20or%20enzalutamide).",https://verupharma.com/pipeline/veru-111-for-covid-19/,https://verupharma.com/pipeline/veru-111-for-covid-19/,,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://verupharma.com/pipeline/veru-111-for-covid-19/,,https://clinicaltrials.gov/ct2/show/NCT04388826,,https://verupharma.com/pipeline/veru-111-for-covid-19/,https://verupharma.com/pipeline/veru-111-for-covid-19/,,,https://verupharma.com/pipeline/veru-111-for-covid-19/,https://verupharma.com/pipeline/veru-111-for-covid-19/,https://verupharma.com/pipeline/veru-111-for-covid-19/,,,,,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,,https://clinicaltrials.gov/ct2/show/NCT04388826,https://clinicaltrials.gov/ct2/show/NCT04388826,,,,,,,,,,,,
709,No,Escin,,Escin,University of Catanzaro,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Italy,Ongoing,,,Phase 2,,Assumed Completed,1/6/2020,,,,Skipped,3/23/2020,3/23/2020,,,,2,COVID-19,120,No,1,University of Catanzaro - Catanzaro - Italy,03/23/2020,06/30/2020,12/30/2020,https://clinicaltrials.gov/ct2/show/NCT04322344,Luca Gallelli,3339245656 ext 3339245656,gallelli@unicz.it,,,,,,,,,,,,
709,Yes,https://clinicaltrials.gov/ct2/show/NCT04322344,,https://clinicaltrials.gov/ct2/show/NCT04322344,https://clinicaltrials.gov/ct2/show/NCT04322344,https://clinicaltrials.gov/ct2/show/NCT04322344,https://clinicaltrials.gov/ct2/show/NCT04322344,https://www.drugbank.ca/drugs/DB13195,https://www.drugbank.ca/drugs/DB13195,https://www.drugbank.ca/drugs/DB13195,,https://clinicaltrials.gov/ct2/show/NCT04322344,https://clinicaltrials.gov/ct2/show/NCT04322344,,,https://clinicaltrials.gov/ct2/show/NCT04322344,,https://web.unicz.it/it/news/85621/il-prof-luca-gallelli-in-collaborazione-con-il-gruppo-cinese-di-farmacologia-di-yantai-university-ha-pubblicato-la-review-severe-acute-lung-injury-related-to-covid-19-infection-a-review-and-the-possible-role-for-escin-su-j-of-clinical-pharmacolog,https://web.unicz.it/it/news/85621/il-prof-luca-gallelli-in-collaborazione-con-il-gruppo-cinese-di-farmacologia-di-yantai-university-ha-pubblicato-la-review-severe-acute-lung-injury-related-to-covid-19-infection-a-review-and-the-possible-role-for-escin-su-j-of-clinical-pharmacolog,,,,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,,,,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,,,https://clinicaltrials.gov/ct2/show/study/NCT04322344#contacts,,,,,,,,,,
710,No,"VPM1002, Bacillus Calmette-Guérin (BCG)",,"VPM1002, Bacillus Calmette-Guérin (BCG)",Vakzine Projekt Management GmbH,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,Repurposed-Not Approved,,Germany,Ongoing,,,Phase 3,,Assumed Completed,Assumed Complete,,,4/17/2020,Skipped,Skipped,6/18/2020,,,,3,COVID-19,2038,Yes,5,Medizinische Hochschule Hannover - Hannover - Germany; SocraTec R&D GmbH - Erfurt - Germany; emovis GmbH - Berlin - Germany; Klinische Forschung Berlin GbR - Berlin - Germany; Klinische Forschung Hamburg GmbH - Hamburg Germany,06/18/2020,05/31/2021,05/31/2021,https://clinicaltrials.gov/ct2/show/NCT04435379,Leander Grode,49 (0)511 169908-14,grode@vakzine-manager.de,,,,,,,,,,,,
710,Yes,https://clinicaltrials.gov/ct2/show/NCT04435379,,https://clinicaltrials.gov/ct2/show/NCT04435379,https://clinicaltrials.gov/ct2/show/NCT04435379,https://clinicaltrials.gov/ct2/show/NCT04435379,https://clinicaltrials.gov/ct2/show/record/NCT04435379,https://www.drugbank.ca/drugs/DB05089,https://www.precisionvaccinations.com/vaccines/vpm1002-tuberculosis-vaccine,https://www.precisionvaccinations.com/vaccines/vpm1002-tuberculosis-vaccine,,https://clinicaltrials.gov/ct2/show/record/NCT04435379,https://clinicaltrials.gov/ct2/show/record/NCT04435379,,,https://clinicaltrials.gov/ct2/show/study/NCT04435379,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001675-33/DE,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001675-33/DE,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001675-33/DE,https://clinicaltrials.gov/ct2/show/study/NCT04435379,https://clinicaltrials.gov/ct2/show/study/NCT04435379,https://clinicaltrials.gov/ct2/show/study/NCT04435379,,,,https://clinicaltrials.gov/ct2/show/record/NCT04435379,https://clinicaltrials.gov/ct2/show/record/NCT04435379,https://clinicaltrials.gov/ct2/show/record/NCT04435379,https://clinicaltrials.gov/ct2/show/record/NCT04435379,https://clinicaltrials.gov/ct2/show/record/NCT04435379,https://clinicaltrials.gov/ct2/show/study/NCT04435379#contacts,https://clinicaltrials.gov/ct2/show/record/NCT04435379,https://clinicaltrials.gov/ct2/show/record/NCT04435379,https://clinicaltrials.gov/ct2/show/record/NCT04435379,,https://clinicaltrials.gov/ct2/show/NCT04435379#contacts,https://clinicaltrials.gov/ct2/show/NCT04435379#contacts,https://clinicaltrials.gov/ct2/show/NCT04435379#contacts,https://clinicaltrials.gov/ct2/show/NCT04435379,https://clinicaltrials.gov/ct2/show/NCT04435379,,,,,,,,,,
711,No,Beijing Institute Innactivated Vaccine; BBIBP-CorV,,Beijing Institute Innactivated Vaccine; BBIBP-CorV,Sinopharm; Beijing Institute of Biological Products; China National Biotec Group,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,China,Ongoing,,,Phase 3,,,,,,,,4/29/2020,7/15/2020,,8/2020 (China),,3,COVID-19,5048,Yes,6,Abu Dhabi Health Services - Abu Dhabi - United Arab Emirates; Abu Dhabi Health Services - Al Ain - United Arab Emirates; Fundación Huésped - Ciudad Autónoma de Buenos Aires - Buenos Aires - Argentina; Vacunar Liniers - Ciudad Autónoma de Buenos Aires - Buenos Aires - Argentina; Vacunar Cañitas - Ciudad Autónoma de Buenos Aires - Buenos Aires - Argentina; Vacunar Coghlan - Ciudad Autónoma de Buenos Aires - Buenos Aires - Argentina,9/6/2020,12/1/21,12/1/21,https://clinicaltrials.gov/ct2/show/NCT04560881?term=NCT04560881&draw=2&rank=1  http://www.chictr.org.cn/showproj.aspx?proj=53003,Pedro Cahn,For Argentina: +54 11 49817777,investigaciones.clinicas@huesped.org.ar,,,,,,,,,,,,
711,Yes,https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving,,https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving,https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving,https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving,http://www.chictr.org.cn/showproj.aspx?proj=53003,http://www.chictr.org.cn/showproj.aspx?proj=53003,http://www.chictr.org.cn/showproj.aspx?proj=53003,http://www.chictr.org.cn/showproj.aspx?proj=53003,,http://www.chictr.org.cn/showproj.aspx?proj=53003,http://www.chictr.org.cn/showproj.aspx?proj=53003,,,http://www.chictr.org.cn/showproj.aspx?proj=53003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
712,No,T-VIVA-19,,T-VIVA-19,Sorrento Therapeutics Inc.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,,Ongoing,,,Pre-Clinical Testing,,,,7/1/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
712,Yes,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,,United States,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,,,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,,,,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-selection-t-viva-19tm-targeted-protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
713,No,Soberana 1,,Soberana 1,Instituto Finlay de Vacunas,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,Cuba,Ongoing,,,Phase 2,,Assumed Complete,Assumed Complete,Assumed Complete,Assumed Complete,Assumed Complete,8/24/2020,8/24/2020,,,,,1/2,COVID-19,676,Yes,,,8/24/2020,,,https://rpcec.sld.cu/ensayos/RPCEC00000332-Sp,Beatriz Paredes Moreno,(+53) 72718331,bparedes@finlay.edu.cu,,,,,,,,,,,,
713,Yes,,,https://rpcec.sld.cu/ensayos/RPCEC00000332-Sp,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,,,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,,,,,,,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,https://www.dw.com/en/cuba-joins-the-race-for-vaccine-against-the-coronavirus/a-54615364,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
714,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
714,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
715,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
715,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
716,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
716,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
717,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
717,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
718,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
718,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
719,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
719,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
720,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
720,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
721,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
721,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
722,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
722,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
723,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
723,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
724,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
724,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
725,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
725,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
726,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
726,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
727,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
727,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
728,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
728,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
729,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
729,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
730,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
730,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
731,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
731,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
732,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
732,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
733,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
733,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
734,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
734,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
735,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
735,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
736,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
736,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
737,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
737,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
738,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
738,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
739,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
739,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
740,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
740,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
741,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
741,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
742,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
742,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
743,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
743,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
744,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
744,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
745,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
745,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
746,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
746,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
747,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
747,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
748,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
748,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
749,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
749,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
750,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
750,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
751,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
751,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
752,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
752,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
753,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
753,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
754,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
754,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
755,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
755,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
756,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
756,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
757,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
757,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
758,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
758,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
759,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
759,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
760,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
760,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
761,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
761,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
762,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
762,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
763,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
763,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
764,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
764,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
765,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
765,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
766,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
766,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
767,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
767,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
768,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
768,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
769,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
769,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
770,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
770,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
771,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
771,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
772,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
772,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
773,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
773,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
774,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
774,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
775,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
775,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
776,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
776,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
777,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,